Essential Drugs

Essential
drugs
Practical guidelines
intended for physicians, pharmacists,

nurses and medical auxiliaries
2010 EDITION
© Médecins Sans Frontières – December 2009
All rights reserved for all countries. No reproduction, translation and adaptation may be done
without the prior permission of the Copyright owner.
ISBN 2-906498-78-5
Essential drugs
Practical guidelines
Editorial committee:
Jacques Pinel (Ph), Françoise Weiss (Ph), Myriam Henkens (MD)
and Véronique Grouzard (N, general editor)
Contributors:
S. Balkan (MD), T. Baubet (MD), V. Boissière (Ph), M.E. Burny (N), A.S. Coutin (MD),
C. Danet (MD), M. De Smet (MD), F. Fermon (N), N. Harris (MD), X. Lassalle (AA),
C. Macé (Ph), J. Menschik (MD), R. Murphy (MD), B. Renchon (Ph), J. Rigal (MD),
M. Schaefer (MD), E. Szumilin (MD), F. Varaine (MD), B. Vasset (MD)
We would like to thank C. Boissinot (Ph), M. Boussinesq (MD), A. Certain (Ph), F. Delange (MD),
P.Y. Fournier (MD), S. Gnamien (Ph), B. Graz (MD), C. Guérin (Ph), C.A Jeanne-Rose (Ph),
J. Van Roey (MD) for their invaluable contributions to this guide.
(MD) Medical doctor, (Ph) Pharmacist, (N) Nurse, (AA) Anaesthetist-assistant
Translated from French by V. Grouzard, N. Harris and C. Lopez-Serraf.
Design and layout: Evelyne Laissu

Preface
The 1978 Alma Ata Conference on primary health care recognized that essential drugs are
vital for preventing and treating illnesses which affect millions of people throughout the
world. Essential drugs save lives and improve health.
In 1981, the World Health Organization established the Action Programme on Essential
Drugs to support countries to implementing national drug policies and to work towards
rational use of drugs. This work was broadened in 1998 when WHO created the department
of Essential Drugs and Other Medicines (EDM), combining the responsabilities of the former
DAP with WHO's global efforts to promote quality, safety, efficacy, and accurate information
for all medicines.
EDM works with countries, international agencies, NGOs like Médecins Sans Frontières,
and other organizations to ensure that people everywhere have access to the essential drugs
they need at a price which is affordable; that the drugs are safe, effective, and of good quality;
and that they are prescribed and used rationally.
Appropriate tools are critical to the effective implementation of essential drugs policies. This
practical handbook, based on Médecins Sans Frontières' field experience, is one of the tools
which we strongly recommend.
Designed to give practical, concise infomation to physicians, pharmacists and nurses, this
“Essential drugs - practical guidelines” is an important contribution from Médecins Sans
Frontières to improve the rational use of drugs, which will be a continuing challenge in the
coming years.
Dr Jonathan D. Quick
Director,
Essential Drugs and Other medicines
World Health Organization
5
Foreword
This guide is not a dictionary of pharmacological agents. It is a practical

manual intended for health professionals, physicians, pharmacists, nurses and health
auxiliaries involved in curative care and drug management.
We have tried to provide simple, practical solutions to the questions and

problems faced by medical staff, using the accumulated field experience of
Médecins Sans Frontières, the recommendations of reference organizations such as
the World Health Organization (WHO) and specialized documentation in each field.
This manual is not only used by Médecins Sans Frontières, but also in a wide
range of other programmes and contexts.
The list of drugs in this edition has been revised: in accordance to the most
recent WHO list of essential medicines, certain drugs have been added, others have
been removed.
Among the entries in this guide, some are not listed in the WHO list of essential
medicines. However these drugs are in the same pharmaceutical class for which the
WHO has named only one "example of a therapeutic group" preceded by a square
symbol to indicate that various drugs can be used as alternatives.
Certain medicines, which are not on the WHO list, are still frequently
administered although their use is not recommended. These medicines have been
included in this guide by entries marked by a grey diagonal line.
The entries are classified according to the route of administration and in

alphabetical order. This classification reflects the drug management system proposed
in this manual (see Organization and management of a pharmacy, page 285).
Only the main contra-indications, adverse effects, precautions and drug

interactions of each drug have been indicated in this manual. For further detailed
information refer to specialised literature. Concerning antiretrovirals, the interactions
are too many to be listed: it is therefore essential to refer to specialised literature.
This manual is a collective effort by medical professionals from many

disciplines, all with field experience.
6
Despite all efforts, it is possible that certain errors may have been overlooked in
this manual. Please inform the authors of any errors detected. It is important to
remember, that if in doubt, it is the responsibility of the prescribing medical
professional to ensure that the doses indicated in this manual conform to the
manufacturer's specifications.
The authors would be grateful for any comments or criticisms to ensure that
this manual continues to evolve and remains adapted to the reality of the field.
Comments should be addressed to:

Médecins Sans Frontières - Medical Department
8 rue St-Sabin - 75544 Paris Cedex 11 - France
Tel.: +33.(0)1.40.21.29.29
Fax: +33.(0)1.48.06.68.68
e.mail: guide.essdrugs@msf.org
This manual is also available on the internet at www.msf.org. As treatment protocols

are constantly changing, medical staff are encouraged to check this website for
updates of this edition.
7
Use of the guide
General organisation
There are two easy ways to find information in this manual:
– A summary at the beginning of the manual lists the chapters and their
corresponding pages.
– A double-entry alphabetical index at the end of the manual with international non-
proprietary and proprietary names.
Nomenclature of drugs
The International Non-proprietary Names (INN) of drugs is used in this manual.
Some frequently used proprietary names, followed by the symbol ®, are also given.
E.g.: amoxicillin (Amoxyl®, Clamoxyl®…)
Dosage
Prescription tables showing average dosage in drug units (tablets, ampoules etc.)
according to weight or age of patients are included for the most commonly used
drugs.
Dosage for children are expressed in milligrams per kilogram per day (mg/kg/day)
for most drugs. For certain symptomatic drugs, dosage is expressed in milligrams
per kilogram per dose (mg/kg/dose). For certain antiretrovirals, dosage is expressed
in milligrams per square meter (mg/m2).
Dosage for adults is expressed in grams or milligrams per day for most drugs. For
certain drugs requiring a more precise dosage, doses are expressed in mg/kg/day. In
malnourished patients, prescriptions should always be adapted to the patient's
weight.
Symbols
This box indicates potentially toxic drugs,

Prescription under medical supervision administered under medical prescription only
in many European countries (e.g. Belgium,
France, Spain, UK).
8
This symbol is used to draw attention to drugs
whose toxic potential is greater, or for which
experience has shown they are frequently
misused.
Drugs marked with a grey diagonal line are

either potentially dangerous and forbidden
in certain countries, or obsolete or ineffective.
These drugs are still widely used, attention is
therefore drawn to the risk and/or unnecessary
cost of their prescription.
Practical recommendations for drug storage:

drug very sensitive to light drug very sensitive to humidity
If no temperature for storage is recommended, this indicates that no information was

found in medical literature.
Abbreviations
Units Administration route Others
kg = kilogram IM = intramuscular v/v = volume in volume

g = gram IV = intravenous
mg = milligram SC = subcutaneous
(1 g = 1000 mg)
µg = microgram
m2 = square meter Presentation
IU = international unit
M = million tab = tablet
mEq = milliequivalent cap = capsule
mmol = millimole vl = vial
ml = millilitre amp = ampoule
(1 cc = 1 ml) susp = suspension
tsp = teaspoon (= 5 ml)
ssp = soupspoon (= 15 ml)
9
Summary
PART ONE
1 Oral drugs page 13
2 Injectable drugs page 149
3 Infusion solutions page 221
4 Vaccines, immunoglobulins and antisera page 231
5 Drugs for external use, antiseptics and disinfectants page 249
10
PART TWO
Organisation and management of a pharmacy page 285
Drug quality and storage page 297
Prescription, cost, compliance page 301
Use of antibacterials page 305
Antiseptics and disinfectants page 311
WHO model list of essential medicines page 317
Main references page 351
Alphabetical index page 352
11
Oral drugs
1
Abacavir (ABC) 15 Codeine 46
Acetaminophen 112 Colecalciferol 57
Acetylsalicylic acid (ASA) 16 Cotrimoxazole 47
Aciclovir 17 d4T/3TC/NVP 136
Albendazole 18 Dapsone 48
Albuterol 130 Desogestrel 49
Albuterol aerosol 131 Diazepam 50
Albuterol nebuliser solution 132 Didanosine (ddI) 51
Aluminium hydroxide 19 Diethylcarbamazine 52
Amitriptyline 20 Digoxin 53
Amodiaquine (AQ) 21 Dihydralazine 74
Amoxicillin 22 Dipyrone 93
Artemether/lumefantrine 23 Doxycycline 54
Artesunate (AS) 24 Efavirenz (EFV - EFZ) 55
Artesunate/amodiaquine (AS/AS) 25 Enalapril 56
Artesunate + sulfadoxine/pyrimethamine 26 Ergocalciferol 57
Ascorbic acid 27 Ergometrine 58
Aspirin 16 Erythromycin 59
Atenolol 28 Ethambutol 60
Azithromycin 29 Ethinylestradiol/levonorgestrel 61
AZT/3TC 145 Ferrous salts 62
AZT/3TC/NVP 146 Ferrous salts/folic acid 63
Beclometasone 30 Fluconazole 64
Bisacodyl 31 Fluoxetine 66
Butylscopolamine 76 Folic acid 63
Cabergoline 32 Folinic acid 33
Calcium gluconate 33 Fosfomycin tromethamine 67
Carbamazepine 34 Furosemide = frusemide 68
Cefixime 35 Glibenclamide 69
Chloramphenicol 38 Glyceryl trinitrate 70
Chloroquine 36 Griseofulvin 71
Chlorphenamine = chlorpheniramine 39 Halofantrine 72
Chlorpromazine 40 Haloperidol 73
Cimetidine 41 Hydralazine 74
Ciprofloxacin 42 Hydrochlorothiazide 75
Clindamycin 43 Hyoscine butylbromide 76
Clomipramine 44 Ibuprofen 77
Cloxacillin 45 Indinavir (IDV) 78
Coartemether 23 Iodized oil 79
Isoniazid (INH) 80 Promethazine 120
Isosorbide dinitrate 81 Pyrantel 121
Itraconazole 82 Pyrazinamide 122
Ivermectin 83 Pyridoxine 123
Lactulose 84 Pyrimethamine 124
Lamivudine (3TC) 85 Quinine 125
Levodopa/carbidopa 86 ReSoMal 126
Levonorgestrel 87 Retinol 127
Levonorgestrel (emergency) 88 Rifampicin 128
Loperamide 89 Ritonavir (RTV) 129
Lopinavir/ritonavir (LPV/r) 90 Salbutamol 130
Mebendazole 91 Salbutamol aerosol 131
Mefloquine (MQ) 92 Salbutamol nebuliser solution 132
Metamizole 93 Saquinavir (SQV) 133
Methyldopa 94 Sodium valproate 143
Methylergometrine 58 Spironolactone 134
Metoclopramide 95 Stavudine (d4T) 135
Metronidazole 96 Stavudine/lamivudine/nevirapine 136
Mifepristone (RU486) 97 Sulfadiazine 137
Misoprostol 98 Sulfadoxine/pyrimethamine (SP) 138
Morphine immediate-release 99 Sulfamethoxazole/trimethoprim 47
Morphine sustained-release 100 Thiamine 139
Multivitamins 102 Tinidazole 140
Nalidixic acid 103 Tramadol 141
Nevirapine (NVP) 104 Triclabendazole 142
Niclosamide 105 Trinitrin 70
Nicotinamide 106 Valproic acid 143
Nifedipine 107 Vitamin A 127
Nitrofurantoin 108 Vitamin B complex 102
Nitroglycerin 70 Vitamin B1 139
Noramidopyrine 93 Vitamin B3 106
Nystatin 109 Vitamin B6 123
Omeprazole 110 Vitamin B9 63
Oral rehydration salts (ORS) 111 Vitamin C 27
Paracetamol 112 Vitamin D2 57
Penicillin V 114 Vitamin D3 57
Phenobarbital 113 Vitamin PP 106
Phenoxymethylpenicillin 114 Zidovudine (AZT - ZDV) 144
Phenytoin 115 Zidovudine/lamivudine 145
Potassium chloride 116 Zidovudine/lamivudine/nevirapine 146
Praziquantel 117 Zinc sulfate 147
Prednisolone and prednisone 118
Proguanil 119
ABACAVIR = ABC
(Abac®, Abamune®, Ziagen®…)
1
Prescription under medical supervision
Therapeutic action
– Antiretroviral, HIV-1 and HIV-2 nucleoside reverse transcriptase inhibitor
Indications
– HIV-1 or HIV-2 infection, in combination with other antiretroviral drugs
Presentation
– 300 mg tablet
– 20 mg/ml oral solution, with oral dosing syringe
Dosage
– Child less than 25 kg: 16 mg/kg/day in 2 divided doses, without exceeding 600 mg/day
– Child ≥ 25 kg and adult: 600 mg/day in 2 divided doses
Weight 20 mg/ml oral solution 300 mg tablet
3 to 5 kg 3 ml x 2 –
6 to 9 kg 4 ml x 2 –
10 to 13 kg 6 ml x 2 –
14 to 19 kg – 1/2 tab x 2
20 to 24 kg – 1 tab AM and 1/2 tab PM
≥ 25 kg – 1 tab x 2
Duration: depending on the efficacy and tolerance of abacavir.
Contra-indications, adverse effects, precautions

– Do not administer to patients with severe hepatic impairment or history of severe intolerance
to abacavir that led to discontinuation of treatment.
– May cause:
• hypersensitivity reactions: skin rash, gastrointestinal disturbances (nausea, vomiting,
diarrhoea, abdominal pain), cough, dyspnoea, malaise, headache, lethargy, oedema,
lymphadenopathy, hypotension, myalgia, arthralgia, renal impairment;
• lactic acidosis and hepatic disorders.
In all these cases, stop taking abacavir immediately and permanently.
– Pregnancy: avoid, except if there is no therapeutic alternative
Remarks
– Tablets are not scored. When half a tablet is required, use a cutter or a tablet cutter to cut
the tablet into two equal parts.
– Also comes in fixed-dose combination tablets containing abacavir-lamivudine (Epzicom®,
etc.) and abacavir-zidovudine-lamivudine (Trizivir®, etc.).
– Storage: below 30°C
Once opened, oral solution kept below30°C may be stored for a maximum of 2 months.
15
ACETYLSALICYLIC ACID = ASPIRIN = ASA
Therapeutic action
– Analgesic, antipyretic, non steroidal anti-inflammatory (NSAID)
Indications
– Mild pain
– Fever
– Rheumatic diseases (except gout)
Presentation
– 100 mg and 500 mg tablets. Also comes in 300 mg tablets.
Dosage
– Pain and fever
Child: 60 mg/kg/day in 3 or 4 divided doses
Adult: 1 to 3 g/day in 3 or 4 divided doses
AGE 0 2 months 1 year 5 years 15 years

ADULT
WEIGHT 4 kg 8 kg 15 kg 35 kg
100 mg tablet – – 1 1/2 tab x 3 3 tab x 3 –

300 mg tablet – – 1/2 tab x 3 1 tab x 3 2 tab x 3
500 mg tablet – – 1/4 tab x 3 1/2 tab x 3 1 tab x 3
– Rheumatic diseases
Child > 20 kg: 50 to 100 mg/kg/day in 4 divided doses
Adult: 3 to 6 g/day in 4 divided doses
– Maximum dose: child: 100 mg/kg/day; adult: 6 g/day
Duration: pain and fever: 1 to 3 days; rheumatic diseases: according to clinical response.
– Do not administer to patients with allergy to aspirin and NSAID, peptic ulcer, coagulation
disorders, haemorrhage; severe renal, hepatic or cardiac impairment.
– Do not administer to children less than one year (use paracetamol).
– Administer with caution to elderly patients or patients with asthma.
– Do not exceed indicated doses, particularly in children and elderly patients. Intoxications
are severe, possibly fatal.
– May cause:
• allergic reactions, epigastric pain, peptic ulcer, haemorrhage;
• dizziness, tinnitus (early signs of overdose).
For all cases above, stop aspirin and use paracetamol.
– Do not combine with methotrexate, anticoagulants and NSAID.
– Monitor combination with insulin (increased hypoglycaemia) and corticosteroids.
– Pregnancy: not recommended during the first 5 months; CONTRA-INDICATED from the beginning of
the 6th month (use paracetamol)
– Breast-feeding: avoid (use paracetamol)
Remarks
– In children less than 16 years, preferably use paracetamol.
– Take during meals, preferably with a lot of water.
– For the treatment of moderate pain, it is recommended to combine aspirin with codeine or
tramadol.
– Aspirin may be administered for its antiplatelet effects in secondary prevention of athero-
thrombosis, at a dose of 75 to 300 mg daily.
– Storage: below 25°C –
Do not use if tablets have a strong smell of vinegar. A slight vinegar smell is always present.
16
ACICLOVIR
(Viratop®, Zovirax®…)
1
Therapeutic action
– Antiviral active against herpes simplex virus and varicella zoster virus
Indications
– Treatment of recurrent or extensive oral herpes in immunocompromised patients
– Treatment of genital herpes
– Secondary prophylaxis of herpes in patients with frequent and/or severe recurrences
– Treatment of herpetic kerato-uveitis
– Treatment of severe forms of zoster: necrotic or extensive forms, facial zoster, ophthalmic
zoster
Presentation
– 200 mg tablet
Also comes in 400 mg and 800 mg tablets and 200 mg/5 ml and 800 mg/10 ml oral suspension.
Dosage and duration

– Treatment of recurrent or extensive oral herpes in immunocompromised patients
Child under 2 years: 200 mg 5 times per day for 7 days
Child over 2 years and adult: 400 mg 5 times per day for 7 days
– Treatment of genital herpes
Child over 2 years and adult: 400 mg 3 times per day for 7 days; in immunocompromised
patients, continue treatment until clinical resolution
– Secondary prophylaxis of herpes in patients with frequent and/or severe recurrences
Child under 2 years: 200 mg 2 times per day
Child over 2 years and adult: 400 mg 2 times per day
– Treatment of herpetic kerato-uveitis
Child under 2 years: 200 mg 5 times per day for 7 days
Child over 2 years and adult: 400 mg 5 times per day for 7 days
– Treatment of severe forms of zoster
Adult: 800 mg 5 times per day for 7 days

– Do not administer to patients with hypersensitivity to aciclovir.
– May cause: headache, skin rash, gastrointestinal disturbances, raised transaminases,
neurologic disorders in patients with renal impairment.
– May (rarely) cause in immunocompromised patients: thrombocytopenic purpura, haemo-
lytic uraemic syndrome.
– Reduce dosage in patients with renal impairment.
– Drink a lot of liquid during treatment.
– Pregnancy: no contra-indication
– Breast-feeding: no contra-indication
Remarks
– For the treatment of herpes simplex, aciclovir should be started within 24-48 hours after the
appearance of lesions to reduce severity and duration of infection.
– For the treatment of herpes zoster, aciclovir should be started as soon as possible, preferably
within 72 hours after the appearance of lesions. Aciclovir administration does not reduce
the likelihood of developing zoster-associated pain but reduces the overall duration of this
pain.
17
ALBENDAZOLE
(Eskazole®, Zentel®…)
Therapeutic action
– Anthelminthic
Indications
– Ascariasis (Ascaris lumbricoides), enterobiasis (Enterobius vermicularis), hookworm infections
(Ancylostoma duodenale, Necator americanus)
– Trichuriasis (Trichuris trichiura), strongyloidiasis (Strongyloides stercoralis)
– Trichinellosis (Trichinella spp)
Presentation
– 400 mg tablet
Dosage and duration

– Ascariasis, enterobiasis, hookworm infections
Child over 6 months and adult: 400 mg as a single dose
Child over 6 months but under 10 kg: 200 mg as a single dose
In the event of enterobiasis, a second dose may be given after 2 to 4 weeks.
– Trichuriasis, strongyloidiasis
Child over 6 months and adult: 400 mg once daily for 3 days
Child over 6 months but under 10 kg: 200 mg once daily for 3 days
– Trichinellosis
Child over 2 years: 10 mg/kg/day in 2 divided doses for 10 to 15 days
Adult: 800 mg/day in 2 divided doses for 10 to 15 days

– Do not administer to children less than 6 months.
– Do not administer to patients with ocular cysticercosis.
– May cause:
• gastrointestinal disturbances, headache, dizziness;
• neurological disorders (headache, seizures) in patients with undiagnosed neuro-
cysticercosis.
– Pregnancy: avoid during the first trimester
Remarks
– Tablets are to be chewed or crushed: follow manufacturer's recommendations.
– In the treatment of strongyloidiasis, ivermectin is more effective than albendazole.
– Albendazole is also used in the treatment of cutaneous larva migrans (Ancylostoma
braziliense and caninum), larval cestode infections (hydatid disease, certain forms of
neurocysticercosis) and in mass treatment for lymphatic filariasis (check national
recommendations).
– Storage: –
18
ALUMINIUM HYDROXIDE
Therapeutic action
– Antacid
Indications
– Stomach pain associated with gastritis and peptic ulcer
Presentation
– 500 mg tablet
There are numerous preparations of aluminium and/or magnesium hydroxide and different
dosages.
Dosage
– Child over 5 years: rarely indicated. When necessary: half a tablet 3 times/day
– Adult: 3 to 6 tablets/day after meals or 1 tablet during painful attacks
Duration: according to clinical response

– May cause: constipation (except when tablets contain magnesium salts or magnesium
hydroxide).
– Decreases intestinal absorption of many drugs such as tetracycline, iron salts, isoniazid,
ethambutol, chloroquine, atenolol, digoxin, fluoroquinolones, corticosteroids, indometacin,
ketoconazole, thyroxine, etc. Do not administer simultaneously with these drugs, administer
2 hours apart.
Remarks
– Chew tablets.
– Storage: no special temperature requirements
19
AMITRIPTYLINE
(Elavil®, Laroxyl®, Triptyzol®…)
Therapeutic action
– Sedating tricyclic antidepressant
Indications
– Depression in adults, especially when a sedative effect is required (anxiety, agitation,
insomnia)
– Neuropathic pain in adults
Presentation
– 10 mg, 25 mg and 50 mg tablets
Dosage
– Depression
Initial dose of 75 mg/day in 2 to 3 divided doses, or once daily at night, gradually
increased, if necessary, to a maximum dose of 150 mg/day
– Neuropathic pain
Initial dose of 25 mg/day at night for one week, followed by 50 mg/day at night for one
week then 75 mg/day at night
– Reduce the dose by one-half in elderly patients.
Duration
– Depression: minimum 3 months. The treatment should be withdrawn gradually ; if signs of
relapse occur, increase the dose.
– Neuropathic pain: continue several months after pain relief is obtained, then attempt to stop
treatment.
– Do not administer if: recent myocardial infarction, arrhythmia, impaired liver function,
acute mania. Do not administer to children.
– May cause:
• antimuscarinic effects: dry mouth, urinary retention, disturbance of accommodation,
constipation, tachycardia
• orthostatic hypotension, arrhythmia, cutaneous reactions, endocrine disorders, weight
gain, sweating
• frequent drowsiness, tremor, insomnia, transient mental confusion
• effects linked to depressive illness: may exacerbate suicidal tendencies and psychotic
symptoms
Adverse effects occur particularly in the elderly and in the event of overdosage.
– Do not combine with another antidepressant, especially an MAOI.
– Avoid combination with atropine, epinephrine (adrenaline), methyldopa (increased
hypotension).
– Use with caution when driving or operating machinery: risk of drowsiness.
– Do not drink alcohol during treatment.
– Administer with caution, under medical supervision, in epilepsy, cardiovascular disease,
hepatic or renal failure, prostatic hyperplasia, thyroid disease.
– Closely monitor patients with suicidal tendencies, especially in the initial stage of
treatment.
– Pregnancy: avoid, especially at the end of pregnancy (antimuscarinic effects in neonates)
– Breast-feeding: avoid
Remarks
– In the treatment of neuropathic pain, amitriptyline is often combined with carbamazepine
(except in pregnant women).
– Sedative action occurs following initial doses. Antidepressant and analgesic effects are
delayed for 10 to 20 days. Wait for several weeks before assessment of efficacy. This must
be explained to the patient to encourage compliance.
– Combination with an anxiolytic or a neuroleptic may be useful in anxious or agitated
patients.
– Storage: –
20
AMODIAQUINE = AQ
(Camoquin®…)
1
Therapeutic action
– Antimalarial
Indications
– Treatment of uncomplicated falciparum malaria, in combination with artesunate
– Completion treatment following parenteral therapy for severe falciparum malaria, in
combination with artesunate
Presentation
– 200 mg amodiaquine hydrochloride tablet, containing 153 mg amodiaquine base
Dosage and duration

– Child and adult: 10 mg base/kg once daily for 3 days
153 mg base tablet

Age
D1 D2 D3
5 to 11 months 1/2 tab 1/2 tab 1/2 tab
1 to 6 years 1 tab 1 tab 1 tab
7 to 13 years 2 tab 2 tab 2 tab
≥ 14 years/adult 4 tab 4 tab 4 tab

– Do not administer in the event of previous severe adverse reaction to treatment with
amodiaquine (e.g. hypersensitivity reaction, hepatitis, leucopenia, agranulocytosis).
– Do not administer to patients taking efavirenz.
– May cause: gastrointestinal disturbances, pruritus.
– Pregnancy: no contra-indication during the 2nd and 3rd trimester. Safety in the first trimester has not
been definitely established. However, given the risks associated with malaria, the combination
artesunate-amodiaquine may be used during the first trimester if it is the only effective treatment
available.
Remarks
– Do not administer the combination artesunate-amodiaquine as separate tablets (i.e.
artesunate tablets + amodiaquine tablets). Use co-formulated tablets (e.g. Coarsucam®) or,
if not available, co-blisters.
– Also comes in 260 mg amodiaquine hydrochloride tablet, containing 200 mg amodiaquine
base.
– Amodiaquine should not be used for prophylaxis.
21
AMOXICILLIN
(Amoxil®, Clamoxyl®…)
Therapeutic action
– Penicillin antibacterial
Indications
– Respiratory and ENT infections (pneumonia, sinusitis, otitis media, streptococcal tonsillitis),
stomatologic infections, urinary infections (cystitis), gastrointestinal and biliary infections,
infection due to Helicobacter pylori (in combination with omeprazole and metronidazole or
tinidazole), leptospirosis, etc.
– Parenteral to oral switch therapy
Presentation
– 250 mg and 500 mg tablets or capsules
– Powder for oral suspension, 125 mg/5 ml
Dosage
– Child: 50 mg/kg/day in 2 to 3 divided dose
– Adult: 1.5 g/day in 3 divided doses or 2 g/day in 2 divided doses
Oral suspension
Age Weight 250 mg tablet 500 mg tablet
125 mg/5 ml
< 2 months < 4 kg 1/2 tab x 2 – 1 tsp x 2
2 months to 1 year 4 to 8 kg 1/2 to 1 tab x 2 – 1 to 2 tsp x 2
1 to 5 years 8 to 15 kg 11/2 tab x 2 1/2 tab x 2 3 tsp x 2
5 to 10 years 15 to 25 kg 2 tab x 2 1 tab x 2 4 tsp x 2
10 to 15 years 25 to 35 kg 3 tab x 2 11/2 tab x 2 –
Adult > 35 kg 4 tab x 2 2 tab x 2 –
– In severe infections, double the dose.
Duration
– Otitis media and cystitis: 5 days; tonsillitis: 6 days; leptospirosis: 7 days; pneumonia and sinusitis:
7 to 10 days; H. pylori infection: 10 to 14 days; typhoid fever: 14 days

– Do not administer to penicillin-allergic patients, patients with infectious mononucleosis.
– Administer with caution to patients allergic to cephalosporins (cross-sensitivity may occur).
– May cause: gastrointestinal disturbances, allergic reactions, sometimes severe. In the event
of allergic reaction, stop treatment immediately.
– Reduce dosage in patients with severe renal impairment.
– Do not combine with methotrexate.
Remarks
– Use amoxicillin rather than ampicillin: as it is absorbed better, only half the dose is required.
Once reconstituted, the oral suspension keeps for 7 days maximum, below 25°C.
22
ARTEMETHER/LUMEFANTRINE = COARTEMETHER
(Coartem®, Riamet®…)
1
Therapeutic action
– Antimalarial
Indications
– Treatment of uncomplicated falciparum malaria
– Completion treatment following parenteral therapy for severe falciparum malaria
Presentation
– 20 mg artemether/120 mg lumefantrine co-formulated tablets, in blister packs, for a complete
treatment for one individual
– Blister packs of 6, 12, 18 or 24 tablets, corresponding to 4 different categories of age/weight
Dosage and duration

The treatment is administered twice daily for 3 days. On D1, the first dose is given at 0 hour
and the second dose at 8-12 hours. Subsequent doses on D2 and D3 are given twice daily
(morning and evening).
20/120 mg tablet
Age Weight
D1 D2 D3
< 5 kg Do not administer
< 3 years
5 to 14 kg 1 tab x 2 1 tab x 2 1 tab x 2
3 to 8 years 15 to 24 kg 2 tab x 2 2 tab x 2 2 tab x 2
9 to 14 years 25 to 34 kg 3 tab x 2 3 tab x 2 3 tab x 2
> 14 years/adult > 34 kg 4 tab x 2 4 tab x 2 4 tab x 2

– Do not combine with azole antifungals (fluconazole, itraconazole, miconazole, etc.), tricyclic
antidepressants, neuroleptics (chlorpromazine, haloperidol, etc.), macrolides, quinolones,
other antimalarials, beta-blockers.
– May cause: nausea, headache, dizziness and gastrointestinal disturbances.
– If the patient vomits within one hour of administration: repeat the full dose.
– Pregnancy: no contra-indication during the 2nd and 3rd trimester. Safety of coartemether in the first
trimester has not been definitely established. However, given the risks associated with malaria, it
may be used during the first trimester if it is the only effective treatment available.
Remarks
– Take with meals.
– Coartemether should not be used for malaria prophylaxis.
– Lumefantrine is also called benflumetol.
– Storage: below 30°C – –
Leave tablets in blisters until use. Once a tablet is removed from its blister, it must be administered
immediately.
23
ARTESUNATE = AS
(Arsumax®, Plasmotrim®…)
Artesunate must be used in combination with another

antimalarial drug (amodiaquine or mefloquine or
sulfadoxine/pyrimethamine). The choice of 2nd anti-
malarial depends on the resistance level in the area
concerned.
Therapeutic action
– Antimalarial
Indications
Presentation
– 50 mg tablet
Also comes in 100 mg and 200 mg tablets.
Dosage and duration

– Child and adult: 4 mg/kg/day once daily for 3 days
Age Weight 50 mg tablet 100 mg tablet 200 mg tablet
2 to 11 months 4.5 to 8 kg 1/2 tab – –
1 to 5 years 9 to 17 kg 1 tab 1/2 tab –
6 to 13 years 18 to 35 kg 2 tab 1 tab 1/2 tab
≥ 14 years/adult ≥ 36 kg 4 tab 2 tab 1 tab

– May cause: gastrointestinal disturbances, headache and dizziness.
– Pregnancy: no contra-indication during the 2nd and 3rd trimester. Safety of artesunate during the
first trimester has not been definitely established. However, given the risks associated with malaria,
a drug combination containing artesunate may be used in the first trimester if it is the only effective
treatment available.
Remarks
– Artesunate should not be used for malaria prophylaxis.
24
ARTESUNATE/AMODIAQUINE = AS/AQ
(Coarsucam®…)
1
Therapeutic action
– Antimalarial
Indications
Presentation
– Co-formulated tablets of artesunate (AS)/amodiaquine (AQ), in blister packs, for a complete
treatment for one individual
– There are 4 different blister packs corresponding to 4 different categories of age/weight:
• 25 mg AS/67.5 mg AQ base tablet, blister pack of 3 tablets
• 50 mg AS/135 mg AQ base tablet, blister pack of 3 tablets
Dosage and duration

– Tablets are to be taken once daily, for 3 days.
Age Weight Tablets D1 D2 D3
2 to 11 months 4.5 to 8 kg 25 mg AS/67.5 mg AQ 1 tab 1 tab 1 tab
1 to 5 years 9 to 17 kg 50 mg AS/135 mg AQ 1 tab 1 tab 1 tab
100 mg AS/270 mg AQ
6 to 13 years 18 to 35 kg 1 tab 1 tab 1 tab
blister pack of 3 tab
100 mg AS/270 mg AQ
≥ 14 years/adult ≥ 36 kg 2 tab 2 tab 2 tab
blister pack of 6 tab

– Do not administer in the event of previous severe adverse reaction to treatment with
amodiaquine (e.g. hypersensitivity reaction, hepatitis, leucopenia, agranulocytosis).
– Do not administer to patients taking efavirenz.
– May cause: gastrointestinal disturbances, headache, dizziness, pruritus.
– If the patient vomits within half an hour of administration: repeat the full dose.
– Pregnancy: no contra-indication during the 2nd and 3rd trimester. Safety in the first trimester has not
been definitely established. However, given the risks associated with malaria, the combination
artesunate/amodiaquine may be used during the first trimester if it is the only effective treatment
available.
Remarks
immediately.
25
ARTESUNATE + SULFADOXINE/PYRIMETHAMINE = AS + SP
(Sulfamon®, Artecospe adult®…)
Therapeutic action
– Antimalarial
Indications
Presentation
– Artesunate (AS) tablets and sulfadoxine/pyrimethamine (SP) tablets, in blister packs, for a
complete treatment for one individual
– There are 4 different blister packs:
• Child 2 months to 6 years: blister pack with 3 tab AS 50 mg and 1 tab SP 500/25 mg
• Child 7 to 13 years: blister pack with 6 tab AS 50 mg and 2 tab SP 500/25 mg
• Child ≥ 14 years and adult: blister pack with 12 tab AS 50 mg and 3 tab SP 500/25 mg
or blister pack with 6 tab AS 100 mg and 3 tab SP 500/25 mg
Dosage and duration

Artesunate is administered once daily for 3 days. Sulfadoxine/pyrimethamine is administered
as a single dose on D1, with the first dose of artesunate.
Age Blister pack D1 D2 D3

2 to 11 months 1/2 tab AS + 1/2 tab SP 1/2 tab AS 1/2 tab AS
3 tab AS + 1 tab SP
1 to 6 years 1 tab AS + 1 tab SP 1 tab AS 1 tab AS
7 to 13 years 6 tab AS + 2 tab SP 2 tab AS + 2 tab SP 2 tab AS 2 tab AS
12 tab AS + 3 tab SP 4 tab AS + 3 tab SP 4 tab AS 4 tab AS
≥ 14 years/adult
6 tab AS + 3 tab SP 2 tab AS + 3 tab SP 2 tab AS 2 tab AS

– Do not administer to patients with allergy to sulfonamides.
– May cause: see artesunate and sulfadoxine/pyrimethamine.
– Do not use in combination with cotrimoxazole.
– Do not give folic acid on the same day SP is administered, or within 15 days thereafter.
– Pregnancy: no contra-indication during the 2nd and 3rd trimester. Safety in the first trimester has
not been definitely established. However, given the risks associated with malaria, the combination
artesunate+SP may be used during the first trimester if it is the only effective treatment available.
Remarks
immediately.
If half tablets are used, remaining 1/2 tablets may be given to another patient if administered within
24 hours.
26
ASCORBIC ACID = VITAMIN C
(Laroscorbine®, Redoxon®, Vitascorbol®…)
Therapeutic action
– Vitamin
Indications
– Treatment and prevention of scurvy (vitamin C deficiency)
Presentation
– 50 mg tablet
Also comes in 250 mg, 500 mg and 1 g tablets.
Dosage and duration

– Treatment:
Child: 150 to 200 mg/day in 3 or 4 divided doses
Adult: 500 to 750 mg/day in 3 or 4 divided doses
The treatment is continued until symptoms improve (1 to 2 weeks), then a preventive
treatment is given as long as the situation requires.
– Prevention:
Child and adult: 25 to 50 mg/day, as long as the situation requires

– Ascorbic acid is well tolerated at indicated doses.
– May cause: gastrointestinal disturbances and nephrolithiasis for doses > 1 g/day; may
interfere with the measurement of glucose in blood and urine for doses ≥ 2 g/day.
– Pregnancy: no contra-indication, do not exceed 1 g/day
Remarks
27
ATENOLOL
(Tenormin®…)
Therapeutic action
– Cardioselective beta-blocker
Indications
– Hypertension (including hypertension in pregnancy)
– Prophylaxis of angina pectoris
– Arrhythmia
Presentation
– 50 mg and 100 mg tablets
Dosage
– Hypertension
Adult: 50 to 100 mg once daily, preferably in the morning
– Prophylaxis of angina pectoris
Adult: 100 mg once daily
– Arrhythmia
Adult: 50 to 100 mg once daily
Duration
– According to clinical response. Do not stop treatment abruptly, decrease doses gradually.
– Do not administer to patients with asthma, chronic obstructive bronchopneumonia,
bradycardia < 50/minute, atrio-ventricular heart blocks, Raynaud's syndrome, severe
hypotension, severe depression.
– May cause: bradycardia, hypotension, heart failure, asthma attack, gastrointestinal
disturbances, hypoglycaemia, dizziness.
– In the event of anaphylactic shock: risk of resistance to epinephrine.
– Administer with caution to patients with diabetes (induces hypoglycaemia, masks the
symptoms of hypoglycaemia) or to patients treated with digitalis glycosides (risk of
bradycardia).
– Do not administer simultaneously with antacids such as aluminium hydroxide, etc.
(decreased intestinal absorption), administer 2 hours apart.
– Monitor combination with epinephrine (hypertension); tricyclic antidepressants, other anti-
hypertensive drugs, nitrates, acetazolamide, ketamine (hypotension); mefloquine, digoxin,
amiodarone, verapamil, diltiazem (bradycardia).
– Pregnancy: no contra-indication. After delivery monitor the newborn for at least 72 hours (risk of
hypoglycaemia, bradycardia, respiratory distress).
Remarks
– Atenolol is also used for the secondary prophylaxis of myocardial infarction (50 mg once
daily).
28
AZITHROMYCIN
(Zithromax®…)
1
Therapeutic action
– Macrolide antibacterial
Indications
– Trachoma
– Genital infections due to Chlamydia trachomatis (urethritis, cervicitis)
– Donovanosis (granuloma inguinale), chancroid
– Streptococcal tonsillitis in penicillin-allergic patients
Presentation
– 250 mg and 500 mg capsules or tablets
– 200 mg/5 ml paediatric oral suspension
Dosage and duration

– Trachoma, genital infections due to C. trachomatis, chancroid
Child > 6 months or 6 kg: 20 mg/kg as a single dose
Adult: 1 g as a single dose
– Donovanosis (granuloma inguinale)
Adult: 1 g on first day then 500 mg/day until healing of lesions (at least 14 days)
– Streptococcal tonsillitis in penicillin-allergic patients
Child: 20 mg/kg once daily for 3 days, without exceeding 500 mg/day
Adult: 500 mg once daily for 3 days

– Do not administer in patients with allergy to azithromycin or another macrolide.
– May cause: gastrointestinal disorders, allergic reactions.
– Do not administer simultaneously with antacids (aluminium hydroxide, etc.). Administer
2 hours apart.
– Avoid combination with co-artemether.
– Administer with caution and reduce doses in patients with severe hepatic impairment.
Remarks
– Patients infected with C. trachomatis are often coinfected with N. gonorrhoeae. Therefore, all
patients with chlamydia should receive an effective treatment for gonorrhoea.
– For the treatment of tonsillitis, the use of azithromycin should be restricted to penicillin-
allergic patients as:
• there are streptococci resistant to macrolides,
• its efficacy in the prevention of rheumatic fever has not been studied.
29
BECLOMETASONE aerosol
(Beclazone®, Becotide®…)
Therapeutic action
– Anti-inflammatory drug (corticosteroid)
Indications
– Long term treatment of persistent asthma
Presentation and route of administration
– Pressurized inhalation solution of beclomatesone dipropionate, 50 micrograms and
250 micrograms /inhalation
Also comes in aerosol inhaler delivering 100 micrograms and 200 micrograms/inhalation.
Dosage and administration
The dosage varies from one person to another. The initial dose depends on the severity of
symptoms. It may be increased or reduced over time. Always try to administer the lowest
effective dose. For information:
– Mild to moderate persistent asthma
Child: 100 to 400 micrograms/day in 2 or 4 divided doses
Adult: 500 to 1000 micrograms/day in 2 or 4 divided doses
– Severe persistent asthma
Child: up to 800 micrograms/day in 2 or 4 divided doses
Adult: up to 1500 micrograms/day in 2 or 4 divided doses
Shake the inhaler. Breathe out as completely as possible. Place the lips tightly around the
mouthpiece. Inhale deeply while activating the inhaler. Hold breath 10 seconds before
exhaling. Verify that the inhalation technique is correct.
Co-ordination between the hand and inhalation is very difficult in certain patients (children
under 6 years, elderly patients, etc.). Use a spacer to facilitate administration and improve the
efficacy of treatment.

– Do not administer to patients with untreated active tuberculosis.
– May cause: throat irritation, hoarseness at the beginning of treatment, oro-pharyngeal
candidiasis.
– In the event of cough and/or bronchospasm following inhalation of beclometasone:
administer salbutamol if necessary, stop inhalation of beclometasone and replace with an
oral corticoid.
– In the event of bronchial infection, administer appropriate antibiotic treatment in order to
optimise the diffusion of beclometasone in the respiratory tract.
– If the maximum dosage becomes insufficient, re-evaluate the severity of asthma and
combine with a short oral anti-inflammatory treatment.
Remarks
– Beclometasone is not a bronchodilator. For asthma attack, use inhaled salbutamol.
– Aerosol inhalers delivering 200 and 250 micrograms/inhalation are not suitable for
children. They should only be used in adults. Only inhalers delivering 50 and 100 micro-
grams/inhalation can be used in children.
– Relief of symptoms may require several days or weeks of continuous therapy.
– Clean the mouthpiece before and after each use.
– Do not pierce or incinerate used aerosol containers. Empty all residual gas, then bury.
30
BISACODYL
(Dulcolax®…)
1
Therapeutic action
– Stimulant laxative
Indications
– Prevention of constipation in patients taking opioid analgesics (codeine, morphine, etc.)
– Short-term, symptomatic treatment of constipation
Presentation
– 5 mg enteric-coated tablet
Dosage
– Child over 3 years: 5 to 10 mg once daily
– Adult: 10 to 15 mg once daily
Duration
– Prevention of constipation in patients taking opioids: start bisacodyl when analgesic treatment
continues more than 48 hours. Tablets must be taken daily, at night (bisacodyl is effective
6 to 12 hours after administration), until the end of the opioid treatment. Regular follow up
(frequency/consistency of stools) is essential in order to adjust dosage correctly.
– Treatment of constipation: until the patient passes stools, maximum 7 days.

– Do not administer to patients with Crohn's disease, ulcerative colitis, intestinal obstruction,
undiagnosed abdominal pain and dehydration.
– May cause: diarrhoea, abdominal cramps, hypokalaemia.
– In the event of diarrhoea: exclude a faecal impaction or intestinal obstruction, stop
treatment for 24 hours and then start again with a half dose.
– In the event of abdominal cramps: reduce or divide the daily dose. Stop treatment if pain
continues.
– Do not combine with drugs that induce torsades de pointe (halofantrine, erythromycin IV,
pentamidine, etc.).
– Closely monitor patients taking drugs that induce hypokalaemia (furosemide, amphotericin B,
corticosteroids, etc.) or cardiac glycosides.
– Pregnancy and breast-feeding: avoid; for routine prevention of constipation due to opioids, use
lactulose.
Remarks
– To prevent constipation in patients taking opioids, use lactulose if the patient’s stools are
solid; use bisacodyl if the patient’s stools are soft.
– In children from 6 months to 3 years, do not use the oral route. Use only 5 mg paediatric
suppositories (one suppository/day).
– Swallow tablets whole; do not crush or chew.
– Bisacodyl is equivalent to senna, the representative example of laxative stimulants in the
WHO list of essential medicines.
– The treatment must be accompanied by dietary measures (plenty of fluids and fibre).
31
CABERGOLINE
(Dostinex®…)
Therapeutic action
– Lactation inhibitor
Indications
– Inhibition of physiological lactation
– Suppression of established lactation
Presentation
– 0.5 mg tablet
Dosage and duration

– Lactation inhibition: 1 mg as a single dose on the first day post-partum
– Lactation suppression: 0.25 mg every 12 hours for 2 days

– Do not administer to patients with hypersensitivity to cabergoline, post-partum
hypertension.
– May cause: nausea, vomiting, headache, dizziness, hypotension, drowsiness.
– Stop treatment in the event of dyspnoea, persistent cough, chest pain, abdominal pain.
– Do not combine with: neuroleptics (chlorpromazine, haloperidol, etc.), metoclopramide,
promethazine and methylergometrine.
– Pregnancy: CONTRA-INDICATED
Remarks
– Cabergoline is a dopamine agonist also used in the treatment of Parkinson’s disease.
– Cabergoline is not included in the WHO list of essential medicines.
32
CALCIUM FOLINATE = FOLINIC ACID
(Refolinon®…)
1
Therapeutic action
– Antidote to folate antagonists
Indications
– Prevention of haemotological toxicity of pyrimethamine when pyrimethamine is used as
prophylaxis for, or in the treatment of toxoplasmosis or isosporiasis in immunodeficient
patients
Presentation
– 15 mg tablet
Also comes in 5 mg and 25 mg capsules.
Dosage
– When pyrimethamine is used as primary or secondary prophylaxis for toxoplasmosis
Adult: 25 to 30 mg once weekly
– During treatment of toxoplasmosis
– During treatment of isosporiasis
Duration
– For the duration of the pyrimethamine treatment

Remarks
– Folic acid cannot be used as an alternative to folinic acid for the treatment of toxoplasmosis:
folic acid reduces the antiprotozoal activity of pyrimethamine.
– Calcium folinate is also called calcium leucovorin.
33
CARBAMAZEPINE
(Tegretal®, Tegretol®…)
Therapeutic action
– Antiepileptic
Indications
– Epilepsy (except absence seizures)
– Neuropathic pain (alone or combined with amitriptyline)
Presentation
Also comes in 100 mg/5 ml oral solution.
Dosage
– Epilepsy
Child: initially 5 mg/kg once daily or in 2 divided doses, then increase every 2 weeks up
to 10 to 20 mg/kg/day in 2 to 4 divided doses
Adult: initially 100 to 200 mg once daily or in 2 divided doses, then increase by 100 to
200 mg increments every 2 weeks up to 800 to 1200 mg/day in 2 to 4 divided doses
– Neuropathic pain
Adult: initially 200 mg once daily at night for one week, then 400 mg/day in 2 divided
doses (morning and night) for one week, then 600 mg/day in 3 divided doses
Duration
– Epilepsy: lifetime treatment. Do not stop treatment abruptly, even if changing treatment to
another antiepileptic.
– Neuropathic pain: continue several months after pain relief is obtained, then attempt to stop
treatment.
– Do not administer to patients with atrioventricular block, history of bone marrow depression.
– Administer with caution to patients with glaucoma, urinary retention, hepatic or renal
impairment, heart failure or blood disorders and to elderly patients.
– May cause:
• headache, dizziness, gastrointestinal and visual disturbances, rash, leucopenia, confusion
and agitation in elderly patients, drowsiness (use with caution when driving or operating
machinery),
• exceptionally: Lyell's and Stevens-Johnson syndromes, agranulocytosis, anaemia, bone
marrow depression, pancreatitis, hepatitis, cardiac conduction defect. If so, stop treatment.
– Do not combine with: erythromycin, isoniazid, valproic acid (increased carbamazepine
plasma concentrations), oestroprogestogens (reduced contraceptive efficacy), saquinavir
(reduced efficacy of saquinavir).
– Monitor combination with: oral anticoagulants, corticosteroids, antidepressants, haloperidol,
protease inhibitors, aminophylline, rifampicine, itraconazole, etc.
– Pregnancy:
• Epilepsy: do not start treatment during the first trimester, except if vital and there is no alternative
(risk of neural tube defect). However, if treatment has been started before a pregnancy, do not stop
treatment. The administration of folic acid before conception and during the first trimester seems
to reduce the risk of neural tube defect.
Due to the risk of haemorrhagic disease of the newborn, administer vitamin K to the mother and
the newborn infant.
• Neuropathic pain: not recommended
Remarks
– Storage:
34
CEFIXIME
(Suprax®…)
1
Therapeutic action
– Third-generation cephalosporin antibacterial
Indications
– Uncomplicated gonorrhoea
– Acute cystitis (when quinolones are contra-indicated)
– Acute pyelonephritis, after initial therapy with injectable ceftriaxone
– Typhoid fever in children
Presentation
– 200 mg tablet or capsule
Also comes in 40 mg/5 ml and 100 mg/5 ml powder for oral suspension.
Dosage
– Uncomplicated gonorrhoea
Adult: 400 mg
– Urinary tract infections
Child: 8 mg/kg/day in 2 divided doses
Adult: 400 mg/day in 2 divided doses
– Typhoid fever in children
Child: 15 to 20 mg/kg/day in 2 divided doses
Duration
– Gonorrhoea: single dose
– Cystitis: 3 to 5 days
– Pyelonephritis: 10 to 14 days depending on severity
– Typhoid fever: 7 days

– Do not administer to children under 3 months.
– Do not administer to patients with allergy to cephalosporins.
– Administer with caution to penicillin-allergic patients (cross-sensitivity may occur).
– May cause: gastrointestinal disturbances; rarely: headache, dizziness, allergic reactions
(rash, pruritus, fever).
– In the event of allergic reactions, stop treatment immediately.
Remarks
– Patients infected with N. gonorrhoeae are often coinfected with C. trachomatis. Therefore, all
patients with gonorrhoea should receive an effective treatment for chlamydia.
Once reconstituted, the oral suspension keeps for 10 days maximum.
35
CHLOROQUINE sulfate or phosphate
(Nivaquine®…)
Given that resistance of P. falciparum to chloroquine is wides-

pread, this drug must not be used for the treatment of falcipa-
rum malaria in Africa, South America, Asia and Oceania.
Therapeutic action
– Antimalarial
Indications
– Treatment of malaria due to P. vivax, P. ovale and P. malariae
– Treatment of uncomplicated falciparum malaria, only in areas where P. falciparum is still
sensitive to chloroquine (Central America, Haiti and Dominican Republic)
– Prophylaxis of falciparum malaria for non-immune individuals, only in areas where resis-
tance to chloroquine is moderate and always in combination with proguanil
Presentation
– 100 mg and 150 mg chloroquine base tablets
– 50 mg chloroquine base/5 ml syrup
The dose written on the labels is sometimes in chloroquine salt and sometimes in chloroqui-
ne base which leads to frequent confusion. The WHO recommends prescriptions and labels
in chloroquine base.
100 mg base = approx. 130 mg sulfate = approx. 160 mg phosphate or diphosphate
150 mg base = approx. 200 mg sulfate = approx. 250 mg phosphate or diphosphate
Dosage and duration

– Treatment of malaria
Child and adult:
Day 1 and Day 2: 10 mg base/kg once daily
Day 3 : 5 mg base/kg
2 1 5 15
AGE 0
months year years years
ADULT
4 8 15 35
WEIGHT kg kg kg kg
100 mg base tablet
Day 1 and Day 2 1/2 tab 1 tab 21/2 tab 6 tab
Day 3 1/4 tab 1/2 tab 1 tab 3 tab
150 mg base tablet
Day 1 and Day 2 1/4 tab 1/2 tab 11/2 tab 4 tab
Day 3 1/8 tab 1/4 tab 3/4 tab 2 tab
36
– Prophylaxis of falciparum malaria in areas where resistance to chloroquine is moderate
1
Child: 1.7 mg chloroquine base/kg once daily (always combined with proguanil)
Adult: 100 mg chloroquine base once daily (always combined with proguanil)
Travellers should start prophylaxis 24 hours before departure, continue throughout the stay
and for at least 4 weeks after return.
In areas where resistance to chloroquine is high, chloroquine must be replaced by another
effective antimalarial suitable for prophylactic use.

– Do not administer to patients with retinopathy.
– May cause: gastrointestinal disturbances, headache, transitory pruritus (lasting 72 hours),
allergic reactions (urticaria, angioedema), visual disturbances.
– If the patient vomits within one hour after administration:
• during the first 30 minutes : repeat the full dose
• after 30 minutes : give half the dose
– There is a narrow margin between the therapeutic and toxic dose. Doses of 20 mg base/kg
in children and 2 g base in adults are considered toxic.
– Do not combine with: coartemether, quinine, mefloquine, halofantrine.
– Do not administer simultaneously with antacids (aluminium hydroxide, etc.): administer
2 hours apart.
Remarks
– Chloroquine alone (without proguanil) is used as a prophylactic drug in certain areas
where only P. vivax is present.
– Resistance of P. vivax to chloroquine exists in Papua New Guinea, Indonesia and Myanmar.
37
CHLORAMPHENICOL
(Chloromycetin®, Kemicetine®…)
Therapeutic action
– Antibacterial
Indications
– Typhoid fever, plague, rickettsial infections
– Parenteral to oral switch therapy (meningitis, severe pneumonia, etc.)
Presentation
– 250 mg capsule
Dosage
– Child from 2 months to 1 year: 50 mg/kg/day in 3 to 4 divided doses
– Child over 1 year: 50 mg/kg/day in 3 to 4 divided doses; 100 mg/kg/day in severe infection
– Adult: 3 to 4 g/day in 3 to 4 divided doses
150 mg/5 ml 250 mg

Age Weight
oral suspension capsule
< 2 weeks – 1 ml x 3 –
< 1 year < 8 kg 2 to 4 ml x 3 –
1 to 5 years 8 to 15 kg 5 to 8 ml x 3 –
5 to 10 years 15 to 25 kg – 1 to 2 caps x 3
10 to 15 years 25 to 35 kg – 2 to 4 caps x 3
Adult > 35 kg – 4 caps x 3
Duration
– Typhoid fever: 10 to 14 days; plague: 10 days; rickettsiosis: continue for 48 hours after the
resolution of fever; pneumonia: 5 to 10 days
– Do not administer to premature infants; avoid in newborns and children under 2 months
of age (if there is no alternative, dosage is 25 mg/kg/day in 3 divided doses).
– Do not administer to patients with a history of previous allergic and/or toxic reaction to
chloramphenicol, G6PD deficiency.
– Reduce dosage in patients with hepatic or renal impairment.
– May cause:
• gastrointestinal disorders,
• allergic reactions, dose-related and reversible marrow depression (anaemia, leucopenia,
thrombocytopenia): if so, stop treatment,
• grey syndrome in premature infants and neonates (vomiting, hypothermia, blue-grey
skin colour and cardiovascular depression), irreversible aplastic anaemia.
– Pregnancy: CONTRA-INDICATED, except if vital, if there is no therapeutic alternative. If used during
the 3rd trimester, risk of grey syndrome in the newborn infant.
– Breast-feeding: CONTRA-INDICATED
Remarks
– Due to its potential haematotoxicity, the use of chloramphenicol should be restricted to
severe infections when other less toxic antibiotics are not effective or are contra-indicated.
– Oral treatment is more effective than parenteral treatment: blood and tissue concentrations
are higher when chloramphenicol is given orally.
38
CHLORPHENAMINE = CHLORPHENIRAMINE
(Teldrin®, Trimeton®…)
1
Therapeutic action
– Sedating antihistaminic
Indications
– Allergic reactions (contact dermatitis, seasonal allergy; allergy to drugs, insect bites, food,
etc.)
Presentation
– 4 mg tablet
Dosage
– Child from 1 to 2 years: 1 mg 2 times per day
– Child from 2 to 5 years: 1 mg every 4 to 6 hours, without exceeding 6 mg/day
– Child from 6 to 12 years: 2 mg every 4 to 6 hours, without exceeding 12 mg/day
– Adult: 4 mg every 4 to 6 hours, without exceeding 24 mg/day
1 2 6 12
AGE 0
year years years years
ADULT
8 10 20 30
WEIGHT kg kg kg kg
Do not
4 mg tablet administer 1/4 tab x 2 1/4 tab x 4 1/2 tab x 4 1 tab x 4
Duration: according to clinical response; as short as possible

– Do not administer to patients with urethro-prostatic disorders, glaucoma.
– Do not administer to children under one year.
– May cause: drowsiness (administer preferably once daily at night), dryness of the mouth,
constipation, urinary retention, blurred vision.
– Risk of increased sedation when combined with alcohol and drugs acting on the central
nervous system: opioid analgesics, neuroleptics (chlorpromazine, haloperidol, etc.), other
antihistamines (chlorphenamine), antidepressants (clomipramine, fluoxetine, etc.), pheno-
barbital, etc.
– Pregnancy: no contra-indication; no prolonged treatment
Remarks
– Chlorphenamine has no anti-emetic effect. It is less sedating than promethazine.
– Dexchlorpheniramine (Polaramine®) has the same indications:
• child from 1 to 2 years: 0.25 mg to be repeated 2 to 3 times daily
• child from 2 to 5 years: 0.5 mg to be repeated 4 to 6 times daily, without exceeding 3 mg/day
• child from 6 to 12 years: 1 mg to be repeated 4 to 6 times daily, without exceeding 6 mg/day
• adult: 2 mg to be repeated 4 to 6 times daily, without exceeding 12 mg/day
39
CHLORPROMAZINE
(Largactil®, Megaphen®, Thorazine®…)
Therapeutic action
– Sedative neuroleptic
Indications
– Acute and chronic psychoses
– Agitation
– Anxiety, not controlled by other anxiolytics
Presentation
– 25 mg tablet
Also comes in 50 and 100 mg tablets.
Dosage
Varies from one person to another, doses should be increased gradually.
– Child: 1 to 1.5 mg/kg/day in 2 to 3 divided doses
– Adult: 25 to 150 mg/day in 2 to 3 divided doses
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
25 mg tablet 1/2 tab x 3 1 to 2 tab x 3
– Do not exceed indicated doses.

– Reduce dose by one-third or one-half for elderly patients.

– Do not administer if: • delirium tremens,
• Parkinson's disease,
• renal or hepatic failure (risk of overdosage).
– Stop treatment if patient becomes febrile: possible neuroleptic malignant syndrome.
– May cause: extrapyramidal disorders, orthostatic hypotension and photosensitisation.
– If prolonged treatment, check blood counts regularly (risk of agranulocytosis).
nervous system such as diazepam, phenobarbital and chlorphenamine.
– Pregnancy: CONTRA-INDICATED; when used in the treatment of psychosis, stop treatment one week
before the expected time of delivery if possible.
Remarks
40
CIMETIDINE
(Tagamet®…)
1
Therapeutic action
– Antiulcer agent (histamine H2-receptor antagonist)
Indications
– Prophylaxis of acid pulmonary aspiration syndrome in anaesthesia:
• in patients with a full stomach (emergency caesarean section, etc.)
• when a difficult intubation is expected
Presentation
– 200 mg effervescent tablet
Also comes 800 mg effervescent tablet.
Dosage and duration

– Adult: 200 to 400 mg as a single dose if possible one hour before anaesthetic induction

– May cause: diarrhoea, headache, dizziness, skin rash, fever.
– Do not administer with an antacid (aluminium hydroxide, etc.).
Remarks
– Effervescent cimetidine can be replaced by effervescent ranitidine (Zantac®), another H2-
receptor antagonist, as a single dose of 150 mg.
– The onset of acid inhibition with cimetidine non-effervescent tablets (200 mg, 400 mg and
800 mg film coated tablets) or ranitidine non-effervescent tablets (150 mg and 300 mg film
coated tablets) occurs 30 minutes after administration. The effervescent tablets containing
sodium citrate have a more rapid onset of action, and can thus be used for emergency sur-
gery.
– Omeprazole (Mopral®), another antiulcer agent (proton pump inhibitor), is not compatible
with emergency situations as it must be administered at least 4 hours before surgery.
– Cimetidine in film coated tablets is also used in the treatment of gastro-oesophageal reflux
and peptic ulcer. Use by preference ranitidine (Azantac®) or omeprazole (Mopral®) for
these indications.
41
CIPROFLOXACIN
(Ciflox®…)
Therapeutic action
– Fluoroquinolone antibacterial
Indications
– Infections due to Gram-negative bacteria: shigellosis, typhoid fever, urinary tract infections,
septicaemia, etc.
Presentation
– 250 mg tablet
Also comes in 100 mg, 500 mg and 750 mg tablets.
Dosage and duration
Ciprofloxacin is administered to children under 15 years only if considered essential.
– Shigellosis
Child > 1 month: 30 mg/kg/day in 2 divided doses for 3 days
Adult: 1 g/day in 2 divided doses for 3 days
– Typhoid fever
Child > 1 month: 30 mg/kg/day in 2 divided doses for 5 to 7 days
Adult: 1 g/day in 2 divided doses for 5 to 7 days
– Uncomplicated acute pyelonephritis
Adult: 1 to 1.5 g/day in 2 to 3 divided doses for 7 days
– Acute prostatitis
– Uncomplicated acute cystitis in non-pregnant women
Adult: 500 mg/day in 2 divided doses for 3 days
– Other indications
Child > 1 month: 10 to 30 mg/kg/day (depending on severity) in 2 divided doses
Adult: 1 to 1.5 g/day (depending on severity) in 2 divided doses
– Do not administer to patients with history of allergy or tendinitis due to fluoroquinolones.
– May cause: gastrointestinal disturbances, neurological disorders (headache, dizziness,
insomnia, hallucinations, seizures), arthralgia, myalgia, tendon damage (especially Achilles
tendinitis), photosensivity (avoid exposure to sunlight), haemolytic anaemia in patients
with G6PD deficiency.
– Stop treatment in the event of tendinitis.
– Administer with caution to epileptic patients (risk of seizures).
– Reduce the dose by half in patients with renal impairment.
– Avoid combination with theophylline (risk of theophylline overdose) or co-artemether.
– Do not administer simultaneously with antacids, iron salts and didanosine. Administer
2 hours apart.
– Drink a lot of liquid during treatment (risk of crystalluria).
– Pregnancy: avoid, administer only if clearly need
Remarks
– Other fluoroquinolones (norfloxacin, ofloxacin, pefloxacin, etc.) have a similar spectrum of
activity and indications to ciprofloxacin: see relevant literature.
– Storage:
42
CLINDAMYCIN
(Dalacin®…)
1
Therapeutic action
– Lincosamide antibacterial
Indications
– Second-line treatment of pneumocystosis, in combination with primaquine
– Second-line treatment and secondary prophylaxis of cerebral toxoplasmosis, in combination
with pyrimethamine
Presentation
– 150 mg capsule
Also comes in 75 mg and 300 mg capsules.
Dosage and duration

– Treatment of pneumocystosis
Adult: 1800 mg/day in 3 divided doses for 21 days
– Treatment of toxoplasmosis
Adult: 2400 mg/day in 4 divided doses for 6 weeks
– Secondary prophylaxis of toxoplasmosis
Adult: 1800 mg/day in 3 divided doses, as long as required

– Do not administer to patients with allergy to lincosamides or history of pseudo-
membranous colitis.
– May cause: diarrhoea (including severe: pseudomembranous colitis), nausea, rash, jaundice,
and allergic reactions sometimes severe.
– In the event of allergic reactions, stop treatment immediately. If pseudomembranous colitis
develops (mucus and false membranes), stop clindamycin and treat for C. difficile disease
(oral metronidazole).
– Do not administer simultaneously with antacids such as aluminium hydroxide, etc.;
administer 2 hours apart.
– Do not combine with: erythromycin and neuromuscular blocking drugs.
– Reduce dosage in patients with hepatic impairment.
– Breast-feeding: administer only if there is no therapeutic alternative. Check infant's stools (risk of
colitis).
Remarks
– In some regions of South-East Asia, clindamycin is used in combination with quinine for
the treatment of malaria in pregnant women and children < 8 years as the association
quinine-doxycycline is contraindicated in these patients.
43
CLOMIPRAMINE
(Anafranil®…)
Therapeutic action
– Tricyclic antidepressant
Indications
– Depression
– Severe post-traumatic stress disorder
– Panic disorder
Presentation
– 10 mg and 25 mg tablets and capsules
Dosage
– Adult: initially 25 mg once daily at bedtime, then increase the dose gradually up to 75 to
150 mg once daily
– Reduce doses in elderly patients and in patients with impaired renal or hepatic function:
initially 10 mg/day, increased to 50 mg/day.
Duration
– 6 to 8 months minimum. The treatment should be withdrawn gradually; if signs of relapse
occur, increase the dose.
– Do not administer to patients with recent myocardial infarction, arrhythmia, severe hepatic
impairment, urethro-prostatic disorders, glaucoma.
– May cause: drowsiness, dry mouth, constipation, tachycardia, orthostatic hypotension,
blurred vision, urinary retention, weight gain, skin allergy, confusion in elderly patients,
suicidal tendencies due to the suppression of psychomotor inhibition, exacerbation of
anxiety or delusional symptoms.
– Administer with caution to patients with epilepsy, cardiovascular disease, renal or hepatic
impairment.
– Do not combine with: sultopride (Barnetil®), MAO inhibitors; do not drink alcohol during
treatment.
– Avoid combination with methyldopa (increased antihypotension), co-artemether.
– Monitor combination with: epinephrine and dopamine (risk of hypertensive crisis and
arrhythmia), valproic acid and selective serotonin re-uptake inhibitors (increased plasma
concentration of clomipramine), carbamazepine, phenytoin and rifampicin (decreased
plasma concentration of clomipramine), antihypertensives, atropinic drugs.
– Closely monitor patients with suicidal tendencies, especially at the beginning of therapy.
– Advise patients that clomipramine may cause drowsiness and to be cautious when driving
or operating machinery.
– Pregnancy: avoid. However, if treatment has been started before a pregnancy, do not stop treatment;
reduce dosage at the end of pregnancy (risk of withdrawal syndrome in the newborn infant).
Remarks
– The use of clomipramine is not recommended in patients aged less than 15 years.
– It takes 10 to 20 days for the patient to feel the antidepressant effect. The therapeutic
efficacy can only be assessed after 3 weeks of treatment. This must be explained to the
patient to encourage compliance.
– Anxiolytic or sedative treatment may be necessary during the first weeks of treatment in
anxious or agitated patients.
– Storage: –
44
CLOXACILLIN
(Cloxapen®, Orbenin®…)
1
Therapeutic action
– Penicillin antibacterial active against penicillinase-producing staphylococci
Indications
– Infections due to staphylococci resistant to penicillin: staphylococcal pneumonia, skin
infections (impetigo, furunculosis), etc.
– Parenteral to oral switch therapy (pyomyositis, septicaemia, etc.)
Presentation
– 250 mg, 500 mg and 1 g capsules
– Powder for oral solution, 125 mg/5 ml
Dosage
– Child: 50 to 100 mg/kg/day depending on severity, in 2 to 4 divided doses, without exceeding
2 g/day
– Adult: 1 to 2 g/day depending on severity, in 2 to 4 divided doses
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
250 mg capsule – – 1 to 2 cap x 2 2 to 3 cap x 2 4 cap x 2

500 mg capsule – – 1 to 2 cap x 2 2 cap x 2
Suspension 125 mg/5 ml 1 tsp x 2 1 to 2 tsp x 2 2 to 3 tsp x 2 – –
Duration
– Skin infections: 8 to 10 days; staphylococcal pneumonia: 10 to 14 days
– Do not administer to penicillin-allergic patients.
– Administer with caution to patients allergic to cephalosporins (cross-sensitivity may
occur).
– May cause: gastrointestinal disturbances, allergic reactions sometimes severe. In the event
of allergic reactions, stop treatment immediately.
Remarks
– Take between meals.
– Dicloxacillin (Diclocil®, etc.), flucloxacillin (Floxapen®, etc.) and oxacillin (Bristopen®, etc.)
are used for the same indications and at the same dosage.
45
CODEINE
Therapeutic action
– Opioid analgesic
Indications
– Moderate pain, alone or in combination with a non-opioid analgesic
Presentation
– 30 mg codeine phosphate tablet
Also comes in 1 mg/ml codeine phosphate syrup.
Dosage
– Child from 6 months to 12 years: 0.5 to 1 mg/kg every 4 to 6 hours
– Child over 12 years and adult: 30 to 60 mg every 4 to 6 hours; maximum 240 mg/day
Duration: according to clinical evolution

– Do not administer to patients with acute respiratory depression or asthma attack.
– May cause:
• constipation, nausea, vomiting, drowsiness, dizziness;
• rarely: respiratory depression, allergic reactions, dependence, withdrawal syndrome.
– Do not combine with:
• other agonist opioids such as morphine (increased risk of respiratory depression);
• agonist-antagonist opioids such as buprenorphine, nalbuphine, pentazocine (competitive
action).
– Reduce dosage in patients with renal or hepatic impairment and in elderly patients.
– Management of respiratory depression includes assisted ventilation and/or administration
of naloxone.
– Pregnancy: no contra-indication. The newborn infant may develop withdrawal symptoms, respiratory
depression and drowsiness in the event of prolonged administration of large doses at the end of the
3rd trimester. In this event, closely monitor the newborn infant.
– Breast-feeding: use with caution, for a short period (2-3 days), at the lowest effective dose. Monitor
the mother and the infant: in the event of excessive drowsiness, stop treatment.
Remarks
– Administer systematically an appropriate laxative (e.g. lactulose) if analgesic treatment
continues more than 48 hours.
– Codeine is also used for the short-term symptomatic treatment of:
• diarrhoea in adult: 30 mg 3 to 4 times per day
• dry, unproductive cough in adult: 15 to 30 mg 3 to 4 times per day
– In some countries, codeine is on the list of narcotics: follow national regulations.
46
COTRIMOXAZOLE
= SULFAMETHOXAZOLE (SMX)/TRIMETHOPRIM (TMP)
(Bactrim®…)
1
Therapeutic action
– Combination of a sulfonamide with another antibacterial
Indications
– First-line treatment of pneumocystosis and isosporiasis
– Prophylaxis of pneumocystosis, toxoplasmosis and isosporiasis
– Brucellosis (when doxycycline is contra-indicated)
Presentation
– 400 mg SMX + 80 mg TMP and 800 mg SMX + 160 mg TMP tablets
– 100 mg SMX + 20 mg TMP tablet for paediatric use
– 200 mg SMX + 40 mg TMP/5 ml oral suspension
Dosage and duration
Child and adult: 100 mg SMX + 20 mg TMP/kg/day in 2 divided doses
– Treatment of isosporiasis
Adult: 3200 mg SMX + 640 mg TMP/day in 2 divided doses
– Prophylaxis of pneumocystosis, toxoplasmosis and isosporiasis
Child: 50 mg SMX + 10 mg TMP/kg once daily, as long as necessary
Adult: 800 mg SMX + 160 mg TMP once daily, as long as necessary
– Brucellosis
Child: 40 mg SMX + 8 mg TMP/kg/day in 2 divided doses
Adult: 1600 mg SMX + 320 mg TMP/day in 2 divided doses
Duration
– Pneumocystosis: 14 to 21 days depending on severity; isosporiasis: 10 days; brucellosis: 6 weeks
– Do not administer to children under one month.
– Do not administer to sulfonamide-allergic patients; patients with severe renal or hepatic
impairment.
– May cause:
• gastrointestinal disturbances, hepatic or renal disorders (crystalluria, etc.), metabolic
disorders (hyperkalaemia); neuropathy, photosensitivity, haemolytic anaemia in
patients with G6PD deficiency.
• allergic reactions (fever, rash, etc.) sometimes severe (Lyell's and Stevens-Johnson
syndromes, haematological disorders, etc.). In these cases, stop treatment immediately.
• megaloblastic anaemia due to folinic acid deficiency in patients receiving prolonged
treatment (in this event, administer calcium folinate).
– Adverse effects occur more frequently in patients with HIV infection.
– In the event of prolonged treatment, monitor blood count if possible.
– Do not combine with methotrexate and phenytoin.
– Avoid combination with drugs inducing hyperkalaemia: potassium, spironolactone, enalapril,
NSAIDs, heparin (increased risk of hyperkalaemia).
– Monitor combination with zidovudine (increased haematotoxicity).
– Pregnancy: no contra-indication. However, avoid using during the last month of pregnancy (risk of
jaundice and haemolytic anaemia in the newborn infant).
– Breast-feeding: avoid if premature infant, jaundice, low-birth weight, infant under one month of age.
If cotrimoxazole is used, observe the infant for signs of jaundice.
Remarks
Once opened, oral suspension keeps for 7 days maximum.
47
DAPSONE
(Avlosulfon®, Disulone®…)
Therapeutic action
– Sulfone antibacterial
Indications
– Prophylaxis of toxoplasmosis and pneumocystosis
– Paucibacillary and multibacillary leprosy, in combination with other antileprotics
Presentation
– 25 mg, 50 mg and 100 mg tablets
Dosage
– Prophylaxis of pneumocystosis only
Child: 2 mg/kg once daily, without exceeding 100 mg/day
– Prophylaxis of toxoplasmosis and pneumocystosis
Child: 2 mg/kg once daily, without exceeding 25 mg/day (in combination with pyrime-
thamine 1 mg/kg once daily + folinic acid 10 mg/week)
Adult:
• 50 mg once daily (in combination with pyrimethamine 50 mg/week + folinic acid 25 to
30 mg/week)
• or 200 mg once weekly (in combination with pyrimethamine 75 mg/week + folinic acid
25 to 30 mg/week)
– Treatment of pneumocystosis (in combination with 15 mg/kg/day of trimethoprime)
Child: 2 mg/kg once daily, without exceeding 100 mg/day
– Paucibacillary and multibacillary leprosy
Child under 10 years: 25 mg once daily
Child from 10 to 14 years: 50 mg once daily
Duration
– Prophylaxis of toxoplasmosis and pneumocystosis: as long as necessary; treatment of pneumocystosis:
21 days; paucibacillary leprosy: 6 months; multibacillary leprosy: 12 months
– Do not administer to patients with allergy to sulfones or severe anaemia (first treat anaemia).
– Administer with caution to patients with renal or hepatic impairment.
– May cause: haemolytic anaemia in patients with G6PD deficiency, dose-related haemolytic
anaemia, neutropenia, methaemoglobinaemia, pruritus, rash, gastrointestinal disturbances,
peripheral neuropathies, agranulocytosis; hypersensitivity reactions during the first month
of treatment (fever, jaundice, hepatitis, adenopathy, exfoliative dermatitis, etc.) requiring
permanent discontinuation of treatment.
– Monitor blood count and transaminases if possible.
– Do not administer simultaneously with didanosine: administer each drug 2 hours apart.
– Monitor combination with zidovudine (increased haematological toxicity).
Remarks
– For the treatment of leprosy, dapsone must always be used in combination with rifampicin
(paucibacillary leprosy) or rifampicin + clofazimine (multibacillary leprosy) in order to
avoid the emergence of resistance.
48
DESOGESTREL
(Cerazette®…)
1
Therapeutic action
– Hormonal contraceptive, (low dose)progestogen
Indications
– Oral contraception
Presentation
– 75 µg (0.075 mg) tablet, 28-day pack
Dosage
– 1 tablet daily at the same time, continuously, including during menstruation
– Start:
the first day of menstruation
or immediately after abortion
or after childbirth: as of the 21st day, if the woman does not breastfeed
Duration: if there are no adverse effects, as long as contraception is desired.

– Do not administer to women with breast cancer, severe or recent liver disease, unexplained
vaginal bleeding, current thromboembolic disorders.
– May cause: oligomenorrhoea, menstrual disturbances, nausea, weight gain, breast tenderness,
mood changes, acne, headache.
– Hepatic enzyme inducers (rifampicin, rifabutin, nevirapine, nelfinavir, ritonavir, phenobarbital,
phenytoin, carbamazepine, griseofulvin, etc.) reduce the contraceptive efficacy. Use copper
intrauterine device or condoms or injectable medroxyprogesterone.
– Breast-feeding: it is recommended to wait 6 weeks after childbirth before starting desogestrel in
breastfeeding women. However, if it is the only contraceptive method available or acceptable, it can
be started 3 weeks after childbirth.
Remarks
– Desogestrel is a possible alternative when estroprogestogens are contra-indicated or poorly
tolerated; it is preferred to levonorgestrel as its contraceptive efficacy is similar to that of
estroprogestogens.
– In a woman misses a tablet, she should take it as soon as possible and continue treatment
as normal. If she misses by over 12 hours, contraceptive protection will be lessened, it is
therefore recommended to use an additional contraceptive method: condoms for 7 days
and, if she has had sexual intercourse within 5 days before forgetting the tablet, emergency
contraception.
49
DIAZEPAM
(Valium®…)
Therapeutic action
– Anxiolytic, sedative, anticonvulsant, muscle relaxant
Indications
– Agitation and anxiety
– Muscle spasms
Presentation
– 5 mg tablet
Also comes in 2 mg and 10 mg tablets and 1% oral solution.
Dosage
– Child: 0.5 mg/kg/day in 3 divided doses
– Adult: 5 to 15 mg/day in 3 divided doses
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
5 mg tablet – – 1/4 tab x 3 1/2 tab x 3 1 tab x 3
Duration: according to clinical response ; the shortest duration possible.

– Do not administer to patients with severe respiratory insufficiency or severe hepatic
impairment.
– Administer only in exceptions and with caution to children.
– May cause:
• feeling of inebriation, drowsiness (administer with caution when driving or operating
machinery),
• dependence and tolerance when used for more than 10-15 days. At the end of treatment,
reduce doses gradually to avoid withdrawal syndrome or rebound effect.
• in the event of overdose: ataxia, muscular weakness, hypotension, confusion, lethargy,
respiratory depression, coma.
– Reduce the dose by one half in elderly patients and in patients with renal or hepatic
impairment.
nervous system: opioid analgesics, neuroleptics (chlorpromazine, haloperidol, etc.), anti-
histamines (chlorphenamine, promethazine), antidepressants (clomipramine, fluoxetine,
etc.), phenobarbital, etc.
– Pregnancy: avoid
Remarks
– Diazepam is subject to international controls: follow national regulations.
– Diazepam is not a treatment for depression, chronic anxiety, or post-traumatic stress
syndrome.
50
DIDANOSINE = ddI
(Divir®, Videx®)
1
Therapeutic action
Indications
Presentation
– 25 mg, 50 mg, 100 mg, 150 mg and 200 mg buffered tablets to be chewed or dispersed in at
least 30 ml water (15 ml in children under 1 year)
– 125 mg, 250 mg and 400 mg enteric-coated capsules, to be taken with at least 100 ml water
Dosage
– Child under 3 months: 100 mg/m2/day in 2 divided doses
– Child from 3 months to 12 years (or over 5 kg): 240 mg/m2 once daily or in 2 divided doses
– Adult under 60 kg: 250 mg once daily or in 2 divided doses
– Adult 60 kg and over: 400 mg once daily or in 2 divided doses
Weight Daily dose Tablets Capsules

5 to 14 kg 100 mg Two 50 mg tab –
15 to 19 kg 150 mg One 100 mg tab + one 50 mg tab –
20 to 24 kg 200 mg Two 100 mg tab –
25 to 59 kg 250 mg One 200 mg tab + one 50 mg tab One 250 mg cap
≥ 60 kg 400 mg Two 200 mg tab One 400 mg cap
Duration: depending on the efficacy and tolerance of didanosine.

– Administer with caution to patients with history of pancreatitis or hepatic disorders.
– May cause:
• peripheral neuropathy, gastrointestinal disturbances (nausea, vomiting, diarrhoea, etc.),
and rarely ophthalmic disorders (particularly in children);
• lactic acidosis, severe pancreatic or hepatic disorders (in these events, stop antiretroviral
treatment; once the symptoms have resolved, prescribe an antiretroviral regimen
without didanosine).
– Do not combine with tenofovir; avoid combination with stavudine.
– Do not administer simultaneously didanosine tablets with tetracyclines, fluoroquinolones
and medications that need stomach acid for absorption (itraconazole, dapsone, etc.). Wait
2 hours between the administration of didanosine and these medications. This precaution
does not apply to didanosine enteric-coated capsules.
– When patients receive didanosine (tablets) and indinavir, administer first indinavir, wait
one hour, then administer didanosine.
– Pregnancy: no contra-indication. Do not combine with stavudine.
Remarks
– Didanosine should be taken 2 hours before (or at least 2 hours after) a meal.
– Tablets: patients must always take at least two tablets at a time to provide sufficient antacid.
– Also comes in powder for oral solution in 2 and 4 g vials to be diluted in an aluminium and
magnesium hydroxide suspension.
– Storage: tablets: below 30°C; capsules: below 25°C –
51
DIETHYLCARBAMAZINE
(Diethizine, Hetrazan®, Notezine®...)
Therapeutic action
– Anthelminthic (antifilarial)
Indications
– Lymphatic filariasis
Presentation
Dosage
– Child under 10 years: 0.5 mg/kg as a single dose on the first day, then increase the dose
gradually over 3 days to 3 mg/kg/day in 3 divided doses
– Child over 10 years and adult: 1 mg/kg as a single dose on the first day, then increase the
dose gradually over 3 days to 6 mg/kg/day in 3 divided doses
Duration
– Wuchereria bancrofti: 12 days
– Brugia malayi and timori: 6 to 12 days

– Do not administer to patients with onchocerciasis or heavy Loa loa microfilareamia; to
infants, elderly patients and patients with heart or renal diseases.
– Do not administer during an acute attack.
– Administer with caution in patients with history of seizures.
– May cause:
• nausea, vomiting, headache, dizziness, drowsiness, fever, joint pain, urticaria, transient
haematuria, subcutaneous nodules, lymphangitis, localized oedema;
• in patients with associated onchocerciasis: severe ocular damages (optic nerve lesions,
retinal lesions);
• in patients with associated loiasis: encephalitis (potentially fatal) if Loa loa microfilaraemia
is high.
– Pregnancy: CONTRA-INDICATED (treatment may be deferred until after delivery)
– Breast-feeding: not recommended
Remarks
– In countries with a national programme for the elimination of bancroftian filariasis, the
combination diethylcarbamazine + albendazole is administered as a single annual dose for
4 to 6 years. This regimen is only suitable for countries that are free from Onchocerca volvulus
and/or Loa loa.
– Diethylcarbamazine is included in the WHO complementary list of essential medicines.
– Storage: between 15°C and 30°C –
52
DIGOXIN
(Coragoxine®, Lanoxin®…)
1
Therapeutic action
– Cardiotonic
Indications
– Supraventricular arrhythmias (fibrillation, flutter, paroxysmal tachycardia)
– Heart failure
Presentation
– 62.5 µg (0.0625 mg) and 250 µg (0.25 mg) tablets
Also comes in 50 µg/ml oral solution (0.05 mg/ml).
Dosage
– Adult:
• loading dose: 750 to 1500 µg (0.75 to 1.5 mg) in 3 to 4 divided doses. Do not exceed 1500 µg
during the first 24 hours.
• maintenance dose: 125 to 250 µg/day (0.125 to 0.25 mg) once daily or in 2 divided doses
– Reduce the dose by one half in elderly patients and in patients with renal impairment.
Duration
– According to clinical response
– Do not administer to patients with bradycardia, ill defined arrhythmia, coronary artery
disease.
– It is essential to monitor pulse in the initial stage of treatment.
– Narrow margin between therapeutic and toxic dose.
– May cause in the event of overdose: gastrointestinal disturbances (nausea, vomiting,
diarrhoea), blurred vision, headache, confusion, conduction and rhythm disorders. If so,
reduce dose or stop treatment.
– Do not combine with calcium, particularly by IV route (serious arrhythmias).
– Monitor combination with:
• amiodarone, macrolides, itraconazole, quinine, chloroquine (increased digoxin concen-
tration),
• potassium-depleting drugs: diuretics, corticoids, amphotericin B (increased risk of
digoxin toxicity).
– Monitor if possible serum potassium level in patients taking potassium-depleting drugs
and serum creatinine level in patients with renal impairment.
– Do not administer simultaneously with antacids such as aluminium hydroxide, etc.,
administer 2 hours apart.
Remarks
– A loading dose may be administered in arrhythmias if a rapid digitalisation is required. It
is usually not necessary for heart failure.
53
DOXYCYCLINE
(Vibramycin®…)
Therapeutic action
– Tetracycline antibacterial
Indications
– Cholera, relapsing fevers, rickettsioses, bubonic plague, leptospirosis, anthrax, endemic
treponematoses, syphilis, chlamydial genital infections, atypical pneumonia; brucellosis (in
combination with streptomycin or rifampicin)
– Onchocerciasis, lymphatic filariasis; falciparum malaria (in combination with quinine)
Presentation
– 100 mg tablet or capsule
Dosage
– Cholera, louse-borne relapsing fever, epidemic typhus
Child: 100 mg as a single dose
Adult: 200 mg as a single dose (for cholera, 300 mg as a single dose)
– Other indications
Child over 8 years: 100 mg once daily or in 2 divided doses (up to 200 mg/day in severe
infections)
Adult: 100 to 200 mg once daily or in 2 divided doses, depending on indication
Duration
– Tick-borne relapsing fever: 5 days; leptospirosis, chlamydial cervicitis, malaria: 7 days; anthrax,
atypical pneumonia: 7-10 days; bubonic plague: 10 days; pelvic inflammatory disease, endemic
treponematoses, lymphogranuloma venereum, syphilis: 14 days; onchocerciasis, lymphatic
filariasis: minimum 4 weeks; brucellosis: 6 weeks

– Do not administer to children under 8 years (may damage teeth) and to tetracycline-allergic
patients.
– Administer with caution to patients with hepatic or renal impairment.
– May cause: gastrointestinal disturbances, allergic reactions, photosensitivity, oesophageal
ulcerations (to avoid oesophageal ulceration, take doxycycline during meals, with a glass
of water, in a upright position).
– Do not give simultaneously with ferrous salts, zinc, calcium, aluminium or magnesium
hydroxide, didanosine, milk: administer at least 2 hours apart.
– Pregnancy: CONTRA-INDICATED during the 2nd and 3rd trimester
– Breast-feeding: avoid if possible (risk of infant teeth discoloration), except if there is no alternative.
Remarks
– Patients infected with C. trachomatis are often coinfected with N. gonorrhoeae. Therefore, all
patients with chlamydia should receive an effective treatment for gonorrhoea.
Never use out-of-date tetracyclines (risk of renal acidosis).
54
EFAVIRENZ = EFV = EFZ
(Aviranz 600®, Efavir 600®, Stocrin®, Sustiva®)
1
Therapeutic action
– Antiretroviral, HIV-1 non nucleoside reverse transcriptase inhibitor
Indications
– HIV-1 infection, in combination with other antiretroviral drugs
Presentation
– 50 mg, 100 mg and 200 mg capsules and 50 mg, 200 mg and 600 mg tablets
– 30 mg/ml oral solution
Dosage
– The dose is given once daily at bedtime:
Weight Oral solution 30 mg/ml Capsules or tablets

10 to 14 kg 9 ml 200 mg
15 to 19 kg 10 ml 250 mg
20 to 24 kg 12 ml 300 mg
25 to 32 kg 15 ml 350 mg
33 to 39 kg – 400 mg
≥ 40 kg – 600 mg
Duration: depending on the efficacy and tolerance of efavirenz.

– Do not administer to children less than 3 years of age.
– Avoid administration in patients with severe hepatic impairment.
– Administer with caution to patients with psychiatric disorders (or history of) or epilepsy.
– Do not combine with amodiaquine.
– May cause:
• neurological disorders (dizziness, insomnia, drowsiness, abnormal dreaming, impaired
concentration, seizures);
• psychiatric disorders (severe depression, suicidal ideation);
• raised liver enzymes (ALAT);
• skin reactions, possibly severe (Stevens-Johnson syndrome).
– When efavirenz is used concomitantly with oestrogen-progestogen oral contraceptives:
increased risk of thromboembolism due to ethinylestradiol.
– Pregnancy: avoid; effective contraception must be used during treatment.
Remarks
– Oral solution requires higher doses than capsules or tablets.
– Also comes in fixed-dose combination tablet containing efavirenz-zidovudine-lamivudine.
Once opened, oral solution keeps for 30 days maximum.
55
ENALAPRIL
(Renitec®…)
Therapeutic action
– Antihypertensive, vasodilator (angiotensin-converting enzyme inhibitor)
Indications
– Hypertension
– Congestive heart failure
Presentation
– 2.5 mg, 5 mg and 20 mg tablets
Dosage and duration

– Hypertension
Adult: initially 5 mg once daily, then increase the dose every 1 to 2 weeks, according to
blood pressure, up to 10 to 40 mg once daily or in 2 divided doses
In elderly patients, patients taking a diuretic or patients with renal impairment: start with
2.5 mg once daily as there is a risk of hypotension and/or acute renal impairment.
– Congestive heart failure
Adult: 2.5 mg once daily, then increase the dose over 2 to 4 weeks, up to 10 to 20 mg once
daily or in 2 divided doses

– Do not administer to patients with history of hypersensitivity to enalapril.
– May cause:
• hypotension, dry cough at night, hyperkalaemia, headache, dizziness, nausea, renal
impairment,
• allergic reactions, angioedema,
• rarely: hepatitis, neutropenia and agranulocytosis in immunodeficient patients, anaemia
in patients with chronic renal impairment.
– Do not combine with potassium-sparing diuretics (spironolactone) or potassium.
– Monitor, if possible, serum creatinine and potassium levels (hyperkalaemia is frequent but
of no concern if it remains below 5.5 mEq/litre).
– In patients taking a diuretic, reduce the dose of the diuretic when adding enalapril.
– Breast-feeding: no contra-indication at recommended doses
Remarks
– Captopril (Lopril®, etc.) has the same indications as enalapril, however its dosage differs
and it must be taken 2 to 3 times daily.
56
ERGOCALCIFEROL = VITAMIN D2
and COLECALCIFEROL = VITAMIN D3
1
Therapeutic action
– Vitamin necessary for the intestinal absorption of calcium and phosphate and for normal
bone calcification
Indications
– Prevention and treatment of vitamin D deficiencies (rickets, osteomalacia)
Presentation
– 1.25 mg tablet or capsule (50 000 IU)
– 250 µg/ml oral suspension (10 000 IU/ml)
Also comes in different strengths, depending on the manufacturers.
Dosage and duration
Ergocalciferol and colecalciferol are used at the same doses:
– Prevention of vitamin D deficiencies
• 50 000 IU tablet or capsule:
Child under 5 years: 100 000 IU every 3 months, during periods of limited sunlight
Child over 5 years and adult: 100 000 IU every 3 months or 200 000 IU every 6 months
Pregnant woman: 100 000 IU around the 6th-7th month of pregnancy
• 10 000 IU/ml oral suspension:
Child and adult: 400 IU once daily (10 µg daily) during periods of limited sunlight
For children rarely exposed to sunlight or dark-skinned children, doses may be doubled.
– Treatment of vitamin D deficiencies
Child and adult: 800 to 4000 IU once daily (20 to 100 µg daily) for 6 to 12 weeks, then
continue with preventive dose
– Do not exceed 600 000 IU/year.
– Do not administer to patients with hypercalcaemia, hypercalciuria, calcic lithiasis.
– Stop treatment if signs of overdosage occur: headache, anorexia, nausea, vomiting, increased
thirst, polyuria.
– Avoid combination with thiazide diuretics (hydrochlorothiazide, etc.).
– Monitor, if possible, calcaemia and calciuria during curative treatment.
– Combine with a calcium supplementation at the start of curative treatment (500 mg to
1 g/day).
– Breast-feeding: no contra-indication. When curative treatment is being administered to the mother,
do not give vitamin D to the child.
Remarks
– The number of IU per drop of oral solution varies according to manufacturers. Check
instructions for use.
– Vitamin D2 and D3 also come in ampoules for oral and/or parenteral use.
Once opened, oral solution keeps 3 months.
57
METHYLERGOMETRINE (Methergin®…)
and ERGOMETRINE (Ergotrate®…)
Therapeutic action
– Uterine stimulant
Indications
– Haemorrhage due to uterine atony after delivery or abortion
– Heavy menorrhagia in non-pregnant women
Presentation
– Methylergometrine maleate: 125 µg tablet
– Ergometrine maleate: 200 µg tablet
Dosage
– Methylergometrine: 125 to 250 µg, 3 times daily
– Ergometrine: 200 to 400 µg, 3 times daily
Duration: according to clinical response, 2 to 3 days

– Do not administer during delivery.
– Do not administer before complete delivery of placenta.
– Do not administer to patients with hypersensitivity to ergot derivatives (cabergoline,
bromocriptine, ergotamine, etc.), severe hypertension, pre-eclampsia or eclampsia.
– May cause: gastrointestinal disturbances, headache, paraesthesia, confusion, dizziness,
tinnitus, hypertension, peripheral vasoconstriction.
– Do not combine with another ergot derivative.
– Monitor combination with: metronidazole, azole antifungals, macrolides, protease inhibitors,
efavirenz, fluoxetine (risk of ergotism).
– Breast-feeding: avoid, except if clearly needed and for less than 3 days (may inhibit lactation)
Remarks
– In emergencies, use injectable route; oral treatment is not suitable for the management of
severe haemorrhage.
– Do not confuse ergometrine with ergotamine, another ergot derivative used in the
treatment of migraine.
– Ergometrine is also called ergonovine or ergobasine.
58
ERYTHROMYCIN
(Erythrocin®, Pantomicina®, Propiocine®…)
1
Therapeutic action
– Macrolide antibacterial
Indications
– Treatment of leptospirosis, non-veneral treponematoses (pian, bejel, pinta), otitis media,
tonsillitis, diphtheria, pneumonia, streptococcal skin infections (erysipela, impetigo),
genital infections (chancroid, chlamydial infections, syphilis), etc., when first-line treatment
cannot be used (allergy, contra-indication, etc.)
– Chlamydial neonatal conjunctivitis
Presentation
– Powder of oral suspension, 125 mg/5 ml
Dosage
– Child: 30 to 50 mg/kg/day in 2 to 3 divided doses
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
250 mg tablet 1/4 tab x 2 1/2 tab x 2 1 tab x 2 2 to 3 tab x 2 4 tab x 2

500 mg tablet – 1/4 tab x 2 1/2 tab x 2 1 to 2 tab x 2 2 tab x 2
125 mg/5 ml oral susp. 1/2 tsp x 3 1/2 to 1 tsp 1 to 2 tsp – –

x3 x3
Duration
– Leptospirosis, non-veneral treponematoses, diphtheria, chancroid, genital chlamydiasis: 7 days
– Syphilis, lymphogranuloma venereum, chlamydial conjunctivitis: 14 days
– Other indications: 5 to 14 days, depending on pathology.
– Do not administer to patients with allergy to erythromycin or another macrolide.
– Do not combine with: ergot derivatives, aminophylline and theophylline (especially in
paediatrics), lumefantrine, carbamazepine.
– Monitor combination with digoxin (increased plasma concentration of digoxin).
– May cause: allergic reactions, gastrointestinal disturbances.
– Administer with caution to patients with hepatic or renal impairment.
Remarks
– Take between meals.
59
ETHAMBUTOL
(Dexambutol®, Myambutol®…)
Therapeutic action
– Antituberculous antibacterial
Indications
– Treatment of tuberculosis, in combination with other antituberculous antibacterials
Presentation
Dosage
– Child: 20 mg/kg once daily
– Adult: 15 mg/kg once daily
– Do not exceed 1200 mg/day
Duration: according to protocol

– Do not administer to patients with severe renal impairment or coexisting visual defects (e.g.
diabetic retinopathy, cataract).
– May cause: retrobulbar optic neuritis. Patients should be warned that they must immediately
stop treatment and seek medical attention in the event of visual disturbances such as blurred
vision, reduced visual acuity, blind spot (scotoma), green-red colour blindness. Visual
alterations are usually reversible a few weeks after stopping ethambutol. The dosage must
be carefully adjusted to the body weight (adverse effects are dose-dependant), especially
for children less than 5 years, as it is more difficult to detect visual alterations at this age.
Remarks
– Fixed dose combinations (isoniazid+rifampicin+pyrazinamide+ethambutol or isoniazid+
ethambutol) should be preferred.
60
ETHINYLESTRADIOL/LEVONORGESTREL
(Microgynon 30®, Minidril®…)
1
Therapeutic action
– Combined hormonal contraceptive, estrogen-progestogen
Indications
Presentation
– 21-day pack: 21 active tablets of 30 µg ethinylestradiol + 150 µg levonorgestrel
– 28-day pack: 21 active tablets of 30 µg ethinylestradiol + 150 µg levonorgestrel and 7 inactive
tablets
Dosage
– Start the first day of menstruation or immediately after abortion or as of the 21st day after
childbirth, if the woman does not breastfeed.
– 21-day pack: 1 tablet daily at the same time, for 21 days, followed by a tablet-free interval
of 7 days
– 28-day pack: 1 tablet daily at the same time, with no interruption, even during menstruation
– Do not administer to women with breast cancer, uncontrolled hypertension, non equilibrated
or complicated diabetes, history of thromboembolic disorders, coronary insufficiency, valvular
disease, stroke, severe or recent liver disease, unexplained vaginal bleeding, migraine with
neurological signs, renal impairment, hyperlipidaemia, to women smokers over age 35.
– May cause: oligo-amenorrhoea, vaginal candidiasis, nausea, weight gain, breast tenderness,
mood changes, acne and headache. Other rare and severe adverse effects require disconti-
nuation of treatment: hypertension, cardiovascular and thromboembolic disorders, jaundice,
hepatic adenoma, migraine, visual disturbances.
– Hepatic enzyme inducers (rifampicin, rifabutin, nevirapine, nelfinavir, ritonavir,
phenobarbital, phenytoin, carbamazepine, griseofulvin, etc.) reduce the contraceptive
efficacy. Use a non-hormonal contraceptive method (copper intrauterine device, condoms)
or an oral contraceptive containing 50 µg ethinylestradiol (however there is still a risk of
contraceptive failure and the risk of adverse effects is increased) or injectable medroxy-
progesterone.
– Clinical examinations must be carried out before (blood pressure, breasts) and during
treatment (blood pressure).
– Breast-feeding: CONTRA-INDICATED before 6 weeks; not recommended between 6 weeks and 6 months
(except if it is the only available or acceptable contraceptive method); no contra-indication after
6 months.
Remarks
– In a woman misses an active tablet, she should take it as soon as possible and continue
treatment as normal. If she misses by over 12 hours, contraceptive protection will be
lessened, it is therefore recommended to use an additional contraceptive method: condoms
for 7 days and, if she has had sexual intercourse within 5 days before forgetting the tablet,
emergency contraception.
– 28-day packs can simplify use as there is no interruption between two packs. Explain to the
woman which are active and inactive tablets. She must be careful not to start with inactive
tablets.
61
FERROUS SALTS
Therapeutic action
– Antianaemia drug
Indications
– Prevention and treatment of iron-deficiency anaemia
Presentation
– 200 mg ferrous sulfate tablet containing 65 mg of elemental iron
Also comes in syrup and in different compositions and strengths.
Dosage (expressed in elemental iron)

– Prevention of iron-deficiency anaemia
Child under 5 years: 2 mg/kg once daily = 1/4 tab/day
Child over 5 years: 30 to 60 mg once daily = 1/2 to 1 tab/day
Pregnant woman: 60 to 120 mg once daily or in 2 divided doses = 1 to 2 tab/day
– Treatment of iron-deficiency anaemia
Child under 2 years: 30 mg/day in 2 divided doses = 1/2 tab/day
Child from 2 to 12 years: 120 mg/day in 2 divided doses = 2 tab/day
Adult: 120 to 180 mg/day in 2 to 3 divided doses = 2 to 3 tab/day
Duration
– Prevention: during risk period (pregnancy, malnutrition)
– Treatment: 3 months

– Do not administer to patients with sickle-cell anaemia.
– May cause: gastrointestinal disturbances (epigastric pain, diarrhoea or constipation, black
stools).
– Do not exceed recommended doses, especially in children.
– Toxic dose: 30 mg/kg of elemental iron (100 mg/kg of ferrous sulfate).
– Signs of overdose: bloody diarrhoea, heart failure.
– Absorption of both ferrous salts and doxycycline or antacids is decreased when they are
given concomitantly. Administer each drug at least 2 hours apart.
– Do not administer simultaneously with doxyccline or antacids: administer 2 hours apart.
Remarks
– Take during meals to reduce gastrointestinal disturbances.
– For treatment, preferably use tablets containing both ferrous salts and folic acid.
– Other ferrous salts may be used. Ensure the dose of elemental iron is the same as that
indicated above (200 mg ferrous fumarate = 65 mg elemental iron; 300 mg ferrous gluconate
= 35 mg elemental iron).
62
FOLIC ACID = VITAMIN B9
1
Therapeutic action
– Antianaemia drug
Indications
– Treatment of folate-deficient megaloblastic anaemias: severe malnutrition, repeated attacks
of malaria, intestinal parasitosis, etc.
Presentation
Dosage and duration
– Child under 1 year: 0.5 mg/kg once daily for 4 months
– Child over 1 year and adult: 5 mg once daily for 4 months; 15 mg once daily in malab-
sorption states
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
5 mg tablet 1/2 tab 1 tab 1 tab 1 tab 1 tab

– Do not combine with sulfadiazine-pyrimethamine in patients with toxoplasmosis nor
sulfadoxine-pyrimethamine (Fansidar®) in patients with malaria: folic acid reduces the
efficacy of these treatments.
Remarks
– Folic acid must not be used for the treatment of anaemia due to antifolates (pyrimethamine,
trimethoprim or methotrexate). Use folinic acid.
– Folic acid is also used for primary and secondary prophylaxis of neural tube defects and
for prophylaxis of acute anaemia in patients with sickle-cell anaemia.
FERROUS SALTS/FOLIC ACID
Indications
– Prevention of iron and folic acid deficiency, mainly during pregnancy
– Treatment of iron deficiency
Presentation
– Tablet of 200 mg ferrous sulfate (65 mg of elemental iron) + 400 µg folic acid
Dosage
– See ferrous salts
Remarks
– This fixed-dose combination is not effective for the treatment of folic acid deficiency because
of its low dose.
63
FLUCONAZOLE
(Triflucan®…)
Therapeutic action
– Antifungal
Indications
– Treatment of oesophageal candidiasis in immunocompromised patients
– Second line treatment of oropharyngeal and vaginal candidiasis, when local treatment fails
– Secondary prophylaxis of oropharyngeal and oesophageal candidiasis, in the event of seve-
re and/or frequent recurrences
– Treatment of systemic candidiasis
– Treatment of cryptococcal infections, after induction therapy with amphotericin B
– Secondary prophylaxis of cryptococcal infections
Presentation
– 50 mg capsule
Also comes in 100 mg, 150 mg and 200 mg capsules, and 200 mg/5 ml oral suspension.
Dosage and duration

– Treatment of oesophageal candidiasis
Child: 3 mg/kg once daily (maximum 12 mg/kg/day) for 14 to 21 days
Adult: 100 to 200 mg once daily (maximum 400 mg/day) for 14 to 21 days
– Treatment of oropharyngeal candidiasis
Child: 3 mg/kg once daily for 7 to 14 days
Adult: 100 mg once daily for 7 to 14 days
– Treatment of vaginal candidiasis
Adult: 150 mg as a single dose (to be repeated after 72 hours if severe)
– Secondary prophylaxis of oropharyngeal and oesophageal candidiasis
Child: 3 to 6 mg/kg once daily, as long as necessary
Adult: 100 to 200 mg once daily (maximum 400 mg/day), as long as necessary
– Treatment of systemic candidiasis
Child: 6 to 12 mg/kg once daily for at least 4 to 6 weeks
Adult: 200 to 400 mg once daily for at least 4 to 6 weeks
– Treatment of cryptococcal infections (after 2 weeks' therapy with IV amphotericin B)
Child: 6 to 12 mg/kg once daily for 8 weeks
Adult: 400 mg once daily for 8 weeks
– Secondary prophylaxis of cryptococcal infections
Child: 3 to 6 mg/kg once daily, as long as necessary
Adult: 200 mg once daily, as long as necessary
Warning: the above doses should be administered every 72 hours to infants aged 0 to 2 weeks
and every 48 hours to infants aged 2 to 4 weeks.
64
1
– Do not administer to patients with hypersensitivity to azole antifungals (itraconazole, keto-
conazole, miconazole, etc.).
– May cause:
• gastrointestinal disturbances, headaches, rashes (possibly severe: Stevens Johnson syn-
drome), anaphylactic reactions, hepatitis,
• raised transaminases, leukopenia, thrombocytopenia.
– Stop treatment in the event of signs of hepatic disease and/or serious cutaneous reactions.
– In the event of hepatic or renal impairment: reduce the dose and monitor hepatic function.
– Do not combine with co-artemether or halofantrine (risk of torsades de pointe).
– Monitor combination with: oral anticoagulants (risk of haemorrhage), oral antidiabetics
(risk of hypoglycaemia), phenytoin, theophylline and aminophylline, benzodiazepines,
ergometrine (increases plasma concentration of these medicines).
– Do not administer simultaneously with rifampicine, administer 12 hours apart (rifampici-
ne in the morning, fluconazole in the evening).
– Pregnancy: CONTRA-INDICATED during the first trimester, except if vital and there is no other thera-
peutic alternative
Remarks
– For the treatment of oropharyngeal candidiasis, use preferably miconazole muco-adhesive
buccal tablets, clotrimazole or nystatin lozenges.
– For the treatment of vaginal candidiasis, use clotrimazole vaginal tablets as first line treat-
ment.
Once reconstituted, oral suspension keeps 14 days.
65
FLUOXETINE
(Fluctine®, Prozac®…)
Therapeutic action
– Antidepressant (selective serotonin re-uptake inhibitor)
Indications
– Depression
– Severe post-traumatic stress disorder
Presentation
– 10 mg and 20 mg capsules or tablets
Dosage
– Adult: 20 mg once daily. For patients who have only a partial clinical response after 15 days,
dosage may be increased to 40 mg/day (up to 60 mg/day if needed).
– Reduce doses in elderly patients and in patients with impaired hepatic function (administer
on alternate days).
Duration
– 6 to 8 months minimum. The treatment should be withdrawn gradually; if signs of relapse
occur, increase the dose.
– Do not administer to patients aged less than 15 years; to patients with hypersensitivity to
fluoxetine.
– May cause, especially at the beginning of therapy:
• nervousness, insomnia, drowsiness, headache, suicidal tendencies due to the suppression
of psychomotor inhibition, exacerbation of anxiety or delusional symptoms,
• gastrointestinal disturbances, allergic reactions, hypoglycaemia (particularly in diabetic
patients, closely monitor blood glucose), confusion due to hyponatraemia, haemorrhage.
– Do not combine with MAOIs; do not drink alcohol during treatment.
– Administer with caution to patients with epilepsy, glaucoma, cardiac disease, hepatic or
renal impairment, thyroid dysfunction, coagulation disorders.
– Monitor combination with: oral anticoagulants (risk of haemorrhage), carbamazepine,
phenytoin, tricyclic antidepressants and ergometrine (increased plasma concentration of
these drugs), lithium, tramadol, pethidine.
– Closely monitor patients with suicidal tendencies, especially at the beginning of therapy.
– Advise patients that fluoxetine may cause drowsiness and to be cautious when driving or
operating machinery.
– Pregnancy: avoid. However, if treatment has been started before a pregnancy, do not stop treatment;
reduce dosage at the end of pregnancy (risk of withdrawal syndrome in the newborn infant).
– Breast-feeding: avoid (safety is not established)
Remarks
– It takes 10 to 20 days for the patient to feel the antidepressant effect. The therapeutic
efficacy can only be assessed after 3 weeks of treatment. This must be explained to the
patient to encourage compliance.
– Anxiolytic or sedative treatment may be necessary during the first weeks of treatment in
anxious or agitated patients.
– Storage:
66
FOSFOMYCIN TROMETHAMINE
(Monuril®…)
1
Therapeutic action
– Antibacterial
Indicaciones
– Acute uncomplicated cystitis, without fever nor flank pain, in women
– Asymptomatic bacteriuria in pregnant women
Presentation
– Granules for oral solution in 3 g sachet, to be dissolved in water
Dosage and duration

– 3 g as a single dose

– This single-dose treatment is not indicated in severe (pyelonephritis) or complicated
urinary tract infections (infection in catheterised patients, in men, in patients with urinary
stones; infection due to multi-resistant organisms) and in recurrent cystitis.
– Do not administer to patients with severe renal impairment, hypersensitivity to fosfomycin.
– May cause (rarely): gastrointestinal disturbances, skin rash.
Remarks
– First perform urinary test (reagent strip). If the test is negative (no leukocytes, no nitrites),
a urinary infection is very unlikely.
– In the treatment of cystitis, symptoms should improve within 3 days of treatment. If not,
the patient should consult again. Treatment failure may be due to the presence of naturally
fosfomycin-resistant organisms (Staphylococcus saprophyticus).
– Fosfomycin is not included in the WHO list of essential medicines.
67
FUROSEMIDE = FRUSEMIDE
(Lasilix®, Lasix®, Seguril®…)
Therapeutic action
– Diuretic
Indications
– Oedema caused by renal, hepatic or congestive heart failure
– Hypertension (prefer hydrochlorothiazide for this indication)
Presentation
– 40 mg tablet
Also comes in 20 mg tablet.
Dosage
– Child: 1 to 2 mg/kg once daily
– Adult: 20 to 40 mg once daily
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
40 mg tablet 1/4 tab 1/2 tab 1 tab
– Reduce doses according to clinical response.

– In case of persistant oedema: 80 to 150 mg once or in 2 divided doses, then reduce dosage.

– Do not administer for other types of oedema, especially those due to kwashiorkor.
– May cause:
• hypokalaemia (especially in case of cirrhosis), poor nutritional status, congestive heart
failure (furosemide enhances toxicity of digoxin);
• dehydration and orthostatic hypotension.
– Pregnancy: avoid, do not use for hypertension in pregnancy
– Breast-feeding: avoid (excreted in milk and may reduce milk production)
Remarks
– Give in the morning.
– A lot of fruit should be eaten during treatment (dates, bananas, mangos, oranges, etc.) in
order to supply additional potassium. Use potassium tablets as well if available.
– Storage: no special temperature requirements –
68
GLIBENCLAMIDE
(Daonil®, Euglucon®…)
1
Therapeutic action
– Sulphonylurea hypoglycaemic which stimulates secretion of pancreatic insulin
Indications
– Adult-onset diabetes, insulin-independent and not controlled by well followed diet
Measurement of blood glucose levels is essential in establishing diagnosis and control of
the disease process.
Presentation
– 2.5 mg and 5 mg tablets
Also comes in 1.25 mg tablet.
Dosage
– Adult: initially, 2.5 to 5 mg once daily in the morning
Adjust dosage until diabetic control is obtained; maximum dose: 15 mg/day.
Adjust dosage gradually and very cautiously for elderly patients.
Duration: according to clinical response and laboratory tests

– Do not administer if:
• insulin-dependent diabetes, juvenile diabetes mellitus;
• renal, hepatic or thyroid function impairment, allergy to sulphonamides.
– May cause:
• hypoglycaemia due to excessive doses, especially in elderly patients; insufficient intake
of sugar; hepatic or renal failure. Treat mild hypoglycaemia with intake of oral sugar and
IV injection of hypertonic glucose solution if severe; adjust dosage;
• allergic reactions.
– Avoid combination with: co-trimoxazole, aspirin and other anti-inflammatory drugs, beta-
blockers (risk of hypoglycaemia), barbiturates, glucocorticoids, oral contraceptives
(antagonise hypoglycaemic effect), etc.
– Avoid combination with alcohol: antabuse reaction.
– Pregnancy: CONTRA-INDICATED during the third trimester
Remarks
– Use only when diabetes cannot be controlled with diet alone, and monitor blood-glucose
levels regularly.
– Use of oral antidiabetics does not mean dietetic measures should be cancelled.
– Insulin may be required in patients having surgery.
– Chlorpropamide (Diabinese®) is a long-acting sulphonylurea hypoglycaemic used at doses
of 125 to 250 mg once daily. Risk of hypoglycaemia is higher than with other antidiabetics.
69
GLYCERYL TRINITRATE = NITROGLYCERIN = TRINITRIN
Therapeutic action
– Vasodilator, antianginal
Indications
– Short-term prophylaxis and treatment of angina
Presentation
– 0.5 mg sublingual tablet
Dosage
– Short-term prophylaxis of acute angina (sublingually)
Adult: 0.5 to 1 mg taken 5 to 10 minutes before a precipitating event (exercise, stress, etc.)
– Treatment of acute angina (sublingually)
Adult: 0.5 to 1 mg, to be repeated 1 to 3 times at 3-4 minute intervals
Maximum dose: 3 mg/day

– Do not administer to patients with obstructive cardiomyopathy, hypotension, shock.
– May cause: orthostatic hypotension (especially in elderly patients), headache, nausea,
flushing of the face, haemolysis in patients with G6PD deficiency, severe hypotension with
risk of circulatory collapse in the event of overdose.
– Use the lowest effective dose in patients taking another nitrate derivative, a vasodilator or
an antihypertensive drug and in elderly patients.
– Combination with antihypertensive drugs, diuretics, vasodilators and alcohol enhances
hypotensive effects.
– Do not combine with sildenafil (risk of acute coronary syndrome).
– Pregnancy: not recommended (safety is not established)
– Breast-feeding: not recommended (safety is not established)
Remarks
– Tablet must be crunched first, then slowly dissolved under the tongue.
– Antianginal effect appears within less than 5 minutes and persists for less than 1 hour.
– Sustained-release formulations (Sustac®, etc.) are used for the long-term management of
angina and the treatment of congestive heart failure.
– Storage: below 25°C, preferably in airtight glass container. –
70
GRISEOFULVIN
(Fulcine®, Grisefuline®, Grisovin®…)
1
Therapeutic action
– Antifungal
Indications
– Dermatophyte infections of:
• scalp (scalp ringworm)
• skin (ringworm of the trunk, groin, foot)
• nails
Presentation
Dosage
– Child: 10 to 20 mg/kg once daily or in 2 divided doses, during meals
– Adult: 500 mg to 1 g once daily or in 2 divided doses, during meals (do not exceed 1 g/day)
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
125 mg tablet – 1/2 tab 1 tab 2 tab –

250 mg tablet – – 1/2 tab 1 tab 2 to 4 tab
500 mg tablet – – – 1/2 tab 1 to 2 tab
Duration
– Scalp: 6 to 12 weeks
– Skin: 4 to 8 weeks
– Nails: 6 months (fingernails); 12 months or more (toenails)
– Do not administer to patients with allergy to griseofulvin, hepatic impairment.
– May cause: gastrointestinal disturbances, headache, dizziness, peripheral neuropathy, skin
allergic reactions, photosensitivity, haematologic disorders.
– Griseofulvin reduces:
• the effect of oral anticoagulants: monitor prothrombine time,
• the effect of oral contraceptives: use another contraceptive method.
– Avoid alcohol during treatment (antabuse effect).
Remarks
– Apply gentian violet solution to lesions.
71
HALOFANTRINE
(Halfan®…)
The drug must only be used in hospital settings. Its potential

cardiotoxicity is unpredictable, even with the aid of an ECG.
Therapeutic action
– Antimalarial
Indications
– Treatment of uncomplicated falciparum malaria, when no other effective antimalarial is
available, never as first-line treatment
Presentation
– 250 mg tablet
– 100 mg/5 ml oral suspension
Dosage
– Child over 1 year or over 10 kg: 24 mg/kg in 3 divided doses every 6 hours, between meals
– Adult: 1500 mg in 3 divided doses every 6 hours, between meals
Duration: one day
– Do not administer to patients with hypersensitivity to halofantrine, cardiopathy, bradycardia,
arrhythmia, family history of unexplained death or of prolongation of the QT interval,
personal history of congenital or acquired prolongation of the QT interval or of unexplained
syncope, severe electrolytic disorders, vitamin B1 deficiency.
– Do not administer to children under one year of age.
– Do not administer to patients who have received mefloquine in the previous 3 weeks
(cardiotoxicity is more marked).
– May cause: prolongation of the QT interval, torsades de pointes and other serious ventricular
arrhythmias, sometimes fatal; diarrhoea, abdominal pain, nausea , vomiting, skin rash.
– ECG monitoring is essential before giving treatment.
– Do not combine with drugs inducing torsades de pointes: anti-arrhythmics (quinidine,
amiodarone, sotalol, etc.), neuroleptics (haloperidol, chlorpromazine), erythromycin IV,
pentamidine; drugs inducing hypokalaemia (diuretics, glucocorticoids, amphotericin B,
etc.), azole antifungals, most of protease inhibitors.
Remarks
– Halofantrine should not be used for prophylaxis.
– Halofantrine is not included in the WHO list of essential medicines.
Once opened, oral suspension keeps for 15 days.
72
HALOPERIDOL
(Haldol®, Serenace®…)
1
Therapeutic action
– Neuroleptic
Indications
– Acute psychoses: severe states of agitation or aggressiveness, delirium, acute mania
– Chronic psychoses: schizophrenic delirium, hallucinations
– Anxiety not controlled by anxiolytics
Presentation
Also comes in 1 mg and 20 mg tablets; 2 mg/ml and 20 mg/ml oral solution.
Dosage
– Psychoses
• Child over 3 years: initial dose of 25 to 50 µg/kg/day in 2 to 3 divided doses
If necessary, increase cautiously up to a maximum of 150 µg/kg/day.
• Adult: 2 to 40 mg/day in 2 to 3 divided doses
If necessary, increase gradually up to 40 mg/day according to clinical response.
– Anxiety
• Adult: 1 mg/day in 2 divided doses
Duration
– Psychoses: according to clinical response
– Anxiety: short-term treatment

– Do not administer to children under 3 years; to patients suffering from Parkinson’s disease.
– In case of isolated hyperthermia (or associated with severe extrapyramidal disorders), stop
treatment: possible neuroleptic malignant syndrome.
– May cause:
• sedation or drowsiness, orthostatic hypotension;
• extrapyramidal syndrome (requiring administration of anticholinergic antiparkinsonian
drugs), early or tardive dyskinesia in case of prolonged treatment (may be exacerbated by
antiparkinsonian drugs);
• galactorrhoea, amenorrhoea, impotence.
– Administer with caution in hepatic or renal failure, to elderly patients, persons who drive
or operate machinery, epileptics.
– Do not combine with levodopa.
– Risk of increased sedation when combined with alcohol and depressants of the central
nervous system (hypnotics, anxiolytics, morphine and derivatives, antihistamines, etc.).
– Avoid alcohol during treatment.
Remarks
– Haloperidol may induce more extrapyramidal reactions than chlorpromazine, but less
often provokes sedation and orthostatic hypotension.
73
HYDRALAZINE (Apresoline®…)
and DIHYDRALAZINE (Nepressol®...)
Therapeutic action
– Vasodilator antihypertensive drug
Indications
– Moderate or severe hypertension when thiazide diuretics or beta-blockers on their own are
ineffective
Presentation
Dosage
– Adult: initial dose of 25 to 50 mg/day in 2 to 3 divided doses
– Increase the dose gradually over 2 weeks to the optimal dose of 100 mg/day in 2 to 3 divided
doses.
– When hypertension is controlled, decrease the dose gradually. A hypertensive crisis may
occur when treatment is discontinued abruptly.
– Do not exceed indicated doses. Maximum dose: 200 mg/day.

– Do not administer in coronary insufficiency or recent myocardial infarction.
– May cause: tachycardia reflex, headache.
– Administer with caution to elderly patients or those with history of cerebrovascular disease.
– Pregnancy: avoid during the first trimester (safety is not established)
Remarks
– Hydralazine and dihydralazine are used for the same indications at the same dosage.
74
HYDROCHLOROTHIAZIDE
(Esidrex®, HydroSaluric®…)
1
Therapeutic action
– Diuretic
Indications
– Moderate or severe hypertension
– Oedema caused by renal, hepatic or congestive heart failure
Presentation
– 50 mg tablet
Dosage
– Hypertension
• Adult: 25 to 50 mg/day in 2 divided doses
– Oedema
• Child: 1 mg/kg/day in 2 divided doses
• Adult: 50 to 100 mg in the morning, on alternate days
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
Hypertension 1/4 to
1 tab
50 mg tablet x2
Oedema 1 to 2 tab
1/4 tab x 2
50 mg tablet every 2 days

– Do not administer if severe renal failure, allergy to sulphonamides; for other types of oedema,
especially those due to kwashiorkor.
– May cause: dehydration, hypotension, hypokalaemia, photosensitivity, hyperglycaemia.
Remarks
– Often used in combination with an antihypertensive drug.
– A lot of fruit should be eaten during treatment (dates, bananas, mangos, oranges, etc.), in
order to supply additional potassium. Use potassium tablets as well if available.
75
HYOSCINE BUTYLBROMIDE = BUTYLSCOPOLAMINE
(Buscopan®...)
Therapeutic action
– Antispasmodic
Indications
– Spasms of the gastrointestinal tract and genitourinary tract
Presentation
– 10 mg tablet
Dosage
– Child from 6 to 12 years: 10 mg to be repeated up to 3 times per day if necessary
– Adult: 10 to 20 mg to be repeated up to 3 or 4 times per day if necessary
Duration: according to clinical response; no prolonged treatment.

– Do not administer tablets to children under 6 years (use injectable hyoscine butylbromide).
– Do not administer to patients with urethro-prostatic disorders, cardiac disorders, glauco-
ma.
– Do not administer to children with high fever.
– May cause: urinary retention, dryness of the mouth, constipation, blurred vision, tachycar-
dia.
– Administer with caution and under close supervision to patients taking other anticholi-
nergic drugs (antidepressants, neuroleptics, H-1 antihistamines, antiparkinsonians, etc.).
– Pregnancy: no contra-indication; NO PROLONGED TREATMENT
– Breast-feeding: no contra-indication; NO PROLONGED TREATMENT
Remarks
– Other antispasmodics are used in certain countries:
• atropine (child: 0.01 mg/kg every 4 to 6 hours, without exceeding 0.4 mg/day; adult: 0.4
to 0.6 mg every 4 to 6 hours),
• propantheline (adult: 45 to 120 mg/day in 3 divided doses).
– Antispasmodic drugs are not included in the WHO list of essential medicines.
76
IBUPROFEN
(Advil®, Brufen®, Nureflex®…)
1
Therapeutic action
– Analgesic, antipyretic, non-steroidal anti-inflammatory (NSAID)
Indications
– Mild to moderate pain, fever, rheumatic diseases
Presentation
– 200 mg and 400 mg enteric-coated tablets
– 100 mg/5 ml oral suspension, with pipette graduated per kg of body weight (each kg
graduation corresponds to 10 mg ibuprofen)
Dosage
– Pain, fever
Child over 3 months: 30 mg/kg/day in 3 divided doses (= one pipette filled up to the
graduation corresponding to the child's weight, 3 times per day)
Adult: 1200 to 1800 mg/day in 3 to 4 divided doses
In post-operative period, ibuprofen should be given on a regular basis, every 8 hours,
rather than “as needed”.
3 6 15
AGE 0
months years years
ADULT
5 20 35
WEIGHT kg kg kg
100 mg/5 ml oral susp. – –
Do not Use the graduated pipette
200 mg tablet 1 to 2 tab x 3 2 tab x 3 or 4
administer for oral solution
400 mg tablet – 1 tab x 3 or 4
– Rheumatoid arthritis
Child: up to 40 mg/kg/day maximum
Adult: up to 3200 mg/day maximum
Duration: according to clinical response; post-operative pain: 8 days maximum
– Do not administer to children under 3 months, patients with allergy to NSAID, peptic ulcer,
coagulation defects, haemorrhage, surgery with risk of major blood loss, severe renal or
hepatic impairment, severe heart failure, severe malnutrition, uncorrected dehydration or
hypovolaemia, severe infection.
– May cause: allergic reactions, epigastric pain, peptic ulcer, haemorrhage, renal impairment.
– Administer with caution to elderly or asthmatic patients.
– Do not combine with: methotrexate, anticoagulants and other NSAIDs.
– Monitor combination with diuretics and angiotensin-converting enzyme inhibitors (drink
plenty of fluids to avoid renal failure).
– Pregnancy: not recommended during the first 5 months. CONTRA-INDICATED from the beginning of
the 6th month (use paracetamol)
– Breast-feeding: no contra-indication (short term treatment)
Remarks
– Clean the graduated pipette after use. Shake the bottle before use.
– If ibuprofen alone does not provide pain relief, combine with paracetamol and/or an
opioid analgesic.
Once opened, oral suspension must be stored between 8°C and 15°C.
77
INDINAVIR = IDV
(Crixivan®)
Therapeutic action
– Antiretroviral, HIV-1 and HIV-2 protease inhibitor
Indications
– HIV-1 or HIV-2 infection, in combination with two nucleoside reverse transcriptase inhibi-
tors and usually with a low-dose of ritonavir as booster
Presentation
– 200 mg, 333 mg and 400 mg capsules
Posologie
– Administration of indinavir without ritonavir
Child from 4 years: 1500 mg/m2/day in 3 divided doses, without exceeding 800 mg per
dose
Weight 200 mg capsule 400 mg capsule

10 to 14 kg 1 cap x 3 –
15 to 19 kg 2 cap x 3 1 cap x 3
20 to 24 kg 2 cap x 3 1 cap x 3
25 to 29 kg 2 cap x 3 1 cap x 3
30 to 49 kg 3 cap x 3 –
≥ 50 kg 4 cap x 3 2 cap x 3
– Concomitant administration of indinavir + ritonavir

Adult: 1600 mg/day of indinavir + 200 mg/day of ritonavir in 2 divided doses
Duration
– The duration of treatment depends on the efficacy and tolerance of indinavir.
– May cause: gastrointestinal disturbances, rash, dry skin, myalgia, taste disturbances, hea-
dache, dizziness, urinary lithiasis (more frequent in children or when combined with rito-
navir), hepatic disorders (raised transaminases or bilirubin), haematological disorders
(neutropenia), metabolic disorders (lipodystrophy, hyperlipidaemia, diabetes mellitus with
glucose intolerance and/or insulin resistance).
– Do not combine with rifampicin, phenobarbital and carbamazepine (reduced indinavir
plasma concentration).
– When used concomitantly with oestrogen-progestogen oral contraceptives: increased risk
of thromboembolism.
– Reduce dosage in patients with hepatic impairment (1800 mg/day).
– Administer with caution to patients with haemophilia (risk of haemorrhage).
– When patients receive indinavir and didanosine, administer first indinavir (as it requires
acid for absorption), wait one hour, then administer didanosine.
Remarks
– Take with plenty of water (200 ml). Drink at least 1.5 to 2 litres of water/day.
– Indinavir administered on its own (without ritonavir) must be taken 1 hour before or
2 hours after a meal.
– Storage:
78
IODIZED OIL
(Lipiodol®)
Therapeutic action
– Iodine supplementation
Indications
– Prevention and treatment of severe iodine deficiency
Presentation
– 200 mg capsule
Dosage and duration

– Child under 1 year: 200 mg (1 capsule) once a year
– Child from 1 to 5 years: 400 mg (2 capsules) once a year
– Child from 6 to 15 years: 600 mg (3 capsules) once a year
– Pregnant woman or women of childbearing age: 400 mg (2 capsules) once a year

– Do not administer to patients with allergy to iodine or hyperthyroidism.
– Do not administer to patients over 45 years.
– May cause: allergic reactions, dysthyroidism.
Remarques
– Also comes in 10 ml ampoule containing 480 mg/ml (Lipiodol® Ultra-Fluide) to be admi-
nistered orally or by IM injection using a glass syringe:
• children under 1 year: 0.5 ml
• children from 1 to 15 years, pregnant women or women of childbearing age: 1 ml
79
ISONIAZID = INH
(Laniazid®, Rimifon®…)
Therapeutic action
Indications
– Treatment of tuberculosis, in combination with other antituberculous antibacterials
– Prophylaxis of tuberculosis in newborn infants of M+ mothers and children < 5 years in
close contact with a M+ patient
Presentation
Dosage
– Child: 10 to 15 mg/kg once daily, on an empty stomach; maximum 300 mg/day
– Adult: 5 mg/kg once daily, on an empty stomach; maximum 300 mg/day
Duration
– Treatment: according to protocol
– Prophylaxis in children < 5 years: 6 months
– Prophylaxis in newborns: 6 months then administer BCG vaccine, or alternatively, 3 months
then perform a tuberculin skin test. If negative, discontinue isoniazid and administer BCG
vaccine; if positive, continue isoniazid 3 more months then administer BCG vaccine.

– Do not administer to patients with severe hepatic impairment.
– Administer with caution to patients with epilepsy, history of seizures or psychosis.
– May cause:
• peripheral neuropathy, especially in malnourished, alcoholic, HIV-infected patients and
patients with renal impairment.
• hepatic disorders (jaundice), especially in alcoholic patients, patients receiving rifampicin,
patients > 35 years; pregnant women including in post-partum period.
• rarely: hypersensitivity reactions (fever, rash).
– If the patient presents symptoms of liver damage (jaundice), discontinue treatment until
the symptoms resolve.
– Administer concomitantly pyridoxine (vitamin B6) in malnourished, alcoholic, HIV-infected
patients and children < 5 years, to avoid peripheral neuropathy.
– Pregnancy and breast-feeding: no contra-indication, administer pyridoxine concomitantly
Remarks
– Isoniazid prophylaxis should be considered only after excluding active tuberculosis.
– For the treatment of tuberculosis, fixed dose combinations (isoniazid+rifampicin+
pyrazinamide+ethambutol or isoniazid+rifampicin+pyrazinamide or isoniazid+rifampicin)
should be preferred.
80
ISOSORBIDE DINITRATE
(Isordil®, Risordan®, Sorbitrate®…)
1
Therapeutic action
– Vasodilator, antianginal
Indications
– Prophylaxis and treatment of acute angina
– Adjunctive therapy in left congestive heart failure
Presentation
– 5 mg tablet
Dosage
– Short-term prophylaxis of acute angina (sublingually)
Adult: 5 to 10 mg taken 10 minutes before a precipitating event (exercise, stress, etc.)
– Long-term prophylaxis of angina and treatment of heart failure (orally)
Adult: 30 to 120 mg/day in 2 to 3 divided doses. Gradually increase the dose until effective.
Do not stop treatment abruptly.
– Treatment of acute angina (sublingually)
Adult: 5 to 10 mg, to be repeated after 10 minutes if necessary

– Do not administer to patients with obstructive cardiomyopathy, hypotension, shock.
– May cause: orthostatic hypotension (especially in elderly patients), headache, nausea,
flushing of the face, haemolysis in patients with G6PD deficiency, severe hypotension with
risk of circulatory collapse in the event of overdose.
– Use the lowest effective dose in patients taking another nitrate derivative, a vasodilator or
an antihypertensive drug and in elderly patients.
– Combination with antihypertensive drugs, diuretics, vasodilators and alcohol enhances
hypotensive effects.
– Do not combine with sildenafil (risk of acute coronary syndrome).
– Pregnancy: not recommended (safety is not established)
– Breast-feeding: not recommended (safety is not established)
Remarks
– Sublingual tablet must be crunched first, then slowly dissolved under the tongue. Oral
tablet must be swallowed whole.
– By sublingual route, antianginal effect appears within less than 10 minutes and persists for
1 to 2 hours.
– Sustained-release formulations are used for the long-term management of angina and the
treatment of congestive heart failure. The time interval between each administration
depends on the preparations.
81
ITRACONAZOLE
(Sporanox®…)
Therapeutic action
– Antifungal
Indications
– Treatment of histoplasmosis and penicilliosis
– Secondary prophylaxis of histoplasmosis and penicilliosis
Presentation
– 100 mg capsule
– 10 mg/ml oral solution
Dosage and duration

– Treatment of histoplasmosis
• moderate:
Adult: 600 mg/day in 2 divided doses for 3 days then 400 mg/day in 2 divided doses
for 12 weeks
• severe, disseminated: same treatment, after 3-10 days' therapy with amphotericin B
– Treatment of penicilliosis (after 2 weeks' therapy with amphotericin B)
Adult: 400 mg/day in 2 divided doses for 10 weeks
– Secondary prophylaxis of histoplasmosis
Adult: 200 to 400 mg once daily, as long as necessary
– Secondary prophylaxis of penicilliosis
Adult: 200 once daily, as long as necessary

– Do not administer to patients with hypersensitivity to azole antifungals (fluconazole, keto-
conazole, miconazole, etc.).
– May cause: gastrointestinal disturbances, headache, rash, anaphylactic reactions, heart fai-
lure, hepatitis; raised transaminases, hypokalaemia.
– Administer with caution to patients with heart failure (risk of pulmonary edema), hepatic
or renal impairment.
– Stop treatment in the event of liver dysfunction.
– In case of prolonged treatment, monitor liver function.
– Do not combine with co-artemether or halofantrine (risk of torsades de pointe).
– Monitor combination with: oral anticoagulants (risk of haemorrhage), digoxine, buprenor-
phine, benzodiazepines, calcium inhibitors, ergometrine, (increased plasma concentration),
phenytoin, carbamazepine, phenobarbital (efficacy of itraconazole reduced).
– Do not administer simultaneously with:
• rifampicin: administer 12 hours apart (rifampicin in the morning, itraconazole in the
evening),
• didanosine, antacids and ulcer-healing drugs: wait 2 hours between the administration
of itraconazole and these medications.
– Pregnancy: CONTRA-INDICATED during the first trimester, except if vital and there is no therapeutic
alternative
Remarks
Once reconstituted, oral suspension keeps for 30 days.
82
IVERMECTIN
(Mectizan®, Stromectol®…)
1
Therapeutic action
– Anthelminthic, scabicide
Indications
– Onchocerciasis
– Scabies
Presentation
Dosage and duration
– Onchocerciasis
Child over 15 kg and adult: 150 µg/kg as a single dose. A 2nd dose should be administered
after 3 months if clinical signs persist. Repeat the treatment every 6 or 12 months to
maintain the parasite load below the threshold at which clinical signs appear.
HEIGHT 0 90 cm 120 cm 140 cm 160 cm
WEIGHT 15 kg 25 kg 45 kg 65 kg
3 mg tablet Do not 1 tab 2 tab 3 tab 4 tab

6 mg tablet administer 1/2 tab 1 tab 11/2 tab 2 tab
– Ordinary scabies
Child over 15 kg and adult: 200 µg/kg as a single dose. A single dose may be sufficient; a
2nd dose one week later reduces the risk of treatment failure.
– Crusted scabies
Child over 15 kg and adult: 2 doses of 200 µg/kg one week apart, in combination with a
topical keratolytic and topical scabicide; additional doses may be necessary.
– May cause:
• increased itching;
• moderate reactions in patients with onchocerciasis: ocular irritation, headache, arthralgia,
myalgia, lymphadenopathy, fever, oedema;
• severe reactions in patients co-infected with Loa loa: marked functional impairment if Loa loa
microfilaraemia > 8,000 mf/ml; encephalopathy if Loa loa microfilaraemia > 30,000 mf/ml.
– Administer with caution in regions where loiasis is endemic:
• For symptomatic onchocerciasis:
Evaluate the severity of Loa loa microfilaraemia and manage accordingly: either treat as
an out-patient under supervision, or hospitalise, or choose an alternative treatment
(doxycycline).
If it is not possible to perform a thick film examination: ivermectin may be administered
if the patient has no history of loiasis (migration of an adult worm under the conjunctiva
or transient « Calabar » swellings), nor history of severe adverse reactions following a
previous treatment with ivermectin. In other cases, it is wiser either to treat under
supervision, or to choose an alternative treatment (doxycycline), or decide not to treat,
according to the severity of the onchocerciasis and the previous history.
• For ordinary scabies: review the patient’s history and if in doubt, topical scabicidal
treatment is preferred.
– Pregnancy: avoid (safety is not established)
Remarks
– Take tablets on an empty stomach.
– Ivermectin is also used for the treatment of strongyloidiasis (200 µg/kg as a single dose)
and cutaneous larva migrans (200 µg/kg daily for 1 to 2 days).
83
LACTULOSE
(Duphalac®…)
Therapeutic action
– Osmotic laxative
Indications
– Prevention of constipation in patients taking opioid analgesics (e.g. codeine, morphine)
Presentation
– 10 g/15 ml oral solution
Dosage and duration

– Child under 1 year: 5 ml/day (1 tsp/day)
– Child from 1 to 6 years: 5 to 10 ml/day (1 to 2 tsp/day)
– Child from 7 to 14 years: 10 to 15 ml/day (2 tsp/day or 1 ssp/day)
– Child over 14 years and adult: 15 to 45 ml/day (1 to 3 ssp/day)
Start lactulose when analgesic treatment continues more than 48 hours. Lactulose must be
taken daily, until the end of the opioid treatment. Regular follow up (frequency/consistency
of stools) is essential in order to adjust dosage correctly.

– Do not administer to patients with Crohn’s disease, ulcerative colitis, intestinal obstruction,
undiagnosed abdominal pain.
– May cause: abdominal discomfort, flatulence and diarrhoea.
– In the event of diarrhoea, exclude a faecal impaction and intestinal obstruction; reduce the
dose.
Remarks
– It may take up to 48 hours, or even longer, before the treatment is effective. Lactulose is not
indicated in acute constipation where a rapid result is needed.
– If necessary, lactulose may be given in combination with a stimulant laxative (e.g. bisacodyl,
senna).
– The oral solution may be taken undiluted, or diluted in water.
– The treatment should be accompanied by dietary measures (fluids and fibre).
– Storage: below 25°C. Do not store in a refrigerator (cristallisation).
84
LAMIVUDINE = 3TC
(Epivir®, Lamivir®…)
1
Therapeutic action
Indications
Presentation
– 50 mg/5 ml oral solution
Dosage
– Child under 1 month: 4 mg/kg/day in 2 divided doses
– Child from 1 month to 12 years: 8 mg/kg/day in 2 divided doses
– Adult: 300 mg once daily or in 2 divided doses
10 mg/ml
Weight 150 mg tablet 300 mg tablet
oral solution
5 to 9 kg 2.5 ml x 2 – –
10 to 14 kg 5 ml x 2 – –
15 to 19 kg 7 ml x 2 1/2 tab x2 –
20 to 24 kg 9 ml x 2 1/2 tab x2 –
25 to 29 kg 11 ml x 2 2 tab 1 tab
≥ 30 kg – 2 tab 1 tab
Duration
– The duration of treatment depends on the efficacy and tolerance of lamivudine.

– Administer with caution to patients with history of hepatic disorders.
– May cause: gastrointestinal disturbances (diarrhoea, nausea, vomiting, etc.) and possibly:
haematological disorders, especially when combined with zidovudine (neutropenia, anae-
mia, thrombocytopenia), myopathy, hepatic or pancreatic disorders.
Remarks
– For prophylactic treatment to reduce mother-to-child HIV transmission, check national
recommendations.
– Also comes in fixed-dose combination tablets incorporating lamivudine-zidovudine
(Combivir®), lamivudine-zidovudine-abacavir (Trizivir®) and lamivudine-stavudine-
nevirapine (Triomune®, Triviro®).
– Storage:
• Tablets : below 30°C
• Oral solution : below 25°C. Once opened, solution keeps for 30 days maximum.
85
LEVODOPA/CARBIDOPA
(Sinemet®…)
Therapeutic action
– Antiparkinson drug
Indications
– Parkinson’s disease and extrapyramidal disorders except those induced by neuroleptics
Presentation
– 100 mg levodopa + 10 mg carbidopa tablet
– 250 mg levodopa + 25 mg carbidopa tablet
Dosage
– Adult:
• Initial dose of levodopa: 50 to 125 mg once or twice daily immediately after meals.
Increase in increments of 50 to 125 mg every day or on alternate days, to individual
optimal dose.
• Maintenance dose: 750 to 1500 mg/day in 3 to 4 divided doses, immediately after meals.
– Reduce dosage in elderly patients.

– Do not administer if severe psychosis, mental confusion, closed-angle glaucoma, recent
myocardial infarction, malignant melanoma.
– May cause:
• early in treatment, when dose is not adjusted : anorexia, vomiting, orthostatic hypotension,
cardiac arrhythmia, agitation, insomnia or drowsiness, depression;
• frequent delayed adverse effects, signs of excessive dosage, mainly:
– dyskinesia, tremor;
– psychiatric disorders more frequent in elderly patients: confusion, hallucinations,
delirium, depression with or without suicidal tendencies;
• later in treatment : fluctuation of the effect during the day (daily dosage may be divided
into smaller doses and taken more frequently); or reduction of the effect (progression of
the disease).
– Administer with caution in psychiatric disorders, cardiac disease, gastro-duodenal ulcer.
– Do not administer simultaneously with MAOIs, antidepressants, neuroleptics, reserpine.
Remarks
– Tablet must be swallowed whole. Do not chew or dissolve.
86
LEVONORGESTREL
(Microlut®, Microval®, Norgeston®…)
1
Therapeutic action
– Hormonal contraceptive, (low-dose)progestogen
Indications
Presentation
– 30 µg (0.03 mg) tablet, 28-day pack or 35-day pack
Dosage
– 1 tablet daily at the same time, continuously, including during menstruation
– Start:
the first day of menstruation
or after childbirth: as of the 21st day, if the woman does not breastfeed

– Do not administer to women with breast cancer, severe or recent liver disease, unexplained
vaginal bleeding, current thromboembolic disorders.
– May cause: oligomenorrhoea, menstrual disturbances, nausea, weight gain, breast tenderness,
mood changes, acne, headache.
– Hepatic enzyme inducers (rifampicin, rifabutin, nevirapine, nelfinavir, ritonavir, phenobarbital,
phenytoin, carbamazepine, griseofulvin, etc.) reduce the contraceptive efficacy. Use copper
intrauterine device or condoms or injectable medroxyprogesterone.
– Breast-feeding: it is recommended to wait 6 weeks after childbirth before starting levonorgestrel in
breastfeeding women. However, if it is the only contraceptive method available or acceptable, it can
be started 3 weeks after childbirth.
Remarks
– Levonorgestrel is a possible alternative when estroprogestogens are contra-indicated or
poorly tolerated. However, it has a lesser contraceptive effect than estroprogestogens and
requires taking tablets at a precise time (no more than 3 hours late).
– In a woman misses a tablet, she should take it as soon as possible and continue treatment
as normal. If she misses by over 3 hours, contraceptive protection will be lessened, it is
therefore recommended to use an additional contraceptive method: condoms for 7 days
and, if she has had sexual intercourse within 5 days before forgetting the tablet, emergency
contraception.
87
LEVONORGESTREL for emergency contraception
(Norlevo®, Plan B®, Vikela®…)
Therapeutic action
– Hormonal contraceptive, progestogen
Indications
– Prevention of pregnancy in the event of a lapse or absence of contraception
Presentation
– 750 µg and 1.5 mg tablets
Dosage and duration

– One 1.5 mg tablet or two 750 µg tablets as a single dose, whatever the day of the cycle, as
soon as possible after unprotected intercourse and preferably within the first 72 hours as
effectiveness decreases with time. It is however recommended to administer the treatment
up to 120 hours (5 days) after unprotected intercourse.

– No contra-indication.
– May cause: vaginal bleeding within 7 days following administration, nausea.
– Re-administer treatment if vomiting occurs within 3 hours of taking treatment.
– In women taking enzyme-inducing drugs (rifampicin, rifabutin, griseofulvin, phenytoin,
phenobarbital, carbamazepine, certain antiretrovirals), contraceptive effectiveness may be
reduced: as a cautionary measure, double the dose (3 mg as a single dose). However, when
prophylactic antiretroviral treatment is initiated together with emergency contraception, it
is not necessary to double the dose of levonorgestrel.
– Pregnancy: in the event of treatment failure (i.e. pregnancy develops) or if used during an undiagnosed
pregnancy, there is no known harm for the foetus.
Remarks
– Emergency contraception is intended to prevent pregnancy; it cannot terminate an ongoing
pregnancy.
– There is a risk of treatment failure. Carry out a pregnancy test if there is no menstruation:
• within 5 to 7 days after the expected date, if the date is known,
• or within 21 days following treatment.
88
LOPERAMIDE
(Imodium®…)
1
Therapeutic action
– Opioid antidiarrhoeal
Indications
– Symptomatic treatment of persistent diarrhoea in HIV patients, in combination with
rehydration
Presentation
– 2 mg capsule or tablet
Dosage
– Child from 2 to 5 years: 3 mg/day in 3 divided doses
– Child over 8 years: 6 mg/day in 3 divided doses
Age 0-2 years 2-5 years 6-8 years > 8 years

Weight < 13 kg 13 - 20 kg 20 - 30 kg > 30 kg
Oral solution Do not 1 tsp x 3 2 tsp x 2 2 tsp x 3
Capsule administer
– 1 caps x 2 1 caps x 3
– Adult: 4 mg (2 capsules), then 2 mg (1 capsule) after each loose stool, without exceeding
16 mg/day (8 capsules/day)

– Do not administer to children under 2 years.
– Do not administer to patients with bloody diarrhoea, acute inflammatory bowel disease,
diarrhoea due to antibiotics.
– May cause: constipation, allergic skin reactions, drowsiness, dizziness.
– In the event of overdosage, treat with naloxone.
Remarks
– Rehydration is essential and must be adapted to the severity of diarrhoea.
– Loperamide is not included in the WHO list of essential medicines.
89
LOPINAVIR/RITONAVIR = LPV/r
(Aluvia®, Kaletra®)
Therapeutic action
– Antiretrovirals, HIV-1 and HIV-2 protease inhibitors
Indications
Presentation
– 100 mg lopinavir/25 mg ritonavir film coated tablet
– 200 mg lopinavir/50 mg ritonavir film coated tablet
– 80 mg lopinavir/20 mg ritonavir per ml oral solution, containing 42% alcohol (v/v), with
a graduated syringe for oral administration
Dosage
– Child from 14 days to 6 months: 32/8 mg/kg/day in 2 divided doses
– Child over 6 months:
• 7 to 15 kg: 24/6 mg/kg/day in 2 divided doses
• 15 to 40 kg: 20/5 mg/kg/day in 2 divided doses
– Adult: 800/200 mg/day in 2 divided doses
80/20 mg/ml 100/25 mg 200/50 mg
Weight
oral solution tablet tablet
< 4 kg 1 ml x 2 – –
4 to 9 kg 1.5 ml x 2 – –
10 to 13 kg 2 ml x 2 – –
14 to 19 kg 2.5 ml x 2 – –
20 to 25 kg 3 ml x 2 2 tab x 2 –
26 to 34 kg – 3 tab x 2 –
> 35 kg – 4 tab x 2 2 tab x 2
Duration: depending on the efficacy and tolerance of LPV/r.

– Do not administer oral solution to patients with renal or hepatic impairment.
– May cause:
• gastrointestinal disturbances (mainly diarrhoea), skin rash, pruritus;
• hepatic disorders (raised transaminases), pancreatic disorders, metabolic disorders
(lipodystrophy, hyperlipidaemia, diabetes mellitus with glucose intolerance and/or
insulin resistance).
– LPV/r may reduce the efficacy of oral contraceptives: use a non-hormonal contraception or
injectable medroxyprogesterone or make sure that the oral contraceptive used contains
50 µg ethinylestradiol per tablet.
– Do not combine with rifampicin (use rifabutin).
– Administer with caution to patients with haemophilia (risk of haemorrhage) or renal or
hepatic impairment.
– Pregnancy: oral solution is CONTRA-INDICATED
Remarks
– Tablets may be taken with meals or on an empty stomach. The oral solution must be taken
with meals. If LPV/r oral solution is used concomitantly with didanosine, administer
didanosine 1 hour before or 2 hours after LPV/r, as it must be taken on an empty stomach.
– The tablets must not be chewed or crushed.
– Storage: tablets: below 30°C; oral solution: between 2°C and 8°C. If refrigeration is not available,
oral solution kept below 25°C may be stored for 6 weeks maximum.
90
MEBENDAZOLE
(Pantelmin®, Vermox®, Wormin®...)
1
Therapeutic action
– Anthelminthic
Indications
– Ascariasis (Ascaris lumbricoides), trichuriasis (Trichuris trichiura), hookworm infections
(Ancylostoma duodenale, Necator americanus), enterobiasis (Enterobius vermicularis), trichinellosis
(Trichinella spp)
Presentation
Dosage and duration

– Ascariasis, trichuriasis, hookworm infections
Child over 6 months and adult: 100 mg twice daily for 3 days
Child over 6 months but under 10 kg: 50 mg twice daily for 3 days
– Enterobiasis
Child over 6 months and adult: 100 mg as a single dose
Child over 6 months but under 10 kg: 50 mg as a single dose
A second dose may be given after 2 to 4 weeks.
– Trichinellosis
Child over 2 years: 5 mg/kg/day in 2 divided doses for 10 to 15 days
Adult: 400 mg/day in 2 divided doses for 10 to 15 days

– Do not administer to children less than 6 months.
– May cause: gastrointestinal disturbances, headache, dizziness.
Remarks
– Albendazole is easier to use and is preferred in mixed infections as it has a broader
spectrum of activity.
– Tablets are to be chewed or crushed: follow manufacturer's instructions.
– Take tablets between meals.
– Storage: –
91
MEFLOQUINE = MQ
(Lariam…®)

Therapeutic action
– Antimalarial
Indications
– Prophylaxis of falciparum malaria for non-immune individuals
Presentation
– 250 mg scored tablet
Dosage and duration
– Treatment of falciparum malaria (in combination with artesunate administered on D1, D2, D3)
Child from 3 months (≥ 5 kg) to 6 years: 25 mg base/kg as a single dose
Child ≥ 7 years and adult: 25 mg base/kg in 2 divided doses (15 mg base/kg on D1
followed by 10 mg base/kg on D2)
250 mg tablet
Age
D1 D2
3 to 11 months 1/2 tab –
1 to 6 years 1 tab –
7 to 13 years 2 tab 1 tab
≥ 14 years/adult 4 tab 2 tab
– Prophylaxis of falciparum malaria

Child ≥ 3 months (≥ 5 kg): 5 mg base/kg once a week
Adult: 250 mg base once a week
Travellers should start prophylaxis 2 to 3 weeks before departure and continue throughout
the stay and for 4 weeks after return.
– Do not administer to patients with neuropsychiatric disorders (or history of), seizures,
hypersensitivity to mefloquine or quinine; mefloquine treatment in the previous 4 weeks.
– For completion treatment following parenteral therapy for severe malaria: do not administer
if the patient developed neurological signs during the acute phase.
– For prophylaxis: do not administer to patients with severe hepatic impairment.
– May cause:
• gastrointestinal disturbances, dizziness, headache, sleeping disorders (effects usually
transitory when used for prophylaxis);
• more rarely: neuropsychiatric reactions, heart rhythm disorders, hypo or hypertension,
skin allergies.
– If the patient vomits less than 30 minutes after administration, repeat the full dose. If the
patient vomits within 30 to 60 minutes, re-administer a half the dose.
– Do not combine with anti-epileptics (risk of seizures), coartemether, chloroquine,
halofantrine (risk of seizures, cardiac toxicity).
– Do not administer simultaneously with quinine (risk of seizures, cardiac toxicity). If meflo-
quine is used after quinine IV, administer mefloquine 12 hours after the last dose of quinine.
– Administer with caution to patients taking antiarrhythmics, beta-blockers, calcium-channel
blockers or digitalis (risk of heart rhythm disorders).
– Pregnancy: no contra-indication during the 2nd and 3rd trimester. Safety in the first trimester has not been
definitely established. However, given the risks associated with malaria, the combination artesunate-
mefloquine may be used during the first trimester if it is the only effective treatment available.
Remarks
92
METAMIZOLE = DIPYRONE = NORAMIDOPYRINE
(Nolotil®, Novalgin®...)
1
The use of this drug is not recommended:

– it is potentially harmful;
– it has been taken off the market in many countries;
– it must never be prescribed as a first choice treatment.
Therapeutic action
– Analgesic
– Antipyretic
Indications
– Severe pain
– High fever
Presentation
– 500 mg tablet
Dosage
– Child over 5 years: 250 mg to 1 g/day in 3 divided doses
– Adult: 500 mg to 3 g/day in 3 divided doses
Duration: according to clinical response, 1 to 3 days

– Do not administer in case of gastric ulcer.
– Severe and fatal cases of agranulocytosis have been reported. Use only when usual antipyretics
and analgesics (acetylsalicylic acid and paracetamol) have been ineffective.
Remarks
– Metamizole is not included in the WHO list of essential drugs.
93
METHYLDOPA
(Aldomet®…)
Therapeutic action
– Centrally acting antihypertensive
Indications
– Hypertension in pregnancy
Presentation
– 250 mg tablet
Dosage
– Initially 500 to 750 mg/day in 2 to 3 divided doses for 2 days, then increase gradually if
necessary by 250 mg every 2 to 3 days, until the optimal dose is reached, usually 1,5 g/day.
Do not exceed 3 g/day.
Duration
– According to clinical response. Do not stop treatment abruptly; reduce doses gradually.

– Do not administer to patients with active liver disease, history of drug-related liver disease,
severe depression.
– Administer with caution to patients with hepatic impairment, and reduce doses in patients
with renal impairment.
– May cause:
• orthostatic hypotension, drowsiness, headache, gastrointestinal disturbances, dry
mouth,
• rarely: haematological, hepatic, psychical disorders; allergic reactions.
– Stop treatment if haemolytic anaemia or jaundice appear during treatment.
– In the event of unexplained fever during treatment, check blood count and transaminases
for possible hepatitis due to methyldopa.
– Monitor combination with lithium (risk of lithium overdose), antidepressants (enhanced
hypotensive effect), CNS depressants (increased sedation).
Remarks
94
METOCLOPRAMIDE
(Primperan®…)
1
Therapeutic action
– Anti-emetic
Indications
– Symptomatic treatment of nausea and vomiting
– Gastro-oesophageal reflux
Presentation
– 10 mg tablet
Also comes in 5 mg and 15 mg tablets, 0.1 mg/drop oral solution for paediatric use and
1 mg/ml syrup for adults only.
Dosage
– Nausea and vomiting
Child:
Oral solution
Age Weight Daily dose 10 mg tablet
0.1 mg/drop
Under 1 year Under 10 kg 1 mg x 2 – 10 drops x 2
1 to 3 years 10 to 14 kg 1 mg x 2 to 3 – 10 drops x 2 to 3
3 to 5 years 15 to 19 kg 2 mg x 2 to 3 1/4 tab x 2 to 3 20 drops x 2 to 3
5 to 9 years 20 to 29 kg 2.5 mg x 3 1/4 tab x 3 –
9 to 14 years 30 kg and over 5 mg x 3 1/2 tab x 3 –
Adult: 10 mg every 6 to 8 hours if necessary

Adult: 40 mg/day in 4 divided doses, 30 minutes before meals and at bedtime
Duration: according to clinical response, as short as possible
– Do not administer to patients with gastrointestinal haemorrhage, obstruction or perforation,
seizures.
– May cause:
• drowsiness, headache,
• rarely, extrapyramidal disorders (dyskinesia, tremor) especially in children and young
patients,
• increased frequency of seizures in epileptics,
• worsening of Parkinson disease,
• hyperprolactinemia in the event of prolonged treatment.
– Avoid combination with antispasmodics (hyoscine butylbromide, atropine propantheline)
and neuroleptics.
– Reduce doses if renal or hepatic impairment.
– Breast-feeding: avoid. If clearly needed, do not exceed a treatment period of 7 days.
Remarks
– Storage:
• Tablet and syrup: below 30°C
• Oral solution for paediatric use: below 25°C
95
METRONIDAZOLE
(Flagyl®…)
Therapeutic action
– Antiprotozoal, antibacterial (group of nitroimidazoles)
Indications
– Amoebiasis, giardiasis, trichomoniasis
– Bacterial vaginitis, infections due to anaerobic bacteria (e.g. Clostridium sp, Bacteroides sp, etc.)
Presentation
– 200 mg, 250 mg, 400 mg and 500 mg tablets
– 125 mg/5 ml and 200 mg/5 ml oral suspensions
Dosage and duration

– Amoebiasis
Adult: 500 to 800 mg 3 times daily
The treatment lasts 5 days in intestinal amoebiasis and 5 to 10 days in hepatic amoebiasis.
– Giardiasis
Child: 30 mg/kg once daily for 3 days
Adult: 2 g once daily for 3 days
– Trichomoniasis and bacterial vaginitis
In the event of trichomoniasis, also treat sexual partner.
– Infections due to anaerobic bacteria
Adult: 500 mg 3 times daily
According to indication, metronidazole may be used in combination with other anti-
bacterials; treatment duration depends on indication.

– Do not administer to patients with hypersensitivity to metronidazole or another nitro-
imidazole (tinidazole, secnidazole, etc.).
– May cause: gastrointestinal disturbances; rarely: allergic reactions, brownish urine,
headache, dizziness. Risk of antabuse reaction when combined with alcohol.
– Administer with caution in patients taking oral anticoagulants (risk of haemorrhage),
lithium, phenytoin, ergometrine (increased plasma concentrations of these drugs).
– Reduce total daily dose to 1/3 and give once daily to patients with severe hepatic
impairment.
– Pregnancy: no contra-indication; divide into smaller doses, avoid prolonged use.
– Breast-feeding: significantly excreted in milk (risk of gastrointestinal disturbances in breastfed
infants); divide into smaller doses, avoid prolonged use.
Remarks
Once the bottle has been opened, oral suspension keeps 15 days maximum.
96
MIFEPRISTONE = RU486
1
Therapeutic action
– Antiprogestogen
Indications
– Termination of intra-uterine pregnancy, in combination with misoprostol (or another
prostaglandin)
– Cervical dilatation before aspiration or curettage
– Induction of labour in the event of intrauterine foetal death
Presentation
– 200 mg tablet
Dosage and duration

– Termination of pregnancy (first and second trimester)
200 mg or 600 mg as a single dose, followed by a dose of misoprostol 36 to 48 hours later
200 mg as a single dose, 36 to 48 hours before aspiration or curettage
– Induction of labour in the event of intrauterine foetal death
600 mg once daily for 2 days

– Do not administer to patients with chronic adrenal failure or severe uncontrolled asthma.
– May cause: gastrointestinal disturbances, vaginal bleeding, uterine contractions, headache,
dizziness.
– The efficacy of mifepristone may be reduced in women taking rifampicin, phenytoin,
phenobarbital and carbamazepine.
Remarks
– Mifepristone is administered by oral route only.
– When used for termination of pregnancy, check for complete uterine emptying after
treatment.
– For labour induction in the event of intrauterine foetal death, mifepristone is administered
as the first line treatment. It may be sufficient to initiate labour, but it is often necessary to
administer misoprostol (or another prostaglandin) if labour is not established within 36 to
48 hours of the 2nd dose of mifepristone.
– Mifepristone cannot terminate an ectopic pregnancy and has no role in the management of
ectopic pregnancy.
97
MISOPROSTOL
Therapeutic action
– Cervical ripening agent, oxytocic drug (prostaglandin)
Indications
– Induction of labour when continuation of pregnancy is dangerous for mother and/or
foetus and the cervix is not favourable, especially in the event of intrauterine foetal death
or severe pre-eclampsia
– Treatment of post-partum haemorrhage due to uterine atony, when injectable oxytocics are
not available or ineffective
– Termination of intra-uterine pregnancy, in combination with mifepristone
– Incomplete abortion in the first trimester.
Presentation
– 200 µg tablet
Dosage and duration
– Induction of labour
• intrauterine foetal death: 200 µg (in the 2nd trimester) or 100 µg (in the 3rd trimester)
vaginally, every 4 to 6 hours until labour occurs, up to a maximum of 3 doses per
24 hours, to be repeated the following day, if necessary
• viable pregnancy: 25 µg vaginally, every 4 to 6 hours until labour occurs, up to a maximum
of 6 doses or 150 µg
400 µg vaginally as a single dose, 3 hours before procedure
– Treatment of post-partum haemorrhage
1000 µg rectally as a single dose
– Termination of pregnancy (first and second trimester)
36 to 48 hours after the administration of mifepristone, administer misoprostol: 400 µg orally
or vaginally, to be repeated every 3 hours, up to a maximum of 5 doses
– Incomplete abortion in the first trimester
600 µg orally as a single dose
– During the 2nd and the 3rd trimester:
• Do not administer in the event of malpresentation, true cephalo-pelvic disproportion,
complete placenta praevia.
• In the event of history of caesarean section or grand multiparity:
- If the foetus is viable: a caesarean section is indicated, do not administer misoprostol
(risk of uterine rupture);
- If the foetus is dead or non-viable, or viable but a caesarean section cannot be performed:
reduce the dose by half (risk of uterine rupture).
– For labour induction:
• Do not administer simultaneously with oxytocin. At least 6 hours must have elapsed
since the last administration of misoprostol before oxytocin can be given.
• Regular monitoring of the intensity and frequency of contractions is mandatory.
• If the foetus is viable, continuous foetal heart monitoring is mandatory for 30 minutes
after administration of each dose of misoprostol and once contractions are experienced
or detected.
– May cause: gastrointestinal disorders, headache, dizziness, fever, chills, uterine hypertonia,
uterine rupture, foetal distress.
– If the woman vomits within 30 minutes of oral administration, administer the same dose
vaginally.
Remarks
– When the cervix is favourable, induce labour through administration of oxytocin and
artificial rupture of the membranes.
– When used for termination of pregnancy, check for complete uterine emptying after treatment.
– Storage: below 30° C
98
MORPHINE immediate-release (MIR)
(Sevredol®…)
1
Therapeutic action
– Centrally acting opioid analgesic
Indications
– Severe pain
Presentation
– 10 mg immediate-release tablet
Also comes in 2 mg/ml oral solution for paediatric use.
Dosage
There is no standard dose. The optimal dose is that which provides efficient pain relief to the
patient. It is adjusted in relation to the regular assessment of pain intensity and the incidence
of adverse effects.
– Day 1:
• Start with a scheduled treatment (scheduled doses):
Child over 6 months: 1 mg/kg/day in 6 divided doses at 4-hour intervals
Adult: 60 mg/day in 6 divided doses at 4-hour intervals
• Adjust the treatment if pain persists by administering “rescue” doses between the
scheduled doses. The rescue doses administered are the same as the scheduled doses.
– Then, adjust scheduled treatment every 24 hours according to the total dose given the day
before (i.e. total scheduled doses + total rescue doses).
For example, Day 1, for a dose of 60 mg/day, i.e. 10 mg every 4 hours:
Hours 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 0 1 2 3 4 5 6 7
10 mg
10 mg
10 mg
10 mg
10 mg
10 mg
Scheduled
doses
10 mg moderate pain
10 mg moderate pain
10 mg moderate pain
severe pain
mild pain
mild pain
mild pain
mild pain
mild pain
Example mild pain

simple
verbal scale
Example
rescue
doses
In this example, the scheduled treatment on Day 2 is 90 mg/day, i.e. 60 mg (total scheduled
doses on Day 1) + 30 mg (total rescue doses on Day 1) in 6 divided doses, i.e. 15 mg every
4 hours.
– Scheduled doses must be administered at regular time intervals and not on demand, even
at night, unless the patient is abnormally drowsy (in this event, delay the administration).
– Reduce the dose by half in elderly patients and patients with renal or hepatic impairment.
Duration: once the pain is controlled, change to sustained-release morphine.
– See sustained-release oral morphine (MSR).
Remarks
– Administer an appropriate laxative (e.g. lactulose) if analgesic treatment continues more
than 48 hours.
– The morphine dose in tablets is not suitable for young children. Use oral solution instead.
If this is not available, use injectable morphine by the oral route: dilute an ampoule of
10 mg/ml (1 ml) with 9 ml of water to obtain a solution containing 1 mg/ml.
– Morphine is on the list of narcotics: follow national regulations.
99
MORPHINE sustained-release (MSR)
(Kapanol® …)
Therapeutic action
Indications
– Severe and persistent pain, especially cancer pain
Presentation
– 10 mg, 30 mg and 60 mg sustained-release capsules or tablets
Dosage
– Usually, the effective daily dose is determined during the initial treatment with immediate-
release morphine (MIR). When changing from MIR to MSR, the daily dose remains the
same. For example, if the effective dose of MIR is 20 mg 6 times/day (120 mg/day), the
dose of MSR is 60 mg 2 times/day (120 mg/day).
– If treatment is initiated directly with MSR:
• Child over 6 months: initially 1 mg/kg/day in 2 divided doses at 12-hour intervals
• Adult: initially 60 mg/day in 2 divided doses at 12-hour intervals
Adjust the dose if necessary, increasing the dose by 50% per day until pain relief is
obtained.
– Patients stabilized on MSR may require rescue doses of MIR in the event of episodic
(breakthrough) pain. A rescue dose corresponds to 10% of the daily MSR dose. If a patient
regularly requires more than 3 rescue doses per day, increase the daily MSR dose by the
sum of rescue doses.
Duration
– According to clinical response. Do not stop long-term treatment abruptly. Decrease doses
progressively to avoid withdrawal symptoms.

– Do not administer to patients with severe respiratory impairment or decompensated
hepatic impairment.
– Do not initiate treatment with the sustained-release formulation in elderly patients or those
with renal or hepatic impairment. Begin treatment with the immediate release formulation
(MIR).
– May cause:
• dose-related sedation and respiratory depression, nausea, vomiting, constipation, urinary
retention, confusion, raised intracranial pressure, pruritus;
• in the event of overdose: excessive sedation, respiratory depression, coma.
of naloxone. Monitor patient closely for several hours.
– Administer with caution to patients with respiratory impairment, head injury, raised intra-
cranial pressure, uncontrolled epilepsy or urethroprostatic disorders.
100
– Do not combine with opioid analgesics with mixed agonist-antagonist activity such as
buprenorphine, nalbuphine, pentazocine (competitive action).
1
– Increased risk of sedation and respiratory depression, when combined with alcohol and
drugs acting on the central nervous system: benzodiazepines (diazepam, etc.), neuroleptics
(chlorpromazine, haloperidol, etc.), antihistamines (chlorphenamine, promethazine),
phenobarbital, etc.
– Pregnancy and breast-feeding: no contra-indication. The child may develop withdrawal symptoms,
respiratory depression and drowsiness when the mother receives morphine at the end of the 3rd trimester
and during breast-feeding. In these situations, administer with caution, for a short period, at the
lowest effective dose, and monitor the child.
Remarks
than 48 hours.
– Do not crush or chew capsules. They can be opened and emptied into food.
101
MULTIVITAMINS – VITAMIN B COMPLEX
Therapeutic action
– Vitamin supplementation
Indications
– Few indications: this drug has no effect in case of real vitamin deficiency. Nevertheless,
vitamin supplementation helps to prevent some deficiencies in people at risk (e.g. pregnant
women).
Presentation
– Tablet. Composition varies in quality and quantity, with manufacturers.
Examples of composition per tablet:
Multivitamins B complex Daily needs (adult)
Vitamin A 2500 IU / 2500 IU
Vitamin B1 1 mg 1 mg 0.9 to 1.3 mg
Vitamin B2 0.5 mg 1 mg 1.5 to 1.8 mg
Vitamin B3 (= PP) 7.5 mg 15 mg 15 to 20 mg
Vitamin C 15 mg / 10 mg
Vitamin D3 300 IU / 100 to 200 IU
Dosage
– Child under 5 years: 1 tab/day
– Child over 5 years: 2 tab/day
– Adult: 3 tab/day
Duration: depending on situation

Remarks
– Specific vitamin deficiency states require appropriate doses of vitamins.
– Multivitamins are not included in the WHO list of essential medicines.
– Storage: keep in a cool place (8°C to 15°C) –
102
NALIDIXIC ACID
(Negram®…)
1
The WHO no longer recommends the use of

nalidixic acid for the treatment of shigellosis, even
in areas where it is still effective.
Therapeutic action
– Antibacterial (group of quinolones)
Indications
– Acute uncomplicated cystitis, without fever or lumbar pain
Presentation
– 500 mg tablet
Dosage and duration

– Child over 3 months: 30 to 50 mg/kg/day in 4 divided doses for 7 days
– Adult: 4 g/day in 4 divided doses for 7 days

– Do not administer to patients with severe renal impairment, history of convulsions, G6PD
deficiency.
– May cause: gastrointestinal disturbances, allergic reactions, photosensitivity, neurological
disorders (headache, dizziness, visual disturbances).
– Administer with caution and reduce doses in patients with hepatic or renal impairment.
Remarks
– Due to its efficacy, safety and ease of administration, ciprofloxacin is the first-line antibiotic
for shigellosis and cystitis.
– Once resistant to nalidixic acid, bacteria become very easily resistant to other quinolones
(ciprofloxacin, etc.).
– Nalidixic acid is not included in the WHO list of essential medicines.
103
NEVIRAPINE = NVP
(Neravir®, Nevimune®,Viramune®…)
Therapeutic action
– Antiretroviral, HIV-1 non nucleoside reverse transcriptase inhibitor
Indications
– HIV-1 infection, in combination with other antiretroviral drugs
Presentation
– 200 mg tablet
– 50 mg/5 ml oral suspension
Dosage
– Child from 2 months to 8 years: 4 mg/kg once daily for 14 days, then 14 mg/kg/day in 2 divided
doses from the 15th day
– Child over 8 years: 4 mg/kg once daily for 14 days, then 8 mg/kg/day in 2 divided doses from
the 15th day, without exceeding 400 mg/day
– Adult: 200 mg once daily for 14 days, then 400 mg/day in 2 divided doses from the 15th day
10 mg/ml oral suspension 200 mg tablet

Weight
Initial Maintenance Initial Maintenance
5 to 9 kg 3 ml 6 ml x 2 Use oral –
10 to 14 kg 5 ml 10 ml x 2 suspension 1/2 tab x 2
15 to 19 kg 7 ml 14 ml x 2 1/2 tab 1 tab AM and 1/2 tab PM
< 8 years: 16 ml x 2 < 8 years: 1 tab AM and 1/2 tab PM
20 to 24 kg 10 ml 1/2 tab
> 8 years: 10 ml x 2 > 8 years: 1/2 tab x 2
< 8 years: 20 ml x 2 < 8 years: 1 tab x 2
25 to 29 kg 12 ml 1/2 tab
> 8 years: 12 ml x 2 > 8 years: 1/2 tab x 2
30 to 39 kg 14 ml 14 ml x 2 1 tab 1 tab AM and 1/2 tab PM
40 to 49 kg – – 1 tab 1 tab x 2
≥ 50 kg – – 1 tab 1 tab x 2
Duration: the duration of treatment depends on the efficacy and tolerance of nevirapine.
– Do not administer to patients with severe hepatic impairment, history of severe intolerance to
nevirapine that led to permanent discontinuation of treatment.
– May cause:
• cutaneous reactions sometimes severe (Lyell's and Stevens-Johnson syndromes), hepatic disorders
possibly severe (fulminant hepatitis). In these cases, stop taking nevirapine immediately and
permanently.
• gastrointestinal disturbances, headache, myalgia.
– Nevirapine reduces the efficacy of oestrogen-progestogen oral contraceptives: offer an alternative
or make sure that there is > 20 µg ethinylestradiol per tablet.
– Avoid combination with rifampicin (decreases the efficacy of nevirapine). If the administration
of rifampicin is required, use efavirenz rather than nevirapine.
– Monitor liver enzyme level (ALAT) during the first 2 months, then every 3 to 6 months. If the
enzyme level reaches 5 times the normal level, stop nevirapine immediately.
Remarks
– For prophylactic treatment to reduce mother-to-child transmission, check national recom-
mendations.
– To improve tolerance, respect the initial 14-day phase of treatment. In the event of restarting
treatment after having stopped for more than 7 days, recommence initial 14-day phase.
– Tablets are not scored. When half a tablet is required, use a cutter to cut the tablet into two
equal parts.
– Also comes in fixed-dose combination tablets incorporating nevirapine-lamivudine-stavudine
(Triomune®, Triviro®…).
Once opened, oral suspension keeps for 2 months maximum.
104
NICLOSAMIDE
(Tredemine®, Yomesan®…)
Therapeutic action
– Anthelminthic (taenicide)
Indications
– Taeniasis: beef tapeworm (Taenia saginata), pork tapeworm (Taenia solium), dwarf tapeworm
(Hymenolepis nana) and fish tapeworm (Diphyllobothrium latum)
Presentation
– 500 mg chewable tablet
Dosage and duration

– T. saginata, T. solium and D. latum
Child under 2 years: 500 mg as a single dose
Child from 2 to 6 years: 1 g as a single dose
Child over 6 years and adult: 2 g as a single dose
– H. nana
Child under 2 years: 500 mg on the first day, then 250 mg/day for 6 days
Child from 2 to 6 years: 1 g on the first day, then 500 mg/day for 6 days
Child over 6 years and adult: 2 g on the first day, then 1 g/day for 6 days

– May cause: gastrointestinal disturbances.
Remarks
– Chew or crush the tablets before swallowing and washing down with water.
– In the event of vomiting, the single dose may be divided in 2 doses taken with an interval
of one hour.
– As niclosamide is a taenicide, do not expect the patient to expel the worm, portions are
voided in a partially digested form.
– Niclosamide is not active against the larval form of T. solium (cysticercosis).
105
NICOTINAMIDE = VITAMIN PP = VITAMIN B3
Therapeutic action
– Vitamin
Indications
– Treatment of pellagra
Presentation
– 50 mg tablet
Dosage
– Child: 100 to 300 mg/day in 2 to 3 divided doses
– Adult: 300 to 500 mg/day in 2 to 3 divided doses

– Pregnancy and breast-feeding: avoid, except if clearly needed (safety is not established)
Remarks
– Nicotinamide is also called niacinamide.
– Vitamin PP deficiency is common when diet is almost entirely based on sorghum, millet or
maize.
– Vitamin PP deficiency often occurs in association with other vitamin B-complex deficiency
(thiamine, pyridoxine), especially in alcoholic patients.
– Vitamin PP is usually one of the components of multivitamin preparations and B-complex
(7.5 mg to 15 mg/tablet).
– Nicotinic acid has a similar action to nicotinamide, but is no longer used because of its
adverse effects, especially its vasodilator action.
– Storage:
106
NIFEDIPINE
(Adalat®, Adalat®LA…)
1
Therapeutic action
– Uterine relaxant
– Antihypertensive drug (calcium channel blocker)
Indications
– Threatened premature labour
– Hypertension
Presentation
– 10 mg short-acting (liquid-filled) capsule
– 10 mg prolonged-release tablet
Also comes in 20 mg, 30 mg, 60 mg and 90 mg prolonged-release tablets to be administered
once daily or to be administered twice daily. Follow manufacturer's instructions.
Dosage
– Threatened premature labour (short-acting capsule)
10 mg by oral route, to be repeated every 15 minutes if uterine contractions persist
(maximum 4 doses or 40 mg), then 20 mg by oral route every 6 hours
– Hypertension (prolonged-release tablets)
20 to 100 mg/day in 2 divided doses or 20 to 90 mg once daily depending on the preparation
used
Duration
– Threatened premature labour: 48 hours
– Hypertension: lifetime treatment
– Do not administer to patients with severe cardiac disease (recent myocardial infarction,
unstable angina).
– Do not administer if systolic blood pressure is below 90 mmHg.
– May cause:
• headache, flushing, peripheral oedema (common adverse effects at the start of
treatment);
• dizziness, hypotension, tachycardia, nausea, gingival hyperplasia, rash.
– Stop nifedipine if ischaemic chest pain occurs or existing pain increases shortly after
starting treatment.
– Do not combine with magnesium sulphate, salbutamol IV, and calcium channel blockers.
– Monitor combination with cimetidine (additive hypotension), phenytoin (risk of phenytoin
toxicity), rifampicin (efficacy of nifedipine diminished), itraconazole (increased risk of
oedema), beta-blockers (enhanced antihypertensive effects).
– Pregnancy: CONTRA-INDICATED during the 1st trimester. Never administer sublingually (risk of
foetal death from placental hypoperfusion).
Remarks
– Methyldopa and beta-blockers are the drugs of choice for treating hypertension in
pregnancy.
– Short-acting formulations of nifedipine should not be used in hypertension since their use
may cause excessive fall in blood pressure and cerebral or myocardial ischaemia.
– Prolonged-release tablets must be swallowed whole.
107
NITROFURANTOIN
(Furadantin®…)
Therapeutic action
– Antibacterial (group of nitrofuranes)
Indications
– Uncomplicated cystitis, without fever or lumbar pain
Presentation
– 100 mg tablet
Also comes in 50 mg tablet or capsule and 25 mg/5 ml oral solution.
Dosage and duration

– Child over 3 months: 3 to 5 mg/kg/day in 3 divided doses for 5 to 7 days
– Adult: 300 mg/day in 3 divided doses for 5 to 7 days
3 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
1/4 to 1/2 tab 1/2 to 1 tab
50 mg tablet 1/4 tab x3 2 tab x 3
Do not x3 x3
administer 1/4 to 1/2 tab
100 mg tablet – – 1 tab x 3
x3

– Do not administer to patients with renal impairment, allergy to nitrofurantoin.
– May cause: nausea, vomiting, allergic reactions; haemolytic anaemia in patients with G6PD
deficiency.
– Do not administer simultaneously with antacids, administer 2 hours apart.
– Pregnancy: CONTRA-INDICATED during the last month of pregnancy (risk of haemolysis in newborn)
– Breast-feeding: avoid during the first month
Remarks
– Take during meals.
108
NYSTATIN
(Mycostatin®, Nystan®…)
1
Therapeutic action
– Antifungal
Indications
– Oropharyngeal, oesophageal and intestinal candidiasis
Presentation
– 100 000 IU lozenge
– 100 000 IU and 500 000 IU film coated tablets
– 100 000 IU/ml oral suspension
Dosage and duration

– Oropharyngeal candidiasis
Child and adult: 400 000 IU/day in 4 divided doses between meals for 7 days. The lozenge
should be sucked. For children, use the oral suspension or crush lozenges and apply to the
affected area.
It may be necessary to increase the dose to 2 000 000 IU/day in immunocompromised
patients.
– Oesophageal and intestinal candidiasis
Child: 400 000 IU/day in 4 divided doses between meals for 20 days
Adult: 2 000 000 IU/day in 4 divided doses between meals for 20 days

– The drug is well tolerated.
Remarks
– Film coated tablets used for the treatment of oesophageal and intestinal candidiasis are
meant to be swallowed. They may be sucked when used for oropharyngeal candidiasis.
– Vaginal tablets may be used for the treatment of oropharyngeal candidiasis, in spite of their
disagreeable taste.
– In immunocompetent patients, oropharyngeal candidiasis may also be treated by applying
gentian violet.
– In immunocompromised patients:
• For oropharyngeal candidiasis: by preference use miconazole muco-adhesive tablets or
clotrimazole lozenge.
• For oesophageal candidiasis: use fluconazole.
Once the vial has been opened, oral suspension keeps 7 days.
109
OMEPRAZOLE
(Mopral®…)
Therapeutic action
– Antiulcer drug (proton pump inhibitor)
Indications
– Benign peptic ulcer
– Complicated peptic ulcer (perforation, haemorrhage), for healing and preventing recurrence,
in combination with 2 antibacterial drugs to eradicate Helicobacter pylori
Presentation
– 10 mg and 20 mg capsules
Dosage and duration

Adult:
• Short-term relief of symptoms: 20 mg once daily in the morning for 3 days
• Treatment of gastro-oesophageal reflux disease: 20 mg once daily in the morning for
4 weeks (up to 8 weeks according to severity)
– Benign peptic ulcer
20 mg once daily in the morning for 7 to 10 days
– H. pylori eradication
40 mg/day in 2 divided doses for 10 days (in combination with metronidazole or tinidazole
+ amoxicillin or clarithromycin)

– May cause: headache, diarrhoea, skin rash, nausea, abdominal pain, dizziness.
– Avoid combination with itraconazole and ketoconazole (decreases efficacy of these drugs).
– Monitor combination with warfarin, digoxin, phenytoin.
– Do not exceed 20 mg/day in patients with severe hepatic impairment.
– Pregnancy: avoid during the 1st trimester (safety is not established)
Remarks
– Swallow capsules whole, do not chew.
– For mild symptoms of gastro-oesophageal reflux, use antacids as first line treatment.
– For peptic ulcer perforation: use omeprazole IV. As soon as the patient can eat, change to
oral treatment (omeprazole is equally effective when given IV or orally).
– Omeprazole is recommended by the WHO for the eradication treatment of H. pylori but is
not included in the WHO list of essential medicines.
110
ORAL REHYDRATION SALTS = ORS
Indications 1
– Prevention and treatment of dehydration from acute diarrhoea, cholera, etc.
Presentation
– Sachet of powder to be diluted in 1 litre of clean water.
– WHO formulation:
grams/litre mmol/litre
sodium chloride 2.6 sodium 75
glucose 13.5 chloride 65
potassium chloride 1.5 glucose 75
trisodium citrate 2.9 potassium 20
citrate 10
Total weight 20.5 Total osmolarity 245
Dosage
– Prevention of dehydration (WHO - Treatment plan A)
Child under 24 months: 50 to 100 ml after each loose stool (approximately 500 ml/day)
Child from 2 to 10 years: 100 to 200 ml after each loose stool (approximately 1000 ml/day)
Child over 10 years and adult: 200 to 400 ml after each loose stool (approximately 2000 ml/day)
– Treatment of moderate dehydration (WHO - Treatment plan B)
Child and adult:
Over the first four hours:
under 4 to 11 12 to 23 15 years
Age 2 to 4 years 5 to 14 years
4 months months months and over
30 kg
Weight under 5 kg 5 to 7.9 kg 8 to 10.9 kg 11 to 15.9 kg 16 to 29.9 kg
and over
ORS in ml 200 to 400 400 to 600 600 to 800 800 to 1200 1200 to 2200 2200 to 4000
After four hours:

If there are no signs of dehydration: follow Treatment plan A.
If there are signs of moderate dehydration: repeat Treatment plan B.
If there are signs of severe dehydration: start IV therapy (Treatment plan C).
– Treatment of severe dehydration (WHO - Treatment plan C)
In combination with IV therapy and only to a conscious patient:
Child and adult: 5 ml/kg/hour
After 3 hours (6 hours in infants), reassess and choose the appropriate plan A, B or C.
Duration: as long as diarrhoea and signs of dehydration persist.
– If the eyelids become puffy during the treatment: stop ORS, give plain water then, resume
ORS according to Treatment plan A when the puffiness is gone.
– If case of vomiting, stop ORS for 10 min and then resume at a slower rate (very small,
frequent, amounts); do not stop rehydration.
Remarks
– A special ORS-formula, ReSoMal, is used under medical supervision, for severely
malnourished children only. However, in malnourished children with cholera, standard
ORS-formula is used instead of ReSoMal.
– Storage:
Do not use the powder if it has turned into a yellow-brownish sticky substance.
Once prepared, the solution must be used within 24 hours.
111
PARACETAMOL = ACETAMINOPHEN
(Doliprane®, Panadol®…)
Therapeutic action
– Analgesic, antipyretic
Indications
– Mild pain
– Fever
Presentation
Dosage
– Child: 60 mg/kg/day in 3 or 4 divided doses
– Adult: 3 to 4 g/day in 3 or 4 divided doses
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
tab
1/2 3/4 to 11/2 tab 11/2 to 3 tab
100 mg tablet – –
x3 x3 x3
1/4 to 1/2 tab 1/2 to 11/2 tab
500 mg tablet – – 2 tab x 3
x3 x3
120 mg/5 ml oral solution 2 ml x 3 3 to 6 ml x 3 – – –
– Maximum doses: child: 80 mg/kg/day; adult: 4 g/day

– Administer with caution to patients with hepatic impairment.
– Do not exceed indicated doses, especially in children and elderly patients. Paracetamol
intoxications are severe (hepatic cytolysis).
Remarks
– For mild pain, paracetamol is used alone or in combination with an NSAID.
– For moderate pain, paracetamol is used in combination with an NSAID and codeine or
tramadol.
– For severe pain, paracetamol is used in combination with an NSAID and morphine.
– Paracetamol is particularly recommended for patients allergic to aspirin, patients with a
history of gastric problems and for pregnant and breast-feeding women and children.
– Paracetamol has no anti-inflammatory properties.
112
PHENOBARBITAL
(Gardenal®, Luminal®…)
1
Therapeutic action
– Anticonvulsant, sedative and hypnotic
Indications
– Epilepsy: tonic-clonic (grand mal) and partial (focal) seizures
Presentation
– 15 mg, 30 mg, 50 mg and 100 mg tablets
Dosage
Follow national protocol.
For information:
– Child: initial dose of 3 to 4 mg/kg once daily or in 2 divided doses, increase to
8 mg/kg/day if necessary
– Adult: initial dose of 2 mg/kg once daily at bedtime (up to 100 mg maximum), then, increase
gradually if necessary, to the maximum dose of 6 mg/kg/day in 2 to 3 divided doses.
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
Initial dose:
30 mg tablet 1/2 tab x 2 11/2 tab x 2 3 tab
50 mg tablet 1 tab x 2 2 tab
100 mg tablet 1 tab 1 tab

– Do not administer in respiratory depression.
– May cause: drowsiness, depression of the central nervous system.
– Do not stop treatment abruptly.
nervous system such as diazepam, chlorphenamine, chlorpromazine, etc.
– Decreases oral contraceptive efficacy.
Remarks
– Phenobarbital is subject to international controls: follow national regulations.
– Plasma-concentrations are stable after 2 to 3 weeks. Caution: risk of accumulation.
– If necessary, phenytoin may be combined with phenobarbital.
113
PHENOXYMETHYLPENICILLIN = PENICILLIN V
(Oracilline®, Ospen®…)
Therapeutic action
Indications
– Streptococcal tonsillitis, buccodental infections, cutaneous anthrax
– Parenteral to oral switch therapy
Presentation
– 250 mg tablet (400 000 IU)
– Powder for oral suspension, 125 mg/5 ml (200 000 IU/5 ml) and 250 mg/5 ml (400 000 IU/5 ml)
Dosage
– Child under one year: 250 mg/day in 4 divided doses
– Child from 6 to 12 years: 1 g/day in 4 divided doses
– Adult: 2 g/day in 4 divided doses
For the treatment of tonsillitis, the daily dose may be given in 2 divided doses.
Duration
– Streptococcal tonsillitis: 10 days
– Buccodental infections: 3 to 5 days
– Cutaneous anthrax: 7 to 10 days

occur).
Remarks
– Storage:
Once reconstituted, the oral suspension keeps for 15 days, below 25°C.
114
PHENYTOIN
(Di-hydan®, Dilantin®, Epanutin®…)
1
Therapeutic action
– Anticonvulsant
Indications
– Epilepsy, except absence seizure (petit mal)
Presentation
– 100 mg tablet
Aslo comes in 25 mg and 50 mg tablets.
Dosage
– Child: 3 to 8 mg/kg/day in 2 to 3 divided doses
– Adult: 2 to 6 mg/kg/day in 2 to 3 divided doses; do not exceed 500 to 600 mg/day
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
1/2tab 1/2 to 1 tab 1/2 to 1 tab
100 mg tablet
x2 x2 x3

– Do not administer in case of hypersensitivity to phenytoin.
– May cause:
• gastro-intestinal disturbances: gingival hypertrophy, nausea, vomiting;
• blood disorders: monitor blood counts if possible and administer folic acid in case of
prolonged use;
• neurological disorders: dizziness, visual disturbances, mental confusion;
• allergic reactions: cutaneous eruption, fever, adenopathy.
– Do not stop treatment abruptly, decrease daily doses gradually.
– It is not recommended to combine phenytoin with oral contraceptives, sulphonamides, or
chloramphenicol. Combination with other drugs must be closely monitored (diazepam,
phenobarbital, digoxin, corticosteroids, etc.).
Remarks
Never use phenytoin after expiry date (risk of underdosage).
115
POTASSIUM CHLORIDE
(Kaleorid®LP, Slow-K®…)
Therapeutic action
– Potassium supplement
Indications
– Hypokalaemia induced by thiazide diuretics (e.g. hydrochlorothiazide) and loop diuretics
(e.g. furosemide)
Presentation
– 600 mg potassium chloride controlled release tablet (8 mmol of K+)
Warning, strengths vary with manufacturers.
Dosage
– Adult: 15 to 25 mmol/day = 2 to 3 tab/day in 2 to 3 divided doses
– Do not exceed indicated doses if potassium serum levels cannot be measured.
Duration: according to clinical response and duration of diuretic treatment

– May cause: diarrhoea, nausea and vomiting; oeso-gastro-duodenal ulcerations.
– Tablets are to be taken at the end of meals in order to reduce the risk of gastrointestinal
ulcerations.
– Do not combine with potassium-sparing diuretics (e.g. spironolactone).
– Administer with caution and reduce dosage in elderly patients and in patients with renal
impairment.
Remarks
– When it is possible to monitor serum-potassium levels, higher doses may be given: if serum-
potassium level is < 3.5 mmol/l, start with 52 mmol/day (4 g potassium chloride/day).
– If tablets are not available, a lack of potassium may be corrected by a diet rich in dates,
bananas, mangos, oranges, tomatoes, etc.
– Storage:
116
PRAZIQUANTEL
(Biltricide®, Cysticide®…)
1
Therapeutic action
– Anthelminthic
Indications
– Urinary (S. haematobium) and intestinal (S. mansoni, S. japonicum, S. mekongi, S. intercalatum)
schistosomiasis
– Taeniasis (T. saginata, T. solium, H. nana)
– Pulmonary (P. westermani), hepatobiliary (O. felineus, O. viverrini, C. sinensis) and intestinal
(F. buski, H. heterophyes, M. yokogawai) flukes
Presentation
Dosage and duration

Child over 2 years and adult:
– Schistosomiasis
• S. haematobium, S. mansoni, S. intercalatum: 40 mg/kg as a single dose or in 2 divided
doses administered 4 hours apart
• S. japonicum, S. mekongi: 40 mg/kg as a single dose or 60 mg/kg in 2 to 3 divided doses
administered 4 hours apart
– Taeniase
• T. saginata, T. solium: 5 to 10 mg/kg as a single dose
• H. nana: 25 mg/kg as a single dose
– Fluke infections
• lung: 75 mg/kg/day in 3 divided doses for 2 to 3 days
• hepatobiliary: 75 mg/kg/day in 3 divided doses for 1 to 2 days
• intestinal: 75 mg/kg in 3 divided doses, 1 day

– Do not administer to patients with ocular cysticercosis.
– May cause:
• drowsiness, headache, gastrointestinal disturbances, dizziness; rarely: allergic reactions.
• neurological disorders (headache, seizures) in patients with undiagnosed neuro-
cysticercosis.
– Pregnancy: no contra-indication for the treatment of schistosomiasis and taeniasis. If immediate
treatment not considered essential for fluke infections, it should be delayed until after delivery.
Remarks
– Praziquantel is not active against certain liver flukes (Fasciola hepatica and gigantica). For
this indication, use triclabendazole.
– Storage:
117
PREDNISOLONE and PREDNISONE
Therapeutic action
– Steroidal anti-inflammatory drug (corticosteroid)
Indications
– Symptomatic treatment of allergic and inflammatory diseases or reactions, e.g.:
• Pneumocystis carinii (jiroveci) pneumonia with severe hypoxia
• Certain severe forms of extra-pulmonary tuberculosis
• Severe immune reconstitution syndrome, following initiation of antiretroviral or anti-
tuberculous treatment
• Leprous neuropathy (especially reversal reaction)
• Severe persistent asthma, in the event of treatment failure with high doses of inhaled
corticoids
– Prevention of inflammatory reaction triggered by antiparasitic treatment (e.g. trichinellosis)
Presentation
– 5 mg tablet
Dosage
The dose depends on indication, patient’s response and tolerance. If treatment lasts over
10 days, a high initial dose should be reduced as quickly as possible to the lowest effective
maintenance dose.
– Child:
initial dose: 0.5 to 2 mg/kg/day maintenance dose: 0.25 to 0.5 mg/kg/day
– Adult:
initial dose: 20 to 70 mg/day maintenance dose: 5 to 15 mg/day
– Administer preferably as a single daily dose, in the morning, with food.
Duration
– According to indication and clinical response. If the treatment lasts more than 3 weeks: do
not stop abruptly, reduce the daily dose gradually.

– Do not administer to patients with active peptic ulcer (except if ulcer under treatment);
infections not controlled by a specific treatment; acute viral infection (e.g. hepatitis, herpes
simplex or zoster).
– May cause (prolonged treatment with high doses): adrenal suppression, muscle atrophy,
growth retardation, increased susceptibility to infections, hypokalaemia, sodium and water
retention (oedema and hypertension), osteoporosis.
– In the event of acute adrenal failure, use IV hydrocortisone.
– Breast-feeding: no contra-indication; take tablets just after a feed and wait 4 hours before the next
feed if possible.
Remarks
– 5 mg of prednisolone has the same anti-inflammatory activity as 5 mg of prednisone,
0.75 mg of dexamethasone and 20 mg of hydrocortisone.
118
PROGUANIL
(Paludrine®…)
1
Therapeutic action
– Antimalarial
Indications
– Malaria prophylaxis in non immune persons, in combination with chloroquine
Presentation
– 100 mg tablet
Dosage
– Child: 3 mg/kg/day in combination with chloroquine
– Adult: 200 mg/day in combination with chloroquine
Age Weight 100 mg tablet

Under 8 months 5 to 8 kg 1/4 tab/day
8 months to 3 years 9 to 16 kg 1/2 tab/day
4 to 7 years 17 to 24 kg 3/4 tab/day
8 to 10 years 25 to 35 kg 1 tab/day
11 to 13 years 36 to 50 kg 1 1/2 tab/day
14 years and over 50 kg and over 2 tab/day
Duration
– Start proguanil (combined with chloroquine) 24 hours before departure, continue throu-
ghout the stay and for at least 4 weeks after return.

– May cause: mild and transient gastrointestinal disturbances, aphthous ulceration.
– Reduce dose in patients with renal impairment.
Remarks
– Take tablets with water, every day at the same time, after a meal.
– A fixed-dose combination of proguanil 200 mg + chloroquine 100 mg (Savarine®) can be
used in adults (1 tab/day). Due to its strength, it cannot be used in children under 15 years.
– A fixed-dose combination tablets of proguanil-atovaquone (Malarone®) are also used in
malaria prophylaxis: proguanil 100 mg + atovaquone 250 mg: 1 tab/day in children over 40
kg and adults; proguanil 25 mg + atovaquone 62.5 mg in children under 40 kg: 1 tab/day
from 11 to 20 kg; 2 tab/day from 21 to 30 kg; 3 tab/day from 31 to 40 kg. For this combi-
nation, start 24 hours before departure, continue throughout the stay and for at least 7 days
after return.
119
PROMETHAZINE
(Phenergan®…)
Therapeutic action
– Sedating antihistaminic, anti-emetic
Indications
etc.)
Presentation
– 25 mg tablet
Also comes in 10 mg tablets and 1 mg/ml syrup.
Dosage
– Allergic reactions
Child from 2 to 5 years: 5 to 15 mg once daily or in 2 divided doses
Child from 5 to 10 years: 10 to 25 mg once daily or in 2 divided doses
Child over 10 years and adult: 25 to 50 mg once daily or in 2 divided doses
Child from 2 to 10 years: 10 to 25 mg to be repeated every 6 hours if necessary
Child over 10 years and adult: 25 mg to be repeated every 6 hours if necessary
Duration
– According to clinical response, single dose or for a few days if necessary

– Avoid in children under 2 years (safety is not established).
– May cause: drowsiness (administer preferably once daily at night), dryness of the mouth,
constipation, urinary retention, blurred vision.
barbital, etc.
– Pregnancy: avoid at the end of pregnancy; no prolonged treatment
– Breast-feeding: not recommended (drowsiness and risk of apnoea in the newborn infant)
Remarks
120
PYRANTEL
(Combantrin®…)
Therapeutic action
– Anthelminthic
Indications
– Ascariasis
– Enterobiasis
– Ancylostomiasis
– Trichinellosis
Presentation
– 250 mg pyrantel embonate chewable tablet
– Oral suspension, 50 mg pyrantel embonate per ml
Dosage and duration

– Ascariasis
Child and adult: 10 mg/kg as a single dose
– Enterobiasis
Child and adult: 10 mg/kg as a single dose followed by a second dose after 2 to 4 weeks
– Ancylostomiasis
Child and adult: 10 mg/kg as a single dose; in severe infection, 10 mg/kg once daily for
4 days
– Trichinellosis
Child and adult: 10 mg/kg once daily for 5 days

– May cause: gastrointestinal disturbances, headache, dizziness, drowsiness, skin rash.
Remarks
– Preferably use albendazole or mebendazole for these indications. However, when these
drugs are contra-indicated, e.g. in children under one year, pyrantel is an alternative.
– Storage:
121
PYRAZINAMIDE
(Trebazid®, Zinamide®…)
Therapeutic action
Indications
– Tuberculosis, in combination with other antituberculous antibacterials
Presentation
– 400 mg tablet
Dosage
– Child: 20 to 40 mg/kg once daily; maximum 2 g/day
– Adult: 25 mg/kg once daily; maximum 2 g/day

– Reduce the dose in patients with renal impairment.
– May cause:
• arthralgia, nausea;
• rarely: hepatic disorders (jaundice), urticaria, rash, acute gout, hypersensitivity reactions.
Remarks
– Fixed dose combinations (isoniazid+rifampicin+pyrazinamide+ethambutol or isoniazid+
rifampicin+pyrazinamide) should be preferred.
122
PYRIDOXINE = VITAMIN B6
(Benadon®, Pyroxin®…)
Therapeutic action
– Vitamin
Indications
– Prevention and treatment of isoniazid-induced peripheral neuropathy
Presentation
– 25 mg tablet
Dosage
– Prevention of isoniazid neuropathy
Child under 5 kg: 5 mg once daily
Child over 5 kg and adult: 10 mg once daily
– Treatment of isoniazid neuropathy
Child: 50 mg once daily
Duration
– Prevention: as long as treatment with isoniazid continues.
– Treatment: according to clinical response (in general, ≤ 3 weeks) then, preventive dose, as
long as treatment with isoniazid continues.

– May cause: peripheral neuropathy in the event of prolonged use with doses ≥ 200 mg/day.
Remarks
– In children receiving isoniazid prophylaxis or treatment for tuberculosis: concomitant
administration of pyridoxine at preventive dosage is recommended for children under
5 years and all children infected with HIV.
– Pyridoxine is also used for the prevention and treatment of cycloserin-induced neuropathy
(150 to 200 mg/day in adults, in divided doses).
– Storage:
123
PYRIMETHAMINE
(Daraprim®, Malocide®…)
Therapeutic action
– Antiprotozoal
Indications
– Treatment and secondary prophylaxis of toxoplasmosis in immunodeficient patients, in
combination with sulfadiazine or clindamycin
– Primary prophylaxis of toxoplasmosis in immunodeficient patients, in combination with
dapsone (only if cotrimoxazole cannot be used)
– Second-line treatment of isosporiasis in immunodeficient patients (only if cotrimoxazole
cannot be used)
Presentation
– 25 mg tablet
Dosage and duration

Adult: 200 mg in 2 divided doses on the first day, then 75 to 100 mg/day for at least 6 weeks
Adult: 25 to 50 mg/day, as long as necessary
– Primary prophylaxis of toxoplasmosis
Adult: 50 to 75 mg/week, as long as necessary
– Treatment of isosporiasis
Adult: 50 to 75 mg/day for 10 days

– Do not administer to patients with severe renal or hepatic impairment.
– May cause: gastrointestinal disturbances, seizures, leucopenia, thrombocytopenia, megalo-
blastic anaemia due to folinic acid deficiency.
– Administer calcium folinate to prevent folinic acid deficiency.
– Avoid if possible combination with other folate antagonists: cotrimoxazole, methotrexate
(increased risk of folinic acid deficiency).
– Monitor combination with zidovudine (increased risk of zidovudine-associated haemato-
toxicity).
– Pregnancy: CONTRA-INDICATED during the first trimester
– Breast-feeding: no contra-indication; however avoid concomitant administration of other folate
antagonists
Remarks
– The combination of pyrimethamine + sulfadoxine (Fansidar®) is used for the treatment of
uncomplicated falciparum malaria.
124
QUININE
1
Therapeutic action
– Antimalarial
Indications
– Shift from injectable to oral quinine for the treatment of severe falciparum malaria
Presentation
– 200 mg and 300 mg quinine sulfate or bisulfate tablets
Dosage and duration

Dosage is expressed in terms of salt. With the exception of quinine bisulfate, the dosage is the
same for all quinine salts (sulfate, hydrochloride, dihydrochloride):
– Child and adult ≤ 50 kg: 30 mg/kg/day in 3 divided doses at 8-hour intervals for 7 days
– Adult > 50 kg: 1800 mg/day in 3 divided doses at 8-hour intervals for 7 days
Weight 200 mg tablet 300 mg tablet

3 to 6 kg 1/4 tab x 3 –
7 to 12 kg 1/2 tab x3 –
13 to 17 kg – 1/2 tab x 3
18 to 25 kg 1 tab x 3 –
26 to 35 kg – 1 tab x 3
36 to 50 kg 2 tab x 3 –
> 50 kg 3 tab x 3 2 tab x 3
As bisulfate tablets contain a lower concentration of quinine, a higher dose is required:

40 mg/kg/day in children and 2.5 g/day in adults, in 3 divided doses.

– May cause: headache, skin rash; visual, auditory and gastrointestinal disturbances.
– Do not exceed indicated doses: risk of toxicity in the event of overdose.
– If the patient vomits within one hour after administration, repeat the full dose.
– Do not combine with chloroquine, halofantrine and mefloquine.
Remarks
– 10 mg of quinine sulfate or hydrochloride or dihydrochloride = 8 mg of quinine base; 14 mg
of quinine bisulfate = 8 mg of quinine base.
– In certain regions of South-East Asia, quinine is combined with doxycycline or clindamycin,
due to a reduction in P. falciparum sensitivity to quinine.
– Quinine should not be used for prophylaxis.
125
RESOMAL
Rehydration Solution for Malnutrition
Therapeutic action
– Oral rehydration salts with high potassium and low sodium contents
Indications
– Prevention and treatment of dehydration, in patients suffering from complicated acute
malnutrition only
Presentation
– Sachet containing 84 g of powder, to be diluted in 2 litres of clean, boiled and cooled water
– Sachet containing 420 g of powder, to be diluted in 10 litres of clean, boiled and cooled
water
Composition for one litre
mmol/litre mmol/litre
Glucose 55 Citrate 7
Saccharose 73 Magnesium 3
Sodium 45 Zinc 0.3
Potassium 40 Copper 0.045
Chloride 70 Osmolarity 294 mEq/litre
Dosage and duration

– Prevention of dehydration
Child under 2 years: 50 to 100 ml after each loose stool as long as diarrhoea persists
Child over 2 years: 100 to 200 ml after each loose stool as long as diarrhoea persists
Adult: 200 to 400 ml after each loose stool as long as diarrhoea persists
– Treatment of dehydration
Child and adult: 5 ml/kg every 30 minutes over the first 2 hours, then 5 to 10 ml/kg/hour
for the next 4 to 10 hours, until dehydration is corrected.

– Do not administer to patients with cholera or uncomplicated acute malnutrition: use
standard ORS instead.
– May cause: heart failure when administered too rapidly. During treatment, closely monitor
the rate of administration in order to avoid overhydration. Increase in respiratory and
pulse rates and appearance or increase of oedema are signs of over rapid rehydration. In
this event, stop ReSoMal for one hour then reassess the patient’s condition.
Remarks
Do not use the powder if it has turned sticky.
Once prepared, the solution should be used within 24 hours.
126
RETINOL = VITAMIN A
Therapeutic action 1
– Vitamin
Indications
– Prevention of vitamin A deficiency
– Treatment of vitamin A deficiency (xerophthalmia)
Presentation
– 200 000 IU capsule
Also comes in 10 000 IU coated tablet, 50 000 IU capsule and 100 000 IU/ml oral solution.
Dosage and duration
– Prevention of vitamin A deficiency
Child under 6 months: 50 000 IU as a single dose
Child from 6 to 12 months: 100 000 IU as a single dose every 4 to 6 months
Child over 1 year: 200 000 IU as a single dose every 4 to 6 months
– Treatment of vitamin A deficiency
Child under 6 months: 50 000 IU once daily on D1, D2 and D8 (or D15)
Child from 6 to 12 months: 100 000 IU once daily on D1, D2 and D8 (or D15)
Child over 1 year and adult: 200 000 IU once daily on D1, D2 and D8 (or D15)
6 1 5 15
AGE 0
ADULT
6 8 15 35
WEIGHT kg kg kg kg
Prevention
50 000 IU capsule 1 cap 2 cap – – –
200 000 IU capsule 2 drops 4 drops 1 cap – –
Treatment
50 000 IU capsule 1 cap 2 cap – – –
200 000 IU capsule 2 drops 4 drops 1 cap 1 cap 1 cap

– Overdosage may cause: gastrointestinal disturbances, headache, raised intracranial pressure
(bulging fontanelle in infants); foetal abnormalities.
– Pregnancy:
Prevention: after delivery only, 200 000 IU as a single dose
Treatment: dosage depends on severity of eye lesions:
• Night blindness and Bitot's spots: 10 000 IU once daily or 25 000 IU once weekly for at least 4 weeks
• Corneal lesion: 200 000 IU once daily on D1, D2 and D8 (or D15)
– Breast-feeding: no contra-indication at recommended doses
Remarks
– Administer routinely preventive treatment to all children suffering from malnutrition (single
dose).
– Administer routinely 2 doses (on D1 and D2) to children suffering from measles to prevent the
complications of measles.
– One 200 000 IU capsule contains about 8 drops (1 drop = 25 000 IU).
127
RIFAMPICIN
(Rifadin®…)
Therapeutic action
– Antituberculous and antileprotic antibacterial
Indications
– Paucibacillary leprosy, in combination with dapsone
– Multibacillary leprosy, in combination with dapsone and clofazimine
Presentation
Dosage
– Tuberculosis
Child: 10 to 20 mg/kg once daily, on an empty stomach; maximum 600 mg/day
Adult: 10 mg/kg once daily, on an empty stomach; maximum 600 mg/day
– Paucibacillary and multibacillary leprosy
Child < 10 years: 12 to 15 mg/kg once monthly, on an empty stomach (round-up to 300 mg
once monthly)
Child from 10 to 14 years: 450 mg once monthly, on an empty stomach
Adult: 600 mg once monthly, on an empty stomach
Duration
– Tuberculosis: according to protocol
– Paucibacillary leprosy: 6 months; multibacillary leprosy: 12 months
– Do not administer to patients with jaundice or allergy to rifamycins.
– May cause:
• orange-red discoloration of urine, tears, saliva, sputum (normal, harmless);
• gastrointestinal disturbances, headache, drowsiness; liver disorders (jaundice);
• influenza-like syndrome (more frequent when treatment is not taken regularly);
• rarely: thrombocytopenia, hypersensitivity reactions.
– If jaundice develops, rifampicin should be discontinued until the symptoms resolve then
re-introduced and administered at low dose (8 mg/kg/day). If purpura develops,
discontinue permanently rifampicin.
– Do not combine with nevirapine, indinavir, nelfinavir, lopinavir/ritonavir.
– Rifampicin accelerates the hepatic metabolism and reduces the effect of many drugs (oral
contraceptives, antidiabetics and anticoagulants; corticoids, phenytoin, azole antifungals, etc.):
• In women, use a non-hormonal contraception or injectable medroxyprogesterone or
make sure that the oral contraceptive used contains 50 µg ethinylestradiol per tablet.
• In the event of concomitant fluconazole administration, administer each drug 12 hours
apart (rifampicin in the morning, fluconazole in the evening).
• For the other drugs, adjust dosage if necessary.
– Pregnancy: no contra-indication. Risk of maternal and neonatal bleeding disorders when the mother
receives rifampicin in late pregnancy. Administer phytomenadione (vitamin K) to reduce the risk.
Remarks
– For the treatment of tuberculosis, fixed dose combinations (isoniazid+rifampicin+pyrazinamide
+ethambutol or isoniazid+rifampicin+pyrazinamide or isoniazid+rifampicin) should be
preferred.
– For the treatment of single skin lesion paucibacillary leprosy, rifampicin (600 mg) + ofloxacin
(400 mg) + minocycline (100 mg) are administered as a single dose.
– Rifampicin is also used in combination with co-trimoxazole for the treatment of brucellosis
in children < 8 years and pregnant/breastfeeding women.
128
RITONAVIR = RTV
(Norvir®)
1
Therapeutic action
Indications
– Booster for protease inhibitors (atazanavir, darunavir, saquinavir, etc.) in HIV-1 or HIV-2
infection. Ritonavir should not be used alone.
Presentation
– 100 mg capsule
– 25 mg and 100 mg heat stable tablets
– 80 mg/ml oral solution, containing 43% alcohol (v/v)
Dosage
– Adult:
• Capsule: 100 mg once daily or 200 mg/day in 2 divided doses, depending on the
protease inhibitor co-administered
• Oral solution: 1.25 ml once daily or 2.5 ml/day in 2 divided doses, depending on the
protease inhibitor co-administered
Duration: depending on the efficacy and tolerance of ritonavir.

– Adverse effects associated with the use of ritonavir as a booster are dependent on the other
protease inhibitor.
– Ritonavir reduces the efficacy of oral contraceptives: use a non-hormonal contraception or
injectable medroxyprogesterone or make sure that the oral contraceptive used contains
– Administer with caution to patients with diabetes or haemophilia and, for oral solution, to
patients with hepatic disease or epilepsy.
– Pregnancy: CONTRAINDICATED for oral solution; no contra-indication for capsules.
Remarks
– Also comes in fixed-dose combination tablets containing lopinavir-ritonavir (Kaletra®).
– Storage:
• Capsule: to be kept refrigerated (2°C to 8°C). The patient may keep an opened bottle of capsules
for 30 days if stored below 25°C.
• Oral solution: between 20°C to 25°C for 30 days maximum. Do not refrigerate.
129
SALBUTAMOL = ALBUTEROL
(Ventolin®…)
Therapeutic action
– Bronchodilator
Indications
– Treatment of persistent asthma not controlled by inhaled corticosteroids
Presentation
– 2 mg/5 ml syrup
Dosage
– Child from 2 to 6 years: 3 to 6 mg/day in 3 divided doses
– Child over 12 years and adult: 6 to 12 mg/day in 3 divided doses

– Administer with caution to patients with diabetes mellitus, hyperthyroidism, arrhythmia,
angina, hypertension.
– May cause: headache, tremor, tachycardia; hypokalaemia, hyperglycaemia.
– Monitor combination with: furosemide, hydrochlorothiazide, corticosteroids, xanthines
(increased risk of hypokalaemia).
Remarks
– The use of oral salbutamol for this indication should only be considered when administration
of inhalated salbutamol is not feasible.
– Oral salbutamol is not very effective in children under 2 years.
– Oral salbutamol is not indicated in the management of acute asthma attack since its onset
of action is within 30 minutes.
130
SALBUTAMOL = ALBUTEROL aerosol
(Ventolin®…)
1
Therapeutic action
– Short-acting bronchodilator
Indications
– Symptomatic treatment of asthma attack
Presentation
– Solution for inhalation in pressurised metered dose inhaler, 100 micrograms/puff
Dosage
Dosage depends on the severity of attack and patient’s response. For information :
– 2 to 4 puffs (up to 10 puffs depending on severity) every 10 to 30 minutes
Administration technique
– Shake the inhaler.
– Breathe out as completely as possible. Place the lips tightly around the mouthpiece. Inhale
deeply while activating the inhaler. Hold breath 10 seconds before exhaling.
– Co-ordination between the hand and inhalation is very difficult in children under 6 years,
elderly patients and patients with severe dyspnoea. Use a spacer to facilitate administration
and improve the efficacy of treatment.

– May cause: headache, tremor and tachycardia.
– In the event of bronchial infection, administer simultaneously with appropriate antibacterial
treatment.
Remarks
– Clean the mouthpiece before and after each use.
– Do not pierce or incinerate used aerosol containers. Empty all residual gas, then bury.
131
SALBUTAMOL = ALBUTEROL nebuliser solution
(Ventolin®…)
Therapeutic action
– Bronchodilator
Indications
– Symptomatic treatment of severe acute bronchospasm, e.g. in severe asthma attack

– Solution for inhalation, in unit dose vial of 5 mg in 2.5 ml (2 mg/ml), to be administered
via a nebuliser
Dosage and duration

– Child under 5 years or under 15 kg: 2.5 mg (1.25 ml)/nebulisation, to be repeated every
20 to 30 minutes if necessary
– Child over 5 years and adult: 2.5 to 5 mg (1.25 to 2.5 ml)/nebulisation, to be repeated every
20 to 30 minutes if necessary
– The nebuliser should always be driven by oxygen.

– May cause: headache, tremor, tachycardia; hyperglycaemia and hypokalaemia (after large
doses); worsening hypoxia if administered without oxygen.
– Never use nebuliser solution by the parenteral route.
Remarks
– Nebulised salbutamol should be reserved for severe asthma attacks when inhalation of
oxygen is also required. Otherwise, salbutamol should be delivered via a metered-dose
inhaler with a spacer: administration is easier and faster, the treatment is as effective, or
even more effective, than with a nebuliser and causes fewer adverse effects.
– Volumes of nebuliser solution to be administered are insufficient to obtain efficient
nebulisation in most nebulisers: dilute salbutamol solution with 0.9% NaCl to obtain a total
volume of 4 ml in the reservoir of the nebuliser. The diluted solution is dispersed with
oxygen at a flow rate of 5 to 8 litres/min. Stop the nebulisation when the reservoir is empty
(± 10-15 minutes).
– Also comes in unit dose vials of 1.25 mg in 2.5 ml, 2.5 mg in 2.5 ml, and in vials of 50 mg
in 10 ml.
132
SAQUINAVIR = SQV
(Fortovase®, Invirase®)
1
Therapeutic action
Indications
– HIV-1 or HIV-2 infection, in combination with two nucleoside reverse transcriptase
inhibitors and with low-doses of ritonavir as booster
Presentation
– 200 mg capsule or soft capsule
Dosage
– Adult: 2 g/day in 2 divided doses (in combination with 200 mg of ritonavir/day in 2 divided
doses)
Duration
– The duration of treatment depends on the efficacy and tolerance of saquinavir.

– Do not administer to patients under 16 years of age.
– May cause:
• neurological disorders (peripheral neuropathy, paraesthesia), hepatic disorders (jaundice,
raised transaminases), metabolic disorders (lipodystrophy, hyperlipidaemia, diabetes
mellitus with glucose intolerance and/or insulin resistance),
• gastrointestinal disturbances, headache, fatigue, fever, rash, pruritus; neutropenia,
thrombocytopenia, raised creatinine phosphokinase.
– Do not combine with rifampicin (hepatotoxicity).
– Administer with caution to patients with haemophilia (risk of haemorrhage) or renal or
hepatic impairment.
Remarks
– Take with meals or immediately after meals.
– Storage:
• Capsule: below 30°C
• Soft capsule: to be kept refrigerated (2°C to 8°C). The patient may keep an opened bottle of soft
capsules for 3 months if stored below 25°C.
133
SPIRONOLACTONE
(Aldactone®, Spiroctan®…)
Therapeutic action
– Potassium-sparing diuretic, antagonist of aldosterone
Indications
– Oedema associated with congestive heart failure, hepatic cirrhosis and nephrotic syndrome
Presentation
– 25 mg tablet
Dosage
– Oedema in congestive heart failure
Adult: 100 mg/day (up to 200 mg/day in severe cases) then, when oedema is controlled,
maintenance dose of 25 mg/day
– Ascites in hepatic cirrhosis
Adult: 100 to 400 mg/day. When weight is stable, administer the lowest possible maintenance
dose, in order to prevent adverse effects.
– Oedema in nephrotic syndrome
Adult: 100 to 200 mg/day
The daily dose can be administered in 2 to 3 divided doses or once daily.
Duration: according to clinical response; avoid prolonged use.
– Do not administer to patients with severe renal impairment, anuria, hyperkalaemia
> 5 mmol/l, hyponatraemia.
– Do not combine with potassium salts, potassium-sparing diuretics; lithium (risk of lithium
toxicity).
– Avoid or closely monitor combination with angiotensin-converting enzyme inhibitors (risk
of severe, potentially fatal hyperkalaemia), digoxin (risk of digoxin toxicity) and reduce
dosages.
– May cause:
• hyperkalaemia (especially in elderly or diabetics patients, patients with renal impairment
or patients taking NSAIDs), hyponatraemia; metabolic acidosis (in patients with decom-
pensated cirrhosis).
• gynecomastia, metrorrhagia, impotence, amenorrhoea, gastrointestinal disturbances,
headache, skin rash, drowsiness.
– Administer with caution in patients with hepatic or renal impairment or diabetes.
– Monitor regularly plasma-potassium levels.
– Pregnancy: avoid, use only if clearly needed (risk of feminisation of foetus); spironolactone is not
indicated in the treatment of pregnancy-related oedema.
Remarks
– In children with oedema, the daily dose is 1 to 3 mg/kg/day.
– Spironolactone is also used for the diagnosis and treatment of primary hyperaldosteronism.
134
STAVUDINE = d4T
(Stavir®, Zerit®, Zeritavir®)
1
Therapeutic action
Indications
Presentation
– 15 mg, 20 mg and 30 mg capsules
– 1 mg/ml, powder for oral solution
Dosage
– Child over 3 months and under 25 kg: 2 mg/kg/day in 2 divided doses
– Child ≥ 25 kg and adult: 60 mg/day in 2 divided doses
1 mg/ml Capsules
Weight
oral solution 15 mg 20 mg 30 mg
5 to 9 kg 7.5 ml x 2 – – –
10 to 14 kg 12.5 ml x 2 1 caps x 2 – –
15 to 19 kg 18 ml x 2 – 1 caps x 2 –
20 to 24 kg – – 1 caps x 2 –
≥ 25 kg – – – 1 caps x 2
Duration: depending on the efficacy and tolerance of stavudine.

– Do not administer to patients with history of peripheral neuropathy or pancreatitis.
– May cause:
• peripheral neuropathy, metabolic disorders (lipodystrophy, hyperlipidaemia, etc.),
gastrointestinal disturbances (diarrhoea, nausea, vomiting, etc.);
• lactic acidosis, severe pancreatic or hepatic disorders (in these events, stop antiretroviral
treatment; once the symptoms have resolved, prescribe an antiretroviral regimen
without stavudine).
– Do not combine with zidovudine (antagonism); avoid combination with didanosine.
– Pregnancy: no contra-indication. Do not combine with didanosine.
Remarks
– Also comes in fixed-dose combination tablets containing stavudine-lamivudine-nevirapine
(Triomune®…) or stavudine-lamivudine (Coviro®…).
Once prepared, the oral solution must be kept refrigerated (2°C to 8°C) and may be used for up to
30 days.
135
STAVUDINE/LAMIVUDINE/NEVIRAPINE = d4T/3TC/NVP
(Triomune®, Triviro®…)
Therapeutic action
– Combination of 3 antiretrovirals
Indications
– HIV-1 infection
Presentation
– 6 mg d4T/30 mg 3TC/50 mg NVP dispersible tablet
– 12 mg d4T/60 mg 3TC/100 mg NVP dispersible tablet
– 30 mg d4T/150 mg 3TC/200 mg NVP tablet
Dosage
– Child less than 25 kg: see table below
6 mg d4T/30 mg 3TC/50 mg NVP 12 mg d4T/60 mg 3TC/100 mg NVP

Weight
tablet tablet
3 to 5 kg 1 tab x 2 –
6 to 9 kg 1 1/2 tab x 2 –
10 to 13 kg 2 tab x 2 1 tab x 2
14 to 19 kg 2 1/2 tab x 2 –
20 to 24 kg 3 tab x 2 1 1/2 tab x 2
– Child ≥ 25 kg and adult: one 30 mg d4T/150 mg 3TC/200 mg NVP tablet twice daily
Duration: depending on the efficacy and tolerance of treatment.

– Do not administer to patients with history of peripheral neuropathy, pancreatitis, hepatic
disorders or intolerance to nevirapine that led to discontinuation of treatment.
– May cause:
• adverse effects common to all 3 antiretrovirals: gastrointestinal disturbances;
• adverse effects of stavudine: see stavudine;
• adverse effects of lamivudine: see lamivudine;
• adverse effects of nevirapine: see nevirapine.
– Monitor if possible liver enzyme level (ALAT) during the first 2 months, then every
6 months. If the enzyme level reaches 5 times the normal level, stop nevirapine immediately.
– Nevirapine reduces the efficacy of oral contraceptives: use a non-hormonal contraception
or injectable medroxyprogesterone or make sure that the oral contraceptive used contains
– Do not combine with zidovudine or rifampicin.
Remarks
– To improve tolerance of NVP, administer half doses for the first 14 days of treatment.
Therefore, start triple therapy by using d4T/3TC co-formulations (Coviro®) and nevirapine
tablets (Neravir®, Nevimune®, Viramune®). After the initial 14-day phase of treatment,
use the co-formulation d4T/3TC/NVP.
136
SULFADIAZINE
(Adiazine®…)
1
Therapeutic action
– Sulfonamide antibacterial
Indications
– Treatment and secondary prophylaxis of toxoplasmosis in immunodeficient patients, in
combination with pyrimethamine
Presentation
– 500 mg tablet
Dosage and duration

Adult: 4 to 6 g/day in 2 to 3 divided doses for 6 weeks minimum
Adult: 2 to 3 g/day in 2 divided doses, as long as necessary

– Do not administer to sulfonamide-allergic patients; patients with severe renal or hepatic
impairment.
– May cause:
• gastrointestinal disturbances, renal disorders (crystalluria, etc.), photosensitivity,
megaloblastic anaemia due to folinic acid deficiency; haemolytic anaemia in patients
with G6PD deficiency,
• allergic reactions (fever, rash, etc.) sometimes severe (Lyell's and Stevens-Johnson
syndromes, haematological disorders, etc.). In these cases, stop treatment immediately.
– Adverse effects occur more frequently in patients with HIV infection.
– Monitor blood count if possible.
– Reduce the dose by half in patients with renal impairment.
– Do not combine with methotrexate and phenytoin.
– Administer calcium folinate systematically to prevent folinic acid deficiency.
– Pregnancy: no contra-indication. However, avoid using during the last month of pregnancy (risk of
jaundice and haemolytic anaemia in the newborn infant).
– Breast-feeding: avoid if premature infant, jaundice, low-birth weight, infant under one month of age.
If sulfadiazine is used, observe the infant for signs of jaundice.
Remarks
– Storage:
137
SULFADOXINE/PYRIMETHAMINE = SP
(Fansidar®…)
Therapeutic action
– Antimalarial
Indications
Presentation
– Sulfadoxine 500 mg/pyrimethamine 25 mg co-formulated tablet
Dosage and duration

– Child and adult: 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine as a single dose
2 1 7 13
Age Adult
500/25 mg tablet 1/2 tab 1 tab 2 tab 3 tab

– Do not administer to patients with allergy to sulfonamides.
– May cause: gastrointestinal disturbances; allergic reactions, sometimes severe (toxic
epidermal necrolysis and Stevens-Johnson syndrome); anaemia, leukopenia, agranulocytosis,
thrombocytopenia, haemolytic anaemia in patients with G6PD deficiency.
– Do not use in combination with cotrimoxazole.
– Do not give folic acid on the same day SP is administered, or within 15 days thereafter.
Remarks
– In stable transmission areas, intermittent preventive treatments can be given to pregnant
women as of the 2nd trimester to reduce the consequences of malaria (anaemia, low birth
weight, etc.). Check national recommendations.
– SP should not be used for malaria prophylaxis.
138
THIAMINE = VITAMIN B1
(Benerva®, Betaxin®…)
Therapeutic action
– Vitamin
Indications
– Vitamin B1 deficiencies: beriberi, alcoholic neuritis
Presentation
– 50 mg tablet
Dosage and duration

– Infantile beriberi
10 mg once daily, until complete recovery (3 to 4 weeks)
– Acute beriberi
150 mg/day in 3 divided doses for a few days, until symptoms improve, then 10 mg/day
until complete recovery (several weeks)
– Mild chronic deficiency
10 to 25 mg once daily

– No contra-indication, or adverse effects with oral thiamine.
Remarks
– In the treatment of severe cases, the use of injectable thiamine is justified to correct the
disorder as rapidly as possible, but is no longer justified when symptoms have improved.
– Vitamin B1 deficiency often occurs in association with other vitamin B-complex deficiencies,
especially in alcoholic patients.
– Thiamine is also called aneurine.
– Storage: in airtight non-metallic container –
139
TINIDAZOLE
(Fasigyn®, Tindamax®, Tindol®…)
Therapeutic action
– Antiprotozoal, antibacterial (group of nitroimidazoles)
Indications
– Amoebiasis, giardiasis, trichomoniasis
– Bacterial vaginitis, infections due to anaerobic bacteria (e.g. Clostridium sp, Bacteroides sp)
Presentation
– 500 mg tablet
Dosage and duration

– Amoebiasis
Child: 50 mg/kg once daily, without exceeding 2 g
Adult: 2 g once daily
The treatment lasts 3 days in intestinal amoebiasis; 5 days in hepatic amoebiasis.
– Giardiasis, trichomoniasis and bacterial vaginitis
Child: 50 mg/kg as a single dose, without exceeding 2 g
In the event of trichomoniasis, also treat sexual partner.
– Infections due to anaerobic bacteria
Child over 12 years and adult: initially 2 g then 1 g once daily or in 2 divided doses
According to indication, tinidazole may be used in combination with other antibacterials;
treatment duration depends on indication.

– Do not administer to patients with allergy to tinidazole or another nitroimidazole (metro-
nidazole, secnidazole, etc.).
– May cause: gastrointestinal disturbances; rarely: allergic reactions, brownish urine,
headache, dizziness. Risk of antabuse reaction when combined with alcohol.
– Administer with caution in patients taking oral anticoagulants (risk of haemorrhage),
lithium, phenytoin (increased plasma concentrations of these drugs).
– Pregnancy: no contra-indication; divide into smaller doses, avoid prolonged use.
– Breast-feeding: significantly excreted in milk (risk of gastrointestinal disturbances in breastfed
infants); divide into smaller doses, avoid prolonged use.
Remarks
140
TRAMADOL
(Tramal®, Zamadol®, Zydol®…)
1
Therapeutic action
– Centrally acting analgesic (weak opioid, serotonin-norepinephrine reuptake inhibitor)
Indications
– Moderate acute pain and moderate to severe chronic pain
Presentation
– 50 mg capsule
– 100 mg/ml oral solution (1 drop = 2.5 mg)
Dosage
– Child over 6 months: 2 mg/kg every 6 hours
– Adult: 50 to 100 mg every 4 to 6 hours, without exceeding 400 mg/day
Duration
– According to clinical evolution. In the event of prolonged treatment, do not stop abruptly,
reduce doses progressively.

– Do not administer in the event of severe respiratory depression and to patients that risk
seizures (e.g. epilepsy, head injury, meningitis).
– May cause:
• dizziness, nausea, vomiting, drowsiness, dry mouth, sweating;
• rarely: allergic reactions, seizures, confusion;
• exceptionally: withdrawal symptoms; respiratory depression in the event of overdosage.
– Do not combine with opioid analgesics, including codeine.
– Avoid combination with carbamazepine, fluoxetine, chlorpromazine, promethazine,
clomipramine, haloperidol, digoxin.
– Reduce doses (1 mg/kg) and administer every 12 hours in elderly patients and in patients
with severe renal or hepatic impairment (risk of accumulation).
– Pregnancy and breast-feeding: no contra-indication. The child may develop adverse effects (drowsiness)
when the mother receives tramadol at the end of the 3rd trimester and during breast-feeding. In these
events, administer with caution, for a short period, at the lowest effective dose, and monitor the child.
Remarks
– Doses administered for the treatment of neuropathic pain are often lower than those
administered for the treatment of acute pain.
– Tramadol is approximately 10 times less potent than morphine.
– In some countries, tramadol is on the list of narcotics: follow national regulations.
– Storage: –
141
TRICLABENDAZOLE
(Egaten®, Fasinex®)
Therapeutic action
– Anthelminthic
Indications
– Fascioliasis (Fasciola hepatica and Fasciola gigantica infections)
– Paragominiasis
Presentation
– 250 mg tablet
Dosage and duration

– Fascioliasis
Child and adult: 10 mg/kg as a single dose
– Paragominiasis
Child and adult: 20 mg/kg in 2 divided doses

– Do not administer to patients with hypersensitivity to triclabendazole or other benzimida-
zoles (albendazole, flubendazole, mebendazole, tiabendazole).
– May cause: abdominal pain, mild fever, headache, dizziness.
Remarks
– Take tablets after meals.
– Due to its efficacy, good tolerance, and ease of administration, triclabendazole is the drug
of choice for fascioliasis.
– Bithionol (Bitin®, Lorothidol®) may be used as an alternative to triclabendazole in the
treatment of fascioliasis: 30 mg/kg/day for 5 days.
– Unlike infections with other flukes, fascioliasis does not respond to praziquantel.
142
VALPROIC ACID = SODIUM VALPROATE
(Convulex®, Depakine®, Epilim®...)
1
Therapeutic action
– Antiepileptic
Indications
– Generalised and partial epilepsy
Presentation
– 200 mg and 500 mg enteric coated tablets
Also comes in syrup and oral solution for paediatric use.
Dosage
– Child under 20 kg: 20 mg/kg/day in 2 divided doses
– Child over 20 kg: initially 400 mg (irrespective of weight) in 2 divided doses, then increase the
dose gradually until the optimal dose is reached, usually 20 to 30 mg/kg/day in 2 divided
doses
– Adult: initially 600 mg/day in 2 divided doses, then increase by 200 mg every 3 days until
the optimal dose is reached, usually 1 to 2 g/day in 2 divided doses (20 to 30 mg/kg/day)
Duration: lifetime treatment
– Do not administer to patients with pancreatitis, hepatic disease (or history of).
– May cause:
• increase in the frequency of seizures at the beginning of therapy, weight gain, gastro-
intestinal disturbances, hepatic dysfunction,
• rarely: pancreatitis, extrapyramidal symptoms, cognitive disorders and behavorial
disturbances, confusion, severe allergic reactions (Lyell’s and Stevens-Johnson syndromes),
amenorrhoea; thrombocytopenia, prolongation of bleeding time.
– Monitor, if possible, liver transaminase concentrations and prothrombine time during first
3-6 months of therapy.
– Stop treatment in the event of jaundice or gastrointestinal manifestations of hepatitis,
significant lasting increase of transaminases, prolonged prothrombine time.
– Do not combine with mefloquine (increased risk of seizures).
– Monitor combination with: tricyclic antidepressants, other antiepileptics.
– If other antiepileptic drugs have been prescribed, reduce the dose of these drugs and
increase the dose of valproic acid gradually over 2 weeks.
– Pregnancy: risk of neural tube defect, limb malformations and craniofacial abnormalities, if used
during the first trimester. Do not start treatment during the first trimester, except if vital and there
is no alternative. However, if treatment has been started before a pregnancy, do not stop treatment,
administer the daily dose in smaller fractioned doses and monitor the newborn infant (risk of
haemorrhagic disease, non related to vitamin K deficiency).
The administration of folic acid before conception and during the first trimester seems to reduce the
risk of neural tube defect.
Remarks
143
ZIDOVUDINE = AZT = ZDV
(Retrovir®)
Therapeutic action
Indications
Presentation
– 100 mg and 250 mg capsules and 300 mg tablet
Dosage
– Premature infant: 3 mg/kg/day in 2 divided doses for the first 2 weeks after birth then
8 mg/kg/day in 2 divided doses
– Child under 4 weeks: 8 mg/kg/day in 2 divided doses
– Child from 4 weeks to 13 years: 360 to 480 mg/m2/day in 2 divided doses
– Adult: 600 mg/day in 2 divided doses
Oral solution
Weight 100 mg capsule 250 mg capsule 300 mg tablet
10 mg/ml
5 to 6 kg 6 ml x 2 – – –
7 to 9 kg 8 ml x 2 – – –
10 to 14 kg 12 ml x 2 1 cap x 2 – –
15 to 19 kg 17 ml x 2 2 cap x 2 – –
20 to 24 kg 20 ml x 2 2 cap x 2 – –
25 to 29 kg 25 ml x 2 3 cap x 2 1 cap x 2 1 tab x 2
30 to 39 kg 28 ml x 2 3 cap x 2 1 cap x 2 1 tab x 2
≥ 40 kg – 3 cap x 2 – 1 tab x 2
Duration
– The duration of treatment depends on the efficacy and tolerance of zidovudine.

– Do not administer to patients with severe haematological disorders (leukopenia, anaemia),
to neonates with hyperbilirubinaemia or raised transaminases.
– May cause: haematological disorders (monitor CBC), gastrointestinal disturbances (nausea,
diarrhoea, etc.), headache, myopathy, hepatic disorders, lactic acidosis. Stop taking zido-
vudine in the event of severe haematological disorders or hepatic disorders (hepatomega-
ly, raised transaminases).
– Reduce dosage in patients with severe renal or hepatic impairment.
– Do not combine with stavudine.
Remarks
– For prophylactic treatment to reduce mother-to-child transmission, check national recom-
mendations.
– Also comes in fixed-dose combination tablets incorporating zidovudine-lamivudine
(Combivir®…) and zidovudine-lamivudine-abacavir (Trizivir®…).
– Storage: below 30°C. For capsules: –
144
ZIDOVUDINE/LAMIVUDINE = AZT/3TC
(Avocomb®, Combivir®, Duovir®…)
1
Therapeutic action
– Combination of 2 antiretrovirals, HIV-1 and HIV-2 nucleoside reverse transcriptase inhibitors
Indications
– HIV-1 or HIV-2 infection, in combination with another antiretroviral drug
Presentation
– 60 mg AZT/30 mg 3TC tablet
– 300 mg AZT/150 mg tablet
Dosage
Weight 60 mg AZT/30 mg 3TC tablet

3 to 5 kg 1 tab x 2
6 to 9 kg 1 1/2 tab x 2
10 to 13 kg 2 tab x 2
14 to 19 kg 2 1/2 tab x 2
20 to 24 kg 3 tab x 2
– Child ≥ 25 kg and adult: one 300 mg AZT/150 mg 3TC tablet twice daily

– Do not administer to patients with severe haematological disorders (neutropenia, anaemia).
– May cause:
• adverse effects of zidovudine: see zidovudine;
• adverse effects of lamivudine: see lamivudine.
– Do not combine with stavudine.
Remarks
145
ZIDOVUDINE/LAMIVUDINE/NEVIRAPINE = AZT/3TC/NVP
(Avocomb N®, Duovir N®…)
Therapeutic action
– Combination of 3 antiretrovirals
Indications
– HIV-1 infection
Presentation
– 60 mg AZT/30 mg 3TC/50 mg NVP dispersible tablet
– 300 mg AZT/150 mg 3TC/200 mg NVP tablet
Dosage
Weight 60 mg AZT/30 mg 3TC/50 mg NVP tablet

3 to 5 kg 1 tab x 2
6 to 9 kg 1 1/2 tab x 2
10 to 13 kg 2 tab x 2
14 to 19 kg 2 1/2 tab x 2
20 to 24 kg 3 tab x 2
– Child ≥ 25 kg and adult: one 300 mg AZT/150 mg 3TC/200 mg NVP tablet twice daily

– Do not administer to patients with severe haematological disorders (neutropenia, anaemia),
hepatic disorders or intolerance to nevirapine that led to discontinuation of treatment.
– May cause:
• adverse effects of zidovudine: see zidovudine;
• adverse effects of lamivudine: see lamivudine;
• adverse effects of nevirapine: see nevirapine.
– Monitor if possible liver enzyme level (ALAT) during the first 2 months, then every 6 months.
If the enzyme level reaches 5 times the normal level, stop nevirapine immediately.
– Nevirapine reduces the efficacy of oral contraceptives: use a non-hormonal contraception
or injectable medroxyprogesterone or make sure that the oral contraceptive used contains
– Do not combine with stavudine or rifampicin.
Remarks
– To improve tolerance of NVP, administer half doses for the first 14 days of treatment.
Therefore, start triple therapy by using AZT/3TC co-formulations (Avocomb®,
Combivir®, Duovir®) and nevirapine tablets (Neravir®, Nevimune®, Viramune®). After
the initial 14-day phase of treatment, use the co-formulation AZT/3TC/NVP.
146
ZINC SULFATE
Therapeutic action
– Micronutrient
Indications
– Zinc supplementation in combination with oral rehydration therapy in the event of acute
and/or persistent diarrhoea in children under 5 years
Presentation
– 20 mg scored and dispersible tablet, packed in a blister
– 20 mg/5 ml syrup
Dosage and duration

– Child under 6 months: 10 mg once daily (1/2 tablet or 1/2 teaspoon once daily) for 10 days
– Child from 6 months to 5 years: 20 mg once daily (1 tablet or 1 teaspoon once daily) for
10 days
Place the half-tablet or full tablet in a teaspoon, add a bit of water to dissolve it, and give the
entire spoonful to the child.

– If the child vomits within 30 minutes after swallowing the tablet, re-administer the dose.
– Do not give simultaneously with ferrous salts, administer at least 2 hours apart.
Remarks
– Zinc sulfate is given in combination with oral rehydration solution in order to reduce the
duration and severity of diarrhoea, as well as to prevent further occurrences in the 2 to
3 months after treatment. Zinc sulfate must never replace oral rehydration therapy which
is essential (nor can it replace antibiotic therapy that may, in specific cases, be necessary).
– Zinc supplementation is not recommended in the event of diarrhoea in malnourished
children taking therapeutic food (BP100®, Plumpy' nut®, milk F75® or F100®, etc.) as these
foods already contain the required amount of zinc.
Tablets are packed in a blister. Leave tablets in blister until use. Once a tablet is removed from the
blister, it must be dissolved and administered immediately.
147
Injectable drugs
Acetaminophen 205 Insulin 184
Adrenaline 172 Insulin intermediate-acting 186
Albuterol 213 Insulin long-acting 186
Amoxicillin 152 Insulin short-acting 187
2
Amphotericin B conventional 151 Ketamine 188
Ampicillin 152 Levonorgestrel implant 189
Artemether 153 Lidocaine = lignocaine 190
Atropine 154 Magnesium sulfate 192
Benzathine benzylpenicillin 155 Medroxyprogesterone 194
Benzylpenicillin 156 Medroxyprogesterone/estradiol 195
Benzylpenicillin procaine 157 Melarsoprol 191
Benzylpenicillin procaine/ Metamizole 196
benzylpenicillin 158 Methylergometrine 173
Butylscopolamine 183 Metoclopramide 197
Calcium gluconate 159 Metronidazole 198
Ceftriaxone 160 Morphine 199
Chloramphenicol 161 Naloxone 200
Chloramphenicol long-acting oil 162 Noramidopyrine 196
Chlorpromazine 163 Norethisterone 201
Clindamycin 164 Norethisterone/estradiol 202
Cloxacillin 165 Omeprazole 203
Dexamethasone 166 Oxytocin 204
Dextrose 50% 177 Paracetamol 205
Diazepam 167 Penicillin G 156
Diclofenac 168 Penicillin G procaine 157
Digoxin 169 Pentamidine 206
Dipyrone 196 Phenobarbital 207
Eflornithine 170 Phytomenadione 208
Ephedrine 171 Potassium chloride 10% 209
Epinephrine (EPN) 172 Promethazine 210
Ergometrine 173 Protamine 211
Etonogestrel implant 174 Quinine 212
Fortified penicillin procaine 158 Salbutamol 213
Furosemide = frusemide 175 Sodium bicarbonate 8.4% 214
Gentamicin 176 Spectinomycin 215
Glucose 50% 177 Streptomycin 216
Haloperidol 180 Suramin 217
Heparin 178 Thiamine 218
Hydralazine 181 Tramadol 219
Hydrocortisone 182 Vitamin B1 218
Hyoscine butylbromide 183 Vitamin K1 208
AMPHOTERICIN B conventional
(Fungizone®…)
Therapeutic action
– Antifungal
Indications
– Severe systemic fungal infections: cryptococcosis, histoplasmosis, penicilliosis, etc.
– Powder for injection, 50 mg vial, to be dissolved in 10 ml of water for injection, to obtain a 2
concentrated solution containing 5 mg/ml. The concentrated solution must be diluted in
490 ml of 5% glucose to obtain 500 ml of 0.1 mg/ml solution, for IV infusion.
Dosage
– Child and adult: initially 0.25 mg/kg over 2 to 6 hours, then increase gradually until
reaching the dose of 1 mg/kg/day (up to 1.5 mg/kg daily maximum in very severe
infections).
Prior to starting treatment, it is recommended to administer a test-dose (1 mg diluted in 5%
glucose and infused over 30 minutes) in order to assess the patient for immediate allergic
reaction. The patient's vital signs (temperature, respiratory and pulse rates, blood pressure)
are monitored. If no serious adverse reactions occur, the initial dose is administered.
Duration
– 6 to 12 weeks or more. If the treatment is interrupted for longer than 7 days, recommence
at initial therapeutic dose and increase gradually.
– Do not administer to patients with severe renal impairment or hypersensitivity to
amphotericin.
– May cause:
• fever, chills, headache, allergic reactions (discontinue if a reaction is observed after test-
dose),
• nephrotoxicity,
• gastrointestinal disturbances, anorexia, muscle or joint pain, blood and cardiovascular
disorders, seizures, blurred/double vision,
• pain and thrombophlebitis at injection site,
• in the event of rapid intravenous infusion: hypotension, arrhythmia, hypokalaemia,
shock.
– Use paracetamol, an antihistamine or hydrocortisone to prevent or treat fever.
– The administration of sodium chloride appears to limit, even prevent, amphotericin
nephrotoxicity (administer 1 litre of 0.9% NaCl before the administration of amphotericin).
– Monitor renal function, blood counts and kalaemia throughout treatment.
– Do not combine with drugs inducing torsades de pointe (quinidine, erythromycin IV,
halofantrine, pentamidine, sotalol, amiodarone, etc.).
– Monitor combination with cardiac glycosides (enhanced digitalis toxicity) and drugs
inducing hypokalaemia such as diuretics or corticosteroids.
– Pregnancy: no contra-indication. When administered during the last month of pregnancy, check for
renal dysfunction in the newborn.
– Breast-feeding: avoid, except if vital
Remarks
– Liposomal amphotericin B (AmBisome®), amphotericin B lipid complex (Abelcet®), and
amphotericin B colloidal (Amphotec®, Amphocil®) are lipid-based formulations which
carry a reduced risk of nephrotoxicity compared to conventional amphotericin B.
– Only use 5% glucose for IV administration (incompatible with other infusion fluids).
– Do not mix with other drugs in the same infusion bottle.
– Storage:
• Before reconstitution: keep refrigerated (between 2°C and 8°C). In the absence of a refrigerator,
the vials of powder may be kept for 7 days maximum, below 25°C.
• After reconstitution: concentrated solution may be kept refrigerated for 24 hours (between 2°C
and 8°C); the solution for injection must be used immediately.
151
AMPICILLIN (Pentrexyl®…)
and AMOXICILLIN (Clamoxyl®…)
Therapeutic action
Indications
– Severe infections: pneumonia, meningitis, septicaemia, endocarditis, puerperal fever,
pyelonephritis, etc., alone or in combination with other antibacterials, depending on indication,
only when oral administration is not possible
– Powder for injection in 500 mg and 1 g vials, to be dissolved in water for injection, for IM
or slow IV injection (over 3 to 5 minutes) or infusion (over 20 to 30 minutes) in 0.9% sodium
chloride
Dosage
– The daily dose must be administered in at least 3 injections or infusions, at 8-hour intervals.
Injectable ampicillin and injectable amoxicillin are used at the same doses for the same
indications:
Child: 100 mg/kg/day in 3 injections or infusions
Adult: 3 to 4 g/day in 3 to 4 injections or infusions
500 mg vial 1 g vial

Age Weight (to be dissolved in 5 ml) (to be dissolved in 5 ml)
< 1 year < 8 kg 2 ml x 3 –
1 to 5 years 8 to 15 kg 4 ml x 3 2 ml x 3
5 to 10 years 15 to 25 kg – 3 ml x 3
1 g vial
10 to 15 years 25 to 35 kg – 3/4 to 1 vial x 3
Adults > 35 kg – 1 vial x 3
– In the event of pyelonephritis or puerperal fever, increase dosage:

Child: 200 mg/kg/day in 3 injections or infusions
Adult: 8 g/day in 3 to 4 injections or infusions
– In the event of meningitis, septicaemia and endocarditis:
Child: 200 mg/kg/day in 3 to 4 injections or infusions or as a continuous infusion
Adult: 12 g/day in 3 to 4 injections or infusions or as a continuous infusion
Duration: according to indication; change to oral treatment as soon as possible

– Do not administer to penicillin-allergic patients, patients with infectious mononucleosis.
occur).
– May cause: gastrointestinal disturbances, allergic reactions, sometimes severe. In the event
of allergic reaction, stop treatment immediately.
Remarks
– Do not mix with another drug in the same in the same syringe or infusion.
• Ampicillin is stable for 12 hours in 0.9% sodium chloride and for 4 hours in 5% glucose.
• Amoxicillin is stable for 6 hours in 0.9% sodium chloride and for 1 hour in 5% glucose.
152
ARTEMETHER
(Paluther®…)
Therapeutic action
– Antimalarial
Indications
2
– Treatment of severe falciparum malaria
– Initial treatment of uncomplicated falciparum malaria, when persistent vomiting precludes
oral therapy

– 80 mg in 1 ml ampoule (80 mg/ml), oily solution for IM injection
When the dose required is less than 1 ml, use a 1 ml syringe graduated in 0.01 ml.
Dosage and duration

– Child and adult:
3.2 mg/kg by IM injection on the first day followed by 1.6 mg/kg once daily
20 mg ampoule 80 mg ampoule
Weight Maintenance Maintenance
Loading dose Loading dose
dose dose
< 3 kg 0.5 ml 0.3 ml – –
3-4 kg 0.8 ml 0.4 ml – –
5-6 kg 1.2 ml 0.6 ml – –
7-9 kg 1.6 ml 0.8 ml – –
10-14 kg 2.5 ml 1.2 ml – –
15-19 kg 3.2 ml 1.6 ml – –
20-29 kg – – 1.2 ml 0.6 ml
30-39 kg – – 1.6 ml 0.8 ml
40-49 kg – – 2 ml 1 ml
50-59 kg – – 2.5 ml 1.2 ml
As soon as the patient can swallow, change to oral route with an artemisinin-based
combination therapy (do not use the combination artesunate-mefloquine if the patient
developed neurological signs during the acute phase).

– May cause: headache, gastrointestinal disturbances, dizziness, neutropenia and transient
increase in liver transaminases.
– Do not administer by IV route.
– Pregnancy: no contra-indication during the 2nd and 3rd trimester. The safety of artemether in the first
trimester has not yet been definitely established. However, given the risks associated with malaria,
artemether may be used during the first trimester when the correct administration of quinine cannot
be assured.
Remarks
153
ATROPINE
Therapeutic action
– Parasympatholytic, antispasmodic
Indications
– Premedication in anaesthesia
– Spasms of the gastrointestinal tract
– Organophosphorus pesticide poisoning

– 1 mg atropine sulfate in 1 ml ampoule (1 mg/ml) for SC, IM, IV injection
Also comes in 0.25 mg/ml and 0.5 mg/ml ampoules.
Dosage
– Premedication in anaesthesia
Child: 0.01 to 0.02 mg/kg by SC or IV injection
Adult: 1 mg by SC or IV injection
– Spasms of the gastrointestinal tract
Child from 2 to 6 years: 0.25 mg by SC injection as a single dose
Child over 6 years: 0.5 mg by SC injection as a single dose
Adult: 0.25 to 1 mg by SC injection, to be repeated every 6 hours if necessary, without
exceeding 2 mg/day.
– Organophosphorus pesticide poisoning
Child: 0.02 to 0.05 mg/kg by IM or slow IV injection
Adult: 2 mg by IM or slow IV injection
Repeat every 5 to 10 minutes until signs of atropinisation appear (reduced secretions,
tachycardia, dilatation of the pupils).

– Do not administer to patients with urethro-prostatic disorders, cardiac disorders, glaucoma.
– May cause: urinary retention, dryness of the mouth, constipation, dizziness, headache,
dilatation of the pupils, tachycardia.
– Administer with caution and under close supervision to patients taking other anti-
cholinergic drugs (antidepressants, neuroleptics, H-1 antihistamines, antiparkinsonians, etc.).
– Breast-feeding: avoid; NO PROLONGED TREATMENT
Remarks
– Atropine IV is also used to prevent bradycardic effects of neostigmine when used to reverse
the effects of competitive muscle relaxants: 0.02 mg/kg in children; 1 mg in adults.
– Do not mix with other drugs in the same syringe.
154
BENZATHINE BENZYLPENICILLIN
(Extencilline®, Penadur®, Penidural®, Penilevel Retard®…)
Therapeutic action
– Penicillin antibacterial with prolonged action (15 to 20 days)
Indications
2
– Treatment of syphilis (except neurosyphilis)
– Treatment of non-venereal treponematoses: bejel, yaws, pinta
– Treatment of streptococcal tonsillitis
– Prophylaxis of rheumatic fever
– Treatment of diphtheria, prophylaxis of diphtheria in the event of direct contact
– Powder for injection, 2.4 M IU (= 1.44 g) vial, to be dissolved in 8 ml water for injection, for
IM injection. NEVER FOR IV INJECTION NOR INFUSION. Shake suspension before administration.
Also comes in 1.2 M IU (= 0.72 g) vial to be dissolved in 4 ml and 0.6 M IU (= 0.36 g) vial to
be dissolved in 2 ml.
Dosage and duration
– Treatment of syphilis
Adult: 2.4 MIU. For early syphilis: administer a single dose; for late syphilis: one injection
per week for 3 weeks. Divide the dose into 2 injections (half-dose in each buttock).
– Bejel, yaws, pinta, streptococcal tonsillitis, prophylaxis and treatment of diphtheria
Child under 30 kg: 600 000 IU as a single dose
Child over 30 kg and adult: 1.2 MIU as a single dose
– Prophylaxis of rheumatic fever
Child under 30 kg: 600 000 IU
Child over 30 kg and adult: 1.2 MIU
For primary prophylaxis: administer a single dose; for secondary prophylaxis: one injection
every 3 to 4 weeks.
– May cause:
• gastrointestinal disturbances; allergic reactions, sometimes severe. In the event of
allergic reactions, stop treatment immediately,
• Jarisch-Herxheimer reaction in patients with syphilis (to be prevented with oral
prednisolone: 3 doses of 20 mg administered at 12 hour-intervals).
– Ensure that the IM injection does not enter a blood vessel: IV administration may result in
cardiorespiratory arrest.
Remarks
– Benzathine benzylpenicillin (or penicillin G benzathine) is a penicillin with a long duration
of action (15 to 20 days), this must not be confused with benzylpenicillin (or penicillin G)
that has a short duration of action (6 hours).
– Benzathine benzylpenicillin should not be used for prevention, except in case of rheumatic
fever or diphtheria.
Once reconstituted, suspension must be kept refrigerated (2°C to 8°C) and may be used for up to
24 hours.
155
BENZYLPENICILLIN = PENICILLIN G
(Crystapen®, Penilevel®…)
This presentation is rarely used as it requires

injections every 4 to 6 hours, which can only be
done in a hospital setting.
Therapeutic action
– Penicillin antibacterial with rapid action and elimination (6 hours)
Indications
– Severe infections: pneumonia, neurosyphilis, meningitis, necrotising fasciitis, gas gangrene,
septicaemia, endocarditis, etc., alone or in combination with other antibacterials, depending
on indication
– Powder for injection in 1 MIU (600 mg) and 5 MIU (3 g) vials, for IM or IV injection (via the
infusion tube) or infusion
Dosage
– Severe pneumonia
Child over 2 months: 200 000 to 400 000 IU (120 to 240 mg)/kg/day in 4 injections
Adult: 8 to 12 MIU (4.8 to 7.2 g)/day in 4 injections
– Neurosyphilis
Adult: 12 to 24 MIU (7.2 to 14.4 g)/day in 6 injections
– Meningitis, streptococcal necrotising fasciitis, gas gangrene, anthrax
Child: 600 000 IU (360 mg)/kg/day in 6 injections
Adult: 24 MIU (14.4 g)/day in 6 injections
Duration
– Pneumonia: 5 days minimum; neurosyphilis and meningococcal or pneumococcal meningitis:
14 days; fasciitis and gas gangrene: 7 days minimum; anthrax: 7 to 10 days
– May cause:
• gastrointestinal disturbances, allergic reactions sometimes severe. In the event of allergic
reactions, stop treatment immediately,
• Jarisch-Herxheimer reaction in patients with syphilis (to be prevented with oral
prednisolone: 3 doses of 20 mg administered at 12 hour-intervals),
• neurotoxicity in patients with renal impairment or when large doses are injected too
rapidly by IV route.
– Reduce dosage in patients with severe renal impairment: maximum 10 MIU/day (6 g/day)
in adults.
Remarks
– Do not confuse rapidly acting benzylpenicillin, which can be used by IV route, with long-
acting penicillins (procaine benzylpenicillin and benzathine benzylpenicillin), which must
never be used for IV injection or infusion.
– Do not mix with other drugs in the same syringe or infusion.
Once reconstituted, suspension must be used immediately.
156
BENZYLPENICILLIN PROCAINE = PENICILLIN G PROCAINE
(Depocillin®, Duracillin®…)
Therapeutic action
– Penicillin antibacterial with prolonged effect (12 to 24 hours)
Indications
– Diphtheria, pneumonia, erysipelas and cellulitis, cutaneous anthrax
2
– Neurosyphilis, in combination with probenecid
– Powder for injection in 1 MIU (1 g) and 3 MIU (3 g) vials, to be dissolved in water for
injection, for IM injection. NEVER FOR IV INJECTION OR INFUSION.
Dosage
– Child: 50 000 IU/kg (50 mg/kg) once daily, without exceeding 1.5 MIU
– Adult: 1 to 1.5 MIU once daily
Age Weight 1 MUI vial 3 MUI vial
< 1 year < 8 kg 1/4 to 1/2 vial –
1 to 5 years 8 to 15 kg 2/3 vial –
5 to 10 years 15 to 25 kg 1 vial 1/3 vial
10 to 15 years 25 to 35 kg 1 vial 1/2 vial
Adult > 35 kg 1 vial 1/2 vial
Duration
– Diphtheria: 7 days; pneumonia: 5 days minimum; anthrax, erysipelas, cellulitis: 7 to 10 days;
neurosyphilis: 10 to 14 days
– Do not administer to patients allergic to penicillin and/or procaine.
– Administer with caution to children under one year: risk of seizures and allergy due to
procaine.
– May cause:
• pain at the injection site, gastrointestinal disturbances, allergic reactions sometimes
severe. In the event of allergic reactions, stop treatment immediately.
• Jarisch-Herxheimer reaction in patients with syphilis (to be prevented with oral predni-
solone: 3 doses of 20 mg administered at 12 hour-intervals).
ischemia at the injection site, psychiatric and neurological disorders (agitation, hallucina-
tions, seizures).
Remarks
– For the treatment of neurosyphilis, benzylpenicillin procaine is combined with oral probe-
necid (2 g/day in 4 divided doses at 6-hour intervals) for the entire length of treatment.
– Benzylpenicillin procaine is replaced in some countries by a combination of benzyl-
penicillin procaine (3 MIU) + benzylpenicillin (1 MIU), often called fortified penicillin
procaine (PPF) which has the advantage of the immediate action of benzylpenicillin,
followed by the delayed action of benzylpenicillin procaine.
– Storage:
157
BENZYLPENICILLIN PROCAINE/ BENZYLPENICILLIN
= FORTIFIED PENICILLIN PROCAINE
(Bicillin®…)
Therapeutic action
– Penicillin antibacterial with both prolonged effect due to procaine benzylpenicillin (12 to
24 hours) and immediate effect due to benzylpenicillin
Indications
– Diphtheria, pneumonia, erysipelas and cellulitis, cutaneous anthrax
– Powder for injection in 3 MIU benzylpenicillin procaine + 1 MIU benzylpenicillin vial, to be
dissolved in 8 ml water for injection, for IM injection. NEVER FOR IV INJECTION OR INFUSION.
Dosage
– Child: 50 000 IU/kg (50 mg/kg) once daily, without exceeding 1.5 MIU
– Adult: 1 to 1.5 MIU once daily
3 MUI + 1 MUI vial

Age Weight
(to be dissolved in 8 ml)
< 1 year < 8 kg 0.75 ml
1 to 5 years 8 to 15 kg 1.5 ml
5 to 10 years 15 to 25 kg 2.5 ml
10 to 15 years 25 to 35 kg 3 ml
Adult > 35 kg 3 ml
Duration
– Diphtheria: 7 days; pneumonia: 5 days minimum; anthrax, erysipelas, cellulitis: 7 to 10 days
– Do not administer to patients allergic to penicillin and/or procaine.
– Administer with caution to children under one year: risk of seizures and allergy due to
procaine.
– May cause: pain at the injection site, gastrointestinal disturbances, allergic reactions sometimes
severe. In the event of allergic reactions, stop treatment immediately.
ischemia at the injection site, psychiatric and neurological disorders (agitation, hallucinations,
seizures).
Remarks
– Storage:
158
CALCIUM GLUCONATE
Therapeutic action
– Calcium therapy
– Antidote to magnesium sulfate
Indications
– Severe hypocalcaemia (hypocalcaemic tetany, neonatal hypocalcaemia, etc.)
– Symptomatic hypermagnesaemia due to excessive doses of magnesium sulfate 2
– 1 g ampoule (100 mg/ml, 10 ml; 10% solution) for slow IV injection or infusion in 5%
glucose or 0.9% sodium chloride or Ringer lactate
Also comes in 5 g ampoule (100 mg/ml, 50 ml), 10 g vial (100 mg/ml, 100 ml), 20 g vial
(100 mg/ml, 200 ml).
Dosage
– Severe hypocalcaemia
Neonate: 2 ml/kg of a 10% solution by IV infusion over 30 minutes followed by 4 ml/kg of
a 10% solution administered by continuous infusion over 24 hours
Adult: 10 ml by slow IV injection (over at least 5 minutes), either repeated as required, or
followed by continuous infusion of 40 ml of a 10% solution over 24 hours
Change to oral route as soon as possible.
– Magnesium sulfate intoxication
Adult: 10 ml of a 10% solution by slow IV injection (over at least 5 minutes), to be repeated
once if necessary
Duration: according to clinical response and plasma-calcium levels
– Do not administer to patients with severe renal disease or patients receiving cardiac
glycosides.
– Do not administer by IM or SC route (pain and risk of tissue necrosis or abscess formation
at injection site, especially in infants and children).
– May cause:
• tingling sensations, warm flushes, dizziness,
• tissue necrosis in the event of extravasation,
• hypercalcaemia in the event of too rapid IV injection or overtreatment. First signs of
hypercalcaemia include nausea, vomiting, thirst and polyuria. In severe cases, hypo-
tension, bradycardia, arrhythmia, syncope and cardiac arrest may develop.
– Hypercalcaemia can be confirmed by monitoring of serum-calcium levels and ECG
changes. Do not use in prolonged treatment if plasma-calcium levels cannot be monitored.
– The patient should be placed in the horizontal position prior to injection and should remain
lying down for 30 to 60 minutes.
Remarks
– Calcium gluconate is also administered as adjunctive therapy in insect bites or stings (black
widow spider, scorpions) for the management of muscle pain and spasms. Several doses at
4-h intervals may be necessary.
– 1 g of calcium gluconate (2.2 mmol or 4.5 mEq) is equivalent to 89 mg of calcium.
– Calcium gluconate is incompatible with many drugs: do not mix with other drugs in the
same syringe or infusion fluid.
– Do not use if a precipitate is present.
159
CEFTRIAXONE
(Rocephin®…)
Therapeutic action
– Third-generation cephalosporin antibacterial
Indications
– Severe infections, e.g.: septicaemia, meningitis (except Listeria), typhoid fever, severe
pneumonia, acute mastoiditis, pyelonephritis, pelvic inflammatory disease, gonococcal
conjunctivitis
– Powder for injection, in 250 mg or 1 g vial, supplied with a solvent containing lidocaine, for
IM injection only. DO NOT ADMINISTER BY IV INJECTION OR INFUSION the solution reconstituted
with this solvent.
– Powder for injection, in 250 mg or 1 g vial, to be dissolved in water for injection, for slow
IV injection (2 to 4 minutes) or infusion in 5% glucose or 0.9% sodium chloride (30 minutes)
Dosage and duration
– Severe infections
Child > 1 month: 50 to 80 mg/kg once daily by IM or slow IV injection or infusion
(30 minutes); up to 100 mg/kg once daily in meningitis
Adult: 1 to 2 g (up to 4 g) once daily by IM (if necessary, administer half the dose into each
buttock) or slow IV injection or infusion (30 minutes)
Duration varies according to indication and clinical response.
– Meningococcal meningitis in an epidemic context
Child ≥ 2 years and adult: 100 mg/kg IM as a single dose; maximum 4 g. If there is no
clinical improvement after 24 hours, administer a second dose.
– Gonococcal conjunctivitis
Neonate: 50 mg/kg IM as a single dose; maximum 125 mg
Adult: 250 mg IM as a single dose
– Do not administer to patients with allergy to cephalosporins; to neonates with jaundice
(risk of bilirubin encephalopathy).
– Administer with caution to penicillin-allergic patients (cross-sensitivity in 0.5 to 6% of
patients).
– May cause: gastrointestinal disturbances, allergic reactions sometimes severe (Stevens-
Johnson syndrome), hepatic dysfunction; rarely: pancreatitis, blood disorders (anaemia,
leucopenia, thrombocytopenia), renal dysfunction.
– In the event of allergic reactions, stop treatment immediately.
Remarks
– Ceftriaxone IM (250 mg as a single dose in adults) may be used for the treatment of gonorrhoea
and chancroid. However, cefixime PO is preferred for gonorrhoea and azithromycin PO for
chancroid.
– Do not mix with other drugs in the same syringe or bottle; do not add to solutions containing
calcium (Ringer or Hartmann).
Once reconstituted, solution keeps 6 hours at a temperature below 25°C.
160
CHLORAMPHENICOL
(Chloromycetin®, Kemicetine®…)
Therapeutic action
– Antibacterial
Indications
– Severe infections: meningitis, septicaemia, typhoid fever, pneumonia, plague, etc., only
2
when oral administration is not possible
– Powder for injection in 1 g vial, to be dissolved in water for injection, for IM or IV injection
(over 1 to 2 minutes)
Dosage
– Child from 2 weeks to 1 year: 50 mg/kg/day in 3 to 4 injections
– Child over 1 year: 50 to 100 mg/kg/day in 3 to 4 injections
– Adult: 3 to 4 g/day in 3 to 4 injections
1 g vial
Age Weight
(to be dissolved in 10 ml)
< 2 weeks Avoid
< 1 year < 8 kg 1 to 2 ml x 3
1 to 5 years 8 to 15 kg 2 to 4 ml x 3
5 to 10 years 15 to 25 kg 4 to 5 ml x 3
1 g vial
10 to 15 years 25 to 35 kg 1/2 to 1 vial x 3
Adults > 35 kg 1 vial x 3
Duration : according to indication; change to oral treatment as soon as possible

– Do not administer to premature infants; avoid in newborns and children under 2 months
(if there is no alternative, dosage is 25 mg/kg/day in 3 injections).
– Do not administer to patients with a history of previous allergic reaction and/or toxic reaction
to chloramphenicol, G6PD deficiency.
– May cause:
• gastrointestinal disorders,
• allergic reactions, dose related and reversible marrow depression (anaemia, leucopenia,
thrombocytopenia): if so, stop treatment,
• grey syndrome in premature infants and neonates (vomiting, hypothermia, blue-grey
skin colour and cardiovascular depression), irreversible aplastic anaemia.
– Pregnancy: CONTRA-INDICATED, except if vital, if there is no therapeutic alternative. If used during
the 3rd trimester, risk of grey syndrome in the newborn infant.
Remarks
– Due to its potential haematotoxicity, the use of chloramphenicol should be restricted to
severe infections when other less toxic antibiotics are not effective or are contra-indicated.
– Oral treatment is more effective than parenteral treatment: blood and tissue concentrations
are higher when chloramphenicol is given orally.
161
Long-acting oily CHLORAMPHENICOL
Therapeutic action
– Antibacterial with prolonged effect
Indications
– Treatment of meningococcal meningitis during epidemics

– 500 mg ampoule (250 mg/ml, 2 ml), oily suspension for IM injection only. NEVER FOR IV
INJECTION.
Dosage
– Child ≥ 2 years and adult: 100 mg/kg/injection, without exceeding 3 g/injection
Age 2 to 5 years 6 to 9 years 10 to 14 years ≥ 15 years
Dose 1.5 g 2g 2.5 g 3g
Volume 6 ml 8 ml 10 ml 12 ml
– If necessary, administer half the dose into each buttock.
Duration
– Single dose. If there is no improvement after 24 hours, a second dose may be administered.

– Do not combine with other antibacterials.
– May cause: gastrointestinal disturbances, allergic reactions, anaemia, leucopenia, thrombo-
cytopenia.
– Shake suspension before use.
Remarks
– Oily chloramphenicol is not recommended as chemoprophylaxis for meningitis contacts
during epidemics. All suspected cases must be examined at the first signs of the disease.
162
CHLORPROMAZINE
(Largactil®…)
Therapeutic action
– Sedative and anti-emetic neuroleptic
Indications
– Acute psychosis, agitation, agressiveness, severe anxiety not controlled by other anxiolytics 2
– Very severe vomiting, intractable hiccup

– 50 mg in 2 ml ampoule (25 mg/ml) for deep IM injection or infusion
Also comes in 5 ml ampoule containing 25 mg (5 mg/ml).
Dosage
Varies from one person to another:
– Child: 0.5 mg/kg/injection, do not exceed 75 mg/day
– Adult: 25 to 50 mg/injection, do not exceed 150 mg/day
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
0.2 ml 0.5 ml 1 to 2 ml
25 mg/ml ampoule
Repeat 4 hours after the first injection,
then every 8 hours if necessary
– Do not exceed indicated dose.
Duration
– According to indication and clinical response; several days of treatment are sometimes
needed for severly agitated patients.

– Stop treatment if patient becomes febrile (possible neuroleptic malignant syndrome).
– May cause: extrapyramidal disorders in case of prolonged treatment; hypotension orthostatic.
nervous system such as diazepam, phenobarbital, chlorphenamine.
– Pregnancy: avoid prolonged use
Remarks
163
CLINDAMYCIN
(Dalacin®…)
Therapeutic action
– Lincosamide antibacterial
Indications
– Second-line treatment of pneumocystosis, in combination with primaquine
– Second-line treatment of cerebral toxoplasmosis, in combination with pyrimethamine

– 300 mg ampoule (150 mg/ml, 2 ml), to be diluted in 5% glucose or 0.9% sodium chloride
or Ringer Lactate, for infusion only. NEVER FOR IV INJECTION.
Dosage
– Adult: 2400 mg/day in 4 divided doses administered at 6-hour intervals
Duration
– Change to oral route as soon as possible. The total duration of treatment is 21 days for
pneumocystosis and 6 weeks for toxoplasmosis.

– Do not administer to patients with allergy to lincosamides or history of pseudo-
membranous colitis.
– May cause: diarrhoea (including severe: pseudomembranous colitis), nausea, rash, jaundice;
allergic reactions sometimes severe.
– In the event of allergic reactions, stop treatment immediately. If pseudomembranous colitis
develops (mucus and false membranes), stop clindamycin and treat for C. difficile disease
(oral metronidazole).
– Do not combine with: erythromycin and neuromuscular blocking drugs.
– Breast-feeding: administer only if there is no therapeutic alternative. Check infant's stools (risk of
colitis).
Remarks
164
CLOXACILLIN
(Cloxapen®, Orbenin®…)
Therapeutic action
– Penicillin antibacterial active against penicillinase-producing staphylococci
Indications
– Severe infections due to staphylococci resistant to penicillin: meningitis, staphylococcal
pneumonia, pyomyositis, septicaemia, endocarditis, etc.
2
– Powder for injection, 500 mg vial, for IM or slow IV injection or infusion (over 60 minutes)
in 5% glucose or 0.9% sodium chloride
Also comes in 1 g vial.
Dosage
– Neonate under 7 days: 75 mg/kg/day in 2 divided doses (IV or perfusion)
– Child under 2 years: 1 to 2 g/day in 3 to 4 divided doses
– Child from 2 to 10 years: 2 to 4 g/day in 3 to 4 divided doses
Child from 2 Child > 10 years

Age Child < 2 years
to 10 years and adult
500 mg vial 1 vial x 3 2 vials x 3 4 vials x 3
1 g vial 1/2 vial x 3 1 vial x 3 2 vials x 3
Duration
– Depending on indication. Change to oral treatment as soon as possible.

occur).
Remarks
– Dicloxacillin (Diclocil®, etc.), flucloxacillin (Floxapen®, etc.) and oxacillin (Bristopen®,
etc.) are used for the same indications and at the same dosage.
– Storage:
Reconstituted solution must be used immediately.
165
DEXAMETHASONE
Therapeutic action
– Corticosteroid
Indications
– Inflammatory syndrome in severe infections: severe typhoid fever, acute subglottic
laryngitis, etc.
– Foetal lung maturation, in the event of threatened premature delivery before 34 weeks of
gestation

– 4 mg dexamethasone phosphate in 1 ml ampoule (4 mg/ml) for IM or IV injection or
infusion
Dosage and duration

– Inflammatory syndrome in severe infections
Dosage and duration vary according to severity and clinical response:
Child: 0.2 to 0.4 mg/kg/day
Adult: initial dose of 0.5 to 24 mg/day
– Foetal lung maturation
Administer to the mother: 6 mg by IM injection every 12 hours for 2 days (total dose: 24 mg)

– For systemic infections, only administer if patient is under antibiotic treatment.
– In the event of treatment longer than 10 days, decrease doses gradually to avoid adrenal
gland failure.
Remarks
– Foetal lung maturation:
• after 34 weeks of gestation, corticosteroid treatment is not indicated;
• dexamethasone may be replaced by betamethasone (Betnesol®): 2 doses of 12 mg by IM
injection at 24-hour interval (total dose: 24 mg).
– For allergic reactions (Quinke’s oedema, anaphylactic shock) and status asthmaticus, use
hydrocortisone.
– Dexamethasone acetate (Dectancyl®), insoluble in water, is a suspension used only for local
treatment: intra-articular or peri-articular injection, epidural injection (sciatica).
The solution precipitates at 0°C, it must not be exposed to cold temperatures.
166
DIAZEPAM
(Valium®…)
Use IV route only if technical equipment for ventilation

is available at hand.
Therapeutic action
– Anxiolytic, sedative, anticonvulsant, muscle relaxant 2
Indications
– Seizures
– Tetanus
– Agitation associated with anxiety or confusion (delirium tremens), when oral administration
is not possible
– 10 mg ampoule (5 mg/ml, 2 ml) for IM or very slow IV injection or infusion
– Injectable solution may be used by oral and rectal route.
– For rectal or IV administration, dilute 2 ml (10 mg) of diazepam in 8 ml of 5% glucose or
0.9% sodium chloride.
– For rectal administration, use a syringe without a needle, or better, cut a nasogastric tube,
CH8, to a length of 2-3 cm and attach it to the tip of the syringe.
Dosage and duration
– Seizures
Child: 0.5 mg/kg rectally or 0.3 mg/kg by slow IV injection, without exceeding 10 mg
Adult: 10 mg rectally or by slow IV injection
If seizures do not stop within 5 minutes after the first dose, repeat once.
– Tetanus
The dosage range is variable, depending on severity. For information:
Child and adult: 0.1 to 0.3 mg/kg by slow IV injection, to be repeated every 1 to 4 hours,
under close medical supervision
– Agitation, delirium tremens
Adult: 5 to 10 mg by IM injection, to be repeated after one hour if necessary
– Do not administer to patients with severe respiratory insufficiency or severe hepatic
impairment.
– May cause:
• pain at the IV or IM injection site,
• hypotension, respiratory depression, particularly if administered IV, if injected too
rapidly by IV route and if large doses are administered (tetanus),
• in the event overdose: hypotonia, lethargy, respiratory distress, coma.
– Reduce the dose by one half in elderly patients and patients with renal or hepatic impairment.
nervous system: opioid analgesics, neuroleptics (chlorpromazine, haloperidol, etc.), anti-
histamines (chlorphenamine, promethazine), antidepressants (clomipramine, fluoxetine,
etc.), phenobarbital, etc.
– Pregnancy: avoid if possible, except if vital
Remarks
– Diazepam is subject to international controls: follow national regulations.
– Diluted solution is normally cloudy.
167
DICLOFENAC
(Cataflam®, Voltaren®, Voltarol®…)
Therapeutic action
– Non-steroidal anti-inflammatory drug, analgesic, antipyretic
Indications
– Moderate pain, particularly due to inflammation (acute sciatic neuralgia, renal colic, post-
operative pain etc.)

– 75 mg in 3 ml ampoule (25 mg/ml) for deep IM injection or infusion
Dosage
– Adult : 75 mg by deep IM injection; combine with 50 mg by oral route if necessary
– For postoperative pain, may be administered by infusion: 75 mg over 30 to 120 minutes; to
be repeated after 4 to 6 hours if necessary.
Maximum dose: 150 mg/day
Duration: maximum 2 to 3 days; change to oral treatment as soon as possible.

– Do not administer in case of:
• renal impairment, uncorrected dehydration or hypovolaemia, severe malnutrition,
• peptic ulcer,
• hypersensitivity to other NSAID (aspirin, ibuprofen, indometacin etc.), hepatic impair-
ment, severe infection,
• coagulation defects, surgery with risk of major blood loss.
– May cause: renal impairment, gastrointestinal disturbances, allergic reactions (rash,
eczema, bronchospasm).
– Administer with caution to elderly or asthmatic patients.
– Do not combine with other NSAID (aspirin, ibuprofen, indometacin etc.), diuretics, anti-
coagulants.
Remarks
– For infusion, use a solution of 5% glucose or 0.9% sodium chloride and add 0.5 ml of 8.4%
sodium bicarbonate per 500 ml.
– Diclofenac is not included in the WHO list of essential drugs.
168
DIGOXIN
(Coragoxine®, Lanoxin®…)
Therapeutic action
– Cardiotonic
2
Indications
– Supraventricular arrhythmias (fibrillation, flutter, paroxysmal tachycardia)
– Heart failure
– 500 µg ampoule (250 µg/ml, 2 ml) for slow IV injection or infusion in 5% glucose or 0.9%
sodium chloride
Dosage
– Adult:
• loading dose: 500 to 1000 µg
The loading dose can be administered either by intravenous infusion as a single dose
given over 2 hours minimum or in divided doses, by slow IV injections over 5 minutes
minimum.
• maintenance dose: change to oral treatment
– Reduce the dose by one half in elderly patients and in patients with renal impairment.
– Do not administer to patients with bradycardia, ill defined arrhythmia, coronary artery
disease.
– It is essential to monitor pulse in the initial stage of treatment.
– Narrow margin between therapeutic and toxic dose.
– May cause in the event of overdose: gastrointestinal disturbances (nausea, vomiting,
diarrhoea), blurred vision, headache, confusion, conduction and rhythm disorders. If so,
reduce dose or stop treatment.
– Do not combine with calcium, particularly by IV route (serious arrhythmias).
– Monitor combination with:
• amiodarone, macrolides, itraconazole, quinine, chloroquine (increased digoxin concen-
tration),
• potassium-depleting drugs: diuretics, corticoids, amphotericin B (increased risk of
digoxin toxicity).
– Monitor if possible serum potassium level in patients taking potassium-depleting drugs
and serum creatinine level in patients with renal impairment.
Remarks
– A loading dose may be administered in arrhythmias if a rapid digitalisation is required. It
is usually not required for heart failure.
169
EFLORNITHINE
(Ornidyl®…)
Therapeutic action
– Trypanocide
Indications
– Meningoencephalitic stage of African trypanosomiasis due to T. b. gambiense

– 20 g in 100 ml ampoule (200 mg/ml) to be diluted in 250 ml of 0.9% sodium chloride, for
IV infusion administered over 2 hours
Dosage and duration

– Child under 12 years: 600 mg/kg/day in 4 divided infusions administered at 6-hour
intervals for 14 days
– Adult: 400 mg/kg/day in 4 divided infusions administered at 6-hour intervals for 14 days

– May cause: haematological disorders (anaemia, leucopenia, thrombocytopenia), gastro-
intestinal disturbances (diarrhoea, abdominal pain, vomiting), seizures, tremor, fever, deep
tissue infection, gastrointestinal bleeding, chest pain, headache, alopecia, mouth ulcers,
dizziness, insomnia, psychosis, hallucinations, hearing impairment.
– The catheter must be handled with great attention to avoid local or general bacterial super-
infections: thoroughly disinfect the insertion site, protect the site with a sterile dressing,
ensure secure catheter fixation, change the catheter every 48 hours or earlier in the event of
phlebitis.
– It is recommended to monitor blood counts, including platelet counts, before treatment, twice
weekly during therapy and once weekly after therapy, until the patient’s haematologic status
returns to normal.
Remarks
– Eflornithine is also called difluoromethylornithine or DFMO.
Diluted solution must be kept refrigerated (2°C to 8°C) and used within 24 hours.
170
EPHEDRINE
Therapeutic action
2
– Sympathomimetic
Indications
– Hypotension induced by regional anaesthesia (spinal and epidural anaesthesia)
– First choice treatment of anaphylactic shock in pregnant women

– 30 mg in 1 ml ampoule (30 mg/ml) for IV injection
Also comes in 1 ml ampoule containing 50 mg (50 mg/ml).
Dosage
– Dilute 1 ampoule of 30 mg in 9 ml of water for injection to obtain a solution containing 3 mg
ephedrine per ml.
– Adult: 3 to 6 mg by slow IV injection (1 to 2 ml of the diluted solution), to be repeated every
minutes until blood pressure stabilizes

– Administer with caution to patients with coronary insufficiency, hyperthyroidism, closed-
angle glaucoma.
– May cause: arrhythmia, hypertension.
– Breast-feeding: avoid (excreted in milk)
Remarks
– For the treatment of anaphylactic shock in pregnant women, ephedrine is preferred over
epinephrine to avoid placental vasoconstriction. However, if ephedrine is not immediately
effective, use epinephrine (adrenaline).
– Ephedrine has a less potent but more prolonged action than epinephrine (adrenaline).
– Ephedrine has been used in the treatment of asthma but more selective sympathomimetics
such as salbutamol are preferred.
– In some countries, ephedrine is a controlled substance: follow national regulations.
171
EPINEPHRINE = EPN = ADRENALINE
Therapeutic action
– Sympathomimetic
Indications
– Anaphylactic shock
– Cardiopulmonary arrest
– 1 mg in 1 ml ampoule (1 mg/ml = 1:1000) for IM or IV injection
Also comes in 1 ml ampoule containing 0.25 mg.
Dosage
– Anaphylactic shock
IM epinephrine is the first line treatment (anterolateral part of the thigh), however use IV
epinephrine in patients with circulatory collapse or those who deteriorate despite receiving
IM epinephrine.
• IM treatment
Use undiluted solution (1:1000 = 1 mg/ml) and a 1 ml syringe graduated in 0.01 ml:
Child from 6 months to 6 years: 0.12 ml
Child from 6 to 12 years: 0.25 ml
Child over 12 years and adult: 0.5 ml
In children, if 1 ml syringe is not available, use a diluted solution, i.e. add 1 mg EPN to
9 ml of 0.9% sodium chloride to obtain a 0.1 mg/ml solution (1:10 000):
Child from 6 months to 6 years: 1.2 ml
Child from 6 to 12 years: 2.5 ml
Repeat after 5 minutes if no clinical improvement.
• IV treatment
Use a diluted solution, i.e. add 1 mg EPN to 9 ml of 0.9% sodium chloride to obtain a
0.1 mg/ml solution (1:10 000):
Child: 0.1 ml/kg (0.01 mg/kg) administered over several minutes
Adult: 1 to 2 ml (0.1 to 0.2 mg), to be repeated every 1 to 2 minutes, until improvement
occurs
– Cardiopulmonary arrest
Use a diluted solution, i.e. add 1 mg EPN to 9 ml of 0.9% sodium chloride to obtain a
0.1 mg/ml solution (1:10 000):
Child: 0.1 ml/kg (0.01 mg/kg), to be repeated every 3 to 5 minutes, until improvement occurs
Adult: 10 ml (1 mg), to be repeated every 3 to 5 minutes, until improvement occurs
– Administer with caution to patients with hypertension, angina, ischaemic heart disease,
hyperthyroidism and to elderly patients.
– Do not exceed indicated dose: risk of arrhythmia.
– Pregnancy: for the treatment of anaphylactic shock in pregnant women, ephedrine is preferred over
epinephrine, however, if ephedrine is not immediately effective, use epinephrine.
Remarks
– For hypotension induced by spinal anaesthesia (unresponsive to ephedrine), administer 0.1
to 0.2 mg of epinephrine IV, every minute, until blood pressure stabilizes.
– Epinephrine is colourless; discard any ampoules with a pink or brownish colour.
– Storage:
172
METHYLERGOMETRINE (Methergin®…)
and ERGOMETRINE (Ergotrate®…)
Therapeutic action
– Uterine stimulant
Indications
2
– Postpartum or postabortal haemorrhage caused by uterine atony (preferably use oxytocin
for this indication)

– Methylergometrine maleate: 200 µg in 1 ml ampoule (200 µg/ml), for IM injection
– Ergometrine maleate: 500 µg in 1 ml ampoule (500 µg/ml), for IM injection
Dosage
– Methylergometrine maleate: 200 µg/injection
– Ergometrine maleate: 250 µg to 500 µg/injection
To be repeated every 2 to 4 hours if necessary, without exceeding a total of 5 injections.

– Do not administer during delivery; do not use to induce or facilitate labour.
– Do not administer to patients with hypersensitivity to ergot derivatives (cabergoline,
bromocriptine, ergotamine, etc.), severe hypertension, pre-eclampsia, eclampsia, septicaemia.
– Before administration always check:
• that expulsion of the placenta is complete,
• that there is no multiple pregnancy. Do not use before the birth of the last child.
– May cause: gastrointestinal disturbances, headache, paraesthesia, confusion, dizziness,
tinnitus, hypertension, peripheral vasoconstriction, chest pain.
– Do not combine with another ergot derivative.
– Monitor combination with: metronidazole, azole antifungals, macrolides, protease inhibitors,
efavirenz, fluoxetine (risk of ergotism).
– Exceptionally, for extensive uterine bleeding and if oxytocin is not available, ergometrine
and methylergometrine may be used by IV route, slowly over a period of no less than one
minute, with careful monitoring of blood pressure (risk of sudden hypertensive accidents).
– Breast-feeding: avoid, except if clearly needed
Remarks
– Do not confuse with dihydroergotamine, a related drug used for totally different indications.
– Ergometrine is also called ergonovine or ergobasine.
– Storage: to be kept refrigerated (2°C to 8°C). Do not freeze –
• Expiry date indicated on the label is only valid if stored under refrigeration and protected from
light.
• If refrigeration is not available, vials can be kept for one month on condition that they are
protected from light and the temperature remains under 30°C.
• Exposure to heat and especially light causes the deterioration of the active ingredients and thus
loss of efficacy. Methylergometrine is as sensitive as ergometrine.
• The solution must be colourless. Discolouration indicated a deterioration of the active ingredients.
Never use a coloured solution.
173
ETONOGESTREL subdermal implant
(Implanon®…)
Therapeutic action
– Flexible rod containing 68 mg of etonogestrel, in a sterile disposable applicator, to be inser-
ted subdermally into the inner side of the non-dominant arm, 6 to 8 cm above the elbow
crease, under local anaesthesia and aseptic conditions.
Indications
Long-term contraception:
– If no current contraception, the implant is inserted:
during the first 5 days of menstruation
or after childbirth:
• if the woman breastfeeds: as of the sixth week postpartum
• if the woman does not breastfeed: as of the 21st day postpartum
However, if there is a risk that the woman may be lost to follow-up, the implant may be
inserted whenever, even after childbirth, whether she breastfeeds or not.
– When switching from another contraceptive method, the implant is inserted:
for an oral estroprogestogen: the day after taking the last active tablet in the pack
for an oral progestogen: at any stage of the cycle
for an injectable progestogen: the day the next injection is due
for an intrauterine device: the day of its removal
Duration
– The implant slowly releases a low dose of etonogestrel. It is left inserted, as long as contra-
ception is desired and it is well tolerated, for a maximum of 3 years (2 years in obese
women) after which it no longer provides contraception and must be changed.
– Do not use in patients with breast cancer, severe or recent liver disease, unexplained vagi-
nal bleeding or current thromboembolic disorders.
– May cause: headache, acne, menstrual irregularities, amenorrhoea, menometrorrhagia,
breast tenderness, weight gain, mood changes, abdominal pain, gastrointestinal distur-
bances, itching, allergic reaction.
– Hepatic enzyme inducers (rifampicin, rifabutin, nevirapine, nelfinavir, ritonavir, pheno-
barbital, phenytoin, carbamazepine, griseofulvin, etc.) may reduce the contraceptive effica-
cy. Use a non-hormonal contraceptive method (copper intrauterine device, condoms) or an
oral contraceptive containing 50 µg ethinylestradiol (however there is still a risk of contra-
ceptive failure and the risk of adverse effects is increased) or injectable medroxyprogeste-
rone.
– Do not insert the implant deeply as the removal can be difficult later on. It should be pal-
pable under the skin. Read carefully manufacturer’s instructions.
– Remove the implant under local anaesthesia and aseptic conditions, using a forceps, after
incision with scalpel.
Remarks
– Implants provide long term contraception, their efficacy is not conditioned by observance.
Fertility returns rapidly after removal of the implant.
174
FUROSEMIDE = FRUSEMIDE
(Lasilix®, Lasix®, Seguril®…)
Therapeutic action
– Diuretic
2
Indications
– Emergency treatment of:
• Oedema caused by renal, hepatic or congestive heart failure
• Hypertensive crisis (except that of pregnancy)
• Pulmonary oedema

– 20 mg in 2 ml ampoule (10 mg/ml) for IM or slow IV injection
Dosage
– Child: 0.5 to 1 mg/kg/injection
– Adult: 20 to 40 mg/injection
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
0.2 ml 0.3 ml 0.75 ml 1.5 ml 2 to 4 ml

10 mg/ml ampoule
Repeat after 2 hours if necessary
– For pulmonary oedema: if an initial IV injection of 40 mg does not produce a satisfactory res-
ponse within one hour, the dose may be increased to 80 mg by slow IV injection.
Duration
– According to clinical response;
– If prolonged use is required, change to oral treatment 3 hours after the last injection.

– Do not administer in other types of oedema, especially those due to kwashiorkor.
– Do not administer in case of hepatic encephalopathy.
– May cause: hypokalaemia, especially in cases of cirrhosis, denutrition, congestive heart
failure.
– Closely monitor combination with digoxin (furosemide enhances toxicity of digoxin).
– Pregnancy: CONTRA-INDICATED to treat hypertension in pregnancy
– Breast-feeding: avoid (excreted in milk and may reduce milk production)
Remarks
– If doses greater than 50 mg are required, it is recommended that they be given by IV infusion.
175
GENTAMICIN
(Genticin®…)
Therapeutic action
– Aminoglycoside antibacterial
Indications
– Severe infections (endocarditis, septicaemia, peritonitis, pyelonephritis, etc.), in combination
with another antibacterial
– 20 mg ampoule (10 mg/ml, 2 ml) and 80 mg ampoule (40 mg/ml, 2 ml) for IM or slow IV
injection or infusion
Also comes in 10 mg ampoule (10 mg/ml, 1 ml), 40 mg ampoule (40 mg/ml, 1 ml), 40 mg
ampoule (20 mg/ml, 2 ml) and 160 mg ampoule (80 mg/ml, 2 ml).
Dosage
– Child and adult: 3 to 6 mg/kg/day
The daily dose in usually administered in 2 injections. For treatments shorter than 7 days,
the daily dose may be given in a single injection.
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
20 mg ampoule 1 ml x 2 1.5 ml x 2 3 ml x 2 – –
(10 mg/ml, 2 ml)
40 mg ampoule 0.5 ml x 2 0.75 ml x 2 1.5 ml x 2 3 ml x 2 –
(20 mg/ml, 2 ml)
80 mg ampoule 0.2 ml x 2 0.4 ml x 2 0.75 ml x 2 1.5 ml x 2 3 ml x 2
(40 mg/ml, 2 ml)
160 mg ampoule – – 0.4 ml x 2 0.75 ml x 2 1.5 ml x 2
(80 mg/ml, 2 ml)
Duration
– According to indication and clinical response. Given the risk of renal and auditory toxicity,
do not prolong treatment unnecessarily.
– Do not administer to patients with allergy to gentamicin or another aminoglycoside.
– Administer with caution to patients with renal impairment, auditory and vestibular damage;
reduce dosage in patients with renal impairment (1 mg/kg/day).
– May cause: renal impairment, auditory and vestibular damage, allergic reactions.
– Do not combine with another aminoglycoside.
– Monitor combination with: neuromuscular blockers, general anaesthetics (potentialization
of their effects); amphotericin B, vancomycin, capreomycin, furosemide (enhanced renal
and/or auditory toxicity).
Remarks
176
GLUCOSE 50% = DEXTROSE 50%
Indications
– Emergency treatment of severe hypoglycaemia

– Vial containing 50% hypertonic glucose solution (500 mg/ml, 50 ml), for very slow IV 2
injection. NEVER BY IM OR SC INJECTION.
Dosage
– Child and adult: 1 ml/kg by very slow IV injection (over 5 minutes)

– May cause:
• vein irritation,
• tissue necrosis in the event of extravasation.
– Check blood glucose level (reagent strip test) after 30 minutes. If blood glucose level is
< 3 mmol/l or < 54 mg/dl, administer another dose or give glucose by oral route, according
to the patient clinical condition. Determine and treat the underlying cause and monitor the
patient as long as required.
– The solution is viscous: use a large vein and a large calibre needle.
Remarks
– 10% glucose solution (100 mg of glucose/ml) may be used to treat severe hypoglycaemia:
5 ml/kg by slow IV injection. 10% glucose solution is preferred in children as it is less
viscous and irritant than 50% solution.
– In neonatal hypoglycaemia, use 10% glucose only, at a rate of 5 ml/kg/hour. Administer a
loading of 2.5 ml/kg over 5 minutes in severe neonatal hypoglycaemia with loss of
consciousness or seizures.
177
HEPARIN
Therapeutic action
– Anticoagulant
By IV injection: acts immediately for about 2 to 4 hours
By SC injection: acts within 1 hour for about 8 to 12 hours
Indications
– Venous and arterial thrombosis: pulmonary embolism, myocardial infarction, thrombo-
phlebitis
– Prevention of venous and arterial thrombosis, especially in pre-operative and postoperative
period and in patients on bedrest
Prescription of heparin requires systematic monitoring of coagulation parameters.

– 1000 IU in 1 ml ampoule (1000 IU/ml) and 5000 IU in 1 ml ampoule (5000 IU/ml) for IV
injection or infusion, diluted in an isotonic solution of glucose or sodium chloride
– 25 000 IU in 1 ml ampoule (25 000 IU/ml) for SC injection
Also comes in various concentrations (500 IU, 12 500 IU, 20 000 IU/ml) and volumes (0.5 ml,
2 ml, 5 ml). Check label before use.
Dosage
– Curative treatment
• By IV route
Child and adult: initial dose of 50 to 100 IU/kg followed by 400 to 600 IU/kg/day, by
continuous infusion over 24 hours or by IV injection every 2 to 4 hours. Adjust dosage
according to coagulation tests.
• By SC route
Child and adult: 1 SC injection every 12 hours. Start with an initial dose of 250 IU/kg
and adjust dosage according to coagulation tests.
– Preventive treatment
Usually: 5000 IU by SC injection 2 hours before surgery, repeated every 8 to 12 hours.
Dosage depends on patient's weight and risk of thrombo-embolic complications:
150 IU/kg/day in 2 to 3 divided doses.
Duration
– About 7 to 10 days or more according to clinical response.
– In postoperative period, administer until fully ambulatory.
– For long-term therapy, administer heparin simultaneously with oral anticoagulants for 2 to
3 days before stopping heparin.
178
– Do not administer if:
• haemorrhage or risk of haemorrhage: haemophilia, active peptic ulcer, acute bacterial
endocarditis, severe hypertension; in postoperative period after neurosurgery or
ophtalmic surgery;
• thrombocytopenia or history of heparin-induced thrombocytopenia.
– Do not administer by IM route. SC injections must be made deep into abdominal fat,
2
between umbilicus and iliac crest.
– Intramuscular or intra-arterial injections and infiltrations are contra-indicated during heparin
therapy.
– May cause:
• severe thrombocytopenia, usually after 5 days of heparin, with thrombo-embolic
complications requiring discontinuation of treatment;
• localised reactions at the injection site, rarely, necrosis;
• allergic reactions, osteoporosis after prolonged use, alopecia;
• haemorrhage in case of overdosage, pre-existing lesions, trauma.
– Use with caution and reduce dosage in elderly patients and in hepatic or renal failure.
– Overdosage: neutralise heparin by slow IV injection of protamine. 1 mg protamine neutralises
100 IU of heparin.
Reduce doses of protamine if more than 15 minutes has elapsed since heparin administration.
– Laboratory tests: monitor coagulation parameters in order to adjust dose. Partial thrombo-
plastin time should be maintained at 1.5 to 2 times the control value (Howell's test at 2 to
3 times the control value).
– Monitor platelet count prior to initiation of treatment and then 2 times per week.
– Avoid combination with aspirin, non-steroidal anti-inflammatory drugs: increased risk of
haemorrhage.
– Closely monitor clinical and biological parameters in case of combination with corticosteroids,
dextran, and transition to an oral anticoagulant.
– Pregnancy: CONTRA-INDICATED at the end of pregnancy (risk of haemorrhage during delivery)
Remarks
– Preparations containing calcium salt of heparin are available. Heparin sodium is usually
used by IV route. Both sodium and calcium heparin are used by SC route. There is a little
difference in the action of these 2 medications.
– Storage: keep in a cool place (8°C to 15°C) –
179
HALOPERIDOL
(Haldol®, Serenace®…)
Therapeutic action
– Neuroleptic
Indications
– Acute psychoses: psychomotor agitation, acute mania, delirium tremens
– Severe vomiting induced by antineoplastic drugs

– 5 mg in 1 ml ampoule (5 mg/ml) for IM injection or IV infusion
Dosage
– Adult: 2 to 10 mg/day by IM injection, repeated at intervals of 4 to 8 hours if necessary
– In patients receiving chemotherapy: 5 mg by IV infusion or 1 to 5 mg by IM injection, repeated
after 12 hours if necessary.

– Do not administer to children and to patients suffering from Parkinson's disease.
– In case of hyperthermia following an injection, stop treatment: possible neuroleptic malignant
syndrome.
– May cause: extrapyramidal syndrome, dyskinesia, orthostatic hypotension.
– Risk of increased sedation when combined with depressants of the central nervous system
(morphine and derivatives, anxiolytics, antihistamines…).
Remarks
– Haloperidol decanoate is a long-acting form acting as a pro-drug, releasing slowly haloperidol,
used in the long-term treatment of psychotic disorders in patients stabilised on oral treat-
ment (one IM injection every 3 to 4 weeks).
– Haloperidol may induce more extrapyramidal reactions than chlorpromazine, but less
often provoke sedation and orthostatic hypotension.
– If administered by infusion, protect the bottle from light.
180
HYDRALAZINE
(Apresoline®…)
Therapeutic action
– Antihypertensive vasodilatator
Indications
2
– Severe hypertension in pregnancy, when oral treatment is not possible
– Powder for injection, 20 mg vial, to be dissolved in 2 ml of water for injection, for slow IV
injection or IV infusion
Dosage
Dosage must be adapted according to BP: treatment is administered if the diastolic BP is
≥ 110 mmHg. Hypertension is controlled when diastolic BP remains between 90 and
100 mmHg. During administration diastolic BP must never fall below 90 mmHg. Monitor
maternal BP and pulse, as well as fœtal heart rate.
– By IV infusion
• Dilute 100 mg (5 ampoules) in 500 ml of sodium chloride 0.9% or Ringer lactate to obtain
a solution containing 200 micrograms/ml.
• Initial dose: 200 to 300 micrograms/minute; maintenance dose: 50 to 150 micro-
grams/minute.
• Administer by increasing the rate up to 20 drops/minute (maximum 30 drops/minute),
check BP every 5 minutes.
• As soon as hypertension is controlled, decrease progressively the rate (15 drops/minute,
then 10, then 5) until stopping infusion. An abrupt discontinuation may provoke a
hypertensive crisis.
– By slow IV injection
Administer 5 mg by slow IV injection (over 2 minutes) and check BP for 20 minutes. If
diastolic BP remains ≥ 110 mmHg, repeat injection. Continue repeating if necessary, waiting
20 minutes between each injection, without exceeding a total dose of 20 mg.
Duration
– Change over to an oral antihypertensive as soon possible.
– Administer with caution to patients with heart failure, coronary insufficiency, recent
myocardial infarction, severe tachycardia, history of stroke.
– Reduce doses in patients with renal or hepatic impairment.
– May cause: tachycardia, headache, nausea, hypotension.
– Respect dosage and administration rate. An overdose or too rapid administration may
provoke an abrupt and excessive fall in maternal blood pressure with placental hypo-
perfusion and fœtal death.
– In the event of hypotension, administer Ringer lactate to maintain diastolic BP ≥ 90 mmHg.
– Pregnancy: avoid during the 1st trimester
Remarks
– For administration, only use sodium chloride 0.9 % or Ringer lactate (incompatibility with
glucose and other solutions).
– Do not mix with other drugs in the same syringe or infusion bottle.
181
HYDROCORTISONE
(Efcortesol®, Solu-cortef®…)
Therapeutic action
– Steroidal anti-inflammatory drug (corticosteroid)
Indications
– Symptomatic treatment of severe allergic and inflammatory reactions, e.g.: severe acute
asthma (in addition to inhaled salbutamol), allergic angioedema, anaphylactic shock (as an
adjunct to epinephrine)

– Powder for injection, 100 mg hydrocortisone (hemisuccinate, succinate or phosphate) in
vial, to be dissolved in 2 ml water for injection, for IM or slow IV injection or infusion
Dosage and duration

– Child under 1 year: 25 mg/injection
– Child from 1 to 5 years: 50 mg/injection
– Child from 6 to 12 years: 100 mg/injection
– Adult: 100 to 500 mg/injection
Doses may be repeated 3 or 4 times daily according to the severity of the symptoms and the
patient’s response.

– Avoid prolonged administration in patients with peptic ulcer, diabetes mellitus or cirrhosis.
– Administer with caution to patients receiving digitalis glycosides: increases digitalis toxicity
associated with hypokalaemia.
– Pregnancy: use only if clearly needed, for a short period
Remarks
– Hydrocortisone acetate is a suspension insoluble in water, used as a local treatment only:
intra- or peri-articular injection, epidural (sciatic neuralgia).
182
HYOSCINE BUTYLBROMIDE = BUTYLSCOPOLAMINE
(Buscopan®…)
Therapeutic action
– Antispasmodic
Indications
– Spasms of the gastrointestinal tract and genitourinary tract
2
– 20 mg in 1 ml ampoule (20 mg/ml) for IM, SC or slow IV injection
Dosage
– Child under 6 years: 5 mg/injection, to be repeated up to 3 times per day if necessary
– Child from 6 years to 12 years: 0.5 mg/kg/injection to be repeated up to 3 to 4 times per
day if necessary
– Adult: 20 to 40 mg/injection, to be repeated if necessary; do not exceed 100 mg/day
Duration: according to clinical response; no prolonged treatment.

– Do not administer to patients with urethro-prostatic disorders, cardiac disorders,
glaucoma.
– May cause: urinary retention, dryness of the mouth, constipation, blurred vision,
tachycardia.
– Administer with caution to children under 6 years.
– Administer with caution and under close supervision to patients taking other anti-
cholinergic drugs (antidepressants, neuroleptics, H-1 antihistamines, antiparkinsonians,
etc.).
– Breast-feeding: no contra-indication; NO PROLONGED TREATMENT
Remarks
– Antispasmodic drugs are not included in the WHO list of essential medicines.
183
INSULIN
General information
Therapeutic action
– Pancreatic hormone, antidiabetic
Classification
– There are 3 main types of insulin preparations, differing in onset and duration of action:
Administration Short-acting Intermediate-acting Long-acting

by SC route insulin insulin insulin
Onset 30 minutes to 1 hour 1 to 2 hours 2 to 4 hours

Time to peak 2 to 5 hours 4 to 12 hours 8 to 20 hours
Duration 6 to 8 hours 10 to 24 hours 24 to 36 hours
Description solution suspension suspension
Appearance clear opalescent opalescent
– Duration of action is indicated for each preparation by the manufacturer. For each preparation,
onset and duration vary greatly according to the patient and route of administration.
– The type of insulin used depends on the type of diabetes, patient's age and blood glucose
levels.
Indications
– Insulin-dependent diabetes
– Diabetes during pregnancy
– Degenerative complications of diabetes : retinopathy, neuropathy...
– Non-insulin-dependent diabetics during periods of severe infection, trauma, surgery.
Dosage
– Dosage must be individualised. Frequency of administration depends on the type of insulin
and the patient's response. There is no standardized protocol.
Never exceed 200 IU/day, whatever the type of insulin.
Duration
– Insulin-dependent diabetics: life-time treatment
– Other cases: according to clinical response and laboratory tests
184
– Do not administer in patients with allergy to insulin (rare).
– May cause :
• hypoglycaemia due to overdosage or inadequate diet. Treat mild hypoglycaemia with
intake of oral sugar and IV injection of hypertonic glucose solution if severe;
• local reactions: pain, erythema at the injection site, lipodystrophy. Rotate injection sites
systematically and use all available sites (upper arm, thighs, abdomen, upper back).
2
– Patient monitoring: blood and urine glucose concentrations, urine ketone tests.
Blood glucose concentrations should be maintained within the range of 4.4 to 8 mmol/litre
under fasting (8 mmol = 1.4 g).
Diabetes is controlled when:
• there are no glucose and ketones in urine;
• before-meal blood glucose levels are < 1.2 g/litre (< 6.67 mmol/litre);
• postprandial blood glucose levels are ≤ 1.4 g/litre (< 7.78 mmol/litre).
– Treatment of diabetes must be initiated in hospital under close supervision.
Treatment includes: insulin administration, specific diet, education and counselling under
medical supervision (self-monitoring of blood glucose, self-administration of insulin,
knowledge about signs of hypoglycaemia and hyperglycaemia).
– Closely monitor combination with:
• drugs enhancing hypoglycaemic effect: acetylsalicylic acid, angiotensin-converting
enzyme inhibitors, beta-blockers (which in addition, may mask symptoms of
hypoglycaemia);
• drugs increasing blood glucose levels: glucocorticoids, salbutamol, chlorpromazine, oral
contraceptives.
– Avoid alcohol: enhances and prolongs hypoglycaemic effect of insulin.
– Use sterile technique.
Remarks
– Insulin is obtained by extraction from bovine or porcine pancreases. The term mono-
component insulin is used for highly purified insulin.
– Insulin of human sequence is prepared either semisynthetically by modification of porcine
material or biosynthetically.
– Preparations of human or animal origin have the same hypoglycemic effect. There is
generally no significant difference.
– Insulin cannot be administered by mouth since it is inactivated in the gastro-intestinal tract.
185
INTERMEDIATE-ACTING INSULIN
(Insulatard®, Semitard®…)
LONG-ACTING INSULIN
(Ultralente®, Ultratard®…)
Therapeutic action
– Insulin suspension modified by addition of protamine and/or zinc, in order to prolong the
duration of action
Indications
– As for insulin in general, except in the emergency treatment of diabetic ketoacidosis and
coma
– 400 IU of insulin suspension in 10 ml vial (40 IU/ml) for deep SC injection, administered
with a calibrated syringe for IU-40 insulin.
Also comes in solution containing 100 IU/ml, administered only with calibrated syringe for
IU-100 insulin.
IM route may be used but SC route is less painfull and drug action is longer and more regular.
Dosage
– 20 to 40 IU/day divided in 2 injections for intermediate-acting insulin, in 1 or 2 injections
for long-acting insulin.
Administer 15 to 30 minutes before meals. Increase by 2 IU/day until reaching the blood
glucose level required. Adjust dosage and frequency of injections according to patient's
needs.
Short-acting insulin is often administered in combination with an intermediate-acting or
long-acting insulin.
Examples of regimens:
Insulin Administration
– Short-acting insulin – 2 times/day before breakfast and lunch
– Intermediate-acting insulin – at bedtime
– Short-acting insulin – 3 times/day before breakfast, lunch and
dinner
– Long-acting insulin – at bedtime or before breakfast
– Intermediate-acting with or without – 2 times/day before breakfast and dinner
short-acting insulin

– See "insulin: general information".
– Never administer by IV injection.
– Do not administer if known allergy to protamine.
– Shake suspension gently before use. Remove from the refrigerator 1 hour before administration
or roll the vial between hands.
Remarks
– Storage: to be kept refrigerated (2°C to 8°C) –
• Do not freeze; discard if freezing occurs.
• Most manufacturers consider that a solution stored by the patient at a temperature up to 25°C
and protected from light is stable for 1 month.
186
SHORT-ACTING INSULIN
(Actrapid®, Velosulin®…)
Therapeutic action
– Soluble insulin, sometimes called neutral insulin, regular insulin or unmodified insulin.
Indications 2
– As for insulin in general, particularly in cases of diabetic ketoacidosis and diabetic coma.

– 400 IU of insulin in 10 ml vial (40 IU/ml) for deep SC injection, IM or IV injection,
administered with a calibrated syringe for IU-40 insulin.
Also comes in solution containing 100 IU/ml, administered only with calibrated syringe for
IU-100 insulin.
Dosage
– Emergency treatment of ketoacidosis and diabetic coma
• Child: initial dose 0.1 IU/kg by direct IV injection followed by 0.3 IU/kg every 4 hours.
• Adult: initial dose of 5 to 20 IU by direct IV injection followed by 10 to 20 IU every hour
via the drip tubing. When ketone bodies are cleared and blood glucose level has fallen
to less than 20 mmol/litre, give 20 IU by SC injection every 4 to 6 hours according to
blood glucose level.
Treat dehydration with a sodium chloride solution, then glucose-saline solution.
Correct cautiously acidosis with isotonic solution of bicarbonate and, if necessary, post-
insulinic hypokalaemia.
– Treatment of diabetes mellitus
Start with 5 IU, 15 minutes before meals, 3 to 4 times/day by SC injection. Adjust dosage
according to blood glucose levels before and after meal. Adjustments should not exceed
10 IU/day.
When hyperglycemia is controlled, an intermediate-acting insulin may be substituted in
order to limit injections.
Short-acting insulin may be mixed with intermediate-acting insulin in the proportion of
10 to 50%.

– See "Insulin: general information".
Remarks
– The terms "cristalline insulin" and "neutral insulin" are used either for soluble insulin or
intermediate and long-acting insulin.
• Do not freeze.
• Most manufacturers consider that a solution stored by the patient at a temperature up to 25°C
and protected from light, is stable for 1 month.
187
KETAMINE
(Calypsol®, Ketalar®, Ketanest®…)
Therapeutic action
– General anaesthetic
Indications
– Induction and maintenance of general anaesthesia

– 500 mg in 10 ml vial (50 mg/ml) for IM, IV injection or infusion
Also comes in 5 ml and 20 ml ampoules containing 10 mg/ml and 5 ml ampoule containing
100 mg/ml for IM, IV injection or infusion.
Dosage
Child and adult:
– Induction
• IV: 2 mg/kg to be injected slowly. Anaesthesia is produced within one minute and lasts
for 10 to 15 minutes.
• IM: 10 mg/kg. Anaesthesia is produced within 5 minutes and lasts for 15 to 30 minutes.
– Maintenance
• IV: 0.5 to 1 mg/kg depending on recovery signs (approximately every 15 minutes)
• IM: 5 mg/kg approximately every 20 to 30 minutes
Duration: depending on duration of the operation

– Do not administer to patients with intraocular hypertension, pre-eclampsia.
– Administer with caution to patients with arterial or intracranial hypertension, coronary
insufficiency, psychiatric disorders.
– May cause: hypertension, hypersalivation, hallucinations during recovery (less frequent in
children or when injected IM), apnoea following rapid IV injection.
– Premedication to prevent hypersalivation and hallucinations:
• atropine IV: 0.01 to 0.015 mg/kg + diazepam slow IV: 0.1 mg/kg, during induction
or
• atropine IM : 0.01 to 0.015 mg/kg + diazepam IM : 0.1 mg/kg, 30 minutes before induction
– Technical equipment for intubation and ventilation must be available and ready for use.
– Pregnancy: no contra-indication, except in pre-eclampsia. For ceaserean sections, do not exceed
1 mg/kg by IV injection (risk of neonatal respiratory depression at higher doses).
Remarks
– Ketamine has no muscle relaxant properties.
– In some countries, ketamine is on the list of narcotics: follow national regulations.
– Storage:
188
LEVONORGESTREL subdermal implant
(Jadelle®…)
Therapeutic action
– Set of two flexible rods containing 75 mg of levonorgestrel, with a sterile applicator (reu-
2
sable after sterilisation or for single use only, depending on the presentation), to be inser-
ted subdermally into the inner side of the non-dominant arm, 6 to 8 cm above the elbow
crease, under local anaesthesia and aseptic conditions
Indications
Long-term contraception:
– If no current contraception, the implant is inserted:
• if the woman breastfeeds: as of the sixth week postpartum
• if the woman does not breastfeed: as of the 21st day postpartum
However, if there is a risk that the woman may be lost to follow-up, the implant may be
inserted whenever, even after childbirth, whether she breastfeeds or not.
– When switching from another contraceptive method, the implant is inserted:
for an oral estroprogestogen: the day after taking the last active tablet in the pack
for an oral progestogen: at any stage of the cycle
for an injectable progestogen: the day the next injection is due
for an intrauterine device: the day of its removal
Duration
– The implant slowly releases a low dose of levonorgestrel. It is left inserted, as long as
contraception is desired and it is well tolerated, for a maximum of 5 years (4 years in
women over 60 kg) after which it no longer provides contraception and must be changed.
– Do not use in patients with breast cancer, severe or recent liver disease, unexplained vagi-
nal bleeding or current thromboembolic disorders.
– May cause: headache, acne, menstrual irregularities, amenorrhoea, menometrorrhagia,
breast tenderness, weight gain, mood changes, abdominal pain, gastrointestinal distur-
bances, itching, allergic reaction.
– Hepatic enzyme inducers (rifampicin, rifabutin, nevirapine, nelfinavir, ritonavir, pheno-
barbital, phenytoin, carbamazepine, griseofulvin, etc.) may reduce the contraceptive effica-
cy. Use a non-hormonal contraceptive method (copper intrauterine device, condoms) or an
oral contraceptive containing 50 µg ethinylestradiol (however there is still a risk of contra-
ceptive failure and the risk of adverse effects is increased) or injectable medroxyprogeste-
rone.
– Do not insert the rods deeply as the removal can be difficult later on. They should be pal-
pable under the skin. Read carefully manufacturer's instructions.
– Remove them under local anaesthesia and aseptic conditions, using a forceps, after incision
with scalpel.
Remarks
– Implants provide long term contraception, their efficacy is not conditioned by observance.
Fertility returns rapidly after removal of the implant.
– The duration of action of the levonorgestrel implant (5 years) is longer than that of the eto-
nogestrel implant (3 years). However, the etonogestrel implant (one rod) is easier to
insert/remove than the levonorgestrel implant (2 rods).
189
LIDOCAINE = LIGNOCAINE
(Xylocaine®…)
Therapeutic action
– Local anaesthetic
Indications
– Local anaesthesia: • minor operations : 1% lidocaine plain
• dental surgery : 2% lidocaine (plain or with epinephrine)

– 1% solution in 20 and 50 ml vials (10 mg/ml), for SC infiltration
– 2% solution in 20 and 50 ml vials (20 mg/ml), for SC infiltration
Dosage
– The volume to be injected depends on the surface area to be anesthetised.
– Do not exceed: Child: 5 mg/kg/injection
Adult: 200 mg = 20 ml of lidocaine 1% or 10 ml of lidocaine 2%
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
1 % solution, 10 mg/ml 2 to 3 ml 4 to 8 ml 9 to 15 ml 15 to 20 ml
2 % solution, 20 mg/ml 1 to 1 1/2 ml 2 to 4 ml 4 to 7 ml 7 to 10 ml
Duration: one injection, repeated if necessary

– Do not administer if known allergy to lidocaine, impaired cardiac conduction.
– When anaesthetising the extremities, inject distally (at the base), in circle, without tourniquet
and without epinephrine (adrenaline).
– Do not use lidocaine for the incision of abscesses: risk of spreading the infection.
– Lidocaine with epinephrine (adrenaline):
• in dental surgery, epinephrine added to lidocaine prolongs anaesthesia;
• never use solutions with epinephrine for the anaesthesia of extremities (fingers, penile
nerve block): risk of ischemia and necrosis.
Remarks
– Anaesthesia is produced within 2 to 5 minutes and lasts 1 to 1.5 hours.
– Do not confuse with lidocaine 5% hyperbaric which is reserved for spinal anaesthesia.
– The more concentrated the lidocaine, the more localised the anaesthetic effect.
– To simplify protocols, use lidocaine 2% with epinephrine for dental anaesthesia and
lidocaine 1% without epinephrine for cutaneous anaesthesia.
190
MELARSOPROL
(Arsobal®…)
Therapeutic action
– Trypanocide (arsenical derivative)
Indications
2
– Meningoencephalitic stage of African trypanosomiasis due to T. b. gambiense and T. b. rhodesiense

– 180 mg in 5 ml ampoule (36 mg/ml), 3.6 % solution in propylene glycol, for slow IV injection.
NEVER BY IM OR SC INJECTION.
Dosage and duration

Patients must be treated in hospital under close medical supervision.
– Gambiense trypanosomiasis
Child and adult: 2.2 mg/kg (max. 5 ml) once daily for 10 consecutive days
– Rhodesiense trypanosomiasis
Child and adult: 3.6 mg/kg/injection (i.e. 1 ml/10 kg, without exceeding 5 ml/injection).
The treatment consists of 9 to 12 injections in total, administered as 3 to 4 courses of 3 to
4 injections (one per day), with an interval of 7 to 10 days between each course.
It is recommended to start with an initial low dose (1.2 to 1.8 mg/kg) then, to increase
gradually to the maximum dose of 3.6 mg/kg.

– May cause:
• reactive encephalopathy (5-10 % of cases): repeated or prolonged seizures, coma, psychical
disorders, usually between the 5th and the 8th day of the ten-day treatment (but sometimes
later, even after the patient has been discharged) or just before/during the 2nd course of
the intermittent treatment;
• arsenical reactions: headache, fever, tachycardia, hypertension, jaw pain, neurological
disorders (hyperreflexia);
• gastrointestinal disturbances, skin reactions (exfoliative dermatitis, urticaria), peripheral
neuropathy, haematological disorders (haemolytic anaemia in patients with G6PD
deficiency, agranulocytosis), hepatic or renal impairment, myocardial damage;
• swelling, pain, phlebitis, venous sclerosis, necrosis at injection site in the event of
extravasation during IV administration.
– Use a completely dry syringe: the solution precipitates in presence of water. As propylene
glycol can dissolve plastic, the drug should preferably be administered using a glass syringe
(only if sterilisation is reliable), otherwise inject immediately (but slowly) using a plastic
syringe.
Remarks
– Oral prednisolone is frequently associated during the course of treatment.
– For the treatment of meningoencephalitic stage of gambiense trypanosomiasis, the drug of
choice is eflornithine.
191
MAGNESIUM SULFATE
Therapeutic action
– Anticonvulsant
Indications
– Eclampsia: treatment of eclamptic seizures and prevention of recurrence
– Severe pre-eclampsia: prevention of eclamptic seizures

– 1 g ampoule (500 mg/ml, 2 ml) and 5 g ampoule (500 mg/ml, 10 ml) for IM injection or IV
infusion
Warning, also comes in different concentrations: ampoule containing 1.5 g (150 mg/ml, 10 ml),
2 g (100 mg/ml, 20 ml), 3 g (150 mg/ml, 20 ml) and 4 g (200 mg/ml, 20 ml). Check concen-
tration before use, there is a risk of potentially fatal overdosage.
Dosage and duration

– IV protocol:
Start with a loading dose of 4 g, to be administered by IV infusion in 0.9% sodium chloride
over 15 to 20 minutes.
Then administer a maintenance dose of 1 g per hour by continuous IV infusion. Continue
this treatment for 24 hours after the delivery or the last seizure.
– IV/IM protocol:
Start with a loading dose of 4 g, to be administered by IV infusion in 0.9% sodium chloride
over 15 to 20 minutes.
Then administer by IM route: 10 g (5 g in each buttock) followed by 5 g every 4 hours
(changing buttock for each injection). Continue this treatment for 24 hours after the
delivery or the last seizure.
Regardless of the protocol chosen, in the event that seizures persist or recur: administer a
further 2 g (patients < 70 kg) to 4 g by IV infusion, without exceeding 8 g total dose during
the first hour.

– Do not administer to patients with severe renal failure.
– Check:
• urine output every hour,
• patellar reflex, blood pressure, pulse and respiratory rate every 15 minutes during the
first hour of treatment. If no signs of overdosage are observed, continue this surveillance
every hour.
– May cause:
• pain at the injection site, warm flushes,
• in the event of overdosage: diminished then absent patellar reflex (early sign of hyper-
magnesaemia), hypotension, drowsiness, difficulty in speaking, confusion, arrhythmias,
respiratory depression (respiratory rate < 12/minute).
192
– In the event of decreased urine output (< 30 ml/hour or 100 ml/4 hour):
• pre-eclampsia: stop magnesium sulfate and perform delivery as soon as possible,
• eclampsia: stop magnesium sulfate and perform delivery immediately. If delivery
cannot be performed immediately, stop magnesium sulfate for one hour then resume
magnesium sulfate perfusion until delivery.
– In the event of overdosage: stop magnesium sulfate and give 1 g calcium gluconate by IV
route as an antidote (in this event, the anticonvulsant effect is reversed and seizures may
recur).
2
– Reduce dose in patients with renal impairment.
– Do not combine with nifedipine and quinidine.
Remarks
– Regardless of the protocol chosen, delivery must be performed:
• within 12 hours after the first seizure in the event of eclampsia,
• within 24 hours after the appearance of symptoms in the event of severe pre-eclampsia.
– 1 g magnesium sulfate contains approximately 4 mmol (or 8 mEq) of magnesium.
– Do not mix with other drugs in the same syringe or infusion fluid.
193
MEDROXYPROGESTERONE
(Depo-Provera®…)
Therapeutic action
– Hormonal contraceptive, long-acting progestogen (3 months)
Indications
– Contraception

– 150 mg in 1 ml vial (150 mg/ml) for IM injection
Dosage
– 150 mg per injection, one injection every 12 weeks
– The first injection is given:
• if the woman breastfeeds: as of the sixth week. However, if there is a risk that the woman
may be lost to follow-up or if this is the only available or acceptable contraceptive, the
injection may be given before 6 weeks, even after childbirth.
• if the woman does not breastfeed: between the 1st and the 21st day postpartum

– Do not administer to patients with breast cancer, uncontrolled hypertension, history of
thromboembolic disorders, coronary insufficiency, stroke, non equilibrated or complicated
diabetes, severe or recent liver disease, unexplained vaginal bleeding.
– May cause: menstrual irregularities, amenorrhoea, menometrorrhagia, nausea, vomiting,
allergic reactions, weight gain.
– In post-partum period, it is better to wait until the fifth day if possible, as the risk of
bleeding is increased if the injection is administered between D0 and D4.
– Clinical examinations must be carried out before (blood pressure, breasts) and, if needed,
during treatment.
– Medroxyprogesterone acetate is a suspension: shake vial before use.
Remarks
– The contraceptive efficacy of medroxyprogesterone does not seem to be reduced in women
taking hepatic enzyme inducers. For these women, medroxyprogesterone is therefore an
alternative to subdermal implants and oral contraceptives.
– The following injections may be administered within the 2 weeks before the scheduled date
and up to 2 weeks after, without the need for additional contraception.
– Return of fertility may be delayed long after the discontinuation of treatment (3 to
12 months).
– There is a combined contraceptive injection containing medroxyprogesterone acetate 25 mg
+ estradiol cipionate 5 mg (Cyclofem®, Lunelle®) administered once monthly.
194
MEDROXYPROGESTERONE/ESTRADIOL
(Cyclofem®, Lunelle®…)
Therapeutic action
– Combined hormonal contraceptive, long-acting estrogen-progestogen (1 month)
Indications
2
– Contraception
Presentation
– 25 mg medroxyprogesterone acetate + 5 mg estradiol cipionate in 0.25 ml vial, for IM injection
Dosage
– 25 mg + 5 mg per injection, one injection every 4 weeks
or as of the 21st day after childbirth, if the woman does not breastfeed

or complicated diabetes, history of thromboembolic disorders, coronary insufficiency,
valvular disease, stroke, severe or recent liver disease, unexplained vaginal bleeding,
migraine with neurological signs, renal impairment, hyperlipidaemia; to women smokers
over age 35.
mood changes, acne and headache. Other rare and severe adverse effects require dis-
continuation of treatment: hypertension, cardiovascular and thromboembolic disorders,
jaundice, hepatic adenoma, migraine, visual disturbances.
progesterone (150 mg vial).
6 months.
Remarks
– The following injections may be administered within 7 days before the scheduled date or
up to 7 days after, without the need for additional contraception.
– The combination medroxyprogesterone + estradiol is better tolerated than injectable
progestogens alone (medroxyprogesterone or norethisterone). However, this combination
cannot be used in women for whom estrogens are contra-indicated and the interval
between each injection in only one month.
195
METAMIZOLE = DIPYRONE = NORAMIDOPYRINE
(Nolotil®, Novalgin®…)
USE THIS DRUG ONLY IN SERIOUS SITUATIONS WHERE NO ALTERNATIVE

IS AVAILABLE.
– it is potentially harmful;
– it is forbidden to market this drug in many countries;
– it must never be prescribed as a first choice treatment.
Therapeutic action
– Analgesic
– Antipyretic
Indications
– Severe pain
– High fever

– 1 g in 2 ml ampoule (500 mg/ml) for IM, SC or slow IV injection or infusion
Dosage
– Child: 10 mg/kg/injection
– Adult: 500 mg/injection
2 1 5 15
AGE 0
ADULT
4 8 15 35
WEIGHT kg kg kg kg
0.2 ml 0.5 ml 1 to 2 ml
500 mg/ml ampoule
Repeat every 8 hours if necessary

– Do not administer in gastric ulcer.
– May cause: severe and fatal cases of agranulocytosis. The risk is unpredictable and
independent of the administered dose.
Remarks
– Metamizole is not included in the WHO list of essential drugs.
196
METOCLOPRAMIDE
(Primperan®…)
Therapeutic action
– Anti-emetic
Indications
– Postoperative nausea and vomiting
2
Presentation and route administration
– 10 mg in 2 ml ampoule (5 mg/ml) for IM or slow IV injection
Also comes in 100 mg in 5 ml ampoule (20 mg/ml).
Dosage
– Child:
Age Weight Daily dose 10 mg ampoule
Under 1 year Under 10 kg 1 mg x 2 0.2 ml x 2

1 to 3 years 10 to 14 kg 1 mg x 2 to 3 0.2 ml x 2 to 3
3 to 5 years 15 to 19 kg 2 mg x 2 to 3 0.4 ml x 2 to 3
5 to 9 years 20 to 29 kg 2.5 mg x 3 0.5 ml x 3
9 to 14 years 30 kg and over 5 mg x 3 1 ml x 3
– Adult: 10 mg every 6 to 8 hours as needed
Duration: according to clinical response, as short as possible

– Do not administer to patients with gastrointestinal haemorrhage, obstruction or perforation,
seizures.
– May cause:
• drowsiness, headache,
• rarely, extrapyramidal disorders (dyskinesia, tremor) especially in children and young
patients,
• increased frequency of seizures in epileptics,
• worsening of Parkinson disease,
• hyperprolactinemia in the event of prolonged treatment.
– Avoid combination with antispasmodics (hyoscine butylbromide, atropine propantheline)
and neuroleptics.
– Reduce doses if renal or hepatic impairment.
– Breast-feeding: avoid. If clearly needed, do not exceed a treatment period of 7 days.
Remarks
– Higher doses are used for prevention and treatment of chemotherapy-induced nausea and
vomiting in adults: 2 to 10 mg/kg/day by IV injection.
197
METRONIDAZOLE
(Flagyl®…)
Therapeutic action
– Antiprotozoal, antibacterial
Indications
– Severe infections due to anaerobic bacteria (Bacteroides sp, Clostridium sp, etc.), usually in
combination with other antibacterials, only when oral administration is not possible

– 500 mg in 100 ml vial or bag (5 mg/ml), for infusion
Dosage
– Child: 20 to 30 mg/kg/day in 2 to 3 divided doses administered over 20 to 30 minutes
– Adult: 1 to 1.5 g/day in 2 to 3 divided doses administered over 20 to 30 minutes (one
500 mg-vial 2 to 3 times per day)
Duration
– According to indication. Change to oral treatment as soon as possible.

– Do not administer to patients with allergy to metronidazole or another nitroimidazole
(tinidazole, secnidazole, etc.).
– May cause: gastrointestinal disturbances, brownish urine, allergic reactions, headache,
dizziness.
– Monitor combination with anticoagulants (increased risk of haemorrhage), lithium, phenytoin
and ergometrine (increased plasma concentrations of these drugs).
– Administer with caution, reduce total daily dose to 1/3 and give once daily to patients with
severe hepatic impairment.
– Pregnancy: no contra-indication, avoid prolonged use
– Breast-feeding: avoid (significantly excreted in milk)
Remarks
– Metronidazole is as effective by oral route than by parenteral route.
– Do not add any drugs in the infusion vial.
198
MORPHINE
Therapeutic action
Indications
2
– Severe pain, especially in surgery, trauma and neoplastic disease
– 10 mg ampoule (10 mg/ml, 1 ml) for SC, IM or IV injection
Dosage
– SC and IM route
Child over 6 months and adult: 0.1 to 0.2 mg/kg/injection, to be repeated every 4 hours if
necessary
– IV route
Child over 6 months and adult: 0.1 mg/kg administered in fractionated doses (0.05 mg/kg
every 10 minutes), to be repeated every 4 hours if necessary
Duration: change to oral treatment as soon as possible.
– Do not administer to patients with severe respiratory impairment or decompensated hepatic
impairment.
– May cause:
• dose-related sedation and respiratory depression, nausea, vomiting, constipation, urinary
retention, confusion, raised intracranial pressure, pruritus;
• in the event of overdose: excessive sedation, respiratory depression, coma.
of naloxone. Monitor patient closely for several hours.
– Administer with caution to patients with respiratory impairment, head injury, raised intra-
cranial pressure, uncontrolled epilepsy or urethroprostatic disorders.
– In elderly patients and in patients with severe renal or hepatic impairment: reduce doses
by half and administer less frequently, according to clinical response (risk of accumulation)
– Do not combine with opioid analgesics with mixed agonist-antagonist activity such as
buprenorphine, nalbuphine, pentazocine (competitive action).
– Increased risk of sedation and respiratory depression, when combined with alcohol and
drugs acting on the central nervous system: benzodiazepines (diazepam, etc.), neuroleptics
(chlorpromazine, haloperidol, etc.), antihistamines (chlorphenamine, promethazine),
phenobarbital, etc.
– Pregnancy and breast-feeding: no contra-indication. The child may develop withdrawal symptoms,
respiratory depression and drowsiness when the mother receives morphine at the end of the 3rd trimester
and during breast-feeding. In these situations, administer with caution, for a short period, at the
lowest effective dose, and monitor the child.
Remarks
than 48 hours.
– Storage:
199
NALOXONE
(Nalone®, Narcan®, Zynox®…)
Therapeutic action
– Specific opioid antagonist
Indications
– Respiratory depression induced by opioids (analgesia, anaesthesia, intoxication)
– Respiratory depression in newborns resulting from the administration of opioids to the
mother

– 0.4 mg in 1 ml ampoule (0.4 mg/ml) for IV, IM injection or infusion in sodium chloride 0.9%
or glucose 5%
Also comes in 10 ml ampoule containing 4 mg (0.4 mg/ml) and 2 ml ampoule containing
40 µg (20 µg/ml) for paediatric use.
Dosage
– Newborn: initial dose of 10 µg/kg by IV injection, followed by 10 µg/kg by IM injection
every 90 minutes
– Child: 5 to 10 µg/kg by IV injection, repeated if necessary after 2 to 3 minutes, until
adequate spontaneous ventilation is restored, followed by a continuous infusion
of 1 to 5 µg/kg/hour, or by 5 to 10 µg/kg by IM injection every 90 minutes
– Adult: 1 to 3 µg/kg by IV injection, repeated if necessary after 2 to 3 minutes, until
adequate spontaneous ventilation is restored, followed by a continuous infusion
of 1 to 5 µg/kg/hour, or by 5 to 10 µg/kg by IM injection every 90 minutes.
Duration
– The duration of action of naloxone (20 to 30 minutes by IV route) is shorter than that of
opioids: administration must be maintained several hours even if breathing improves.

– May cause:
• tachycardia, fibrillation, hypertension, pulmonary oedema when given postoperatively,
due to a sudden reversal of analgesia;
• nausea, vomiting;
• acute withdrawal syndrome in opioid-dependent patients.
– Administer with caution and reduce dosage in case of heart failure or coronary artery
disease.
– Naloxone is used in addition to assisted ventilation and must be administered under close
medical supervision.
– Pregnancy: risks linked to respiratory depression appear greater than risks linked to naloxone
Remarks
– Naloxone is a specific opioid antidote. It cannot be used to antagonise the effects of other
drugs producing CNS or respiratory depression.
– Efficacy in antagonising opioid effects depends not only on the dose of naloxone but also
on the dose and potency of the specific opioid involved.
– IV route is preferred, use IM route if IV route is not feasible.
– Storage:
200
NORETHISTERONE
(Noristerat®…)
Therapeutic action
– Hormonal contraceptive, long-acting progestogen (2 months)
Indications
– Contraception
2
Dosage
– 200 mg per injection, one injection every 8 weeks
• if the woman breastfeeds: as of the sixth week. However, if there is a risk that the woman
may be lost to follow-up or if this is the only available or acceptable contraceptive, the
injection may be given before 6 weeks, even after childbirth.
• if the woman does not breastfeed: between the 1st and the 21st day postpartum

– Do not administer to patients with breast cancer, uncontrolled hypertension, history of
thromboembolic disorders, coronary insufficiency, stroke, non equilibrated or complicated
diabetes, severe or recent liver disease, unexplained vaginal bleeding, hyperlipidaemia.
– May cause: menstrual irregularities, amenorrhoea, menometrorrhagia, nausea, vomiting,
breast tenderness, weight gain.
– Clinical examinations must be carried out before (blood pressure, breasts) and if needed,
during treatment.
Remarks
– The following injections may be administered within the 2 weeks before the scheduled date
and up to 2 weeks after, without the need for additional contraception.
– Return of fertility may be delayed long after the discontinuation of treatment.
– There is also a combined contraceptive injection containing norethisterone enantate 50 mg
+ estradiol valerate 5 mg (Mesigyna®) administered once monthly.
201
NORETHISTERONE/ESTRADIOL
(Mesygina®…)
Therapeutic action
– Combined hormonal contraceptive, long-acting estrogen-progestogen (1 month)
Indications
– Contraception
Presentation
– 50 mg norethisterone enantate + 5 mg estradiol valerate in 1 ml ampoule, for IM injection
Dosage
– 50 mg + 5 mg per injection, one injection every 4 weeks
or as of the 21st day after childbirth, if the woman does not breastfeed

or complicated diabetes, history of thromboembolic disorders, coronary insufficiency,
valvular disease, stroke, severe or recent liver disease, unexplained vaginal bleeding,
migraine with neurological signs, renal impairment, hyperlipidaemia; to women smokers
over age 35.
mood changes, acne and headache. Other rare and severe adverse effects require dis-
continuation of treatment: hypertension, cardiovascular and thromboembolic disorders,
jaundice, hepatic adenoma, migraine, visual disturbances.
progesterone (150 mg vial).
6 months.
Remarks
– The following injections may be administered within 7 days before the scheduled date or
up to 7 days after, without the need for additional contraception.
– The combination norethisterone + estradiol is better tolerated than injectable progestogens
alone (medroxyprogesterone or norethisterone). However, this combination cannot be used
in women for whom estrogens are contra-indicated and the interval between each injection
in only one month.
202
OMEPRAZOLE
(Mopral®…)
Therapeutic action
2
– Antiulcer drug (proton pump inhibitor)
Indications
– Peptic ulcer perforation

– Powder for injectable solution, 40 mg vial, to be dissolved in 100 ml of 0.9% sodium
chloride or 5% glucose, for IV infusion
Dosage
– Adult: 40 mg once daily to be administered over 20 to 30 minutes
Duration: change to oral treatment as soon as the patient can eat.

– May cause: headache, diarrhoea, skin rash, nausea, abdominal pain, dizziness.
– Avoid combination with itraconazole and ketoconazole (decreases efficacy of these drugs).
– Monitor combination with warfarin, digoxin, phenytoin.
– Do not exceed 20 mg/day in patients with severe hepatic impairment.
– Breast-feeding: avoid, administer only if clearly need
Remarks
– Only use 0.9% sodium chloride or 5% glucose for dilution.
– Omeprazole is not included in the WHO list of essential medicines.
203
OXYTOCIN
(Syntocinon®…)
Therapeutic action
– Synthetic oxytocic
Indications
– Induction and augmentation of labour in the event of dynamic dystocia
– Treatment of postpartum haemorrhage due to uterine atony
– Prevention of postpartum haemorrhage, after vaginal delivery or caesarean section
– 10 IU/ampoule (10 IU/ml, 1 ml) for IM or slow IV injection or infusion in Ringer lactate or
0.9% sodium chloride or 5% glucose
Also comes in 5 IU/ampoule (5 IU/ml, 1 ml).
Dosage
– Induction and augmentation of labour
• Dilute 5 IU in 500 ml of solution for infusion.
• Initially 5 drops/minute, then increase by 5 drops/minute every 30 minutes until efficient
contractions are obtained (i.e. over 10 minutes, 3 contractions lasting 40 seconds). Do not
exceed 60 drops/minute.
– Treatment of postpartum haemorrhage due to uterine atony
Immediately start an infusion of 20 IU in 1000 ml of Ringer lactate or 0.9% sodium chloride,
at the rate of 80 drops/minute. Simultaneously, administer 5 to 10 IU by slow IV injection, to
be repeated if necessary until retraction of the uterus. Do not exceed a total dose of 60 IU.
– Prevention of postpartum haemorrhage (vaginal delivery)
5 to 10 IU by IM or IV injection after delivery of the placenta
Only competent medical staff with experience in obstetrics can administer oxytocin before
delivery of the placenta (risk of placental retention).
– Prevention of postpartum haemorrhage (caesarean section)
5 to 10 IU by slow IV injection, systematically and immediately after the child is delivered
and/or 20 UI in 1000 ml of Ringer lactate or 0.9% sodium chloride, administered over 2 hours
Contra-indications, adverse effects, precautions (during labour)
– Before administering oxytocin, ensure that delivery can be accomplished by vaginal route.
Do not administer oxytocin in the event of malpresentation, true cephalopelvic disproportion,
complete placenta praevia, history of two caesarean sections or more.
– Administer with caution and do not exceed 30 drops/minute in the event of history of
single caesarean section and grand multiparity (risk of uterine rupture).
– May cause, especially when administered too rapidly by IV route or when excessive doses
are used: uterine hypertonia and/or uterine rupture, foetal distress.
– Respect the dosage and rate of administration, monitor uterine contractility and foetal
heart rate.
– Do not administer simultaneously with prostaglandins. Only administer oxytocin 6 hours
after the last administration of prostaglandins.
Remarks
– Storage: to be kept refrigerated (2°C to 8°C). Do not freeze.
• Expiry date indicated on the label is only valid if stored under refrigeration and protected from
light. Exposure to light and heat causes the deterioration of the active ingredients and thus loss
of efficacy.
• If refrigeration is not available, vials kept below 30°C and protected from light may be stored for
a maximum of one month.
204
PARACETAMOL = ACETAMINOPHEN
(Perfalgan®, Perfusalgan®…)
Therapeutic action
– Analgesic, antipyretic
Indications
– Very high fever, only when oral administration is not possible
– Mild pain, only when oral administration is not possible
2
– 500 mg vial (10 mg/ml, 50 ml), for infusion
Dosage
– Neonate and child < 10 kg: 7.5 mg/kg (0.75 ml/kg) every 6 hours, to be administered over
15 minutes. Do not exceed 30 mg/kg/day.
– Patient 10 to 50 kg: 15 mg/kg (1.5 ml/kg) every 6 hours, to be administered over 15 minutes.
Do not exceed 60 mg/kg/day.
– Patient over 50 kg: 1 g (100 ml) every 6 hours, to be administered over 15 minutes. Do not
exceed 4 g/day.
Duration
– According to clinical response. Change to oral route as soon as possible.

– Administer with caution to patients with moderate hepatic impairment, severe renal
impairment, chronic alcoholism, malnutrition, dehydration.
– May cause (very rarely): malaise, hypotension and rash.
– Do not exceed indicated doses, especially in children and elderly patients. Paracetamol
intoxications are severe (hepatic cytolysis).
Remarks
– As the efficacy of IV paracetamol is not superior to the efficacy of oral paracetamol, the
IV route is restricted to situations where oral administration is not possible.
– For mild pain, IV paracetamol is used alone or in combination with an NSAID administered
parenterally.
– For moderate pain, IV paracetamol is used in combination with an NSAID and tramadol
administered parenterally.
– For severe pain, IV paracetamol is used in combination with an NSAID and morphine
administered parenterally.
– Paracetamol has no anti-inflammatory properties.
205
PENTAMIDINE
(Pentacarinat®, Pentam®…)
Therapeutic action
– Antiprotozoal active against Pneumocystis jiroveci (carinii)
Indications
– Second-line treatment of pneumocystosis, in the event of contra-indication, intolerance or
unresponsiveness to cotrimoxazole

– Powder for injection, 200 mg and 300 mg vials, to be dissolved in 10 ml water for injection,
for IM injection or infusion in 250 ml of 5% glucose
Dosage and duration

– Child and adult: 4 mg/kg once daily by IM injection or slow infusion (over 60 minutes
minimum) for 14 to 21 days

– Do not administer to patients with severe renal impairment.
– May cause:
• aseptic abscess by IM route; venous thrombosis by IV route,
• malaise, hypotension, particularly if administered too rapidly by IV route,
• gastrointestinal disturbances; renal, hepatic and haematologic disorders; pancreatitis,
arrhythmia, torsades de pointes, hypoglycaemia followed by hyperglycaemia.
– Do not combine with drugs inducing torsades de pointes: anti-arrhythmics, neuroleptics,
tricyclic antidepressants, IV erythromycin, halofantrine, etc.
– Avoid combination with: mefloquine, cardiac glycosides, azole antifungals, drugs inducing
hypokalaemia (diuretics, glucocorticoids, injectable amphotericin B, etc.).
– Administer on a empty stomach, keep the patient supine during injection and 30 min after.
– Monitor blood pressure, blood glucose level, serum creatinine level, blood counts.
– Pregnancy and breast-feeding: CONTRA-INDICATED, except if vital and there is no therapeutic
alternative
Remarks
– For the prophylaxis of pneumocystosis, pentamidine may be used by inhalation of nebulised
solution using suitable equipment.
– Pentamidine is also used in the treatment of African trypanosomiasis and leishmaniasis.
Once reconstituted, solution keeps for 24 hours maximum, between 2°C to 8°C.
206
PHENOBARBITAL
(Gardenal®, Luminal®…)
Therapeutic action
– Anticonvulsant, sedative
Indications
– Status epilepticus: prolonged seizures or repeated seizures at short intervals without 2
consciousness recovery

– 200 mg in 1 ml ampoule (200 mg/ml) for deep IM or slow and diluted IV injection
Also comes in 40 mg and 200 mg vial containing phenobarbital in powder to be dissolved in
2 ml water for injection.
Dosage
– Child: 15 to 20 mg/kg by slow IV injection
– Adult: 10 to 15 mg/kg by slow IV injection (at a rate of 100 mg/minute maximum)
Phenobarbital solution must be diluted: 1 ml in 10 ml water for injection.

– Do not administer in severe respiratory depression.
– Assisted ventilation is essential in case of respiratory distress.
– May cause: drowsiness, respiratory depression.
nervous system such as diazepam, chlorphenamine, chlorpromazine.
– Pregnancy and breast-feeding: risks linked to status epilepticus appear greater than risks linked to
phenobarbital
Remarks
– For febrile convulsions in children, use diazepam by parenteral or rectal route.
– In the treatment of status epilepticus, administer first diazepam (rapid effect) rectally or by
slow IV route, then phenobarbital (prolonged effect) by slow IV route.
– Phenobarbital IM has been used for prophylaxis of convulsions in patients suffering from
cerebral malaria, as a single dose of 5 to 7 mg. This use is being discussed; in addition, the
optimal dose is not yet agreed upon.
– SC route may cause necrosis.
– Warning: also comes in 200 mg in 2 ml ampoule (100 mg/ml). Before any injection, check
concentration.
– Phenobarbital is subject to international controls: follow national regulations.
207
PHYTOMENADIONE = VITAMIN K1
Therapeutic action
– Vitamin, anti-haemorrhagic
Indications
– Prophylaxis and treatment of haemorrhagic disease of the newborn
– 1 mg ampoule (1 mg/ml, 1 ml), only for IM or slow IV injection
– 2 mg ampoule (10 mg/ml, 0.2 ml), for oral administration, IM or slow IV injection
– 10 mg ampoule (10 mg/ml, 1 ml), for oral administration, IM or slow IV injection
Dosage
– Systematic prophylaxis of haemorrhagic disease of the newborn
IM route Oral route

Breastfed infants Single dose: 3 doses:
1 mg the day of birth 2 mg the day of birth
2 mg 4 to 7 days after birth
2 mg 4 weeks after birth
Formula fed infants Single dose: 2 doses:
1 mg the day of birth 2 mg the day of birth
2 mg 4 to 7 days after birth
Prophylaxis by oral route is effective only if all the doses are administered. Therefore, use
IM route systematically in all newborn infants if treatment compliance cannot be guaran-
teed.
In newborns at high risk (preterm neonates, jaundice, neonatal diseases; newborns whose
mother is treated with enzyme-inducing drugs), always use IM route.
– Treatment of haemorrhagic disease of the newborn
1 mg by IM injection, to be repeated every 8 hours if necessary
Duration: according to clinical response and results of coagulation tests
– May cause: allergic reactions, especially by IV route, haematoma at IM injection site.
Remarks
– To pregnant women taking enzyme-inducing drugs (rifampicin, phenobarbital, phenitoin,
carbamazepine), administer 10 mg/day orally for the 15 days prior to the expected date of
delivery. This maternal prevention does not change the need for IM prophylactic treatment
in newborns at high risk.
– Phytomenadione is also used for the treatment of haemorrhage due to antivitamin K
agents: 5 mg by slow IV route in the event of severe haemorrhage; 0.5 mg by slow IV route
or 5 mg orally in the event of minor haemorrhage or risk of haemorrhage.
– Vitamin K has no direct or immediate haemostatic action, it is not indicated for traumatic
haemorrhage.
208
POTASSIUM CHLORIDE 10% = KCL 10%
Indications
– Treatment of severe hypokalaemia

– Ampoule containing 10% potassium chloride hypertonic solution (100 mg/ml, 10 ml), i.e. 2
1 g of potassium chloride (KCl) per 10 ml ampoule
– Ionic composition:
• potassium (K+): 13.4 mmol per 10 ml ampoule (13.4 mEq)
• chloride (Cl–): 13.4 mmol per 10 ml ampoule (13.4 mEq)
– For slow IV infusion diluted in 5% glucose or 0,9% sodium chloride solution. NEVER BY IV
OR IM OR SC INJECTION.
Dosage
– Dosage depends on the severity of hypokalaemia and the patient’s underlying condition.
– Do not exceed 4 g of KCl/litre and 13 mmol of KCl/hour (1 g of KCl/hour).

– May cause: hyperkalaemia (cardiac conduction and rhythm disorders, potentially fatal) in
the event of rapid or excessive administration; necrosis in case of extravasation.
– Administer with caution to elderly patients; administer with caution and reduce the dose
in patients with renal impairment (increased risk of hyperkalaemia).
Remarks
– Check concentration before use: potassium chloride also comes in 10 ml and 20 ml
ampoules containing 7.5%, 11,2%, 15% and 20% solutions.
– Normal plasma potassium is 3.5 to 5.0 mmol/L. Moderate hypokalaemia is defined as a
potassium level < 3.5 mmol/L; severe hypokalaemia as a potassium level ≤ 2 mmol/L.
209
PROMETHAZINE
(Phenergan®…)
Therapeutic action
– Sedating antihistaminic, anti-emetic
Indications
etc.), when oral administration is not possible

– 50 mg in 2 ml ampoule (25 mg/ml) for IM injection
Dosage
– Allergic reactions
Child from 5 to 10 years: 12.5 mg/injection
Child over 10 years and adult: 25 to 50 mg/injection
To be repeated if necessary without exceeding 3 injections/day.
Child from 5 to 10 years: 12.5 mg/injection
Child over 10 years and adult: 25 mg/injection
To be repeated if necessary every 4 to 6 hours.
– Never exceed 100 mg daily.
Duration
– According to clinical response, single dose or for a few days if necessary. Change to oral
treatment as soon as possible.

– Avoid in children under 5 years.
– May cause: drowsiness, dryness of the mouth, constipation, urinary retention, blurred
vision.
barbital, etc.
– Pregnancy: avoid at the end of pregnancy; no prolonged treatment
– Breast-feeding: not recommended (drowsiness and risk of apnoea in the newborn infant)
Remarks
210
PROTAMINE
(Prosulf®…)
Therapeutic action
– Neutralisation of the anticoagulant action of unfractionated heparin
– Partial neutralisation of the anticoagulant action of low molecular weight heparin
Indications
– Haemorrhagic syndromes resulting from accidental heparin overdosage
2
– 50 mg protamine sulfate in 5 ml ampoule (10 mg/ml) for slow IV injection
Concentration may be expressed in antiheparin units (AHU): 1000 AHU = 10 mg.
Dosage
Depends on the amount of heparin to be neutralised.
– Heparin overdosage
If administered between 0 and 30 minutes after the heparin injection, 1 mg of protamine
sulfate (100 AHU) neutralises 100 units of heparin.
If more than 30 minutes have elapsed since the heparin injection, the dose of protamine to
be given should be one half the dose of heparin injected.
Do not administer more than 50 mg for any one dose.
– Nadroparin overdosage
1 mg of protamine sulfate (100 AHU) neutralises 100 units of nadroparin. The dose of
protamine to be given is equal to that of the nadroparin injected.
Duration: according to clinical response. Monitor coagulation parameters.

– May cause: hypotension, bradycardia and dyspnoea; allergic reactions, notably in diabetics
treated by protamine-insulin.
– If excessive doses are used, haemorrhage may persist or reappear, as protamine sulfate
itself has some anticoagulant activity.
– Administer by very slow IV (over 10 minutes) in order to reduce risks of hypotension and
bradycardia.
Remarks
– In the case of nadroparin overdose, it is recommended to administer 1 or 2 units of fresh
whole blood at the same time to counteract its activity against Factor Xa.
– Anticoagulant effect of protamine may vary according to the origin of the heparin: follow
manufacturer's recommendations.
– Protamine sulfate may be used to neutralize the effect of heparin before surgery.
211
QUININE
Therapeutic action
– Antimalarial
Indications
– Treatment of severe falciparum malaria
– 600 mg of quinine dihydrochloride in 2 ml ampoule (300 mg/ml), to be diluted in 5% glucose,
for slow infusion. NEVER FOR IV INJECTION.
Dosage
The dosage is expressed in terms of salt; it is the same for quinine dihydrochloride or for
quinine formate:
– Child and adult:
• loading dose: 20 mg/kg administered over 4 hours, then keep the vein open with an
infusion of 5% glucose over 4 hours
• maintenance dose: 8 hours after the start of the loading dose, 10 mg/kg every 8 hours
(alternate quinine over 4 hours and 5% glucose over 4 hours)
For adults, administer each dose of quinine in 250 ml. For children under 20 kg, administer
each dose of quinine in a volume of 10 ml/kg.
Do not administer a loading dose to patients who have received oral quinine, mefloquine
or halofantrine within the previous 24 hours: start with maintenance dose.
Duration
– As soon as the patient is able to take oral treatment, administer either oral quinine to complete
7 days of treatment or an artemisinin-based combination (if patient developed neurological
signs during the acute phase, do not use the combination artesunate-mefloquine).
– May cause: hypoglycaemia; auditory and visual disturbances, cardiac disorders (especially in
the event of overdose), hypersensitivity reactions, cardiac depression if injected undiluted
by direct IV route.
– In patients with acute renal failure, reduce the dose by one-third if the parenteral treatment
lasts more than 48 hours.
– Monitor blood glucose (reagent strip test).
– Do not combine with chloroquine or halofantrine.
– Do not administer simultaneously with mefloquine (risk of seizures, cardiac toxicity).
Administer mefloquine 12 hours after the last dose of quinine.
– Pregnancy: no contra-indication. The risk of quinine-related hypoglycaemia is very high in pregnant
women.
Remarks
– 10 mg quinine dihydrochloride = 8 mg quinine base.
– Administration by IM deep injection (into the anterior thigh only) is possible when infusion
cannot be performed (e.g. before transferring a patient). However this may cause numerous
complications. Doses are the same as for the IV route. Quinine should be diluted (1/2 or 1/5).
For the loading dose, administer half the dose into each thigh.
– In certain regions of South-East Asia, quinine is combined with doxycycline or clindamycin,
due to a reduction in P. falciparum sensitivity to quinine.
212
SALBUTAMOL = ALBUTEROL
(Salbumol®…)
Therapeutic action
– Uterine relaxant
Indications
– Threatened premature labour 2
– 0.25 mg in 5 ml ampoule (0.05 mg/ml) for SC, IM, slow IV injection or infusion
Also comes in 1 ml ampoule containing 0.5 mg (0.5 mg/ml) and 5 ml ampoule containing
5 mg (1 mg/ml).
Dosage
– Dilute 5 mg (10 ampoules of 0.5 mg) in 500 ml of 5% glucose or 0.9% sodium chloride to
obtain a solution of 10 micrograms/ml.
Start infusion at the rate of 15 to 20 micrograms/minute (30 to 40 drops/minute).
If contractions persist, increase the rate by 10 to 20 drops/minute every 30 minutes until
uterine contractions cease. Do not exceed 45 micrograms/minute (90 drops/minute).
Continue for one hour after contractions have ceased, then reduce the rate by half every
6 hours.
Monitor maternal pulse regularly, decrease the infusion rate in the event of maternal tachy-
cardia > 120/minute.
Duration
– 48 hours maximum

– Do not administer to patients with pre-eclampsia, eclampsia, uterine haemorrhage, intra-
uterine infection, intra-uterine foetal death, placenta praevia, placental abruption, rupture
of membranes, multiple pregnancy; severe cardiopathy, uncontrolled hypertension.
– Do not combine with nifedipine.
– May cause: foetal and maternal tachycardia, tremor, headache, dizziness, hypokalaemia,
hyperglycaemia, gastrointestinal disturbances.
– Administer with caution to patients with diabetes, hyperthyroidism.
Remarks
– Do not mix with other drugs in the same syringe or the same infusion fluid.
213
SODIUM BICARBONATE 8.4%
Indications
– Severe metabolic acidosis
Presentation
– 10 ml or 20 ml ampoule
Composition
Sodium bicarbonate in hypertonic solution: 8.4 g per 100 ml
– Ionic composition: sodium (Na+) : 10 mmol (10 mEq) per 10 ml ampoule
bicarbonate : 10 mmol (10 mEq) per 10 ml ampoule
Contra-indications, adverse effects, precautions, remarks

– Do not use in case of alkalosis or respiratory acidosis.
– Do not administer hypertonic solutions by IM or SC route. Administer under close medical
supervision, by slow direct IV injection diluted in 5% glucose or by continuous infusion in
5% glucose.
– Contains a high concentration of bicarbonate and sodium ions. Its use is rarely justified in
case of metabolic acidosis caused by dehydration. Inaccurate administration may induce
hypernatraemia and hypokalaemia.
– Do not add: penicillins, chloramphenicol, aspirin, atropine, calcium, insulin, vitamins, etc.
to sodium bicarbonate solution.
214
SPECTINOMYCIN
(Kempi®, Stanilo®, Trobicin®…)
Cephalosporins are the first choice treatment of gono-

coccal infections. Spectinomycin may be used as an
2
alternative, when cephalosporins are not available or
are contraindicated.
Therapeutic action
– Antibacterial (group of aminoglycosides)
Indications
– Second choice treatment of gonococcal infections

– Powder for injection in 2 g vial, to be dissolved with the diluent supplied by the manufacturer
(3.2 ml ampoule of water for injection with benzyl alcohol), for IM injection
Dosage and duration

– Anogenital gonococcal infection and gonococcal conjunctivitis
Adult: 2 g as a single dose (a dose of 4 g may be required, divided between two sites)
– Disseminated gonococcal infection

– May cause: nausea, dizziness, fever and chills, urticaria; pain at injection site.
– Pregnancy: CONTRA-INDICATED (safety is not established)
– Breast-feeding: no contra-indication for a single dose treatment
Remarks
– Administer a concurrent anti-chlamydia treatment to patients with gonococcal infections
(co-infections are frequent).
– Spectinomycin is poorly effective against pharyngeal gonococcal infections.
– For the treatment of neonatal gonococcal conjunctivitis, use cephalosporins.
– Shake well prior to withdrawal medication and use a 19-gauge needle.
215
STREPTOMYCIN
Therapeutic action
– Antibacterial (group of aminoglycosides)
Indications
– Powder for injection, vial containing 1 g of streptomycin base, to be dissolved in 5 or 10 ml
of water for injection, for IM injection. NEVER FOR IV INJECTION.
Dosage
– Child and adult: 15 mg/kg once daily; maximum 1 g/day
1 g vial dissolved in 10 ml 1 g vial dissolved in 5 ml
Weight
Dose in g Dose in ml Dose in g Dose in ml
≤ 9 kg 0.2 2 ml – –
10 to 14 kg 0.25 2.5 ml – –
15 to 19 kg – – 0.3 g 1.5 ml
20 to 34 kg – – 0.5 g 2.5 ml
35 to 39 kg – – 0.6 g 3 ml
40 to 49 kg – – 0.8 g 4 ml
50 to 54 kg – – 0.9 g 4.5 ml
> 55 kg – – 1g 5 ml

– Do not administer to patients with renal impairment.
– May cause: vestibular and auditory damage, renal impairment and hypersensitivity
reactions.
– Due to the ototoxicity and nephrotoxicity of streptomycin, do not exceed a total dose of 60 g
for the treatment of tuberculosis in adults.
– Stop treatment in the event of dizziness, persistent giddiness, tinnitus or hearing defects.
– Reduce the dose to 500-750 mg/day in patients over 60 years or under 50 kg and if renal
impairment occurs (albuminuria, decreased urine output).
Remarks
– Streptomycin is also used in the treatment of:
• Brucellosis: 15 mg/kg once daily in children and 1 g once daily in adults, for 2 weeks, in
combination with doxycycline for 6 weeks.
• Plague: 30 mg/kg/day in children and 2 g/day in adults, divided into 2 daily injections,
for 7 to 10 days.
Reconstituted solution can be kept 24 hours maximum, below 25°C and protected from light.
216
SURAMIN
(Germanin®…)
Therapeutic action
– Trypanocide
Indications
– Haemolymphatic stage of African trypanosomiasis due to T. b. rhodesiense
2
– Powder for injection in 1 g vial, to be dissolved in 10 ml of water for injection to obtain a
10% solution, for slow IV injection (or slow infusion in 500 ml of 0.9% NaCl). NEVER BY IM
OR SC INJECTION.
Dosage
– Patients must be treated in hospital, under close medical supervision.
– Child and adult: 4 to 5 mg/kg by slow IV at D1 (test dose) then, in the absence of reaction
after the test dose, 20 mg/kg by slow IV at D3, D10, D17, D24 and D31 (max. 1 g/injection)

– Do not administer in patients with severe renal or hepatic disease.
– May cause:
• anaphylactic reaction: administer a test dose before starting treatment. In the event of
anaphylactic reaction, the patient should never receive suramin again.
• proteinuria (renal toxicity), diarrhoea, haematological disorders (haemolytic anaemia,
agranulocytosis, etc.), eye disorders (photophobia, lachrymation), neurological disorders
(paraesthesia, hyperaesthesia of the palms and soles, polyneuropathy), high fever, skin
eruption, malaise, intense thirst, polyuria.
• local inflammation and necrosis when administered by IM or SC injection.
– Before each injection, check for proteinuria: moderate proteinuria is common at the start of
treatment, heavy proteinuria calls for dose reduction and modification of treatment
schedule; in the event of persisting heavy proteinuria, treatment should be discontinued.
– Ensure that the patient is well hydrated.
– Pregnancy: although suramin is toxic, it is recommended to treat pregnant women with rhodesiense
trypanosomiasis at the haemolymphatic stage. Suramin is also used at the meningoencephalitic stage
until the woman can be given melarsoprol after delivery, as melarsoprol is contra-indicated during
pregnancy.
Remarks
– Suramin is not administered at the meningoencephalitic stage (except in pregnant women)
as it poorly penetrates into the cerebrospinal fluid.
– Due to its toxicity, suramin is no longer used for the treatment of onchocerciasis.
– Storage:
217
THIAMINE = VITAMIN B1
(Benerva®, Betaxin®…)
Therapeutic action
– Vitamin
Indications
– Initial treatment of severe thiamine deficiency: severe acute forms of beriberi, neurological
complications of chronic alcoholism (severe polyneuritis, Wernicke’s encephalopathy,
Korsakoff syndrome)

– 100 mg thiamine hydrochloride in 2 ml ampoule (50 mg/ml) for IM or very slow IV injection
Dosage and duration

– Infantile beriberi
25 mg by IV injection then, 25 mg by IM injection once or twice daily then, change to oral
route (10 mg/day) as soon as symptoms have improved.
– Acute beriberi
50 mg as a single IM injection then change to oral treatment (150 mg/day in 3 divided
doses until symptoms improve then, 10 mg once daily)
or, depending on severity, 150 mg/day in 3 IM injections for a few days then change to oral
route (10 mg/day).
– Wernicke’s encephalopathy, Korsakoff syndrome
250 mg once daily by IV injection until the patient can take oral treatment. Higher initial
doses may be required during the first 12 hours.

– May cause: hypotension; anaphylactic reaction, especially when injected IV (inject very
slowly over 30 minutes).
Remarks
– Thiamine is also called aneurine.
– Injectable thiamine is not included in the WHO list of essential medicines.
– Storage:
218
TRAMADOL
(Tramal®, Zamadol®, Zydol®…)
Therapeutic action
– Centrally acting analgesic (weak opioid, serotonin-norepinephrine reuptake inhibitor)
Indications
– Moderate acute pain
2
– 100 mg ampoule (50 mg/ml, 2 ml) for SC, IM, slow IV injection or infusion
Dosage
– Child over 6 months: 2 mg/kg/injection every 6 hours
– Adult: 50 to 100 mg/injection every 4 to 6 hours, without exceeding 600 mg/day
Duration: change to oral route as soon as possible.

– Do not administer in the event of severe respiratory depression and to patients that risk
seizures (e.g. epilepsy, head injury, meningitis).
– May cause:
• dizziness, nausea, vomiting, drowsiness, dry mouth, sweating;
• rarely: allergic reactions, seizures, confusion;
• exceptionally: withdrawal symptoms; respiratory depression in the event of overdosage.
– Do not combine with opioid analgesics, including codeine.
– Avoid combination with carbamazepine, fluoxetine, chlorpromazine, promethazine,
clomipramine, haloperidol, digoxin.
– Reduce doses (1 mg/kg) and administer every 12 hours in elderly patients and in patients
with severe renal or hepatic impairment (risk of accumulation).
– For IV administration, it is better to use tramadol by infusion over 20-30 minutes rather
than by IV injection, in order to limit adverse effects.
– Pregnancy and breast-feeding: no contra-indication. The child may develop adverse effects (drowsiness)
when the mother receives tramadol at the end of the 3rd trimester and during breast-feeding. In these
events, administer with caution, for a short period, at the lowest effective dose, and monitor the child.
Remarks
– Tramadol is approximately 10 times less potent than morphine.
– In some countries, tramadol is on the list of narcotics: follow national regulations.
– Storage:
219
Infusion fluids
3
Use of infusion fluids 223

Volume expanders 224
Glucose 5% = dextrose 5% 225
Glucose 10% = dextrose 10% 226
Modified fluid gelatin 227
Polygeline 227
Ringer Lactate (Hartmann’s solution) 228
Sodium chloride 0.9% 229
Use of infusion fluids
Choice of infusion fluids according to indications
3 kinds of infusion fluids should be available:

– For IV rehydration: Ringer Lactate is the most suitable.
– For administration of IV drugs: 5% glucose solution and 0.9% sodium chloride solution are
the most suitable.
3
– For volume expansion: see table next page.
Precautions for the use of infusion fluids
– Carefully read the labels on the infusion bottle to avoid mistakes.

– Indicate on the label any drugs added to the infusion as well as the patient’s name and/or
bed number.
– If drugs are added to the intravenous fluid, think of the risks of:
• physical and chemical incompatibilities,
• microbial contamination: aseptic technique.
– Examine each bottle against the light to check clearness. Discard any bottles that show particles
in suspension or cloudiness.
223
224
Volume expanders
Contra-
Duration* Volume Dosage Indications indications Advantages Disadvantages
CRISTALLOIDS
Ringer Lactate 1 to 2 hours 3 times According to - Hypovolaemia - None - Free from adverse - Large amounts to
NaCl 0.9 % the estimated patient’s - Prevention of effects be infused rapidly
fluid loss condition hypotension - Inexpensive - Expansion of short
induced by duration
spinal
anaesthesia
COLLOIDS
Polygeline 2 to 3 hours 1 to 1.5 times According to - Hypovolaemia - Allergy to - Relatively good - Allergic reactions
Modified fluid the estimated patient’s gelatins volume expansion - Expansion of short
gelatin fluid loss condition duration
- Expensive
* Length of time during which the fluid remains in the intravascular compartment after infusion.
For more information, refer to relevant fact-sheet.
Indications
– Vehicle for the administration of parenteral drugs
Composition and presentation

– Isotonic solution (50 mg of glucose/ml) for infusion
– 500 ml and 1000 ml bottles or bags

– Do not use glucose solution for the administration of hydralazine (incompatibility, rapid
3
degradation of hydralazine): use only 0.9% sodium chloride or Ringer Lactate solution.
– Other drugs such as amoxicillin + clavulanic acid, aciclovir, phenytoin, bleomycin or
chloroquine must also be administered in 0.9% sodium chloride solution.
– Amoxicillin diluted in 5% glucose must be administered in less than one hour. If infusion
over more than one hour is required, use 0.9% sodium chloride.
Remarks
– This solution does not contain electrolytes or lactate. Its use is not recommended for the IV
treatment of dehydration. Use Ringer Lactate solution. If not available, add KCl (2 g/litre)
+ NaCl (4 g/litre) to 5% glucose.
– 10% glucose solution may be used for the administration of the loading dose of IV quinine
in order to prevent hypoglycaemia. If 10% glucose solution is not available, it can be
prepared using 10 ml of 50% glucose per 100 ml of 5% glucose.
– Low nutritional value: 200 kcal/litre.
225
Indications
– Emergency treatment of severe hypoglycaemia
– Vehicle for the administration of the loading dose of IV quinine

– Hypertonic solution (100 mg of glucose/ml) for slow IV injection or infusion
– 500 ml bottle or bag

– Do not administer by IM or SC route.
Remarks
– The dose in severe hypoglycaemia is 5 ml/kg by very slow IV injection (over 5 minutes) or
infusion.
– In neonatal hypoglycaemia, 10% glucose is administered by infusion at a rate of
5 ml/kg/hour. In addition, a loading of 2.5 ml/kg IV is administered slowly (over
5 minutes) in the event of loss of consciousness or seizures.
– 10% glucose solution may be used as vehicle for administration of the loading dose of IV
quinine in order to prevent hypoglycaemia. However, the following doses must be
administered in 5% glucose solution.
– Nutritional value: 400 kcal/litre.
226
MODIFIED FLUID GELATIN (Gelofusine®, Plasmion®...)
and POLYGELINE (Haemaccel®…)
solution for INFUSION
Therapeutic action
– Colloidal plasma substitute
Indications
– Fluid replacement in hypovolaemic shock (haemorrhagic shock, septic shock)
Presentation
3
– 500 ml plastic bottle or bag
Composition
– Varies according to the manufacturer. Example:
Plasmion® Haemaccel®
Modified fluid gelatin 30 g/litre –
Polygeline – 35 g/litre
Sodium (Na+) 150 mmol (150 mEq) 145 mmol (145 mEq)
Potassium (K+) 5 mmol (5 mEq) 5.10 mmol (5.10 mEq)
Calcium (Ca++) – 6.25 mmol (12.50 mEq)
Chloride (Cl–) 100 mmol (100 mEq) 145 mmol (145 mEq)
Magnesium (Mg++) 1.5 mmol (3 mEq) –
Lactate 30 mmol (30 mEq) –
Dosage
– Adjust dosage according to the patient’s haemodynamic status.
– In the event of haemorrhage, replace the lost volume by the same volume of plasma sub-
stitute.

– May cause: allergic reactions, possibly severe (anaphylactic shock).
– Pregnancy: CONTRA-INDICATED: risk of maternal anaphylactic reaction with serious consequences
for the foetus. Use Ringer lactate.
Remarks
– Do not add any drugs to the bottle.
– When plasma substitutes are not available, use Ringer lactate (giving 3 times the lost blood
volume).
227
RINGER LACTATE = COMPOUND SODIUM LACTATE
= Hartmann’s solution
isotonic solution for INFUSION
Indications
– Severe dehydration
– Hypovolaemia (trauma, surgery, anaesthesia...)
Presentation
Composition
– Varies with manufacturer.
– Most frequent ionic composition per litre:
sodium (Na+): 130.50 mmol (130.50 mEq)
potassium (K+): 4.02 mmol (4.02 mEq)
calcium (Ca++): 0.67 mmol (1.35 mEq)
–
chloride (Cl ): 109.60 mmol (109.60 mEq)
lactate: 28.00 mmol (28.00 mEq)
– Isotonic solution. Does not contain glucose.
Contra-indications, adverse effects, precautions, remarks

– In cases of metabolic alkalosis, diabetes, severe hepatic failure, head injury: isotonic solu-
tion of NaCl 0.9% is preferred.
– Ringer Lactate provides appropriate amounts of sodium and calcium. It contains lactate
which is converted to bicarbonate for correction of metabolic acidosis when it exists (if
haemodynamic and liver function are normal). WARNING, SOME COMMERCIALLY AVAILABLE
SOLUTIONS DO NOT CONTAIN LACTATE.
– It contains 4 mEq of potassium/litre, which is sufficient for short-term use. For prolonged
use (after 2 to 3 days), addition of potassium chloride is necessary: 1 or 2 g per litre = one
to two 10 ml ampoules of KCL 10%/litre.
– For moderate and mild dehydration, administer oral rehydration salts (ORS).
– For correction of hypovolaemia due to haemorrhage; administer 3 times the lost volume
only if:
• cardiac and renal function are not impaired,
• blood loss does not exceed 1500 ml in adults.
– May be used to prevent hypotension induced by spinal anaesthesia.
228
SODIUM CHLORIDE 0.9% = NaCl = Physiological saline
Indications
– Vehicle for the administration of parenteral drugs
– Fluid replacement

– Isotonic solution of sodium chloride (0.9 g per 100 ml) for infusion
– Ionic composition: sodium (Na+): 150 mmol per litre (150 mEq)
chloride (Cl–): 150 mmol per litre (150 mEq)
3
– Use with caution in patients with hypertension, heart failure, oedema, ascites due to
cirrhosis, renal impairment and other conditions associated with sodium retention.
– May cause: pulmonary oedema in the event of too rapid infusion or infusion of excessive
amounts.
– Do not use as vehicle for the administration of amphotericin B (incompatibility): use only
5% glucose solution.
Remarks
– For correction of hypovolaemia due to haemorrhage, administer 3 times the lost volume
only if:
• blood loss does not exceed 1500 ml in adults,
• cardiac and renal function are not impaired.
– 0.9% sodium chloride solution may be used to prevent hypotension induced by spinal
anaesthesia.
– This solution contains neither potassium nor lactate. In case of severe dehydration, use
Ringer Lactate. If Ringer Lactate is not available, add KCl (2 g/l) + NaCl (4 g/l) to 5% glucose.
– For external use: sterile 0.9% sodium chloride solution is used for cleansing of non-infected
wounds, wound irrigation, eye cleansing (conjunctivitis, eye irrigations), nasal lavage in
the event of obstruction, etc.
229
Vaccines, immunoglobulins
and antisera
Antituberculous vaccine (BCG) 233
Diphtheria-Tetanus-Pertussis vaccine (DTP) 234
4
Hepatitis B vaccine 235
Japanese encephalitis vaccine 236
Measles vaccine 237
Meningococcal vaccine A + C 238
Meningococcal vaccine A + C + W135 239
Oral antipoliomyelitis vaccine (OPV) 240
Rabies vaccine 242
Human rabies immunoglobulin (HRIG) 241
Tetanus vaccine (TT) 244
Human tetanus immunoglobulin (HTIG) 246
Tetanus antitoxin (equine) 247
Yellow fever vaccine 248

ANTITUBERCULOUS VACCINE = BCG VACCINE
Indications
– Prevention of tuberculosis
Composition, presentation and route of administration

– Live attenuated bacterial vaccine
– Powder for injection in multidose vial, to be dissolved with the entire vial of the diluent
supplied by the manufacturer, for intradermal injection into the external face of the left
upper arm
Dosage and vaccination schedule

– Child: 0.05 ml as a single dose as soon after birth as possible
– If child is over one year old: 0.1 ml as a single dose

– Do not administer to patients with immunodeficiency (symptomatic HIV infection,
immunosuppressive therapy, etc.) and malignant haemopathy.
4
– Vaccination should be postponed in the event of evolutive extensive dermatosis, acute
complicated malnutrition (vaccine should be given just before the child is discharged from
the nutrition centre) and severe acute febrile illness (minor infections are not contra-
indications).
– May cause:
• normal local reaction 2 to 4 weeks after injection: papule which changes to an ulcer, that
usually heals spontaneously (dry dressing only), leaving a permanent scar;
• occasionally: persistent ulcer with serous discharge up to 4 months after injection,
non-suppurative adenitis, keloid formation, abscess at the injection site;
• exceptionally: suppurative lymphadenitis, osteitis.
– Clean the injection site with boiled and cooled water and allow drying. Do not use
antiseptics (risk of inactivation of live vaccine).
– Do not mix with other vaccines in the same syringe (inactivation of vaccines).
– If administered simultaneously with EPI vaccines, use different syringes and injection sites.
Remarks
– Inject the vaccine in the same place for each child to make it easy to find the BCG scar
subsequently.
– If the injection is correctly performed an “orange-skin” papule, measuring 5-8 mm in
diameter, should appear at the injection site.
– Duration of protection is not known, and decreases over time.
– Storage:
• Powder: between 2°C and 8°C. Freezing is possible but unnecessary.
• Diluent: a cold chain is not required for storage. However, at least 12 hours before reconstitution
of the vaccine, the diluent must be refrigerated between 2ºC and 8ºC so that the diluent and
lyophilised powder are at the same temperature: a temperature difference during reconstitution
may reduce vaccine efficacy. Do not freeze.
• Reconstituted vaccine: between 2°C and 8°C for 4 hours maximum.
233
DIPHTHERIA-TETANUS-PERTUSSIS VACCINE (DTP)
Indications
– Prevention of diphtheria, tetanus and pertussis in children under 7 years (primary vaccination)
– Trivalent vaccine combining diphtheria toxin, tetanus toxin and whole-cell (DTwP) or
acellular (DTaP) pertussis vaccine
– Suspension for injection in multidose vial, for IM injection into the anterolateral part of the
thigh
– Child: 0.5 ml/injection
– 3 injections in infancy (age < 1 year), with an interval of 4 weeks between each injection. It
is recommended to administer the 1st dose at 6 weeks of age, the 2nd dose at 10 weeks of age
and the 3rd dose at 14 weeks of age. If a child has not been vaccinated at 6 weeks of age, start
vaccination as soon as possible.
– For booster doses, use DTP or DT or Td vaccine, depending on age.
– Do not administer in the event of significant reactions to a previous dose of DTP vaccine or
evolving neurological disease (encephalopathy, uncontrolled epilepsy): in both cases, use
DT vaccine.
– Vaccination should be postponed in the event of severe acute febrile illness (minor infections
are not contra-indications).
– Do not administer into the gluteal region.
– May cause:
• mild reactions at the injection site: swelling, redness and pain;
• general reactions: fever within 24 hours after injection;
• rarely: anaphylactic reactions, seizures.
– Respect an interval of 4 weeks between each dose.
– Shake before use to homogenise the vaccine.
Remarks
– If the vaccination is interrupted before the complete series has been administered, it is not
necessary to start again from the beginning. Continue the vaccination schedule from where
it was interrupted and complete the series as normal.
– There are two bivalent vaccines containing diphtheria and tetanus toxins:
• diphtheria-tetanus vaccine (DT), used for children < 7 years for booster doses, or when
pertussis vaccine is contra-indicated, or after a significant reaction to a previous dose of
DTP;
• tetanus-diphtheria vaccine with low dose diphtheria toxoid (Td), used for primary
vaccination and booster doses in children ≥ 7 years, adolescents and adults.
– There is also a quadrivalent vaccine against diphtheria, tetanus, pertussis and hepatitis B.
– There is also a pentavalent vaccine against diphtheria, tetanus, pertussis, hepatitis B and
Haemophilus influenzae.
– Storage: between 2°C and 8°C. Do not freeze.
234
HEPATITIS B VACCINE
Indications
– Prevention of hepatitis B
– There are 2 types of vaccines: recombinant vaccines (Engerix B®, GenHevac B®,
HBvaxpro®, etc.) and human plasma-derived vaccines (Heptavax®, etc.)
– Solution for injection, in single-dose syringe or multidose vial, for IM injection into the
deltoid muscle (into the anterolateral part of the thigh in children under 2 years)
Dosage varies according to age and type of vaccine used: follow manufacturer's instructions.
– Standard schedule
• Newborns and infants:
In countries where perinatal infection is common: one injection after birth, then at 6 and
14 weeks
Where perinatal infection is less common: one injection at 6, 10 and 14 weeks
• Children, adolescents, adults:
4
Schedule 0-1-6: 2 injections 4 weeks apart, then a 3rd injection 5 months after the 2nd injection
– Accelerated schedules, when rapid protection is required (imminent departure in highly endemic
areas, post-exposure prophylaxis)
• Schedule D0-D7-D21: 3 injections administered during the same month, then a 4th injection
one year after the 1st injection
• Schedule 0-1-2-12: 3 injections 4 weeks apart, then a 4th injection one year after the
1st injection
Contre-indications, effets indésirables, précautions
– Do not administer to patients with hypersensitivity to any component of the vaccine, or
history of an allergic reaction to a previous injection. Vaccination should be postponed in the
event of severe acute febrile illness (minor infections are not contra-indications).
– Do not administer into the gluteal region (diminished antibody response to vaccine).
– In patients with multiple sclerosis, assess the benefit-risk balance of vaccination.
– May cause:
• minor local or general reactions (pain or redness at injection site, fever, headache,
myalgia, etc.),
• very rarely: anaphylactic reaction, serum disease, lymphadenopathy, peripheral neuro-
pathy.
– Shake before use to homogenise the vaccine.
– Pregnancy: only administer if there is a high risk of contamination
Remarks
– Immunity develops 1 to 2 months after the 3rd injection. Vaccine efficacy is > 80%.
– If the vaccination schedule is interrupted before the complete series has been administered,
it is not necessary to start again from the beginning. Continue the vaccination schedule
from where it was interrupted and complete the series as normal.
– SC route may be used, only if IM route is contra-indicated.
– Storage: between 2°C and 8°C - Do not freeze.
235
JAPANESE ENCEPHALITIS VACCINE
(Je-Vax®…)
Indications
– Prevention of Japanese encephalitis:
• in children from 1 year and adults in endemic countries (rural areas of Southeast and
Southwest Asia and Western Pacific countries)
• in travellers spending more than 1 month in endemic countries, in rural areas and
during the wet season

– Inactivated virus vaccine
– Powder for injection in single-dose vial, to be dissolved with the entire vial of the diluent
supplied by the manufacturer, for SC injection

– Child from 1 to 3 years: 0.5 ml/injection
– Child over 3 years and adult: 1 ml/injection
There are several vaccination schedules. For information, for travellers:
3 injections on Day 0, Day 7 and Day 28; a booster dose every 3 years if risk persists.
An accelerated schedule is possible (3 doses on Day 0, Day 7 and Day 14) but this is likely to
result in lower antibody levels than the standard schedule.
The 3rd dose should be given at least 10 days before departure to ensure an adequate immune
response and access to medical care in the event of adverse reactions.

– Do not administer to patients with history of an allergic reaction to a previous injection of
Japanese encephalitis vaccine.
– May cause:
• redness and swelling at the injection site;
• fever, headache, chills, asthenia;
• hypersensitivity reactions (urticaria, angioedema), immediate or delayed (up to 2 weeks
after injection);
• rarely: encephalitis, encephalopathy.
– Pregnancy: only administer if there is a high risk of contamination.
Remarks
– Protection lasts at least 2 years after 3 doses.
– Caution: there are different vaccines against EJ, with different dosages and administration
schedules (e.g. Ixiaro® vaccine, suspension for injection in pre-filled syringe, administered in
2 doses (0.5 ml on D0 and D28) in adults, by IM route). For each vaccine, follow manufacturer's
instructions.
– Storage:
• Powder: between 2°C and 8°C. Do not freeze.
• Reconstituted vaccine: between 2°C and 8°C, for 6 hours maximum.
236
MEASLES VACCINE
Indications
– Prevention of measles

– Live-attenuated virus vaccine, derived from different viral strains (Schwarz, Edmonston,
CAM70, Moraten, etc.)
– Powder for injection in single multidose vial, to be dissolved with the diluent supplied by
the manufacturer, for IM or SC injection into the anterolateral part of the thigh or into the
deltoid muscle

– In the EPI: one dose of 0.5 ml in children from 9 months of age.
– In situations where there is high risk of infection (overcrowding, epidemics, malnutrition,
infants born to a mother with HIV infection, etc.), administer one dose from 6 months of
age and one dose from 9 months of age (respect an interval of at least 4 weeks between two
injections).
4
– The measles control programme recommends the administration of a 2nd dose though
catch-up immunization campaigns to reach unvaccinated children or children who did not
respond to primary vaccination. Check national recommendations.

– Do not administer to patients with severe immune depression or history of an allergic
reaction to a previous injection of measles vaccine.
– Vaccination should be postponed in the event of severe acute febrile illness (minor
infections are not contra-indications).
– May cause:
• fever, skin rash, coryza;
• exceptionally: seizures, encephalitis.
– Pregnancy and breast-feeding: this vaccination is usually not indicated in adults
Remarks
– Immunity develops 10 to 14 days after injection, and lasts for at least 10 years (when
administered at 9 months).
– Storage:
• Powder: between 2°C and 8°C.
• Reconstituted vaccine: between 2°C and 8°C for 6 hours maximum.
237
MENINGOCOCCAL VACCINE A + C
(AC Vax®, Mencevax® AC, Mengivac® AC…)
Indications
– Prevention of meningitis due to meningococci groups A and C:
• in mass immunisation campaigns in the event of an outbreak due to meningococcus A
or C
• in travellers spending more than 1 month in hyperendemic areas

– Inactivated bacterial vaccine, polysaccharide
– Powder for injection in monodose or multidose vial, to be dissolved with the entire vial of
the diluent supplied by the manufacturer, for deep SC or IM injection, into the deltoid
muscle or the anterolateral part of the thigh in children (follow manufacturer's instructions)

– Child from 2 years and adult: 0.5 ml as a single dose

meningococcal vaccine.
– May cause: mild local reaction, mild fever.
Remarks
– Immunity develops 7 to 10 days after injection, and lasts for approximately 3 years.
– Storage:
238
MENINGOCOCCAL VACCINE A + C + W135
(Mencevax® ACW)
Indications
– Prevention of meningitis due to meningococci groups A, C and W135:
• in mass immunisation campaigns in the event of an outbreak due to meningococcus A,
C or W135
• in travellers spending more than 1 month in hyperendemic areas

– Inactivated bacterial vaccine, polysaccharide
– Powder for injection in multidose vial, to be dissolved with the entire vial of the diluent
supplied by the manufacturer, for SC injection only

– Child from 2 years and adult: 0.5 ml as a single dose
4
meningococcal vaccine.
– May cause: mild local reaction, mild fever.
Remarks
– Immunity develops 7 to 10 days after injection, and lasts for approximately 3 years.
– Storage:
of the vaccine, the diluent must be refrigerated between 2°C and 8°C so that the diluent and
239
ORAL ANTIPOLIOMYELITIS VACCINE (OPV)
Indications
– Prevention of poliomyelitis

– Live-attenuated virus vaccine, trivalent (poliovirus types 1, 2 and 3)
– Oral suspension in multidose vial, to be administered on the tongue, with dropper

– One dose = 2 to 3 drops depending on manufacturer.
• in non endemic areas, administer 3 doses 4 weeks apart: at 6, 10 and 14 weeks of age
• in endemic areas, administer 4 doses 4 weeks apart: at birth then at 6, 10 and 14 weeks of
age

– Vaccination should be postponed in the event of severe acute febrile illness (minor
infections are not contra-indications).
– If a child has diarrhoea when the vaccine is administered, give the usual dose then give an
extra dose 4 weeks later.
– May cause (exceptionally): paralytic poliomyelitis, encephalopathy.
– Respect an interval of 4 weeks between each dose.
– Pregnancy: CONTRA-INDICATED during the first trimester, except if there is a high risk of
contamination.
Remarks
– Protection lasts at least 5 years after 3 doses.
For prolonged storage: freeze (–20°C).
240
Human RABIES IMMUNOGLOBULIN (HRIG)
(Imogam Rabies®…)
Therapeutic action
– Neutralisation of rabies virus. HRIG provides passive immunization against rabies for 3 to
4 weeks.
Indications
– Prevention of rabies after category III exposure (except in patients correctly vaccinated
against rabies before exposure), in combination with rabies vaccine
– Prevention of rabies after category II and III exposures in immunodeficient patients (even
in patients correctly vaccinated against rabies before exposure), in combination with rabies
vaccine
– Solution for injection in 300 IU (150 IU/ml, 2 ml) or 1500 IU (150 IU/ml, 10 ml) vials, for
infiltration into the wound and IM injection
Dosage and duration
– Child and adult: 20 IU/kg as a single dose on D0, along with the first dose of rabies vaccine.
4
– Infiltrate as much of the dose as possible in and around the wound(s), which has been
cleaned beforehand. Inject any residual product, using the IM route, in a different site from
that used for vaccination. In the event of multiple wounds, dilute the dose 2 to 3-fold with
sterile 0.9% NaCl to obtain a sufficient quantity to infiltrate all the sites exposed.
– If HRIG is not available on D0, the first dose of rabies vaccine is administered alone. HRIG
can still be given as soon as possible within the next few days. However, HRIG is no longer
recommended when 7 or more days have elapsed since the first dose of vaccine was given,
as vaccine-induced immunity will have developed by this time.
– No contra-indication (including during pregnancy and breast-feeding).
– May cause: fever, myalgia, headache, gastrointestinal disturbances; rarely: allergic and
anaphylactic reactions.
– Ensure that the HRIG does not enter a blood vessel (risk of shock): aspirate prior to
injection to confirm that the needle is not in a vein.
– For finger wounds, infiltrate with caution to avoid causing a compartment syndrome.
– Do not administer HRIG and rabies vaccine in the same syringe and in the same injection
site.
Remarks
– Immunocompetent patients are considered as correctly vaccinated against rabies if they
present a document confirming pre-exposure vaccination with 3 doses of cell culture rabies
vaccine.
– Highly purified equine immune globulin derivative F(ab’)2 may replace HRIG if
unavailable. The method of administration is the same but the dose is 40 IU/kg.
241
RABIES VACCINE
(Verorab®, Rabipur®, Imovax Rabies®…)
Indications
– Prevention of rabies after category II and III exposures

– Inactivated virus vaccine, prepared from cell culture (CCV): purified Vero-cell vaccine
(VPCV) or purified chick embryo-cell vaccine (PCECV) or human diploid-cell vaccine
(HDCV)
– Powder for injection in monodose vial, to be dissolved with the entire vial of the diluent
(0.5 ml or 1 ml) supplied by the manufacturer
– HDCV (Imovax Rabies®) is administered by IM route only, into the anterolateral part of the
thigh in children < 2 years and into the deltoid in children > 2 years and adults.
– VPCV (Verorab®) and PCECV (Rabipur®) may be administered by IM route as above or by
ID route into the arm.

– The 1st dose of vaccine should be administered as soon as possible after exposure, even if
the patient seeks medical attention long after exposure (rabies incubation period may last
several months). The patient must receive all the recommended doses.
– Vaccination schedules may vary from country to country, check national recommendations.
The schedule will depend on the patient’s vaccination status prior to exposure and the
route of administration used (follow manufacturer’s instructions).
– Child and adult: one IM dose = 0.5 or 1 ml, depending on the vaccine used; one ID dose =
0.1 ml
The simplest vaccination schedules endorsed by the WHO are the following:
No rabies vaccination or
Vaccination
Incomplete vaccination or Complete vaccination
status at the
Complete vaccination with a NTV or with a CCV
time of exposure
Unknown vaccination status
Administration
route and IM ID IM or ID
schedule
2 doses* 2 doses*
D0 1 dose
(1 dose in each arm or thigh) (1 dose in each arm)
2 doses
D3 1 dose
(1 dose in each arm)
2 doses
D7 1 dose
D21 1 dose
2 doses
D28
* And, depending on the category of exposure, rabies immunoglobulin as a single dose.
242
– No contra-indication for post-exposure vaccination (including during pregnancy and
breast-feeding).
– May cause:
• benign local reactions at the injection site (pain, induration),
• general reactions (fever, malaise, headache, gastrointestinal disturbances, etc.),
• exceptionally: anaphylactic reaction.
– For patients receiving chloroquine for prophylaxis or treatment of malaria, use IM route
only.
– Do not administer corticoids concomitantly (vaccine efficacy diminished).
– IM vaccination: do not administer into the gluteal region (risk of treatment failure); ensure
that the vaccine does not enter a blood vessel (risk of shock): aspirate prior to injection to
confirm that the needle is not in a vein.
– ID vaccination: incorrect ID technique results in treatment failure. If correct ID technique
cannot be assured, use the IM regimen.
– Do not mix with other vaccines in the same syringe.
– If administered simultaneously with rabies immunoglobulin or other vaccines, use different
syringes and injection sites.
Remarks
– Only patients that present a document confirming complete pre-exposure vaccination with
4
3 doses of a VCC are considered as correctly vaccinated.
– The use of vaccines prepared from animal nerve tissue (NTVs) is not recommended.
– Rabies vaccine is also used for pre-exposure vaccination in persons at high risk of infection
(prolonged stay in rabies endemic areas, professionals in contact with animals susceptible
of carrying the virus). The vaccination schedule includes 3 doses given at D0, D7 and D21
or D28. Booster doses are recommended for persons exposed to permanent or frequent
contact with the virus.
– Storage:
• Powder: between 2°C and 8°C. Do not freeze.
• Reconstituted vaccine: use immediately.
243
TETANUS VACCINE (TT)
Indications
– Prevention of tetanus in wound management
– Prevention of maternal and neonatal tetanus in women of childbearing age and pregnant
women

– Purified tetanus toxoid
– Suspension for injection in multidose vial or single-dose syringe, for IM or SC injection into
the anterolateral part of the thigh or the deltoid muscle

– 0.5 ml per injection
– Prevention of tetanus in wound management
Complete vaccination (3 doses or more) Incomplete vaccination

Wound risk (less than 3 doses)
category Time elapsed since last dose: or no vaccination
< 5 years 5-10 years > 10 years or unknown vaccination status
TT
Clean, minor No booster No booster Start* or complete tetanus
one booster
wounds required required vaccination
dose
TT TT Start* or complete tetanus

All other No booster
one booster one booster vaccination and administer
wounds required
dose dose tetanus immunoglobulin
* At least 2 doses administered 4 weeks apart, then 3 additional doses administered

according to the same protocol as that used for women of childbearing age, to ensure
longer lasting immunity.
– Prevention of maternal and neonatal tetanus in women of childbearing age and pregnant women
5 doses administered according to the following protocol:
TT1 On first contact with medical service or as early in pregnancy as possible
TT2 At least 4 weeks after TT1
TT3 6 to 12 months after TT2 or during subsequent pregnancy
TT4 1 to 5 years after TT3 or during subsequent pregnancy
TT5 1 to 10 years after TT4 or during subsequent pregnancy
Pregnant women should receive at least 2 doses of tetanus vaccine administered at least
4 weeks apart, with the last dose at least 2 weeks before delivery. After delivery, continue
vaccination as described in the table above until the required five doses have been
administered.
244
– Do not administer in the event of significant reactions to a previous dose of tetanus vaccine.
– May cause: minor local reactions (redness, pain at the injection site); exceptionally,
anaphylactic reactions.
Remarks
– For the prevention of tetanus in wound management, preferred vaccines are:
• diphtheria-tetanus-pertussis (DTP) or diphtheria-tetanus (DT) in children < 7 years,
• tetanus-diphtheria (Td) in children ≥ 7 years, adolescents and adults.
– For the prevention of maternal and neonatal tetanus in women of childbearing age and
pregnant women, administer either TT vaccine or tetanus-diphtheria vaccine (Td).
245
Human TETANUS IMMUNOGLOBULIN (HTIG)
Therapeutic action
– Neutralisation of tetanus toxin. HTIG provides passive immunization against tetanus for
3 to 4 weeks.
Indications
– Prevention of tetanus in wound management, in patients non immunised or incompletely
immunised or in patients whose immunisation status is unknown, in combination with
tetanus vaccine
– Treatment of clinical tetanus

– Solution for injection, in 250 IU (250 IU/ml, 1 ml) or 500 IU (250 IU/ml, 2 ml) ampoule or
single-dose syringe, for IM injection. DO NOT ADMINISTER BY IV ROUTE.
Dosage and duration

– Prevention of tetanus
HTIG is administered in the event of tetanus-prone wounds, e.g. wounds with fracture,
deep penetrating wounds, bite wounds, wounds containing foreign bodies, wounds conta-
minated with soil, infected wounds, extensive tissue damage (contusions, burns).
Child and adult: 250 IU as a single dose; 500 IU if more than 24 hours has elapsed
HTIG should be administered as soon as possible after injury, along with the tetanus
vaccine, in a separate syringe and injection site.
– Treatment of tetanus
Neonate, child and adult: 500 IU as a single dose, to be injected into 2 different sites

– Do not administer to patients with known allergy to HTIG.
– May cause (very rarely): allergic reactions.
– Ensure that the HTIG does not enter a blood vessel (risk of shock): aspirate prior to
Remarks
– For minor clean wounds, tetanus vaccine is administered alone.
– SC route may be used but only if IM route is contra-indicated.
246
TETANUS ANTITOXIN (EQUINE)
Equine tetanus antitoxin should no longer be used, as there is a risk of

hypersensitivity and serum sickness.
It should be replaced by human tetanus immunoglobulin.
Therapeutic action
– Neutralisation of tetanus toxin. Tetanus antiserum provides temporary passive immunity
against tetanus for 15 days.
Indications
– Prevention of tetanus in wound management, in patients non immunised or incompletely
immunised or in patients whose immunisation status is unknown, in combination with
tetanus vaccine
– Treatment of clinical tetanus

– Solution prepared from the serum of horses immunised against tetanus toxin
4
– 1500 IU in 1 ml ampoule, for IM injection. DO NOT ADMINISTER BY IV ROUTE.
Dosage and duration

– Prevention of tetanus
Tetanus antiserum is administered in the event of tetanus-prone wounds, e.g. wounds with
fracture, deep penetrating wounds, bite wounds, wounds containing foreign bodies,
wounds contaminated with soil, infected wounds, extensive tissue damage (contusions,
burns).
Child and adult: 1500 IU as a single dose; 3000 IU if more than 24 hours has elapsed
It is administered as soon as possible after injury, along with the tetanus vaccine, in a
separate syringe and injection site.
– Treatment of tetanus
Neonate: 1500 IU as a single dose
Child and adult: 10 000 IU as a single dose

– Do not administer to patients with known allergy to tetanus antiserum.
– May cause: hypersensitivity reactions, anaphylactic shock, Quinke oedema; serum sickness
up to 10 days after injection.
– Administer following Besredka's method: inject 0.1 ml by SC route and wait 15 minutes; if
no local or general allergic reactions occur, inject 0.25 ml by SC route and wait 15 minutes;
if no reactions, administer the injection by IM route.
– Ensure that the injection does not enter a blood vessel (risk of shock): aspirate prior to
– Pregnancy and breast-feeding: no contra-indication
Remarks
– Equine tetanus antitoxin is not included in the WHO list of essential medicines.
247
YELLOW FEVER VACCINE
Indications
– Prevention of yellow fever:
• in children from 9 months of age and adults living in or travelling through endemic areas
• in mass immunisation campaigns in the event of an outbreak

– Live-attenuated virus vaccine
– Powder for injection in multidose vial, to be dissolved with the entire vial of diluent supplied
by the manufacturer, for IM injection into the anterolateral part of the thigh in children under
2 years and SC injection into the deltoid muscle in children over 2 years and adults

– Child and adult: 0.5 ml as a single dose
– In routine immunisation (EPI), the vaccine is usually administered from 9 months of age,
along with the measles vaccine.
– Vaccination is contra-indicated in children less than 6 months. In children between 6 and
9 months, vaccination is only recommended in epidemics, as the risk of virus transmission
may be very high.
Contra¬indications, adverse effects, precautions

yellow fever vaccine, true allergy to egg, immunodeficiency (e.g. symptomatic HIV infection,
immunosuppressive therapy).
– May cause:
• minor reactions: mild fever, headache, myalgia;
• severe reactions (exceptionally): hypersensitivity reactions, encephalitis (especially in
children < 9 months and adults > 60 years), multiple organ failure (especially in adults
> 60 years).
– Pregnancy: not recommended. However, given the severity of yellow fever, the vaccine is administered
when the risk of contamination is very high (epidemics, unavoidable travel to regions of high
endemicity).
Remarks
– Immunity develops approximately 10 days after injection, and lasts for at least 10 years.
– Storage:
248
Drugs for external use,
antiseptics and disinfectants
Aciclovir eye ointment 251
Alcohol-based solution or gel 252
Artesunate rectal 253
Benzoic acid + salicylic acid 254
Benzyl benzoate 255
Calamine 256
Chlorhexidine 257
Chlorine-releasing compounds 258
Clotrimazole 260
Dinoprostone 261
Ethanol 262
Ethyl alcohol 262
Fluorescein 263
Gentian violet 267
Iodine, alcoholic solutions 264
5
Malathion 265
Merbromin 266
Methylrosanilinium chloride 267
Miconazole 268
Miconazole buccal tablet 269
NaDCC 279
Nystatin 270
Permethrin 1% 271
Permethrin 5% 272
Podophyllotoxin 273
Podophyllum resin 274
Polyvidone iodine aqueous solution 275
Polyvidone iodine scrub solution 276
Potassium permanganate 277
Silver sulfadiazine 278
Sodium dichloroisocyanurate 279
Sodium mercurescein 266
Tetracycline dermal ointment 280
Tetracycline eye ointment 281
Zinc oxide ointment 282
ACICLOVIR eye ointment
(Zovirax®…)
Therapeutic action
– Antiviral active against herpes virus
Indications
– Treatment of herpes keratitis
– Prevention of herpes keratitis in neonate born to a mother suffering from genital herpes at
the moment of childbirth
Presentation
– 3% ointment, tube
Dosage and duration

– Treatment of herpes keratitis
Child and adult: 5 applications/day into the conjunctival sac of both eyes for 14 days or for
3 days after lesions have healed
– Prevention of herpes keratitis in neonate
Immediately after birth: wash the eyes with sterile sodium chloride 0,9% then apply a
single dose of aciclovir into the conjunctival sac of both eyes

– In neonates, wait 12 hours after application of aciclovir 3% then apply tetracycline eye oint-
5
ment 1% to prevent gonococcal neonatal conjunctivitis.
Remarks
– Conservation: below 30°C
Use within 30 days after first opening.
To avoid contamination, close the tube properly after opening.
251
ALCOHOL-BASED solution or gel
(Manugel®, Manurub®, Sterillium®...)
Therapeutic action
– Antiseptic
Indications
– Antiseptic hand rub, before and after procedures, whether gloves are used or not
Presentation
– Ready to use alcohol-based hand rub solution or gel
Use
– Alcohol-based hand rubs can only be used if hands are not visibly dirty or soiled with
organic matter. There must be no residual powder on hands (use powder-free gloves) and
hands must be dry.
– Apply 3 ml of solution or gel in a cupped hand and spread to cover the entire surface of
hands. Rub hands for 20-30 seconds, palm to palm, palm over dorsum, between fingers
(fingers interlaced), around the thumbs and nails, until hands are completely dry. Do not
dilute the product. Do not rinse off or dry hands.
– As long as hands are not visibly soiled, the product may be reapplied as many times as
necessary without handwashing before or after applying the product.

– Do not use if:
• hands are visibly dirty or soiled with organic matter (wash hands),
• there is residual powder on hands (wash hands),
• hands are wet (water dilutes alcohol and impedes drying).
– Do not use after direct contact with a patient with a parasitic skin infection (scabies, lice):
wash hands.
– Do not use simultaneously with soap or another antiseptic (antagonism, inactivation, etc.).
– Do not use for disinfection of material, patient's skin or mucous membranes.
– May cause: stinging sensation on broken skin.
– In case of eye contact flush immediately with plenty of water.
Remarks
– Dose required and duration of handrubbing may vary depending on the product used.
Read the manufacturer's instructions carefully.
– To avoid difficulty in putting on gloves, rub hands until the product is completely dry.
– Use of alcohol-based hand rubs may result in a sticky residue on hands after several
applications. In this event, wash hands.
– Some alcohol-based hand rubs can be used for surgical hand antisepsis, however the
technique is not the same as for antiseptic hand rub.
Close bottles tightly to avoid evaporation. Keep away from sources of ignition (flame, spark,
incandescent material).
252
ARTESUNATE rectal
(Plasmotrim®…)
Therapeutic action
– Antimalarial
Indications
– Initial (pre-referral) treatment of severe falciparum malaria, before transferring the patient
to a facility where parenteral antimalarial treatment can be administered
– Initial treatment of uncomplicated falciparum malaria, when persistent vomiting precludes
oral therapy
– 50 mg and 200 mg rectal capsules
Dosage and duration
– Severe falciparum malaria
Child and adult: 10 to 20 mg/kg as a single dose before transferring the patient
– Uncomplicated falciparum malaria
Child and adult: 10 to 20 mg/kg once daily. As soon as patient can take oral treatment,
administer a 3-day course of an artemisinin-based combination.
Weight 50 mg rectal capsule 200 mg rectal capsule

3 to 5 kg 1 –
6 to 10 kg 2 –
5
11 to 20 kg – 1
21 to 40 kg – 2
41 to 60 kg – 3
61 to 80 kg – 4

– May cause: gastrointestinal disturbances, headache and dizziness.
– Pregnancy: no contra-indication during the 2nd and 3rd trimester. Safety of artesunate during the
first trimester has not been definitely established. However, given the risks associated with malaria,
it may be used during the first trimester if it is the only effective treatment available.
Remarks
– Buttocks should be held together for at least 1 minute to ensure retention. If capsules are
expelled from the rectum within 30 min of insertion, re-administer the treatment.
– Up to 2 or 3 capsules can be administered simultaneously. When the dose to be administered
is 4 capsules, insert 3 capsules then wait 10 minutes before administering the fourth.
– The treatment of choice of severe falciparum malaria is based on IV artesunate or IM
artemether or IV quinine. When it is absolutely impossible to transfer a patient to a facility
where parenteral antimalarial treatment can be administered, artesunate rectal capsules
should be administered once daily until the patient is able to take a 3-day course of an
artemisinin-based combination.
253
BENZOIC ACID + SALICYLIC ACID ointment
= Whitfield’s ointment
Therapeutic action
– Antifungal and keratolytic agent
Indications
– Dermatophytoses of the scalp (ringworms), in combination with griseofulvin
– Dermatophytoses of the skin, in combination with griseofulvin in the event of extensive
lesions
Presentation
– Benzoic acid 6% + salicylic acid 3% ointment, tube or jar
Dosage
– 2 applications/day
Duration
– 3 to 6 weeks according to clinical response

– Do not apply to exudative lesions, mucous membranes or eyes.
– In case of secondary bacterial infection, start appropriate local (antiseptic) or systemic
(antibiotic) treatment before applying Whitfield’s ointment.
– May cause: skin irritation and inflammation.
– In case of contact with eyes or mucous membranes, flush immediately with plenty of water.
Remarks
Once the ointment has been exposed to a high temperature the active ingredients are no longer
evenly distributed: the ointment must be homogenized before using.
To avoid contamination, close the tube or the jar properly after opening.
254
BENZYL BENZOATE
Therapeutic action
– Scabicide
Indications
– Scabies
Presentation
– 25% lotion
Preparation and use

– Shake the bottle before application or dilution.
– Dilute the lotion, as required, according to age. Use drinking or boiled water.
Child > 12 years
Child < 2 years Child 2-12 years and adult
1 part of 25% lotion 1 part of 25% lotion
Preparation + + Undiluted 25% solution
3 parts of water 1 part of water
12 hours (6 hours
Contact time in children < 6 months) 24 hours 24 hours
– Apply the lotion to the whole body, including scalp, postauricular areas, palms and soles.
Pay particular attention to skin creases and interdigital web spaces. Do not apply to the face
and mucous membranes.
– In children under 2 years: apply only once; wrap hands to avoid accidental ingestion; rinse
off when the recommended contact time has elapsed.
5
– In children ≥ 2 years and adults: a second application (e.g. after 24 hours, with a rinse
between the two applications; or two successive applications, 10 minutes apart, when the
first application has dried, with a rinse after 24 hours) reduces the risk of treatment failure.

– Do not apply to broken or infected skin. In the event of secondary bacterial infection,
administer an appropriate local (antiseptic) and/or systemic (antibiotic) treatment 24 to
48 hours before applying benzyl benzoate.
– May cause: burning sensation; contact dermatitis in case of repeated applications; seizures
in the event of marked transcutaneous absorption (broken skin, children < 2 years).
– Avoid contact with eyes. In case of eye contact, flush immediately with plenty of water.
– DO NOT SWALLOW (risk of seizures). In case of ingestion: do not induce vomiting, do not
perform gastric lavage; administer activated charcoal.
– Pregnancy: no contra-indication; do not leave on skin longer than 12 hours; do not repeat application.
– Breast-feeding: no contra-indication; do not apply to breasts.
Remarks
– Close contacts should be treated at the same time regardless of whether they have
symptoms or not. Decontaminate clothes and bed linen of patients and close contacts
simultaneously.
– Itching may persist for 1 to 3 weeks despite successful treatment. Do not re-treat during this
period. The treatment may be repeated if specific scabies lesions (scabious burrows) are still
present after 3 weeks.
– 5% permethrin cream or lotion is preferred when available, especially in children less than
2 years and pregnant or lactating women.
255
CALAMINE lotion
Action thérapeutique
– Antipruritic drug
Indications
– Pruritic dermatoses
Presentation
– Calamine 8% or 15% lotion, bottle
Dosage
– 2 to 4 applications/day
Duration

– Clean the skin before applying the lotion.
– Do not apply to exudative and/or superinfected lesions, mucous membranes or eyes.
– In case of contact with eyes or mucous membranes, flush immediately with plenty of water.
– Breast-feeding: no contra-indication, do not apply on breasts
Remarks
– Shake the lotion well before using.
To avoid contamination, close the bottle properly after opening.
256
CHLORHEXIDINE
(Hibitane®…)
Therapeutic action
– Antiseptic
Indications
– Antisepsis of minor and superficial wounds and burns
Presentation
– 5% concentrated solution of chlorhexidine gluconate to be diluted before use
Check that the solution may be diluted with ordinary, non-distilled water (in this event the
formulation should contain a surfactant to prevent the precipitation of chlorhexidine).
Preparation
– Use as a 0.05% aqueous solution:
For one litre: 10 ml of 5% concentrated solution + 990 ml of clear water, boiled a few
minutes and cooled

– Do not use undiluted solution.
– Do not bring into contact with body cavities, eyes (risk of corneal damage), brain and
meninges, middle ear (risk of deafness if ear drum is perforated).
– Avoid applications to mucous membranes, especially to genital mucous membranes.
5
– Do not use with soap or other antiseptics (incompatibility).
Remarks
– Also comes in 20% chlorhexidine gluconate concentrated solutions. These solutions usually
do not contain a surfactant and must be diluted with distilled water.
– Storage:
• Concentrated solution: below 25°C
• Diluted solution: maximum one week
257
CHLORINE-RELEASING COMPOUNDS
(NaDCC, HTH, bleach, chlorinated lime)
Therapeutic action
– Disinfectants
Indications
– Disinfection of medical devices, instruments, linen, floors and surfaces
Presentation
– The potency of chlorine disinfectants is expressed in terms of available chlorine in either:
• percentage (%)
• g/litre or mg/litre
• parts per million (ppm)
• chlorometric degree (1°chl. = approximately 0.3% available chorine)
1% = 10 g/litre = 10 000 ppm
1 mg/litre = 1 ppm = 0.0001%
– The most widely used chlorine disinfectants are:
• Sodium dichloroisocyanurate (NaDCC), 1,67 g tab ..................1 g available chlorine/tab
• Calcium hypochlorite (HTH), granules .......................................65-70% available chlorine
• Sodium hypochlorite solutions (liquid bleach):
- concentrated bleach (extrait de javel) ............................36°chl. = 9.6% available chlorine
- bleach (eau de Javel)............................9°chl or 12°chl. = 2.6% or 3.6% available chlorine
• Chlorinated lime, powder ..............................................................25-35% available chlorine
Preparation and use

– The concentration required depends on the amount of organic material present (how
clean/unclean the surface is).
– The available chlorine content must always be checked on the product packaging in order
to adjust the dilution if necessary.
– Prepare solutions with cold water in non-metallic containers.
– A deposit in HTH solutions and chlorinated lime solutions is normal (use only the supernatant).
Examples Clean medical Surfaces, beds, Surfaces, equipment Corpses, excreta,

devices, equipment, utensils contaminated boots
surfaces and linen in case of cholera with blood and other in case of cholera
(after cleaning) (after cleaning) body fluids spills
(before cleaning)
Concentration 0.1% 0.2% 0.5% 2%
required expressed
= 1000 ppm = 2000 ppm = 5000 ppm = 20 000 ppm
in available chlorine
NaDCC
(1 g available 1 tab/litre water 2 tab/litre water 5 tab/litre water 20 tab/litre water
chlorine/tablet)
Calcium 15 g/10 litres 30 g/10 litres 7.5 g/litre 300 g/10 litres
hypochlorite (70% = 1 level tablespoon = 2 level tablespoons = 1/2 tablespoon = 20 level tablespoons
available chlorine) for 10 litres water for 10 litres water for 1 litre water for 10 litres water
Bleach For 5 litres: For 5 litres: For 1 litre: For 5 litres:
(2.6% available 200 ml 400 ml 200 ml 4000 ml
chlorine) + 4800 ml water + 4600 ml water + 800 ml water + 1000 ml water
For more information, refer to the appendix Antiseptics and disinfectants.
258
Precautions
– Handle concentrated products with caution (avoid jolts and exposure to high temperatures
or flames).
– Do not bring dry products, particularly HTH and chlorinated lime, in contact with organic
materials (e.g. corpses): risk of explosion.
– Avoid inhaling vapours and dust when opening or handling the containers.
Remarks
– Sodium dichloroisocyanurate (NaDCC) is less corrosive than the other products.
– Bleach or concentrated bleach, or if not available HTH, may be used to prepare an antiseptic
solution at 0.5% available chlorine (as substitute to Dakin's solution), provided sodium
bicarbonate (one tablespoon per litre) is added to the final solution to neutralise the
alkalinity (e.g. for one litre: 200 ml of bleach 2.6% + 800 ml distilled or filtered water, or if
not available, boiled and cooled water + 1 tablespoon of sodium bicarbonate).
– Chloramine T (powder or tablet, 25% available chlorine) is another chlorine-releasing
compound used above all as an antiseptic.
– Trichloro-isocyanuric acid (TCCA), in powder or granules (90% available chlorine), is very
similar to NaDCC, but its use is limited due to its poor solubility.
– Storage: in airtight, non-metallic containers, protected from light, heat (and humidity for dry
products). –
Chlorinated lime, bleach and concentrated bleach are unstable. HTH is more stable. NaDCC is by
far the most stable.
259
CLOTRIMAZOLE
(Canestene®, Mycoril®…)
Therapeutic action
– Antifungal
Indications
– Vaginal candidiasis

– 200 mg and 500 mg vaginal tablets with applicator
Also comes in 1% and 10% vaginal cream.
Dosage and duration

– Adult:
• one vaginal tablet of 500 mg as a single dose, inserted high into the vagina, at bedtime
or
• one vaginal tablet of 200 mg/day for 3 days, inserted high into the vagina, at bedtime

– Do not administer to patients with:
• hypersensitivity to other azole antifungals (fluconazole, itraconazole, ketoconazole, etc.),
• vulvar or vaginal sores or ulcers.
– May cause: local irritation (due to infection, a true allergy is exceptional).
– Do not combine with nystatin vaginal tablets (antagonism).
– Pregnancy: no contra-indication (but do not use the applicator to avoid mechanical trauma)
Remarks
– Also comes in 100 mg vaginal tablet (one vaginal tablet/day for 6 days).
– Do not interrupt treatment during menstruation.
260
DINOPROSTONE
Therapeutic action
– Cervical ripening agent, oxytocic drug (prostaglandin)
Indications
– Induction of labour when continuation of pregnancy is dangerous for mother and/or foe-
tus and the cervix is not favourable (e.g. severe pre-eclampsia)

– 3 g of vaginal gel containing 1 mg of dinoprostone, in prefilled syringe, to be administered
intra-vaginally into the posterior fornix of the vaginal canal
Dosage and duration

– One dose of 1 mg. Administer a second dose of 1 mg, 6 hours later, if there has been no
change in the cervix or no onset of uterine contractions.

– Do not administer in the event of malpresentation, true cephalopelvic disproportion, com-
plete placenta praevia, history of caesarean section.
– Administer with caution in the event of grand multiparity (risk of uterine rupture).
– Do not administer simultaneously with oxytocin. At least 6 hours must have elapsed since
the last administration of dinoprostone before oxytocin can be given.
– May cause: gastrointestinal disorders, uterine hypertonia, uterine rupture, modification of
5
the foetal heart rate, foetal distress.
– Regular monitoring of the intensity and frequency of contractions is mandatory.
– Continuous foetal heart monitoring is mandatory for 30 minutes after administration of
each dose of dinoprostone and once contractions are experienced or detected.
Remarks
– Oral misoprostol is another prostaglandin used in the induction of labour. It is less expen-
sive and easier to store than dinoprostone.
– Misoprostol is preferred in the event of intrauterine foetal death. On the other hand, the
dose of misoprostol used for induction of labour with a viable foetus is difficult to manage
using the 200 µg tablet of misoprostol. Dinoprostone is easier to use in these situations.
– When the cervix is favourable, induce labour through administration of oxytocin and arti-
ficial rupture of the membranes.
261
ETHYL ALCOHOL = ETHANOL
Therapeutic action
– Antiseptic and disinfectant
Indications
– Antisepsis of intact skin prior to injections and venopunctures
– Disinfection of latex stopper of infusion bottles and drug vials (except vaccines), latex
injection sites of infusion sets
Presentation
– Mixtures of alcohol (ethanol) and water in different concentrations (e.g. 95% v/v ethanol),
sometimes containing additives to avoid their ingestion.
– Alcoholic strength is expressed:
• preferably as a percentage by volume of alcohol (% v/v); e.g. 1000 ml of 95% v/v alcohol
contains 950 ml of absolute alcohol.
• sometimes as a percentage by weight of alcohol (% w/w). The % w/w is not equal to the
% v/v because the mixture of water and alcohol produces a reduction in volume.
• sometimes in degrees (°) but this should be discouraged as it is a source of error. There
are at least 3 different definitions of degrees: the old UK definition (° British proof), the
American (° proof) and the one used in French speaking countries (1° = 1% v/v). For
example: 40% v/v = 70° proof (British system) = 80° proof (American system) = 40° in
French speaking countries.
Preparation
– Use 70% v/v ethanol, which is more effective than higher concentrations.
– To obtain 1 litre of 70% v/v ethanol:
• take 785 ml of 90% v/v ethanol, or 730 ml of 95% v/v ethanol, or 707 ml of 99% v/v
ethanol,
• add distilled or filtered water to make up a volume of 1 litre,
• leave to cool and top up with water again to bring the volume back to 1 litre (mixing
water and ethanol together produces a reaction whereby volume is reduced).
Precautions
– Do not apply to mucous membranes, wounds or burns: it is painful, irritating and slows
the healing process.
– Do not apply on neonatal skin.
Remarks
– Ethanol can be used for disinfection of non-critical medical items (items that are in contact
with intact skin only) that are not soiled by blood or other body fluids.
– Critical medical items (surgical instruments, etc.) cannot, under any circumstances, be
“sterilized” by alcohol flaming, immersion in ethanol or wiping with ethanol.
Close bottles tightly to avoid evaporation. Keep away from sources of ignition (flame, spark,
incandescent material).
262
FLUORESCEIN
Therapeutic action
– Ophthalmic diagnostic agent
Indications
– Diagnosis of corneal and conjunctival lesions
– Detection of corneal and conjunctival foreign bodies
Presentation
– 0,5%, 1% and 2% fluorescein eye drops in single use vial
– Sterile, individually wrapped paper strips impregnated with fluorescein
Use
– Eye drops: instill 1 or 2 drops into the conjunctival sac.
– Paper strips: place a strip into the conjunctival sac.
– After instillation of fluorescein, the eye should be examined under cobalt blue illumination.

– Before use, check that the patient is not wearing soft contact lenses (fluorescein can per-
manently stain soft contact lenses).
Remarks
– Vials and paper strips are designed for single use only; they must be discarded after use.
5
263
Alcoholic solutions of IODINE
(iodised alcohol, iodine tincture)
The use of alcoholic solutions of iodine is not

recommended. They are very irritating, expensive
and difficult to store ; the alcohol evaporates
(solutions become even more irritating as they
age).
Polyvidone iodine is much less irritating and
easier to store.
Therapeutic action
– Antiseptic
– Antifungal
Indications
– Antisepsis of intact skin (skin cleansing prior to injections, puncture, surgery)
– Treatment of fungal infections of the skin
Presentation
– Iodised alcohol (1 or 3% iodine in 50 to 90% ethanol v/v)
– Iodine tincture (5% iodine in 80 or 90% ethanol v/v + 3% potassium iodine) is a very
concentrated preparation that should no longer be used.

– Do not apply to mucous membranes, wounds or burns: the alcohol is painful, irritating and
slows the healing process.
– May cause: skin reactions, allergic reactions.
– Incompatible with mercury compounds (merbromine, etc).
Remarks
– Storage: maximum of a few weeks
264
MALATHION
(Prioderm®…)
Therapeutic action
– Pediculicide (organophosphorus insecticide)
Indications
– Head pediculosis (lice)
Presentation
– 0.5% lotion
Use
– Apply lotion to hair and scalp; pay particular attention to the areas behind the ears and
around the nape of the neck.
– Leave on hair for:
• 8 hours in children from 6 months to 2 years
• 12 hours in children over 2 years and adults
– Rinse with plenty of water.
– It is recommended to repeat the application after 10 days.

– Use with caution and under medical supervision in children under 2 years.
5
– May cause: scalp irritation.
– Avoid contact with eyes. In the event of product entering the eye, rinse with plenty of
water.
– NEVER SWALLOW. The first signs of poisoning after accidental ingestion are gastrointestinal
disturbances (vomiting, diarrhoea). Dyspnoea, seizures or coma are signs of severe intoxication.
As soon as the first signs appear, administer injectable atropine as an antidote.
Remarks
– Examine everyone in contact with a patient and treat only those infected. Preventive
treatment of non-infected persons is ineffective and increases the risk of resistance.
– Malathion is flammable. Keep medication away from heat sources.
– Malathion is not included in the WHO list of essential medicines.
265
MERBROMIN = SODIUM MERCURESCEIN
(Mercurochrome®…)
The use of this drug is not recommended:

– it is toxic and allergenic,
– it is a weak antiseptic,
– it is inactivated by organic matter,
– it is expensive.
Therapeutic action
– Antiseptic
Indications
– Antisepsis of minor and superficial wounds
Presentation
– Powder to be dissolved
– 1 or 2% aqueous solutions ready for use
– 2% alcoholic solution ready for use

– Do not use with iodine compounds (iodised alcohol, polyvidone iodine): risk of necrosis.
– May cause:
• renal, neurologic and gastrointestinal toxicity due to the resorption of mercury through
skin,
• frequent allergic reactions, often associated with a hypersensitivity to all mercurial
compounds (other mercurial antiseptics, dental amalgams, preservatives used in
cosmetics).
– Colours the skin: may mask an inflammatory reaction.
Remarks
– Aqueous solutions have a very weak antiseptic activity. Alcoholic solutions are more
effective. However merbromin carries serious adverse effects and the use of all solutions
must therefore be abandoned.
– Other mercurial compounds: phenylmercuric borate, mercurobutol (Mercryl®), thiomersal
(Thimerosal®) have the same adverse effects and must also be abandoned.
– Merbromin is not included in the WHO list of essential medicines.
266
METHYLROSANILINIUM CHLORIDE
= GENTIAN VIOLET = GV = CRYSTAL VIOLET
Therapeutic action
– Antifungal
– Drying agent
Indications
– Treatment of candidal infections:
• oral candidiasis
• mammary candidiasis in nursing mothers
• candidal diaper dermatitis
– Treatment of oozing dermatosis (dermatophytosis, impetigo, etc.)
Presentation
– Powder to be dissolved
– 0.5% solution
Preparation
– Dissolve one teaspoon of powder (= 5 g) in 1 litre of clear water (boiled a few minutes and
cooled) to obtain a 0.5% aqueous solution.
– Shake well and leave to settle. Filter through cotton or pour carefully into another bottle to
eliminate any possible sediment.
– Before use, carefully wash both the bottle for dilution and the storage bottle with hot water
5
and leave to dry.
Use
– 2 applications/day until lesions disappear

– Do not apply to wounds or ulcerations.
– Do not apply to the face or mucous membranes (except oral cavity).
– May cause:
• irritation, ulcerations, allergic reactions,
• persistent staining of the skin.
– The solution may be applied to the oral cavity but should not be swallowed.
– The use of cooking oil or vaseline around lips before swabbing can limit the risk of skin
coloration.
– Stop treatment in the event of allergic reactions or if new ulcerations develop.
– In the event of product entering the eye, rinse with plenty of water.
Remarks
– Avoid contact with clothes (causes permanent staining of fabrics).
– Storage:
• Powder to be dissolved: unlimited
• Diluted solution: maximum 1 week
267
MICONAZOLE
(Daktarin®, Micatin®…)
Therapeutic action
– Antifungal
Indications
– Treatment of cutaneous candidiasis
– Treatment of genital candidiasis (vulvovaginal candidiasis, in combination with the intra-
vaginal antifungal treatment; candidal balanitis)
– Treatment of dermatophytoses (ringworm, etc.)
Presentation
– 2% cream, tube
Also comes in powder, ointment and gel for external use.
Dosage
– 2 applications/day, sparingly, on clean and dry skin
Duration
– Cutaneous candidiasis: 7 to 14 days
– Genital candidiasis: 7 days
– Scalp ringworm: 4 to 8 weeks; ringworm of the body: 2 to 3 weeks

– Do not use in patients with hypersensitivity to azole antifungals (fluconazole, ketoconazole,
itraconazole, etc.).
– May cause: skin reactions (irritation, burning sensation). In the event, stop treatment.
– When applied to a large area of skin and/or when used in newborns: risk of systemic
absorption.
– Breast-feeding: no contra-indication. Do not apply on breast, except in the event of mammary
candidiasis (in this event, apply cream two times a day after breast-feeding).
Remarks
– For the treatment of vulvovaginal candidiasis, miconazole cream may complement, but
does not replace, treatment with clotrimazole or nystatin.
268
MICONAZOLE muco-adhesive buccal tablet
(Tibozole®)
Therapeutic action
– Antifungal
Indications
– Oro-pharyngeal candidiasis in immunodeficient patients

– 10 mg muco-adhesive buccal tablet
Dosage and duration

– Child and adult: one tablet once daily for 7 days
Moisten the tablet with the tongue. Place the tablet on the upper gingiva, above a lateral
incisor and cover with the upper lip. Apply a slight pressure with the index finger to the
outside of the upper lip for 20 seconds, directly over the tablet, until it sticks to the gingiva.
The tablet remains on the gingiva and releases miconazole for 8 to 12 hours.

Remarks
– Do not swallow tablets: the treatment being local, swallowing is not harmful but is 5
ineffective.
– Miconazole is not contra-indicated in young children but it is difficult to use correctly
muco-adhesive buccal tablets in children under 7 years.
– Miconazole also exists as an oral gel (Daktarin®‚ etc.) applied on the lesions for 7 to 15 days
(child: 1 measure 4 times a day; adult: 2 measures 4 times a day).
Tablets are packed in a blister containing 7 tablets. Leave tablets in blister until use. Once a tablet
is removed from the blister, it must be used immediately.
269
NYSTATIN
(Mycostatin®…)
Therapeutic action
– Antifungal
Indications
– Vaginal candidiasis

– 100 000 IU vaginal tablet
Dosage and duration

– Adult: 1 or 2 tablets of 100 000 IU/day at bedtime for 14 days
Tablets must be moistened and inserted high into the vagina.

– Do not combine with clotrimazole vaginal tablets (antagonism).
Remarks
– By preference use clotrimazole vaginal tablets for this indication.
– Do not interrupt treatment during menstruation.
270
PERMETHRIN 1%
Therapeutic action
– Pediculicide (pyrethroid insecticide)
Indications
– Head pediculosis (lice)
Presentation
– 1% lotion
Use
– Apply lotion to hair and scalp; pay particular attention to the areas behind the ears and
around the nape of the neck.
– Leave on hair for 10 minutes.
– Rinse with plenty of water.
– It is recommended to repeat the application after 10 days.

– Use with caution and under medical supervision in children under 6 months.
– May cause: scalp irritation.
– Avoid contact with eyes. In case of eye contact, flush immediately with plenty of water.
5
– NEVER SWALLOW. In case of accidental swallowing, the treatment is symptomatic.
Remarks
– Examine everyone in contact with a patient and treat only those infected. Preventive treatment
of non-infected persons is ineffective and increases the risk of resistance.
– For better results, use the lotion rather than the shampoo.
– Permethrin 5% cream is used for the treatment of scabies in children over 2 months and
adults.
271
PERMETHRIN 5%
Therapeutic action
– Scabicide (pyrethroid insecticide)
Indications
– Scabies
Presentation
– 5% cream or lotion
Use
– Apply the cream or lotion to the whole body, including scalp, postauricular areas, palms
and soles. Pay particular attention to skin creases and interdigital web spaces. Do not apply
to the face and mucous membranes.
– In children under 2 years: wrap hands to avoid accidental ingestion.
– Leave on skin for 8 to 12 hours then rinse off.
– A single application may be sufficient. A second application 7 days later reduces the risk of
treatment failure.

– Do not use in children under 2 months (safety not established).
– Do not apply to broken or infected skin. In the event of secondary bacterial infection,
administer an appropriate local (antiseptic) and/or systemic (antibiotic) treatment 24 to
48 hours before applying permethrin.
– May cause (rarely): skin irritation.
– Avoid contact with eyes. In case of eye contact flush immediately with plenty of water.
– NEVER SWALLOW. In case of accidental ingestion, the treatment is symptomatic.
– Breast-feeding: no contra-indication; do not apply to breasts.
Remarks
– Close contacts should be treated at the same time regardless of whether there have
symptoms or not. Decontaminate clothes and bed linen of patients and close contacts
simultaneously.
– Itching may persist for 1 to 3 weeks despite successful treatment. Do not re-treat during this
period. The treatment may be repeated if specific scabies lesions (scabious burrows) are still
present after 3 weeks.
– 5% permethrin used for the treatment of scabies is not to be confused with 1% permethrin
used for the treatment of head and pubic lice.
272
PODOPHYLLOTOXIN
(Condyline®, Condylox®, Wartec®…)
Therapeutic action
– Antiviral, antimitotic, cytolytic agent active against human papillomaviruses (HPVs)
Indications
– Treatment of external genital warts, perianal warts and vaginal warts
Presentation
– 0.5% solution or gel, with applicator tips
Dosage
– Apply podophyllotoxin to warts twice daily.
– For vaginal warts, allow to dry before removing the speculum.
Duration
– 3 consecutive days per week, for a maximum of 4 weeks

– Do not use to treat genital warts in children.
– Do not apply to warts > 3 cm.
– Do not apply to cervical, urethral, anorectal or oral warts.
– Do not apply to healthy skin.
5
– May cause local reactions: erythema, ulceration, pain in area where applied.
– Use a new applicator tip for each application.
Remarks
– When treatment is contra-indicated or has failed after 4 weeks, change treatment method
(cryosurgery, electrosurgery, surgical removal).
273
PODOPHYLLUM resin
Therapeutic action
– Antiviral, antimitotic, cytolytic agent active against human papillomaviruses (HPVs)
Indications
– Treatment of external genital warts, perianal warts and vaginal warts
Presentation
– Podophyllum resin in alcohol or compound benzoin, 10%, 15% and 25% solution.
Use
– Always apply a protective layer of vaseline or zinc ointment on the surrounding skin prior
to treatment.
– Apply podophyllum resin to warts:
• For external warts, leave on the warts for 1 to 4 hours then wash with soap and water.
• For vaginal warts, allow to dry before removing the speculum.
Duration
– Apply once weekly if necessary, for a maximum of 4 weeks.

– Do not use to treat genital warts in children.
– Do not apply to healthy skin or mucous membranes, or to warts > 3 cm, or to cervical,
urethral, anorectal or oral warts.
– May cause:
• local reactions: erythema, ulceration, pain in area where applied,
• systemic adverse effects: gastrointestinal disturbances, haematological and neurological
disorders (possibly severe) in the event of prolonged or excessive application, or when
applied to bleeding lesions.
Remarks
– Use by preference 0.5% podophyllotoxin solution: it is as effective as podophyllum resin,
but less irritant and toxic. Another advantage is that the patient may apply the solution to
the warts himself; whereas the resin must always be applied by medical staff.
– When treatment is contra-indicated or has failed after 4 weeks, change treatment method
(cryosurgery, electrosurgery, surgical removal).
274
POLYVIDONE IODINE = POVIDONE IODINE = PVI
aqueous solution (Betadine dermal solution®…)
Therapeutic action
– Antiseptic and disinfectant
Indications
– Antisepsis of intact or broken skin and mucous membranes
– Local treatment of bacterial, viral or fungal infections of the oral cavity
– Disinfection of latex stopper of infusion bottles and drug vials (except vaccines), latex
injection sites of infusion sets
Presentation
– 10% aqueous solution
Use
– Antisepsis of intact skin (injections, punctures)
Apply 10% solution to the puncture/injection site and allow to dry before inserting the
needle. The skin should be cleaned beforehand if soiled or if the procedure is invasive
(lumbar puncture, epidural/spinal anaesthesia, etc.).
– Preoperative skin antisepsis
Apply 10% solution twice. Allow to dry between each application (do not dab to accelerate
drying). Incise once the 2nd application has dried. The surgical site should be cleaned
beforehand with PVI scrub solution.
5
– Wound antisepsis
Apply 10% solution to small superficial wounds.
For large wounds and burns, wound irrigation, etc., dilute PVI (1/4 of 10% PVI and 3/4 of
0.9% NaCl or sterile water) then rinse with 0.9% NaCl or sterile water.
– Mouth washes (in adults)
Dilute 1 or 2 teaspoons of 10% solution in 200 ml of water. Rinse around the mouth, do not
swallow, spit out, repeat. Use twice daily.

– Do not use with other antiseptics such as chlorhexidine-cetrimide (incompatibility) or
mercury compounds (risk of necrosis).
– Do not use in preterm neonates and neonates < 1.5 kg.
– Due to the risk of transcutaneous resorption of iodine, do not use repeatedly nor on large
areas, especially in pregnant and lactating women and infants < 1 month.
– May cause: local skin reactions; exceptionally, allergic reactions.
Remarks
– The antiseptic effect of PVI begins after 30 seconds of contact. However, a minimum contact
time of 1 minute is recommended to eliminate bacteria.
– Storage: below 30ºC –
Once the bottle has been opened, solution keeps 30 days.
275
POLYVIDONE IODINE = POVIDONE IODINE = PVI
scrub solution (Videne scrub®, Betadine scrub®…)
Therapeutic action
– Antiseptic
Indications
– Antiseptic hand wash and surgical hand antisepsis
– Preoperative skin preparation (patient preoperative showering, antiseptic cleansing of the
surgical site)
– Cleansing of contaminated wounds
Presentation
– 7.5% scrub solution. Also comes in 4% scrub solution.
Use
– Antiseptic hand wash
Wet hands; pour 5 ml of solution; rub hands for 1 min; rinse thoroughly; dry with a clean
towel.
– Surgical hand antisepsis
There are different protocols, for information:
Wet hands and forearms; spread 5 ml of solution on hands and forearms and rub for 1 or
2 min (i.e. 30 seconds or 1 min for each side); brush the nails of each hand for 30 seconds;
rinse.
Spread again 5 ml of solution on hands and forearms and rub for 2 min; rinse thoroughly;
dry with a sterile towel.
– Patient preoperative showering
Wet the whole body including hair; apply the solution and rub until the foam is white, start
at the head and move down, finishing with the feet. Pay special attention to hair, armpit,
hands, perineum, genitals and toes. Leave in contact a few minutes and rinse. Dry with a
clean towel; put on clean clothes.
– Antiseptic cleansing of surgical site
Rub for 1 min the surgical site, using sterile gauze soaked with sterile water and solution;
rinse with sterile water; dry with sterile gauze.
– Cleansing of contaminated wounds
Prepare a diluted solution:
With 7.5% solution: 1 part of solution + 4 parts of sterile 0.9% NaCl or water
With 4% solution: 1 part of solution + 2 parts of sterile 0.9% NaCl or water
Clean the wound; rinse thoroughly.

– Do not use with others antiseptics such as chlorhexidine-cetrimide (incompatibility) or
mercury compounds (risk of necrosis). Given the possible interactions between different
groups of antiseptics, PVI scrub solution must only be used with products of the same
group (i.e. PVI aqueous or alcoholic solutions).
– Do not use in preterm neonates and neonates < 1.5 kg (use ordinary soap).
– May cause: local skin reactions (contact dermatitis); exceptionally: allergic reactions.
– Pregnancy and breast-feeding: no contra-indication for brief application; no prolonged use.
Remarks
– For preoperative skin preparation, cleansing of the surgical site is followed by the application
of 10% PVI solution.
– Storage: below 25ºC –
276
POTASSIUM PERMANGANATE
The use of this drug is not recommended because of

frequent mistakes in dilution when using crystals or
solutions, and the risk of ingestion when using tablets.
Therapeutic action
– Weak antiseptic
Indications
– Cleansing of wounds, ulcers, abscesses
– Treatment of oozing eczema
Presentation
– 0.25 g, 0.40 g and 0.50 g tablets to be dissolved before use
– Crystals to be dissolved before use
– 0.1% concentrated aqueous solution to be diluted before use
Preparation and use

– Prepare a 0.01% solution with clear water, boiled a few minutes and cooled. The concen-
tration must be precise:
• if it is too low: ineffective
• if it is too high: caustic
5
Tablets: one 0.25 g tablet in 2.5 litres of water or one 0.40 g tablet in 4 litres of water or one
0.50 g tablet in 5 litres of water
0.1% concentrated aqueous solution: dilution 1:10
Crystals: 100 mg in 1 litre of water. Use scales to weigh the crystals in order to obtain the
correct concentration.
– Use as wet dressings and baths.

– Do not insert into vagina (risk of haemorrhage, perforation, peritonitis).
– May cause: irritation and dryness of skin in the event of repeated applications.
– Do not store permanganate tablets near oral tablets.
– NEVER SWALLOW. Ingestion may cause: nausea, vomiting, gastrointestinal damages (oedema,
burns, haemorrhage); cardiovascular depression, etc.
– Handle crystals, tablets and concentrated solutions with caution: risk of burns (wear
gloves); risk of explosion when brought into contact with readily oxidisable substances.
– In the event of product entering the eye, rinse with plenty of water for 15 minutes.
Remarks
– Storage:
• Dry product: in a cool place, in airtight containers – –
• 0.01% solution diluted for use: do not store, prepare just before use.
277
SILVER SULFADIAZINE
(Dermazin®, Flamazine®, Sicazine®…)
Therapeutic action
– Antibacterial (group of sulfonamides)
Indications
– Prophylaxis and treatment of infections of burns (except superficial, first-degree burns)
– Treatment of infections of leg ulcers and bed sores
Presentation
– 1% sterile cream, tube or jar
Use
– Clean the wound then apply a 3 to 5 mm layer of silver sulfadiazine cream to the wound
once daily and cover with sterile compresses.
Duration
– Until satisfactory healing has occurred.
– For burns that require skin grafting: until skin graft is performed.

– Do not use:
• in patients with hypersensitivity to sulfonamides.
• in infants less than one month.
– Do not apply other topical treatments to wounds where silver sulfadiazine is applied.
– May cause:
• skin reactions,
• when applied to a large burned area: systemic absorption with risk of adverse effects
related to sulfonamides (haematologic disorders, gastrointestinal disturbances, etc.).
– Pregnancy: avoid if possible during the last month of pregnancy
Remarks
Close the tube or the jar properly after opening to avoid contamination and exposure to light.
278
SODIUM DICHLOROISOCYANURATE = NADCC
Therapeutic action
– Antiseptic and disinfectant (chlorine-releasing compound)
Indications
– Antisepsis of wounds (only if the formulation can be used for this purpose)
– Disinfection of medical devices, instruments, linen, floors and surfaces
Presentation
– 1.67 g NaDCC effervescent tablet, releasing 1 g available chlorine when dissolved in water.
Also comes in different strengths and in granules and powder.
– Some formulations used for disinfecting floors contain additives (detergents, colouring,
etc.) and cannot be used on wounds. Check label or leaflet.
Preparation and use

– Antisepsis of wounds
0.1% available chlorine solution (1000 ppm): 1 tablet of 1 g available chlorine per litre
Use in wet dressing, irrigation or bath. For prolonged use, protect the healthy skin around
the wound with vaseline.
– Pre-disinfection of soiled instruments
Immediately after use, soak instruments for 15 minutes, then clean instruments.
– Disinfection of clean instruments
5
Soak previously cleaned instruments for 20 minutes, rinse thoroughly and dry.
– Disinfection of linen
Soak for 15 minutes, rinse thoroughly (at least 3 times).
– General disinfection (surfaces, floors, sinks, equipment, etc.): see Chlorine-release compounds and
the appendix Antiseptics and disinfectants.
Precautions
– Prepare solutions with cold water, in non metallic containers.
– NaDCC can corrode metal. The risk is limited for good quality stainless steel instruments
if concentration, contact time (20 minutes maximum) and thorough rinsing recommendations
are respected.
– For disinfection of linen: use only for white cotton or linen (risk of discolouration).
– Do not expose the product to flames. Do not incinerate.
– DO NOT SWALLOW. Do not store NaDCC tablets near oral tablets.
– Avoid inhaling vapours and dust when opening or handling the containers.
– Do not mix with acid solutions such as urine, etc. (release of toxic chlorine gas) and detergents.
Remarks
– Some formulations can be used for the disinfection of drinking water (Aquatabs®, etc.).
Follow manufacturer's instructions.
– NaDCC is also called sodium troclosene, sodium dichloro-s-triazinetrione.
– Storage: in airtight container, protected from light, heat and humidity, in a well ventilated
room. –
279
TETRACYCLINE dermal ointment
The use of antibacterial ointments is not recom-

mended: local applications of antibacterials that
are also used orally increase the risk of selecting
resistant strains of bacteria.
Therapeutic action
– Antibacterial
Indications
– No indications.
– Regular washing with antiseptic is often enough to treat a skin infection. If this fails, use
oral antibiotics rather than local antibiotics.
Presentation
– 3% tetracycline ointment, tube or jar

– May cause: eczema, photosensitivity.
– In the event of eye infection, do not apply dermal ointment to the eyes. Use only tetracycline
eye ointment.
Remarks
Do not use after expiry date.
280
TETRACYCLINE eye ointment
Therapeutic action
– Antibacterial
Indications
– Conjunctivitis
– Trachoma (by preference use oral azithromycin for this indication)
– Prevention of chlamydial and gonococcal neonatal conjunctivitis
Presentation
– 1% ointment, tube
Dosage and duration

– Wash the eyes with boiled and cooled water before each application. Use sterile sodium
chloride 0.9% for newborns.
– Apply tetracycline 1% into the conjunctival sac of both eyes:
• Conjunctivitis: 2 applications/day for 7 days
• Trachoma: 2 applications/day for 6 weeks
• Prevention of neonatal conjunctivitis: one single application immediately after birth
5
– Do not use in patients with hypersensitivity to tetracyclines.
– May cause allergic reactions; stop treatment in the event of serious reaction.
Remarks
– Tetracycline eye ointment replaces silver nitrate 1% eye drops for the prevention of
neonatal conjunctivitis.
– For the treatment of trachoma, azithromycin as single dose is as effective as a 6-week course
of tetracycline ointment.
– Gonococcal neonatal conjunctivitis must be treated systemically with ceftriaxone IM
(125 mg as a single dose). When systemic treatment cannot be given immediately, apply
tetracycline eye ointment to both eyes every hour until ceftriaxone is available.
– Oxytetracycline (Terramycin®) and chlortetracycline (Aureomycin®) are used in the same
way as tetracycline.
– In the event of eye infection, use only eye ointment; dermal ointment must never be
applied to the eyes.
Do not use after expiry date.
281
ZINC OXIDE ointment
Therapeutic action
– Skin protector
Indications
– Dermatosis of kwashiorkor
– Nappy rash
– Eczema
– First-degree burns
– Protection of healthy skin when caustic products such as podophyllum resin or podophyllo-
toxin are to be applied
Presentation
– 10% zinc oxide ointment, tube or jar
Dosage
– 1 to 3 applications/day
Duration

– Clean the skin before applying the ointment.
– Do not apply to exudative and/or superinfected lesions.
– Breast-feeding: no contra-indication, do not apply on breasts
Remarks
Once the ointment has been exposed to a high temperature the active ingredients are no longer
evenly distributed: the ointment must be homogenized before using.
282
Part two
1. Organisation and management of a pharmacy 285
2. Drug quality and storage 297
3. Prescription, cost, compliance 301
4. Use of antibacterials 305
5. Antiseptics and disinfectants 311
6. WHO list of essential medicines 317
7. Main references 351
8. Alphabetical index 352

Organisation and management of a pharmacy
Organisation and management of

a pharmacy
Preliminary information
Layout of a pharmacy
Management of a pharmacy
Organisation and rigorous management of the pharmacy are crucial in all health
facilities in order to:
– maintain a permanent stock of essential medicines and supplies of quality;
– reduce costs;
– save time and optimise the work of the staff;
– facilitate management and continuous consumption evaluation.
In any case, national pharmaceutical policies and regulations must be taken into
account when implementing pharmaceutical activities.
Preliminary information
Drug designation
All active ingredients have an international non-proprietary name (INN). Drugs are
designated by their INN in all standardised lists. The INN should also be used in
standard therapeutic regimens and management documents, in order to avoid
confusion, since drugs are sold under their INN or a variety of brand names,
depending on the manufacturer (e.g. ampicillin may be sold as Britapen®,
Penbritin®, Pentrexyl®, Totapen®).
Generic drugs are copies of drugs whose patents have expired. They can therefore be
made by any pharmaceutical laboratory and are most often sold under their INN or
occasionally under a new brand name.
285
Selection of essential medicines

Most countries have a national list of essential medicines. If there is no national list,
refer to the latest WHO list.
The use of such a list presents several advantages:
– it simplifies supply and reduces costs: most drugs on the WHO list are available in
generic forms at affordable prices;
– it facilitates co-ordination of international aid and obtains approval from
organisations which subsidise projects (United Nations, European Union, etc.).
The list of selected drugs is drawn in accordance with pre-established standardised
therapeutic regimens. This offers two major advantages:
– better treatments due to more rational use of a restricted number of essential
drugs;
– economic and administrative improvements concerning purchasing, storage,
distribution and control.
Proposing the same drug in many different strengths or forms should be avoided. In
most cases, one form/strength for adults and one paediatric form/strength are
sufficient. This facilitates management and avoids confusion in prescriptions.
At times, local prescription usages should be taken into account, e.g. in French-
speaking Africa, 500 mg aspirin tablets are used; in English-speaking Africa, 300 mg
tablets.
Note: medical supplies (dressing, injections, sutures, etc.) should be limited to
essentials and the object of a standardised list.
Drug classification
In the WHO list, drugs are classified according to their therapeutic action. This
classification presents a certain pedagogical advantage but cannot be used as the
basis of a storage arrangement system (e.g. a drug may appear in several
classes).
Médecins Sans Frontières recommends a storage arrangement system according to
the route of administration and in alphabetical order.
Drugs are divided into 6 classes and listed in alphabetical order within each class:
– oral drugs
– injectable drugs
– infusion fluids
– vaccines, immunoglobulins and antisera
– drugs for external use and antiseptics
– disinfectants
This classification should be used at every level of a management system (order
forms, stock cards, inventory lists, etc.) in order to facilitate all procedures.
Levels of use
More limited lists should be established according to the level of health structures
and competencies of prescribers. Restricted lists and the designation of prescription
286
and distribution levels should be adapted to the terminology and context of

each country.
Quantitative evaluation of needs when launching a programme

Once standard therapeutic regimens and lists of drugs and supplies have been
established, it is possible to calculate the respective quantities of each product
needed from the expected number of patients and from a breakdown of
diseases.
Several methods have been suggested (see "Estimating drug requirements", WHO).
Quantities calculated may differ from those corresponding to true needs or demands
(this can be the case when the number of consultations increases or when prescribers
do not respect proposed therapeutic regimens).
In an emergency situation (especially with displaced population), the Emergency
Health Kit, developed in collaboration with the WHO, UNHCR, MSF, etc., is designed
to meet the care needs of a displaced population of 10,000 people for 3 months.
Afterwards, specific local needs should be evaluated in order to establish a suitable
supply.
Routine evaluation of needs allows verification of how well prescription schemes are
respected and prevents possible stock ruptures.
Layout of a pharmacy
Whether constructing a building, converting an existing building, central warehouse
or health facility pharmacy, the objectives are the same only the means differ.
Premises
Functional premises should be designed in order to assure:
– the safe keeping of stocks;
– correct storage of drugs and supplies;
– rational and easy management.
Characteristics of a warehouse
Dimensions of warehouse are determined by storage needs, which depend on:
– the number of drugs and supplies to be stocked;
– the number and activities of facilities;
– distribution and receiving frequency: the lesser the frequency the greater the
volume needed, thus the greater the space needed.
287
It is better to have too much space than not enough: a cramped warehouse is difficult
to work, and any increases in stock or activity are also difficult. For 1 m2 of storage
space count 3 m2 of floor space.
Security of stocks requires solid doors, locks, windows and ceilings.
Correct preservation of drugs depends on temperatures and humidity, conditions
that are very often difficult to control in tropical countries.
– Correct ventilation is necessary; fans mainly reduce humidity, air-conditioning
reduces heat and humidity.
– A ceiling underneath the roof is essential in order to reduce the ambient
temperature; the space between the ceiling and roof must be ventilated.
– Windows should be shaded to avoid exposure of drugs to direct sunlight.
– Floors should be covered in cement (slightly inclined, if possible, to facilitate
maintenance).
Interior layout of a warehouse

The organisation should be logical and correspond to the circuit "reception, storage,
distribution".
Shelves and pallets

Solid and stable shelves are indispensable. In tropical countries where termites attack
wood, metal structures are preferred. As they can be dismantled, it is easy to adjust
spaces between shelves and alleys to better accommodate goods to be stored.
Space between shelves and walls improves ventilation.
No products or packaging, even large-sized, should be stored on the floor, but on
pallets which permit air circulation and protect against humidity.
Stocking areas
Within a warehouse, or close by, stocking areas should be provided.
– Receiving area: for stocking parcels before unpacking and checking freight and
quality control.
– Distribution area: for stocking peripheral orders before distribution. Each
destination should have a designated area where parcels may be stocked before
distribution.
Receiving and distribution areas should be near access doors in order to facilitate
handling.
It is also recommended to plan a stocking area for empty boxes, used to prepare
orders for peripheral health facilities.
288
Workspace(s)
A workspace should be set up in order to verify deliveries and prepare orders.
Desk
For the person in charge of the pharmacy, a desk near a light source should be set up
for administrative work and for keeping documents.
Examples of pharmacy layout
Schema 1
Schema 2
The arrangement of shelves, tables or other furniture, varies according to the layout of
the premises.
For larger stocks or central pharmacies, use several rooms and apply the same
principles by adapting layouts to needs: administration, cold room, refrigerators, etc.
289
Arrangement of drugs and supplies

Storage of drugs not requiring a cold chain
Drugs are arranged according to the classification adopted:
– oral drugs
– injectable drugs
– infusions
– drugs for external use and antiseptics
– disinfectants
In each category of products (oral, injectable, etc.) are classified alphabetically.
Each product should have a designated place, well identified by a fixed label
indicating the INN, form and strength. By attributing a specific place to each item it
is possible to immediately see the quantity available and to react quickly to avoid
stock shortages.
Provide for sufficient space between and for each product.
Clearly indicate expiry dates on boxes (large marker). Arrange products with the
earliest expiry date at the front of the shelves and those with the latest at the back.
This is essential to avoid drugs expiring during storage.
So that persons not familiar with the INN system can find their way around in case
of emergency or replacement, a list of commercial names and the corresponding INN
can be put up, e.g.:
Bactrim® see cotrimoxazole
Clamoxyl® see amoxicillin
Flagyl® see metronidazole
Valium® see diazepam
Storage of controlled substances

Narcotics and other controlled substances should be placed under lock and key.
Storage of products requiring a cold chain

Products needing a cold chain should be stored in a refrigerator (between 2–8°C):
vaccines, immunoglobulins, serums, insulin, ergometrine, oxytocin, dinoprostone,
certain laboratory tests, etc.
Storing medical materials/supplies

Given the diversity of items, do not to use alphabetical ordering, but group
articles by category: injections, dressings, sutures, reagents and laboratory
material, etc.
Storing bulky materials

Put a few boxes in their normal place and, on a label, indicate where the rest of the
stock is kept. Do not disperse the rest of the stock in several places.
290
– The storage arrangement should allow a ‘visual stock check’:

• It should be possible to quickly count the number of boxes for each product
and evaluate, in a few minutes, the number of weeks or months that can be
covered with the stock available.
• An empty space behind a label immediately shows that the product is out of
stock.
– Only a few hours should be needed to perform a complete inventory.
Management of a pharmacy
Organisation of activities
The management of the pharmacy should be entrusted to a single person having
received adequate training. This person is the only person possessing keys to the
pharmacy and narcotics cupboard and is helped by one or more assistants,
depending on the workload.
Tasks and responsibilities should be clearly defined. One assistant should be able to
replace the person in charge if necessary.
It is important to draw up a work calendar (orders, distributions, inventories,
management of expired drugs, etc.) in order to spread out the workload.
Stock management
Stock cards
The stock card is the principle instrument for stock control. A stock card is
established for each product (drugs and supplies) and updated at each movement.
Stock cards are used to:
– identify all stock movements: in and out;
– determine at any moment the theoretical level of stocks;
– follow–up the consumption of different facilities;
– correctly plan and prepare orders;
– determine losses (differences between theoretical stock and actual stock).
The following should be noted on stock cards:
– the INN, form and strength;
– all movements (in, out, origin, destination, loss due to expiration, damages) and
dates;
– inventories and dates.
291
The following may also be included:

– average monthly consumption;
– stock levels: buffer stock, running stock;
– other stock areas for a product;
– unit price;
– current orders and dates.
Quantities in and out are always recorded in units (e.g. 5,000 tablets, 80 ampoules) and
never in number of boxes.
Write a single operation per line, even if several operations take place the same day.
Example of a stock card
Item: AMOXICILLIN Strength/Form: 250 mg, tab
Code: Packaging unit: box 1,000 tab
AMC = 9,000
Date Origin/Destination IN OUT STOCK Remarks/Signature
01/02/09 Brought forward 20,000

(previous stock card)
01/02/09 Central warehouse 80,000 100,000 Exp. 08/2011
02/02/09 Health centre 1 5,000 95,000
06/02/09 Health centre 2 2,000 93,000
06/02/09 Health centre 3 2,000 91,000
10,000 (03/09) 11,000 (01/10)

01/03/09 Inventory 91,000 70,000 (08/11)
02/03/09 Health centre 1 6,000 85,000
05/03/09 Health centre 2 2,000 83,000
05/03/09 Health centre 3 1,000 82,000
31/03/09 Expired March 09 1,000 81,000 Exp. 03/2009
01/04/09 Health centre 1 6,000 75,000
06/02/09 Health centre 2 1,000 74,000
06/02/09 Health centre 3 2,000 72,000
Note: stock cards are always required, even when computer assisted stock
management is used.
292
Quantities to retain and order (stock level)

Average monthly consumption (AMC)
Calculated from outgoing stock recorded on stock cards: add the quantities of several
months (3, 6 or 12) in the out column and divide the total by the number of months
considered.
Running stock = consumption between two supply deliveries

Running stock corresponds to the quantity of each drug consumed between two
supply deliveries (e.g. if deliveries are quarterly, running stock = AMC x 3).
Buffer stock
This stock is planned to compensate for possible late deliveries, losses, and increases
in consumption. It is calculated according to the delivery delay of orders.
Buffer stock quantities are generally evaluated as half of the consumption during the
period between two deliveries. It depends on risks that a programme may run: stock
ruptures or drug expiration in specific situations (resources, seasonal supply
problems, etc.).
For example, if the delivery delay is two months, the buffer stock corresponds to the
quantity consumed in one month.
Quantities to be ordered
Quantities to order are based on data from stock cards:
– actual stock level (inventory) on the day of the order
– running stock
– buffer stock
– delay period between order and delivery
– orders not yet delivered
Order = (running stock + buffer stock + probable consumption during delivery
delay) – (inventory + orders not yet delivered).
Order forms
Concerning orders from peripheral facilities to the central pharmacy, it is
recommended to use pre-printed order forms which indicate the INN, form (tablet,
capsule, vial, ampoule, etc.) and strength.
The following may also be included:
– stock levels,
– AMC.
Orders should be in triplicate, dated and countersigned by persons in charge of

health structures. Two copies are sent to the supplier: one serves as a way bill and
may also be used for invoicing, the second stays with the supplier. The third copy
stays at the health facility.
293
E.g.: health facility order form, 6-month supply period, minimum stock of 3 months (2 month
delivery delay + 1 month buffer stock)
Health structure: Beboro

Head of structure: Jack Pinel, Ph
Date: 26.06.09 Signature: XXX
ORAL DRUGS
Price Stock Monthly Qty Qty

NAME PREPARATION consump. ordered delivered
ACETAZOLAMIDE tab 250 mg 0.14 — — —
ACETYLSALICYLIC ACID tab 300 mg 0.01 55,000 10,000 5,000
ASCORBIC ACID tab 250 mg 0.04 — — —
ALUMINIUM HYDROXYDE tab 500 mg 0.03 15,000 6,000 21,000
AMOXICILLIN tab 250 mg 0.18 16,000 4,000 8,000
CHLORAMPHENICOL tab 250 mg 0.09 3,000 500 —
Receiving orders
All orders should be accompanied by a way bill or invoice and packing list.
On reception, the number of parcels should be checked, then their contents should be
verified:
– ensure that products delivered correspond to products ordered, and that the
quantities conform to those on the packing list;
– packaging, labelling and expiry dates of each product should be checked, as well
as the aspect of the product;
– look for special storage conditions (cold chain).
The supplier should be notified of all irregularities.
Then, drugs and material are integrated into stocks at their designated places.
Incoming quantities are recorded on stock cards.
Way bills, invoices and packing lists are to be classed with orders in an "orders" file
and kept for 3 years or more according to current regulations.
294
Inventory
An inventory of current stock quantities and expiry dates should be done before each
order.
Stock cards give a theoretical figure of stock quantities, but actual quantities of each
product should be verified (physical stock). Differences may arise due to errors in
recording or due theft. These differences should be clarified.
An inventory may only be easily done if the pharmacy is correctly arranged. It is an
indispensable task.
During an inventory there should be no stock movements, i.e. incoming or outgoing
stock.
Distribution
Distribution to health facilities
Each health facility sends the central warehouse two copies of the order form.
On both copies, actual quantities supplied by the central warehouse are recorded in
the “Qty delivered” column.
One on these copies is sent with the delivery.
After verifying that all products have been correctly recorded on their respective
stock cards, the second copy is placed in a file established for health facility. The exit
date on the stock card should be the same as the date on the order form.
Dispensing drugs to patients

Drug packaging should be presentable. Use plastic bags that can be resealed by
pressure (Minigrip®).
Prepare labels for each drug, clearly showing:
– the name of the drug (INN), form and strength;
– the dosage written out in full or in symbols.
Put the number of tablets corresponding to a complete treatment and the label into
the bag.
In busy centres it is better to have two people responsible for dispensing drugs in
order to double check prescription deliveries; the first collects the drugs prescribed,
the second verifies and gives them to patients with all necessary explanations,
slightly away from other patients.
So that patients correctly follow treatment, adequate explanations should be given:
– how to take the drug,
– for how long,
– possible adverse effects (e.g. drowsiness caused by anti-histamines),
– precautions to be taken (e.g. avoid alcohol with metronidazole).
Persons dispensing drugs should be able to give patients the information they need.
Interpreters are needed if several languages exist in the same region.
295
Donations of recuperated medicines and medical samples

It is not recommended to solicit or accept supplies coming from collections of drugs
recuperated from consumers in industrialised countries, or free samples distributed
by manufacturers.
They are very often specialised drugs unknown to prescribers and unsuitable for
local pathologies. The multiplication of different drugs supplied interfere with the
implementation of standardised therapeutic regimens and makes any form of
management impossible.
296
Drug quality and storage
Quality standards
Storage conditions
Deterioration
Expiration
Drug quality influences treatment efficacy and safety. Quality depends on correct
manufacturing and storage: high-quality drugs are available when using rational
buying procedures and when suppliers are reliable. It is also essential to assure
optimum transportation and storage conditions.
Quality standards
Each drug is characterised by particular norms written in pharmacopoeia or files
presented by manufacturers and recognised by competent authorities in each
country. These norms concern aspects (colour, odour, etc.), physicochemical
properties, analysis procedures, shelf life and storage conditions.
Analysis certificates guarantee that products from one batch (products from the
same production cycle) conform to official quality standards in the country of
manufacture. These certificates are provided for each product by manufacturers.
Every unit (box and bottle) should be clearly labelled; each label should clearly
indicate the:
– INN,
– form and dosage,
– number of units (tablets, ampoule, etc.) or the volume (syrup, etc.),
– name and address of the manufacturer,
– batch number,
– expiry date.
Storage conditions
Stability of drugs depends on both environmental factors such as temperature, air,
light and humidity, and drug-related factors such as the active ingredient itself, the
dosage form (tablet, solution, etc.) and the manufacturing process. It is therefore
297
necessary to respect storage instructions given in this guide or by manufacturers (on

notices and labels) if the recommendations are not identical.
Temperature
The temperature in the store should not be above 30°C.
Storage temperatures are defined by European pharmacopoeia as follows:
freezer - 15 to 0°C
refrigerator + 2 to + 8°C
cool + 8 to + 15°C
ambient temperature + 15 to + 30°C
During transit and transportation temperatures may attain 50 to 60°C inside vehicles,
shipping containers or on docks and, in this case, shelf life and expiry dates may no
longer be guaranteed.
Freezing may be detrimental, particularly for solutions, leading to the precipitation
of active ingredients or the shattering of ampoules.
Vaccines, immunoglobulins and antisera are products that are sensitive to heat and
light. Even though new techniques produce vaccines that are less sensitive to heat
(called "thermostable"), they still have to be stored in the refrigerator between 2°C
and 8°C, and the cold chain must be strictly respected during transport.
The vaccine vials may have a heat-sensitive monitor (VVM). The square on the
monitor changes colour when exposed to heat over a period of time: if the square is
lighter than the circle, the vaccine can be used. If the square is the same colour or
darker than the circle, the vial must be destroyed.
Vials of oral polio (OPV), measles, tuberculosis (BCG), yellow fever, hepatitis B,
tetanus (TT) and diphtheria-tetanus-pertussis (DTP) vaccines may have a VVM.
Air and humidity

In a store, relative humidity should not be above 65% (there are several devices for
humidity measurement).
Air is a factor of deterioration due to its content of oxygen and humidity. All
containers should remain closed. In airtight and opaque containers (hospital type),
drugs are protected against air and light. Opening containers long before the use of
drugs should be avoided.
Patients should be informed that tablets should not be removed from blisters until
immediately before administration.
Light
Drugs should be protected from light, particularly solutions. Parenteral forms should
be preserved in their packaging. Coloured glass may give illusory protection against
light.
298
Deterioration
It is important to be familiar with the normal aspects of each drug (colour, odour,
solubility, consistency) in order to detect changes, which may indicate its
deterioration. It is important to know that deterioration does not always lead to a
detectable external modification.
The principal consequence of deterioration is a reduction of therapeutic activity, which
leads to more or less grave consequences for the individual and/or community.
For example, the use of expired antibacterials does not cure an infection and also
favours the emergence of resistant strains.
It is not recommended to compensate for a possible reduction of activity by a
random increase in the usual dose, as there is a real danger of overdose when using
toxic drugs.
In time, certain drugs undergo a deterioration leading to the development of
substances much more dangerous, thus an increase in toxicity. Tetracycline is the
principal example: the pale, yellow powder becomes brownish and viscous, its use
therefore being dangerous even if before the expiry date.
An increase in allergen strength has been observed in certain drugs such as penicillins
and cephalosporins.
Suppositories, pessaries, creams and ointments that have been melted under heat
should not be used. The active ingredient is no longer distributed in a homogenous
manner.
Oral rehydration salts may be used as long as they keep their aspect of white
powder. Humidity transforms them into a compact mass, more or less brownish and
insoluble. They are therefore unfit for consumption, whatever their expiry date.
Expiration
Drugs deteriorate progressively and according to various processes, even if stored in

adequate conditions. In most countries, regulations impose an obligation on
manufacturers to study the stability of their products in standardised conditions and
to guarantee a minimum shelf life period. The expiry date indicated by
manufacturers designates the date up to and including which the therapeutic effect
remains unchanged (at least 90% of the active ingredient should be present and with
no substantial increase in toxicity).
The expiry date indicated on the label is based on the stability of the drug in its
original and closed container. Shelf life period currently guaranteed is from 3 to
5 years. Less stable substances are only guaranteed for 1 or 2 years.
The expiry date should be indicated on the label with storage instructions.
299
Expired drugs
Expiry dates are to be respected due to legal obligations and considerations of
therapeutic responsibility.
In cases where the only available drugs have expired, a doctor may be led to take on
the responsibility of using these drugs.
It is evident that a drug does not become unfit for consumption the day after its
expiry date. If a product has been stored in adequate conditions (protected from
humidity and light, packaging intact and at a medium temperature) and if
modification of aspects or solubility have not been detected, it is often preferable to
use the expired drug than to leave a gravely ill patient without treatment.
Expiry dates for drugs that require very precise dosage should be strictly respected
due to a risk of under-dosage. This is the case for cardiotonic and antiepilectic drugs,
and for drugs that risk becoming toxic, such as cyclines.
Destruction of expired or unusable drugs and material

It is dangerous to throw out expired or unusable drugs or to bury them without
precaution. For more information about destruction of drugs and material see
"Interagency Guidelines For Safe Disposal of Unwanted Pharmaceuticals in and after
emergencies", WHO/99.2.
300
Prescription, cost, compliance

SOME SUGGESTIONS FOR
Reducing risks - Reducing costs - Facilitating compliance
Limiting the use of injectable drugs

Limiting the use of syrups and oral supensions
Studying the choice of treatment regimens
Considering non-essential drugs and placebos
It is possible to promote a more rational use of medicines, as much for safety as for
cost, by a judicious choice of therapeutic regimens and the resulting lists of
medicines.
Limiting the use of injectable drugs

Numerous patients demand treatment with injectable drugs, which they imagine to
be more effective. Certain prescribers also believe that injections and infusions are
more technical acts and thus increase their credibility.
Parenteral treatment is always more costly than oral treatment. The price of the drug
itself is higher for an equal dose of active ingredient. It requires costly disposable
material. It exposes patients to complications due to poorly tolerated products
(abscesses, necrosis due to IM quinine injections or antibacterials, etc.) or badly
performed injection techniques (symptoms of overdose after a IV injection given too
rapidly, sciatic nerve damage, etc.). If disposable injection supplies are re-used, there
is a risk of bacterial or viral contamination (tetanus, hepatitis, HIV, etc.).
When both oral and injectable drugs are equally effective, parenteral administration
is only justified in case of emergency, digestive intolerance or when a patient is
unable to take oral medication. Oral drugs should replace injectable drugs as soon as
possible during the course of treatment.
301
Limiting the use of syrups and oral suspensions

Taking liquid drugs is often easier, especially for young children and more so if they
are sweetened or flavoured. It is, however, recommended to limit their use for
numerous reasons:
– Risk of incorrect usage

Outside of hospitals, determining the correct dosage is hazardous: spoons never
contain standard volumes (soup spoons, dessert spoons, tea spoons). Oral
suspensions should be prepared with a specified amount of clean water, and well
shaken prior to administration. There is therefore a risk of overdose or giving an
insufficient dosage.
Some oral suspensions must be kept refrigerated; their storage at room
temperature is limited to a few days, and with syrups there is a risk of
fermentation.
In numerous countries syrups are thought of as "cough medicine". Confusion
between cough mixtures and antibacterial suspensions or syrups is common.
– Economic considerations
Compared to the price of tablets or capsules, the price of syrups and oral
suspensions is considerably higher. Even using a powder for subsequent
reconstitution, the costs may be 2 to 7 times higher than an equivalent dose due
to the cost of the bottle itself and higher transportation costs due to weight and
volume.
Studying the choice of treatment regimens

The choice of a treatment regimen often influences compliance and cost. The shortest
and least divided (1 to 2 doses per day) treatments are most often recommended.
Single dose treatments are ideal, when indicated.
For the treatment of malaria, tuberculosis and HIV infection, fixed-dose
combinations (coformulated tablets) should preferably be used in order to improve
compliance.
Considering non–essential medicines and placebos

In developing countries as in industrialised countries, patients with psychosomatic
complaints are numerous. The problems that motivate their consultations may not
necessarily be remedied with a drug prescription. Is it always possible or desirable to
send these patients home without a prescription for a symptomatic drugs or
placebo? If so, what placebo should be prescribed?
302
When national drug policy is strict and allows neither the use of placebos nor non-
essential symptomatic drugs, other products are often used in an abusive manner,
such as chloroquine, aspirin, and even antibacterials.
Conversely, a placebo may take the place of an effective and needed drug. This risk is
real, but seems less frequent, which makes the introduction of placebos on a list of
essential drugs relevant. Multivitamins may present a type of harmless and
inexpensive placebo. Their composition generally corresponds to preventive
treatment of vitamin deficiency and they have no contra–indications.
Numerous non–prescription drug products (tonics, oral liver treatments presented in
ampoules) have no therapeutic value and, due to their price, cannot be used as
placebos.
303
Use of antibacterials
Possible causes of antibacterial treatment failure

Choosing an antibacterial treatment
Antibacterial combinations
Principal antibacterial groups
In peripheral health facilities, the diagnosis of an infection is based essentially on

clinical criteria, as laboratory testing (culture, isolation and identification of bacteria)
is rarely available.
The choice of treatment protocol depends on the context in which the patient is
examined:
– Dispensaries: numerous patients examined rapidly and difficult to follow. Standard
protocols should be drawn up for diagnosis and treatment of the most frequent
infections. The number of available antibacterials is limited.
– Medical centres and hospitals: the number of available antibacterials is greater,
alternatives are possible in the event of failure or intolerance to first line treatment.
Possible causes of antibacterial treatment failure

– Clinical signs that are in fact due to viral or parasitic infections
– Choice of antibacterial that penetrates poorly into infected tissues (abscess,
cerebrospinal fluid)
– Insufficient dosage and/or treatment duration
– Poor treatment compliance
– Vomiting after oral ingestion
– Drug interactions reducing absorption (e.g. simultaneous administration of
antacids)
– Inactivation of an antibacterial after mixing several drugs in the same infusion
bottle
– Use of antibacterial that has expired or that has deteriorated due to poor storage
conditions (most antibacterials become only ineffective, except expired
tetracyclines that become toxic to the kidneys)
– Bacterial resistance to the antibacterial
305
Choosing an antibacterial treatment

The table below summarises the choice of antibacterials appropriate both for their
penetration into the infected tissue and the most probable bacteria.
Other possible
Infections First choice
first-line treatments
Upper respiratory tract
infections
Tonsillitis benzathine benzylpenicillin penicillin V or amoxicillin
or erythromycin or azithromycin
(in penicillin-allergic patients only)
Diphtheria benzathine benzylpenicillin penicillin G procaine
or erythromycin
Epiglottitis ceftriaxone chloramphenicol
Sinusitis amoxicillin erythromycin
Lower respiratory tract amoxicillin ceftriaxone
infections or ampicillin + gentamicin
Acute otitis media amoxicillin erythromycin or azithromycin
(in penicillin-allergic patients only)
Intestinal infections
Typhoid fever ciprofloxacin cefixime
Shigellosis ciprofloxacin ceftriaxone
Urinary tract infections
Upper ciprofloxacin cefixime or ceftriaxone
or ampicillin + gentamicin
Lower ciprofloxacin cefixime or nitrofurantoin
Urethritis and azithromycin + cefixime doxycycline + cefixime
cervicitis or azithromycin + ceftriaxone or doxycycline + ceftriaxone
or erythromycin + cefixime
or erythromycin + ceftriaxone
Genital ulcers
Syphilis benzathine benzylpenicillin doxycycline or erythromycin
Chancroid azithromycin ceftriaxone or ciprofloxacin
or erythromycin
Upper genital tract
infections
Sexually transmitted cefixime + doxycycline ceftriaxone or spectinomycin
or erythromycin + metronidazole + doxycycline or erythromycin
+ metronidazole
Post-partum amoxicillin/clavulanic acid ampicillin + gentamicin
+ gentamicin + metronidazole
Meningococcal oily chloramphenicol ampicillin
meningitis or ceftriaxone
Eye infections
Bacterial conjunctivitis tetracycline eye ointment chloramphenicol eye drops
Trachoma azithromycin erythromycin
or tetracycline eye ointment
306
Antibacterial combinations
Combining several antibacterials is only justified in severe infections (brucellosis,

leprosy, tuberculosis, pelvic inflammatory disease, etc.).
Certain combinations should be avoided, as the action of one antibacterial can
neutralise the action of another antibacterial administered simultaneously (e.g.
penicillins and tetracyclines).
Principal antibacterial groups
Penicillin and derivatives

• Amoxicillin and ampicillin
• Benzylpenicillin (penicillin G)
• Benzathine benzylpenicillin (penicillin G benzathine)
• Procaine benzylpenicillin with or without benzylpenicillin
• Cloxacillin
• Phenoxymethylpenicillin (penicillin V)
Fast-acting penicillins
– Benzylpenicillin should be reserved for treating severe acute infections. Due to
rapid elimination, an injection every 4 to 6 hours is required, which is impossible if
the patient is not hospitalised.
– Oral phenoxymethylpenicillin is used in the treatment of tonsillitis.
Long-acting penicillins
– Benzathine benzylpenicillin has a concentration that slowly increases in the
24 hours following the injection. It remains active for 15 to 20 days. Due to its
delayed action and low concentration in the blood, its use is restricted to infections
susceptible to penicillin that evolve slowly (e.g syphilis). Its use is contra-indicated
in acute infections. It is only administered by IM route.
– Procaine benzylpenicillin has the advantage of being injected only once daily. It
acts rapidly (45 to 60 minutes) and is only administered by IM route.
– The combination of procaine benzylpenicillin and benzylpenicillin is also known
as fortified penicillin procaine (PPF). It acts within 15 to 30 minutes after injection,
thus more rapidly than procaine benzylpenicillin alone due to the presence of
benzylpenicillin. It is only administered by IM route.
Penicillin derivatives
– Amoxicillin and ampicillin are broad-spectrum antibacterials with good tissue
penetration and are therefore used for many infections. They are frequently used
in pregnant women, for whom other antibacterials may be contra-indicated.
307
Amoxicillin is better absorbed through the intestinal tract than ampicillin and
therefore requires lower oral doses.
For oral administration, use amoxicillin rather than ampicillin. On the other hand,
injectable ampicillin is preferable to injectable amoxicillin. Injectable forms should
be reserved for severe infections only.
– Cloxacillin is a narrow-spectrum antibacterial, essentially limited to treatment of
staphylococcal infections, most of which have become resistant to penicillin.
Cephalosporins
• Cefixime
• Ceftriaxone
Cefixime and ceftriaxone are third-generation cephalosporins particularly active
against Gram-negative bacteria. These are an alternative to fluoroquinolones,
especially in children and pregnant women.
Macrolides
• Erythromycin
• Azithromycin
– Erythromycin is reserved for penicillin-allergic patients.
– Azithromycin is effective as a single-dose for the treatment of Chlamydia
trachomatis infections, due to its prolonged half-life.
Chloramphenicols
• Chloramphenicol
• Long-acting oily chloramphenicol
– Chloramphenicol is a broad-spectrum antibacterial, effective against numerous
infections. Due to its effectiveness and low cost, it is still widely used. However,
due to its potential haematotoxicity, its use should be restricted to severe infections
when other less toxic antibacterials are not effective or are contra-indicated.
Oral treatment is more effective than parenteral treatment: blood and tissue
concentrations are higher when chloramphenicol is given orally.
– Oily chloramphenicol is reserved for meningococcal meningitis epidemics.
Sulphonamides
• Sulfadiazine
• Sulfadoxine
• Cotrimoxazole (sulfamethoxazole/trimethoprim)
Simple sulphonamides
– Sulfadiazine in combination with pyrimethamine is the first-line treatment of
toxoplasmosis.
– Sulfadoxine is a long-acting sulphonamide (approximately one week). Due to the
existence of resistant strains it should not be used for meningitis or cholera
epidemics.
308
– The use of non-absorbable sulphonamides (sulfaguanidine, etc.) is not

recommended, as they are ineffective in the majority of intestinal bacterial
infections.
Combined sulphonamides
– The combination of sulfamethoxazole and trimethoprim (cotrimoxazole) benefits
from the synergic effect of both active ingredients. Indications are more numerous
than for sulphonamides alone. However, there are an increasing number of strains
resistant to cotrimoxazole.
Tetracyclines
• Doxycycline
• Tetracycline
– Due to the multiplication of organisms resistant to tetracyclines, their use should
be reserved for specific infections: brucellosis, cholera, relapsing fevers, typhus,
chlamydial infections and certain pneumopathies.
– Doxycycline has the advantage of being administered in a single dose for the
treatment of cholera, epidemic typhus and louse-borne relapsing fever.
Aminoglycosides
• Gentamicin
• Spectinomycin
• Streptomycin
Due to their renal and auditory toxicity, aminoglycosides should only be prescribed
for their specific indications and ensuring the monitoring of renal and auditory
function.
Quinolones
• Nalidixic acid
• Ciprofloxacin, ofloxacin, etc.
– First generation quinolones: nalidixic acid
Nalidixic acid is no longer recommended for the treatment of shigellosis. It may be
used for the treatment of cystitis, only in the absence of a better option.
– Second generation quinolones (fluoroquinolones): ciprofloxacin, ofloxacin, etc.
Fluoroquinolones have a broader antibacterial spectrum than first-generation
quinolones and have good tissular penetration. Ciprofloxacin is used as first-line
treatment in shigellosis, typhoid fever or certain urinary tract infections.
Nitrofuranes
• Nitrofurantoin
Nitrofurantoin may be prescribed in cystitis, particularly in young women, except
during the last month of pregnancy.
309
Antiseptics and disinfectants
Definition
Selection
Preparation and use of antiseptic solutions
Preparation and use of disinfectant solutions
Definition
Antiseptics are used to kill or eliminate microorganisms and/or inactivate virus on
living tissues (intact or broken skin and mucous membranes).
Disinfectants are used to kill or eliminate microorganisms and/or inactivate virus on
inanimate objects and surfaces (medical devices, instruments, equipment, walls,
floors).
Certain products are used both as an antiseptic and as a disinfectant (see specific
information for each product).
Selection
Recommended products
1) Core list
No single product can meet all the needs of a medical facility with respect to
cleaning, disinfection and antisepsis. However, use of a limited selection of products
allows greater familiarity by users with the products in question and facilitates stock
management:
– ordinary soap
– a detergent and, if available, a detergent-disinfectant for instruments and a
detergent-disinfectant for floors and surfaces
– a disinfectant: chlorine-releasing compound (e.g. NaDCC)
– an antiseptic: 10% polyvidone iodine or chlorhexidine
2) Complementary list
Other products can be used, according to the activities carried out, resources, and
options for obtaining the product, locally or otherwise:
– Ethanol and isopropanol
By virtue of its rapid action (< 30 seconds), alcohol, if available locally, is useful to
disinfect:
• intact skin, before taking a blood sample or performing an injection (except
vaccines),
• latex stoppers of drug vials.
311
Alcohol acts faster than polyvidone iodine, but its duration of action is shorter.
Alcohol can only be used on intact skin. Application to mucous membranes or
broken skin is contra-indicated, however, alcohol may be used on broken skin in
the event of accidental exposure to blood.
Alcohol is more effective at 60-70% concentration than at 90-95%.
– Alcohol-based hand rubs

Alcohol-based hand rubs (ABH) are used for hand antisepsis. Some, but not all,
ABH may also be used for surgical hand antisepsis.
Not all ABH preparations are equivalent. For example, for antiseptic hand rub,
depending on the product specifications:
• Bactericidal effect may be achieved with a single application of 30 seconds duration,
or 2 consecutive applications of 30 seconds each, or a single application of 60 seconds
duration.
• The volume of rub required per application may be 3 or 5 ml.
Thus, when purchasing locally, it is important to verify the quality of the product
and specific instructions for use (number of applications, duration of application,
and volume to be used per application).
For surgical activity, ensure that the product is suitable for use as a surgical hand
rub. Follow manufacturer’s instructions for use.
All alcohols and alcohol-based products are flammable. Precautions should be
taken during storage and use to avoid contact with a heat source (flame,
electrocautery, etc.)
– Polyvidone iodine (PVI) scrub solution

7.5% or 4% PVI scrub solution is used for antiseptic cleansing of healthy skin,
contaminated wounds and surgical site, as well as antiseptic hand wash and
surgical hand wash.
Given the possible interactions between different groups of antiseptics, antiseptic
cleansing and antisepsis should only be carried out using products from the same
class. For example, for pre-operative skin preparation, PVI scrub solution is used
for cleansing, then PVI 10% dermal solution is used for antisepsis.
– Glutaraldehyde (2% solution)

Glutaraldehyde is used for high-level disinfection of heat-sensitive items,
which cannot withstand heat sterilisation, notably endoscopes/endoscopy
equipment.
Instructions for glutaraldehyde use must be followed scrupulously: 1) two
preliminary washes of the equipment through immersion in a detergent-
disinfectant solution for instruments, followed each time by rinsing;
2) complete immersion of the equipment in a 2% glutataldehyde solution for
20 minutes; 3) thorough final rinsing, with filtered water (or sterile water for
endoscopes introduced into a sterile cavity) to eliminate any residue;
4) thorough drying with a sterile towel; 5) sterile wrapping and use within
24 hours.
312
Glutaraldehyde is available as 2% ready-to-use solution (e.g. Korsolex RTU®,

Steranios 2%®); concentrated solution that must be diluted to obtain a 2% solution
(e.g. 25% or 38.5% solutions); preparations requiring « activation » (alkalinisation)
before use, through addition of the agent provided with the product (e.g. Cidex®,
Glutrex®).
Glutaraldehyde solution is irritating to skin and mucous membranes, and releases
toxic vapours. Personnel exposed to glutaraldehyde should take precautions to
protect skin and eyes and avoid inhalation of vapours (risk of nausea, headache,
breathing disorders, rhinitis, eye irritation, dermatitis).
Glutaraldehyde solutions are flammable. Precautions should be taken during
storage and use to avoid contact with a heat source.
Non-recommended products
– Hydrogen peroxide (3% or 10 volumes) has limited efficacy as antiseptic agent but
can be useful to clean contaminated wounds. In addition, concentrated solutions
are dangerous to transport and handle.
– Mercury compounds such as phenylmercuric borate, merbromin
(Mercurochrome®), mercurobutol (Mercryl®), thimerosal (Merthiolate®,
Timerosal®) have limited efficacy, may cause serious adverse effects (toxic for
kidneys, central nervous system and digestive tract; allergies) and pollute the
environment. Their use must be abandoned.
– Hexachlorophene is toxic for the central nervous system and its efficacy is limited.
– Ether is often wrongly used as an antiseptic; it removes sticky residues of plaster.
– Eosin is a drying agent, often wrongly used as an antiseptic.
None of these products is included in the WHO list of essential medicines.
Preparation and use of antiseptic solutions

Preparation
Aqueous solutions of many antiseptics can be contaminated by pathogens (especially
Pseudomonas aeruginosa) during handling.
To avoid this, the following precautions must be taken:
– Prepare all aqueous antiseptic solutions with clean water that has been boiled for a
few minutes and cooled.
– Replace all aqueous solutions at least once a week.
– Only prepare small amounts at a time to avoid wastage and the temptation to keep
expired solutions.
– Never mix a fresh solution with a “leftover” solution.
313
– Wash bottles with hot water and leave to dry before each refill.
– Never use a cork stopper (it promotes contamination; cork inactivates certain
antiseptics such as chlorhexidine).
– Mark on the bottles:
• the name of the product
• its concentration
• the date of preparation or the date of expiry
Every medical facility should define a clear policy concerning the renewal of
antiseptic solutions.
Use
– Do not use antiseptic solutions belonging to different classes for the same
procedure: incompatibilities between different compounds exist.
– Antiseptics should be used when wounds are contaminated or infected. Clean,
non-infected wounds may be cleaned with 0.9% sodium chloride; it is not
necessary to apply an antiseptic.
– In case of accidental exposure to blood (needlestick or broken skin): the injured
area should be washed well with soap and water. No evidence exists that
antiseptics reduce the risk of transmission, however, their use – after thorough
cleaning – is not contraindicated. Use 2.6% bleach diluted 1/5 or 1/10, or 70%
alcohol, or 10% polyvidone iodine solution and leave in contact for 5 minutes.
– Disinfection of skin when administrating a vaccine is not recommended; rather,
simply clean the injection site with clean water. Certain vaccines (for example,
BCG) may be inactivated in the presence of an antiseptic. If an antiseptic is used
despite this recommendation, it must be allowed to dry before vaccine injection.
Preparation and use of disinfectant solutions

The effectiveness of disinfection can be impaired by error in preparation
(concentration, temperature), failure to follow recommended contact times, or
deterioration of the product due to poor storages conditions.
Personnel carrying out disinfection should wear protective clothing when preparing
or using disinfectant solutions: gown, rubber apron, gloves with long cuffs, goggles
and mask.
Preparation
Solutions should be prepared with clean water (chlorine solutions should be
prepared with cold water only, in non-metal containers).
– Solution for disinfecting floors and surfaces: prepare just before use, and discard
any unused solution.
– Solution for pre-disinfection of medical devices and instruments: replace daily. The
solution may be used for a maximum of 24 hours; if visibly soiled, discard and
replace with fresh soaking solution before 24 hours are up.
314
– Solution for disinfection of medical devices and instruments: prepare just before
and discard after use.
Do not add any product (e.g. a detergent, descaling agent) to disinfectant solutions.
Disinfection of floors and surfaces

– Apply detergent-disinfectant intended for floors and surfaces1, without rinsing.
Follow manufacturer ’s instructions for dilution and specific preparation
procedures.
Or
– After cleaning with a detergent (cleaning product without an antimicrobial agent)
and rinsing with water, apply a 0.1 % active chlorine solution. Preliminary washing
and rinsing are essential: the activity of chlorine is reduced in the presence of
organic material (sputum, vomit, faeces, blood and other body fluids), and the
detergent used may be incompatible with chlorine. Contact time is 15 minutes.
Stainless steel surfaces should be rinsed with water after disinfection with chlorine
solution.
The use of detergent-disinfectant products reduces workload (cleaning and
disinfection are carried out as a single procedure), but they have the disadvantage of
being weak detergents and leaving a film, which causes dirt to build up on the floors.
It is thus necessary to alternate their use with that of a detergent alone. Each medical
facility should establish a clear policy addressing this issue.
Disinfection of linen
After hand washing, followed by rinsing: soak the clean linen in a solution of 0.1%
active chlorine for 15 minutes and rinse thoroughly (3 rinses).
After machine-washing at 60°C: soak the linen in a 0.1% active chlorine solution for
2 to 3 minutes and rinse thoroughly (3 rinses).
Pre-disinfection of reusable medical devices/instruments

– After use, soak medical devices (disassembled, forceps and scissors opened):
• In a detergent-disinfectant solution intended for medical devices and
instruments1. Use a syringe to irrigate the cavities of hollow devices with the
same solution. For correct dilution and soak times, follow manufacturer ’s
instructions; use a timer.
Or
• In 0.1% available chlorine solution for 15 minutes (use a timer). Use a syringe to
irrigate the cavities of hollow devices with the solution. Comply with
recommended soaking times and concentrations (risk of corrosion of metal
instruments). Soaking for too long (> 15 minutes) and/or in a solution that is too
concentrated will increase the risk of corrosion.
– Rinse with clean water, using a syringe for hollow cavities.
– Dry with a clean, dry, lint-free cloth.
1 For example a quaternary ammonium detergent-disinfectant.
315
Cleaning-disinfection of reusable medical devices/instruments

After the pre-disinfection step:
– Immerse the material in a detergent-disinfectant solution intended for medical
devices and instruments 2 (for correct dilution and soak times, follow
manufacturer’s directions). Scrub with a soft, non-abrasive brush. Use a bottle
brush for hollow devices, or irrigate with a syringe. Rinse with clean water, drain
and dry with a clean, dry, lint-free cloth.
Or
– Wash (as above) with detergent and rinse with clean water. Then soak in 0.1%
available chlorine solution for 20 minutes (use a timer). Comply with
recommended soak times and concentrations (risk of corrosion of metal
instruments). Rinse with clean water, drain and dry with a clean, dry, lint-free
cloth.
2 For example a quaternary ammonium detergent-disinfectant.
316
ȱ
16thȱeditionȱ
EssentialȱMedicinesȱ
WHOȱModelȱListȱ(revisedȱMarchȱ2009)ȱ
ExplanatoryȱNotesȱ
ȱ
TheȱcoreȱlistȱpresentsȱaȱlistȱofȱminimumȱmedicineȱneedsȱforȱaȱbasicȱhealthȬcareȱsystem,ȱlistingȱtheȱmostȱ
efficacious,ȱsafeȱandȱcostȬeffectiveȱmedicinesȱforȱpriorityȱconditions.ȱPriorityȱconditionsȱareȱselectedȱonȱtheȱ
basisȱofȱcurrentȱandȱestimatedȱfutureȱpublicȱhealthȱrelevance,ȱandȱpotentialȱforȱsafeȱandȱcostȬeffectiveȱ
treatment.ȱ
ȱ
Theȱcomplementaryȱlistȱpresentsȱessentialȱmedicinesȱforȱpriorityȱdiseases,ȱforȱwhichȱspecializedȱdiagnosticȱ
orȱmonitoringȱfacilities,ȱand/orȱspecialistȱmedicalȱcare,ȱand/orȱspecialistȱtrainingȱareȱneeded.ȱInȱcaseȱofȱdoubtȱ
medicinesȱmayȱalsoȱbeȱlistedȱasȱcomplementaryȱonȱtheȱbasisȱofȱconsistentȱhigherȱcostsȱorȱlessȱattractiveȱcostȬ
effectivenessȱinȱaȱvarietyȱofȱsettings.ȱȱ
ȱ
Theȱsquareȱboxȱsymbolȱ()ȱisȱprimarilyȱintendedȱtoȱindicateȱsimilarȱclinicalȱperformanceȱwithinȱaȱ
pharmacologicalȱclass.ȱTheȱlistedȱmedicineȱshouldȱbeȱtheȱexampleȱofȱtheȱclassȱforȱwhichȱthereȱisȱtheȱbestȱ
evidenceȱforȱeffectivenessȱandȱsafety.ȱInȱsomeȱcases,ȱthisȱmayȱbeȱtheȱfirstȱmedicineȱthatȱisȱlicensedȱforȱ
marketing;ȱinȱotherȱinstances,ȱsubsequentlyȱlicensedȱcompoundsȱmayȱbeȱsaferȱorȱmoreȱeffective.ȱWhereȱthereȱ
isȱnoȱdifferenceȱinȱtermsȱofȱefficacyȱandȱsafetyȱdata,ȱtheȱlistedȱmedicineȱshouldȱbeȱtheȱoneȱthatȱisȱgenerallyȱ
availableȱatȱtheȱlowestȱprice,ȱbasedȱonȱinternationalȱdrugȱpriceȱinformationȱsources.ȱNotȱallȱsquareȱboxesȱareȱ
applicableȱtoȱmedicineȱselectionȱforȱchildrenȱ—ȱseeȱtheȱsecondȱEMLcȱforȱdetails.ȱ
ȱ
Therapeuticȱequivalenceȱisȱonlyȱindicatedȱonȱtheȱbasisȱofȱreviewsȱofȱefficacyȱandȱsafetyȱandȱwhenȱconsistentȱ
withȱWHOȱclinicalȱguidelines.ȱNationalȱlistsȱshouldȱnotȱuseȱaȱsimilarȱsymbolȱandȱshouldȱbeȱspecificȱinȱtheirȱ
finalȱselection,ȱwhichȱwouldȱdependȱonȱlocalȱavailabilityȱandȱprice.ȱȱ
ȱ
Theȱaȱsymbolȱindicatesȱthatȱthereȱisȱanȱageȱorȱweightȱrestrictionȱonȱuseȱofȱtheȱmedicine;ȱdetailsȱforȱeachȱ
medicineȱcanȱbeȱfoundȱinȱTableȱ1.ȱ
ȱ
Whereȱtheȱ[c]ȱsymbolȱisȱplacedȱnextȱtoȱtheȱcomplementaryȱlistȱitȱsignifiesȱthatȱtheȱmedicine(s)ȱrequire(s)ȱ
specialistȱdiagnosticȱorȱmonitoringȱfacilities,ȱand/orȱspecialistȱmedicalȱcare,ȱand/orȱspecialistȱtrainingȱforȱ
theirȱuseȱinȱchildren.ȱ
ȱ
Whereȱtheȱ[c]ȱsymbolȱisȱplacedȱnextȱtoȱanȱindividualȱmedicineȱorȱstrengthȱofȱmedicineȱitȱsignifiesȱthatȱthereȱ
isȱaȱspecificȱindicationȱforȱrestrictingȱitsȱuseȱtoȱchildren.ȱ
ȱ
TheȱpresenceȱofȱanȱentryȱonȱtheȱEssentialȱMedicinesȱListȱcarriesȱnoȱassuranceȱasȱtoȱpharmaceuticalȱquality.ȱItȱ
isȱtheȱresponsibilityȱofȱtheȱrelevantȱnationalȱorȱregionalȱdrugȱregulatoryȱauthorityȱtoȱensureȱthatȱeachȱ
productȱisȱofȱappropriateȱpharmaceuticalȱqualityȱ(includingȱstability)ȱandȱthatȱwhenȱrelevant,ȱdifferentȱ
productsȱareȱinterchangeable.ȱ
ȱ
ForȱrecommendationsȱandȱadviceȱconcerningȱallȱaspectsȱofȱtheȱqualityȱassuranceȱofȱmedicinesȱseeȱtheȱWHOȱ
Medicinesȱwebȱsiteȱhttp://www.who.int/medicines/areas/quality_assurance/en/index.html.ȱ
ȱ
Medicinesȱandȱdosageȱformsȱareȱlistedȱinȱalphabeticalȱorderȱwithinȱeachȱsectionȱandȱthereȱisȱnoȱimplicationȱ
ofȱpreferenceȱforȱoneȱformȱoverȱanother.ȱStandardȱtreatmentȱguidelinesȱshouldȱbeȱconsultedȱforȱinformationȱ
onȱappropriateȱdosageȱforms.ȱ
ȱ
ȱ
TheȱmainȱtermsȱusedȱforȱdosageȱformsȱinȱtheȱEssentialȱMedicinesȱListȱcanȱbeȱfoundȱinȱAnnexȱ1.ȱ
ȱ
Definitionsȱofȱmanyȱofȱtheseȱtermsȱandȱpharmaceuticalȱqualityȱrequirementsȱapplicableȱtoȱtheȱdifferentȱ
categoriesȱareȱpublishedȱinȱtheȱcurrentȱeditionȱofȱTheȱInternationalȱPharmacopoeiaȱ
http://www.who.int/medicines/publications/pharmacopoeia/en/index.html.ȱ
ȱ
ȱ
ȱ
EssentialȱMedicinesȱ 16thȱeditionȱ(Marchȱ2009)ȱȱ
WHOȱModelȱListȱ
1. ANAESTHETICS
1.1 General anaesthetics and oxygen
ȱhalothaneȱȱ Inhalation.ȱ
ketamineȱ Injection:ȱ50ȱmgȱ(asȱhydrochloride)/mlȱinȱ10Ȭmlȱvial.ȱ
nitrousȱoxideȱ Inhalation.ȱ
oxygenȱ Inhalationȱ(medicinalȱgas).ȱȱ
ȱthiopentalȱ Powderȱforȱinjection:ȱ0.5ȱg;ȱ1ȱgȱ(sodiumȱsalt)ȱinȱampoule.ȱȱ
1.2 Local anaesthetics
Injection:ȱ0.25%;ȱ0.5%ȱ(hydrochloride)ȱinȱvial.ȱȱ
ȱbupivacaineȱ Injectionȱforȱspinalȱanaesthesia:ȱ0.5%ȱ(hydrochloride)ȱinȱ
4Ȭmlȱampouleȱtoȱbeȱmixedȱwithȱ7.5%ȱglucoseȱsolution.ȱ
Injection:ȱ1%;ȱ2%ȱ(hydrochloride)ȱinȱvial.ȱ
Injectionȱforȱspinalȱanaesthesia:ȱ5%ȱ(hydrochloride)ȱinȱȱ
ȱlidocaineȱ
2Ȭmlȱampouleȱtoȱbeȱmixedȱwithȱ7.5%ȱglucoseȱsolution.ȱ
Topicalȱforms:ȱ2%ȱtoȱ4%ȱ(hydrochloride).ȱ
Dentalȱcartridge:ȱ2%ȱ(hydrochloride)ȱ+ȱepinephrineȱ1:80ȱ000.ȱ
lidocaineȱ+ȱepinephrineȱ(adrenaline)ȱȱ
Injection:ȱ1%;ȱ2%ȱ(hydrochloride)ȱ+ȱepinephrineȱ1:200ȱ000ȱinȱvial.ȱ
ComplementaryȱListȱ
Injection:ȱ30ȱmgȱ(hydrochloride)/mlȱinȱ1Ȭmlȱampoule.ȱ
ephedrineȱ
(Forȱuseȱinȱspinalȱanaesthesiaȱduringȱdelivery,ȱtoȱpreventȱhypotension).ȱ
1.3 Preoperative medication and sedation for short-term procedures
atropineȱ Injection:ȱ1ȱmgȱ(sulfate)ȱinȱ1Ȭmlȱampoule.ȱ
Injection:ȱ5ȱmg/mlȱinȱ2Ȭmlȱampoule.ȱ
ȱdiazepamȱ
Tablet:ȱ5ȱmg.ȱ
morphineȱ Injection:ȱ10ȱmgȱ(sulfateȱorȱhydrochloride)ȱinȱ1Ȭmlȱampoule.ȱ
promethazineȱ Oralȱliquid:ȱ5ȱmgȱ(hydrochloride)/5ȱml.ȱ
2. ANALGESICS, ANTIPYRETICS, NON-STEROIDAL ANTI-INFLAMMATORY

MEDICINES (NSAIMs), MEDICINES USED TO TREAT GOUT AND DISEASE MODIFYING
AGENTS IN RHEUMATOID DISORDERS (DMARDs)
2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
Suppository:ȱ50ȱmgȱtoȱ150ȱmg.ȱ
acetylsalicylicȱacidȱ
Tablet:ȱ100ȱmgȱtoȱ500ȱmg.ȱ
Tablet:ȱ200ȱmg;ȱ400ȱmg.ȱ
ibuprofenȱaȱȱ
a >3 months.
ȱ
WHOȱModelȱListȱ
Oralȱliquid:ȱ125ȱmg/5ȱml.ȱ
Suppository:ȱ100ȱmg.ȱ
paracetamol*ȱ Tablet:ȱ100ȱmgȱtoȱ500ȱmg.ȱ
*ȱNotȱrecommendedȱforȱantiȬinflammatoryȱuseȱdueȱtoȱlackȱofȱ
provenȱbenefitȱtoȱthatȱeffect.ȱ
ComplementaryȱListȱ[c]ȱ
Suppository:ȱ50ȱmgȱtoȱ150ȱmg.ȱ
acetylsalicylicȱacid*ȱ Tablet:ȱ100ȱmgȱtoȱ500ȱmg.ȱ
*ȱForȱuseȱforȱrheumaticȱfever,ȱjuvenileȱarthritis,ȱKawasakiȱdisease.ȱ
2.2 Opioid analgesics
codeineȱ Tablet:ȱ15ȱmgȱ(phosphate)ȱ[c];ȱ30ȱmgȱ(phosphate).ȱ
Injection:ȱ10ȱmgȱ(morphineȱhydrochlorideȱorȱmorphineȱsulfate)ȱ
inȱ1Ȭmlȱampoule.ȱ
Oralȱliquid:ȱ10ȱmgȱ(morphineȱhydrochlorideȱorȱmorphineȱ
morphineȱ sulfate)/5ȱml.ȱ
Tablet:ȱ10ȱmgȱ(morphineȱsulfate).ȱ
Tabletȱ(prolongedȱrelease):ȱ10ȱmg;ȱ30ȱmg;ȱ60ȱmgȱ(morphineȱ
sulfate).ȱ
2.3 Medicines used to treat gout
allopurinolȱ Tablet:ȱ100ȱmg.ȱ
2.4 Disease modifying agents used in rheumatoid disorders (DMARDs)
chloroquineȱ Tablet:ȱ100ȱmg;ȱ150ȱmgȱ(asȱphosphateȱorȱsulfate).ȱ
ComplementaryȱList
azathioprineȱ Tablet:ȱ50ȱmg.ȱ
methotrexateȱ Tablet:ȱ2.5ȱmgȱ(asȱsodiumȱsalt).ȱ
penicillamineȱ Solidȱoralȱdosageȱform:ȱ250ȱmg.ȱ
sulfasalazineȱ Tablet:ȱ500ȱmg.ȱ
3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS
Injection:ȱ10ȱmgȱ(hydrogenȱmaleate)ȱinȱ1Ȭmlȱampoule.ȱ
Oralȱliquid:ȱ2ȱmg/5ȱml [c].ȱ
ȱchlorphenamineȱa ȱ
Tablet:ȱ4ȱmgȱ(hydrogenȱmaleate).ȱ
a >1 year.ȱ
Injection:ȱ4ȱmgȱdexamethasoneȱphosphateȱ(asȱdisodiumȱsalt)ȱinȱ
dexamethasone
1Ȭmlȱampoule.ȱ
Injection:ȱ1ȱmgȱ(asȱhydrochlorideȱorȱhydrogenȱtartrate)ȱinȱȱ
epinephrineȱ(adrenaline)
1Ȭmlȱampoule.ȱ
ȱ
WHOȱModelȱListȱ
hydrocortisone Powderȱforȱinjection:ȱ100ȱmgȱ(asȱsodiumȱsuccinate)ȱinȱvial.ȱ
Oralȱliquid:ȱ5ȱmg/mlȱ[c].ȱ
ȱprednisoloneȱ
4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS
4.1 Non-specific
charcoal,ȱactivatedȱ Powder.ȱ
4.2 Specific
acetylcysteineȱ
Oralȱliquid:ȱ10%ȱ[c];ȱ20%ȱ[c].ȱ
atropineȱ Injection:ȱ1ȱmgȱ(sulfate)ȱinȱ1Ȭmlȱampoule.ȱ
calciumȱgluconateȱ Injection:ȱ100ȱmg/mlȱinȱ10Ȭmlȱampoule.ȱ
deferoxamineȱ Powderȱforȱinjection:ȱ500ȱmgȱ(mesilate)ȱinȱvial.ȱ
dimercaprolȱ Injectionȱinȱoil:ȱ50ȱmg/mlȱinȱ2Ȭmlȱampoule.ȱ
Tablet:ȱ250ȱmg.ȱ
DLȬmethionine*ȱ
*ȱWillȱbeȱreviewedȱforȱpossibleȱdeletion.ȱ
methylthioniniumȱchlorideȱȱ
(methyleneȱblue)ȱ
naloxoneȱ Injection:ȱ400ȱmicrogramsȱ(hydrochloride)ȱinȱ1Ȭmlȱampoule.ȱ
penicillamineȱ Solidȱoralȱdosageȱform:ȱ250ȱmg.ȱ
potassiumȱferricȱhexacyanoȬferrate(II)ȱȬ
Powderȱforȱoralȱadministration.ȱ
2H20ȱ(Prussianȱblue)ȱ
sodiumȱcalciumȱedetateȱȱ Injection:ȱ200ȱmg/mlȱinȱ5Ȭmlȱampoule.ȱ
sodiumȱnitriteȱ Injection:ȱ30ȱmg/mlȱinȱ10Ȭmlȱampoule.ȱ
sodiumȱthiosulfateȱ Injection:ȱ250ȱmg/mlȱinȱ50Ȭmlȱampoule.ȱ
5. ANTICONVULSANTS/ANTIEPILEPTICS
carbamazepineȱ Tabletȱ(chewable):ȱ100ȱmg;ȱ200ȱmg.ȱ
Tabletȱ(scored):ȱ100ȱmg;ȱ200ȱmg.ȱ
diazepamȱ Gelȱorȱrectalȱsolution:ȱ5ȱmg/mlȱinȱ0.5ȱml;ȱ2Ȭmlȱandȱ4Ȭmlȱtubes.ȱ
Parenteralȱformulation:ȱ2ȱmg/mlȱinȱ1Ȭmlȱampoule;ȱ4ȱmg/mlȱinȱȱ
lorazepamȱ
1Ȭmlȱampoule.ȱȱ
Injection:ȱ500ȱmg/mlȱinȱ2Ȭmlȱampoule;ȱ500ȱmg/mlȱinȱȱ
10Ȭmlȱampoule.ȱ
magnesiumȱsulfate*ȱ
*ȱForȱuseȱinȱeclampsiaȱandȱsevereȱpreȬeclampsiaȱandȱnotȱforȱotherȱ
convulsantȱdisorders.ȱ
ȱ
WHOȱModelȱListȱ
Injection:ȱ200ȱmg/mlȱ(phenobarbitalȱsodium).ȱ
phenobarbitalȱȱ Oralȱliquid:ȱ15ȱmg/5ȱmlȱ(phenobarbital).ȱ
Tablet:ȱ15ȱmgȱtoȱ100ȱmgȱ(phenobarbital).ȱ
Capsule:ȱ25ȱmg;ȱ50ȱmg;ȱ100ȱmgȱ(sodiumȱsalt).ȱ
Injection:ȱ50ȱmg/mlȱinȱ5Ȭmlȱvialȱ(sodiumȱsalt).ȱ
Oralȱliquid:ȱ25ȱmgȱtoȱ30ȱmg/5ȱml.*ȱ
phenytoinȱ Tablet:ȱ25ȱmg;ȱ50ȱmg;ȱ100ȱmgȱ(sodiumȱsalt).ȱ
Tabletȱ(chewable):ȱ50ȱmg.ȱ
*ȱTheȱpresenceȱofȱbothȱ25ȱmg/5ȱmlȱandȱ30ȱmg/5ȱmlȱstrengthsȱonȱ
theȱsameȱmarketȱwouldȱcauseȱconfusionȱinȱprescribingȱandȱ
dispensingȱandȱshouldȱbeȱavoided.ȱ
valproicȱacidȱ(sodiumȱvalproate)ȱ Tabletȱ(crushable):ȱ100ȱmg.ȱ
Tabletȱ(entericȬcoated):ȱ200ȱmg;ȱ500ȱmgȱ(sodiumȱvalproate).ȱ
Capsule:ȱ250ȱmg.ȱ
ethosuximideȱ
6. ANTI-INFECTIVE MEDICINES
6.1 Anthelminthics
6.1.1 Intestinal anthelminthics
albendazoleȱ Tabletȱ(chewable):ȱ400ȱmg.ȱ
levamisole Tablet:ȱ50ȱmg;ȱ150ȱmgȱ(asȱhydrochloride).ȱ
ȱmebendazoleȱ Tabletȱ(chewable):ȱ100ȱmg;ȱ500ȱmg.ȱ
Tabletȱ(chewable):ȱ500ȱmg.ȱ
niclosamide*ȱ
*ȱNiclosamideȱisȱlistedȱforȱuseȱwhenȱpraziquantelȱtreatmentȱfails.ȱ
praziquantelȱ Tablet:ȱ150ȱmg;ȱ600ȱmg.ȱ
Oralȱliquid:ȱ50ȱmgȱ(asȱembonate)/ml.ȱ
pyrantelȱ
Tabletȱ(chewable):ȱ250ȱmgȱ(asȱembonate).ȱ
6.1.2 Antifilarials
ivermectinȱ Tabletȱ(scored):ȱ3ȱmg;ȱ6ȱmg.ȱ
diethylcarbamazineȱ Tablet:ȱ50ȱmg;ȱ100ȱmgȱ(dihydrogenȱcitrate).ȱ
Powderȱforȱinjection:ȱ1ȱgȱinȱvial.ȱ
suraminȱsodium*ȱ
*ȱWillȱbeȱreviewedȱforȱpossibleȱdeletion.ȱ
ȱ
WHOȱModelȱListȱ
6.1.3 Antischistosomals and antitrematode medicinesȱ
praziquantelȱ Tablet:ȱ600ȱmg.ȱ
triclabendazoleȱ Tablet:ȱ250ȱmg.ȱ
oxamniquine*ȱ Oralȱliquid:ȱ250ȱmg/5ȱml.ȱ
*ȱOxamniquineȱisȱlistedȱforȱuseȱwhenȱpraziquantelȱtreatmentȱfails.ȱ
6.2 Antibacterials
6.2.1 Beta Lactam medicines
Powderȱforȱoralȱliquid:ȱ125ȱmgȱ(anhydrous)/5ȱml;ȱ250ȱmgȱ
amoxicillinȱ (anhydrous)/5ȱmlȱ[c].ȱ
Solidȱoralȱdosageȱform:ȱ250ȱmg;ȱ500ȱmgȱ(anhydrous).ȱ
Oralȱliquid:ȱ125ȱmgȱamoxicillinȱ+ȱ31.25ȱmgȱclavulanicȱacid/5ȱmlȱ
amoxicillinȱ+ȱclavulanicȱacidȱȱ ANDȱ250ȱmgȱamoxicillinȱ+ȱ62.5ȱmgȱclavulanicȱacid/5ȱmlȱ[c].ȱ
Tablet:ȱ500ȱmgȱ+ȱ125ȱmg.ȱ
ampicillinȱ Powderȱforȱinjection:ȱ500ȱmg;ȱ1ȱgȱ(asȱsodiumȱsalt)ȱinȱvial.ȱ
Powderȱforȱinjection:ȱ900ȱmgȱbenzylpenicillinȱ(=1.2ȱmillionȱIU)ȱ
benzathineȱbenzylpenicillinȱ inȱ5Ȭmlȱvialȱ[c];ȱ1.44ȱgȱbenzylpenicillinȱ(=2.4ȱmillionȱIU)ȱinȱ5Ȭmlȱ
vial.ȱ
Powderȱforȱinjection:ȱ600ȱmgȱ(=ȱ1ȱmillionȱIU);ȱ3ȱgȱ(=ȱ5ȱmillionȱIU)ȱ
benzylpenicillinȱ
(sodiumȱorȱpotassiumȱsalt)ȱinȱvial.ȱ
Powderȱforȱreconstitutionȱwithȱwater:ȱ125ȱmg/5ȱml;ȱ
cefalexinȱ[c] 250ȱmg/5ȱml.ȱȱ
Solidȱoralȱdosageȱform:ȱ250ȱmg.ȱ
Powderȱforȱinjection:ȱ1ȱgȱ(asȱsodiumȱsalt)ȱinȱvial.ȱ
cefazolin*ȱaȱ *ȱForȱsurgicalȱprophylaxis.ȱ
a >1 month.ȱ
cefixime*ȱ *ȱOnlyȱlistedȱforȱsingleȬdoseȱtreatmentȱofȱuncomplicatedȱanoȬ
genitalȱgonorrhoea.ȱ
Powderȱforȱinjection:ȱ250ȱmg;ȱ1ȱgȱ(asȱsodiumȱsalt)ȱinȱvial.ȱ
*ȱDoȱnotȱadministerȱwithȱcalciumȱandȱavoidȱinȱinfantsȱwithȱ
ceftriaxone*ȱaȱȱ
hyperbilirubinemia.ȱ
a >41 weeks corrected gestational age.ȱ
Capsule:ȱ500ȱmg;ȱ1ȱgȱ(asȱsodiumȱsalt).ȱ
ȱcloxacillinȱ Powderȱforȱinjection:ȱ500ȱmgȱ(asȱsodiumȱsalt)ȱinȱvial.ȱ
Powderȱforȱoralȱliquid:ȱ125ȱmgȱ(asȱsodiumȱsalt)/5ȱml.ȱ
ȱ
WHOȱModelȱListȱ
Powderȱforȱoralȱliquid:ȱ250ȱmgȱ(asȱpotassiumȱsalt)/5ȱml.ȱ
phenoxymethylpenicillinȱ
Tablet:ȱ250ȱmgȱ(asȱpotassiumȱsalt).ȱ
Powderȱforȱinjection:ȱ1ȱgȱ(=1ȱmillionȱIU);ȱ3ȱgȱ(=3ȱmillionȱIU)ȱinȱ
vial.ȱȱ
procaineȱbenzylpenicillin*ȱ *ȱProcaineȱbenzylpenicillinȱisȱnotȱrecommendedȱasȱfirstȬlineȱ
treatmentȱforȱneonatalȱsepsisȱexceptȱinȱsettingsȱwithȱhighȱ
neonatalȱmortality,ȱwhenȱgivenȱbyȱtrainedȱhealthȱworkersȱinȱ
casesȱwhereȱhospitalȱcareȱisȱnotȱachievable.ȱ
Powderȱforȱinjection:ȱ250ȱmgȱperȱvial.ȱ
cefotaxime*ȱ[c]ȱȱ *ȱ3rdȱgenerationȱcephalosporinȱofȱchoiceȱforȱuseȱinȱhospitalizedȱ
neonates.ȱ
ceftazidimeȱ Powderȱforȱinjection:ȱ250ȱmgȱorȱ1ȱgȱ(asȱpentahydrate)ȱinȱvial.ȱ
Powderȱforȱinjection:ȱ250ȱmgȱ(asȱmonohydrate)ȱ+ȱ250ȱmgȱ(asȱsodiumȱ
salt);ȱ500ȱmgȱ(asȱmonohydrate)ȱ+ȱ500ȱmgȱ(asȱsodiumȱsalt)ȱinȱvial.ȱ
*ȱOnlyȱlistedȱforȱtheȱtreatmentȱofȱlifeȬthreateningȱhospitalȬbasedȱ
imipenem*ȱ+ȱcilastatin*
infectionȱdueȱtoȱsuspectedȱorȱprovenȱmultidrugȬresistantȱinfection.ȱ
Meropenemȱisȱindicatedȱforȱtheȱtreatmentȱofȱmeningitisȱandȱisȱlicensedȱ
forȱuseȱinȱchildrenȱoverȱtheȱageȱofȱ3ȱmonths.ȱ
6.2.2 Other antibacterials
Capsule:ȱ250ȱmg;ȱ500ȱmg.ȱ
azithromycin*ȱ
*ȱOnlyȱlistedȱforȱsingleȬdoseȱtreatmentȱofȱgenitalȱChlamydiaȱ
trachomatisȱandȱofȱtrachoma.ȱ
Oilyȱsuspensionȱforȱinjection*:ȱ0.5ȱgȱ(asȱsodiumȱsuccinate)/mlȱinȱ
2Ȭmlȱampoule.ȱ
chloramphenicolȱ *ȱOnlyȱforȱtheȱpresumptiveȱtreatmentȱofȱepidemicȱmeningitisȱinȱ
childrenȱolderȱthanȱ2ȱyears.ȱ
Oralȱliquid:ȱ150ȱmgȱ(asȱpalmitate)/5ȱml.ȱ
Powderȱforȱinjection:ȱ1ȱgȱ(sodiumȱsuccinate)ȱinȱvial.ȱ
Oralȱliquid:ȱ250ȱmg/5ȱmlȱ[c].ȱ
ȱciprofloxacinȱ SolutionȱforȱIVȱinfusion:ȱ2ȱmg/mlȱ[c].ȱ
Tablet:ȱ250ȱmgȱ(asȱhydrochloride).ȱ
Oralȱliquid:ȱ25ȱmg/5ȱmlȱ[c];ȱ50ȱmg/5ȱmlȱ[c].ȱ
doxycyclineȱaȱ Solidȱoralȱdosageȱform:ȱ50ȱmgȱ[c];ȱ100ȱmgȱ(hydrochloride).ȱȱ
aȱUse in children <8 years only for life-threatening infections when no
alternative exists.ȱ
ȱ
WHOȱModelȱListȱ
Powderȱforȱinjection:ȱ500ȱmgȱ(asȱlactobionate)ȱinȱvial.ȱ
Powderȱforȱoralȱliquid:ȱ125ȱmg/5ȱmlȱ(asȱstearateȱorȱethylȱ
ȱerythromycinȱ
succinate).ȱ
Solidȱoralȱdosageȱform:ȱ250ȱmgȱ(asȱstearateȱorȱethylȱsuccinate).ȱ
ȱgentamicinȱ Injection:ȱ10ȱmg;ȱ40ȱmgȱ(asȱsulfate)/mlȱinȱ2Ȭmlȱvial.ȱ
Injection:ȱ500ȱmgȱinȱ100Ȭmlȱvial.ȱ
Oralȱliquid:ȱ200ȱmgȱ(asȱbenzoate)/5ȱml.ȱ
ȱmetronidazoleȱ
Suppository:ȱ500ȱmg;ȱ1ȱg.ȱ
nitrofurantoinȱ
Tablet:ȱ100ȱmg.ȱ
spectinomycinȱ Powderȱforȱinjection:ȱ2ȱgȱ(asȱhydrochloride)ȱinȱvial.ȱ
Injection:ȱȱ
80ȱmgȱ+ȱ16ȱmg/mlȱinȱ5Ȭmlȱampoule;ȱȱ
sulfamethoxazoleȱ+ȱtrimethoprimȱȱ 80ȱmgȱ+ȱ16ȱmg/mlȱinȱ10Ȭmlȱampoule.ȱ
Oralȱliquid:ȱ200ȱmgȱ+ȱ40ȱmg/5ȱml.ȱ
Tablet:ȱ100ȱmgȱ+ȱ20ȱmg;ȱ400ȱmgȱ+ȱ80ȱmg.ȱ
trimethoprimȱa ȱ Tablet:ȱ100ȱmg;ȱ200ȱmg.ȱ
a >6 months.ȱ
clindamycinȱ Injection:ȱ150ȱmgȱ(asȱphosphate)/ml.ȱ
vancomycinȱ Powderȱforȱinjection:ȱ250ȱmgȱ(asȱhydrochloride)ȱinȱvial.ȱ
6.2.3 Antileprosy medicinesȱ
Medicinesȱ usedȱ inȱ theȱ treatmentȱ ofȱ leprosyȱ shouldȱ neverȱ beȱ usedȱ exceptȱ inȱ combination.ȱ Combinationȱ
therapyȱisȱessentialȱtoȱpreventȱtheȱemergenceȱofȱdrugȱresistance.ȱColourȱcodedȱblisterȱpacksȱ(MDTȱblisterȱ
packs)ȱ containingȱ standardȱ twoȱ medicineȱ (paucibacillaryȱ leprosy)ȱ orȱ threeȱ medicineȱ (multibacillaryȱ
leprosy)ȱcombinationsȱforȱadultȱandȱchildhoodȱleprosyȱshouldȱbeȱused.ȱMDTȱblisterȱpacksȱcanȱbeȱsuppliedȱ
freeȱofȱchargeȱthroughȱWHO.ȱ
clofazimineȱ Capsule:ȱ50ȱmg;ȱ100ȱmg.ȱ
dapsoneȱ Tablet:ȱ25ȱmg;ȱ50ȱmg;ȱ100ȱmg.ȱ
rifampicinȱ Solidȱoralȱdosageȱform:ȱ150ȱmg;ȱ300ȱmg.ȱ
ȱ
ȱ
ȱ
ȱ
WHOȱModelȱListȱ
6.2.4 Antituberculosis medicines
ethambutolȱ
Tablet:ȱ100ȱmgȱtoȱ400ȱmgȱ(hydrochloride).ȱ
ethambutolȱ+ȱisoniazidȱȱȱ Tablet:ȱ400ȱmgȱ+ȱ150ȱmg.ȱ
ethambutolȱ+ȱisoniazidȱ+ȱpyrazinamideȱ
Tablet:ȱ275ȱmgȱ+ȱ75ȱmgȱ+ȱ400ȱmgȱ+ȱ150ȱmg.ȱ
+ȱrifampicinȱȱ
ethambutolȱ+ȱisoniazidȱ+ȱrifampicinȱ Tablet:ȱ275ȱmgȱ+ȱ75ȱmgȱ+ȱ150ȱmg.ȱ
isoniazidȱ Tablet:ȱ100ȱmgȱtoȱ300ȱmg.ȱ
Tabletȱ(scored):ȱ50ȱmg.ȱȱ
Tablet:ȱȱ
isoniazidȱ+ȱpyrazinamideȱ+ȱrifampicinȱȱȱ 75ȱmgȱ+ȱ400ȱmgȱ+ȱ150ȱmg.ȱ
150ȱmgȱ+ȱ500ȱmgȱ+ȱ150ȱmgȱ(Forȱintermittentȱuseȱthreeȱtimesȱ
weekly).ȱ
Tablet:ȱȱ
isoniazidȱ+ȱrifampicinȱȱ 75ȱmgȱ+ȱ150ȱmg;ȱ150ȱmgȱ+ȱ300ȱmg.ȱ
60ȱmgȱ+ȱ60ȱmgȱ(Forȱintermittentȱuseȱthreeȱtimesȱweekly).ȱ
150ȱmgȱ+ȱ150ȱmgȱ(Forȱintermittentȱuseȱthreeȱtimesȱweekly).ȱ
Tablet:ȱ400ȱmg.ȱ
pyrazinamideȱ
Tabletȱ(dispersible):ȱ150ȱmg.ȱ
Tabletȱ(scored):ȱ150ȱmg.ȱ
Capsule:ȱ150ȱmg.*ȱ
rifabutinȱ
*ȱForȱuseȱonlyȱinȱpatientsȱwithȱHIVȱreceivingȱproteaseȱinhibitors.ȱȱ
rifampicinȱ
Solidȱoralȱdosageȱform:ȱ150ȱmg;ȱ300ȱmg.ȱ
streptomycinȱ Powderȱforȱinjection:ȱ1ȱgȱ(asȱsulfate)ȱinȱvial.ȱ
ReserveȱsecondȬlineȱdrugsȱforȱtheȱtreatmentȱofȱmultidrugȬresistantȱtuberculosisȱ(MDRȬTB)ȱshouldȱbeȱ
usedȱinȱspecializedȱcentresȱadheringȱtoȱWHOȱstandardsȱforȱTBȱcontrol.ȱȱ
amikacinȱ Powderȱforȱinjection:ȱ100ȱmg;ȱ500ȱmg;ȱ1ȱgȱinȱvial.ȱ
capreomycinȱ Powderȱforȱinjection:ȱ1ȱgȱinȱvial.ȱ
cycloserineȱ Solidȱoralȱdosageȱform:ȱ250ȱmg.ȱ
ethionamideȱ Tablet:ȱ125ȱmg;ȱ250ȱmg.ȱ
kanamycinȱ Powderȱforȱinjection:ȱ1ȱgȱinȱvial.ȱ
ȱ
WHOȱModelȱListȱ
ofloxacin*ȱ *ȱLevofloxacinȱmayȱbeȱanȱalternativeȱbasedȱonȱavailabilityȱandȱ
programmeȱconsiderations.ȱ
Granules:ȱ4ȱgȱinȱsachet.ȱ
pȬaminosalicylicȱacidȱ
Tablet:ȱ500ȱmg.ȱ
6.3 Antifungal medicinesȱ
Vaginalȱcream:ȱ1%;ȱ10%.ȱ
clotrimazoleȱ
Vaginalȱtablet:ȱ100ȱmg;ȱ500ȱmg.ȱ
Capsule:ȱ50ȱmg.ȱ
ȱfluconazoleȱ Injection:ȱ2ȱmg/mlȱinȱvial.ȱ
griseofulvinȱ
Solidȱoralȱdosageȱform:ȱ125ȱmg;ȱ250ȱmg.ȱ
Lozenge:ȱ100ȱ000ȱIU.ȱ
Oralȱliquid:ȱ50ȱmg/5ȱmlȱ[c];ȱ100ȱ000ȱIU/mlȱ[c].ȱ
nystatinȱ
Pessary:ȱ100ȱ000ȱIU.ȱ
Tablet:ȱ100ȱ000ȱIU;ȱ500ȱ000ȱIU.ȱ
Powderȱforȱinjection:ȱ50ȱmgȱinȱvial.ȱ
amphotericinȱBȱ
Asȱdeoxycholateȱorȱliposomal.ȱ
flucytosineȱ
Infusion:ȱ2.5ȱgȱinȱ250ȱml.ȱ
potassiumȱiodideȱ Saturatedȱsolution.ȱ
6.4 Antiviral medicines
6.4.1 Antiherpes medicines
ȱaciclovirȱ Powderȱforȱinjection:ȱ250ȱmgȱ(asȱsodiumȱsalt)ȱinȱvial.ȱ
Tablet:ȱ200ȱmg.ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
WHOȱModelȱListȱ
6.4.2 Antiretrovirals
Basedȱonȱcurrentȱevidenceȱandȱexperienceȱofȱuse,ȱmedicinesȱinȱtheȱfollowingȱthreeȱclassesȱofȱantiretroviralsȱ
areȱ includedȱ asȱ essentialȱ medicinesȱ forȱ treatmentȱ andȱ preventionȱ ofȱ HIVȱ (preventionȱ ofȱ motherȬtoȬchildȱ
transmissionȱ andȱ postȬexposureȱ prophylaxis).ȱ Theȱ Committeeȱ emphasizesȱ theȱ importanceȱ ofȱ usingȱ theseȱ
productsȱ inȱ accordanceȱ withȱ globalȱ andȱ nationalȱ guidelines.ȱ ȱ Theȱ Committeeȱ recommendsȱ andȱ endorsesȱ
theȱ useȱ ofȱ fixedȬdoseȱ combinationsȱ andȱ theȱ developmentȱ ofȱ appropriateȱ newȱ fixedȬdoseȱ combinations,ȱ
includingȱ modifiedȱ dosageȱ forms,ȱ nonȬrefrigeratedȱ productsȱ andȱ paediatricȱ dosageȱ formsȱ ofȱ assuredȱ
pharmaceuticalȱquality.ȱ
Scoredȱtabletsȱcanȱbeȱusedȱinȱchildrenȱandȱthereforeȱcanȱbeȱconsideredȱforȱinclusionȱinȱtheȱlistingȱofȱtablets,ȱ
providedȱadequateȱqualityȱproductsȱareȱavailable.ȱ
6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitorsȱ
Oralȱliquid:ȱ100ȱmgȱ(asȱsulfate)/5ȱml.ȱ
abacavirȱ(ABC)ȱ
Tablet:ȱ300ȱmgȱ(asȱsulfate).ȱ
Bufferedȱpowderȱforȱoralȱliquid:ȱ100ȱmg;ȱ167ȱmg;ȱ250ȱmgȱpackets.ȱ
Capsuleȱ(unbufferedȱentericȬcoated):ȱ125ȱmg;ȱ200ȱmg;ȱ250ȱmg;ȱ
didanosineȱ(ddI)ȱ 400ȱmg.ȱ
Tabletȱ(bufferedȱchewable,ȱdispersible):ȱ25ȱmg;ȱ50ȱmg;ȱ100ȱmg;ȱ
150ȱmg;ȱ200ȱmg.ȱ
Oralȱliquid:ȱ10ȱmg/ml.ȱ
emtricitabineȱ(FTC)*ȱaȱ *ȱFTCȱisȱanȱacceptableȱalternativeȱtoȱ3TC,ȱbasedȱonȱknowledgeȱofȱ
theȱpharmacology,ȱtheȱresistanceȱpatternsȱandȱclinicalȱtrialsȱofȱ
antiretrovirals.ȱ
a >3 months.ȱ
lamivudineȱ(3TC)ȱ
Tablet:ȱ150ȱmg.ȱ
Capsule:ȱ15ȱmg;ȱ20ȱmg;ȱ30ȱmg.ȱ
stavudineȱ(d4T)ȱ
Powderȱforȱoralȱliquid:ȱ5ȱmg/5ȱml.ȱ
Tablet:ȱ300ȱmgȱ(tenofovirȱdisoproxilȱfumarateȱ–ȱequivalentȱtoȱȱ
tenofovirȱdisoproxilȱfumarateȱ(TDF)ȱ
245ȱmgȱtenofovirȱdisoproxil).ȱ
Capsule:ȱ100ȱmg;ȱ250ȱmg.ȱ
zidovudineȱ(ZDVȱorȱAZT)ȱ
SolutionȱforȱIVȱinfusionȱinjection:ȱ10ȱmg/mlȱinȱ20Ȭmlȱvial.ȱ
Tablet:ȱ300ȱmg.ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
WHOȱModelȱListȱ
6.4.2.2 Non-nucleoside reverse transcriptase inhibitorsȱ
Capsule:ȱ50ȱmg;ȱ100ȱmg;ȱ200ȱmg.ȱ
efavirenzȱ(EFVȱorȱEFZ)ȱa ȱ
Tablet:ȱ600ȱmg.ȱ
a >3 years or >10 kg weight.ȱ
nevirapineȱ(NVP)ȱ
Tablet:ȱ200ȱmg.ȱ
6.4.2.3 Protease inhibitorsȱ
Selectionȱ ofȱ proteaseȱ inhibitor(s)ȱ fromȱ theȱ Modelȱ Listȱ willȱ needȱ toȱ beȱ determinedȱ byȱ eachȱ countryȱ afterȱ
considerationȱofȱinternationalȱandȱnationalȱtreatmentȱguidelinesȱandȱexperience.ȱRitonavirȱisȱrecommendedȱ
forȱuseȱinȱcombinationȱasȱaȱpharmacologicalȱbooster,ȱandȱnotȱasȱanȱantiretroviralȱinȱitsȱownȱright.ȱAllȱotherȱ
proteaseȱinhibitorsȱshouldȱbeȱusedȱinȱboostedȱformsȱ(e.g.ȱwithȱritonavir).ȱ
Solidȱoralȱdosageȱform:ȱ100ȱmg;ȱ150ȱmg;ȱ300ȱmg.ȱ
atazanavirȱaȱ
a >25 kg.ȱȱ
indinavirȱ(IDV)ȱ Solidȱoralȱdosageȱform:ȱ400ȱmgȱ(asȱsulfate).ȱ
Capsule:ȱ133.3ȱmgȱ+ȱ33.3ȱmg.ȱȱ
lopinavirȱ+ȱritonavirȱ(LPV/r)ȱȱ Oralȱliquid:ȱ400ȱmgȱ+ȱ100ȱmg/5ȱml.ȱ
Tabletȱ(heatȱstable):ȱ100ȱmgȱ+ȱ25ȱmg;ȱ200ȱmgȱ+ȱ50ȱmg.ȱ
ritonavirȱ Solidȱoralȱdosageȱform:ȱ100ȱmg.ȱ
Tabletȱ(heatȱstable):ȱ25ȱmg;ȱ100ȱmg.ȱȱ
Solidȱoralȱdosageȱform:ȱ200ȱmg;ȱȱ500ȱmg.ȱ
saquinavirȱ(SQV)ȱa ȱ
a >25 kg.ȱ
FIXED-DOSE COMBINATIONSȱ
efavirenzȱ+ȱemtricitabine*ȱ+ȱtenofovirȱȱ Tablet:ȱ600ȱmgȱ+ȱ200ȱmgȱ+ȱ300ȱmg.ȱ
*ȱFTCȱisȱanȱacceptableȱalternativeȱtoȱ3TC,ȱbasedȱonȱknowledgeȱofȱ
antiretrovirals.ȱ
emtricitabine*ȱ+ȱtenofovirȱȱ Tablet:ȱ200ȱmgȱ+ȱ300ȱmg.ȱ
*ȱFTCȱisȱanȱacceptableȱalternativeȱtoȱ3TC,ȱbasedȱonȱknowledgeȱofȱ
antiretrovirals.ȱ
lamivudineȱ+ȱnevirapineȱ+ȱstavudineȱȱ Tablet:ȱ150ȱmgȱ+ȱ200ȱmgȱ+ȱ30ȱmg.ȱ
Tabletȱ(dispersible):ȱȱ
30ȱmgȱ+ȱ50ȱmgȱ+ȱ6ȱmgȱ[c];ȱ60ȱmgȱ+ȱ100ȱmgȱ+ȱ12ȱmgȱ[c].ȱ
ȱ
lamivudineȱ+ȱnevirapineȱ+ȱ Tablet:ȱ30ȱmgȱ+ȱ50ȱmgȱ+ȱ60ȱmgȱ[c];ȱ150ȱmgȱ+ȱ200ȱmgȱ+ȱ300ȱmg.ȱ
zidovudineȱȱ
ȱ
WHOȱModelȱListȱ
lamivudineȱ+ȱzidovudineȱ Tablet:ȱ30ȱmgȱ+ȱ60ȱmgȱ[c];ȱ150ȱmgȱ+ȱ300ȱmg.ȱ
6.4.3 Other antiviralsȱ
Injectionȱforȱintravenousȱadministration:ȱ800ȱmgȱandȱ1ȱgȱinȱ10Ȭmlȱ
phosphateȱbufferȱsolution.ȱ
ribavirin*ȱȱ
*ȱForȱtheȱtreatmentȱofȱviralȱhaemorrhagicȱfeversȱonly.ȱ
6.5 Antiprotozoal medicinesȱ
6.5.1 Antiamoebic and antigiardiasis medicinesȱ
Tablet:ȱ500ȱmgȱ(furoate).ȱ
diloxanideȱaȱȱ
a >25 kg.
Injection:ȱ500ȱmgȱinȱ100Ȭmlȱvial.ȱ
ȱmetronidazoleȱ Oralȱliquid:ȱ200ȱmgȱ(asȱbenzoate)/5ȱml.ȱ
6.5.2 Antileishmaniasis medicinesȱ
amphotericinȱBȱ
Asȱdeoxycholateȱorȱliposomal.ȱ
paromomycin Solutionȱforȱintramuscularȱinjection:ȱ750ȱmgȱofȱparomomycinȱ
baseȱpresentȱasȱtheȱsulfate.ȱ
sodiumȱstibogluconateȱorȱmeglumineȱ Injection:ȱ100ȱmg/ml,ȱ1ȱvialȱ=ȱ30ȱmlȱorȱ30%,ȱequivalentȱtoȱ
antimoniateȱ approximatelyȱ8.1%ȱantimonyȱinȱ5Ȭmlȱampoule.ȱȱ
6.5.3 Antimalarial medicines
6.5.3.1 For curative treatment
MedicinesȱforȱtheȱtreatmentȱofȱP.ȱfalciparumȱmalariaȱcasesȱshouldȱbeȱusedȱinȱcombination.ȱȱTheȱlistȱcurrentlyȱ
recommendsȱcombinationsȱaccordingȱtoȱtreatmentȱguidelines.ȱȱTheȱCommitteeȱrecognizesȱthatȱnotȱallȱofȱ
theseȱFDCsȱexistȱandȱencouragesȱtheirȱdevelopmentȱandȱrigorousȱtesting.ȱȱTheȱCommitteeȱalsoȱencouragesȱ
developmentȱandȱtestingȱofȱrectalȱdosageȱformulations.ȱ
Tablet:ȱ153ȱmgȱorȱ200ȱmgȱ(asȱhydrochloride).ȱ
amodiaquine*ȱ *ȱToȱbeȱusedȱ(a)ȱinȱcombinationȱwithȱartesunateȱ50ȱmgȱORȱȱ
(b)ȱmayȱbeȱusedȱaloneȱforȱtheȱtreatmentȱofȱP.vivax,ȱP.ovaleȱandȱ
P.malariaeȱinfections.ȱ
Oilyȱinjection:ȱ80ȱmg/mlȱinȱ1Ȭmlȱampoule.ȱ
artemether*ȱ
*ȱForȱuseȱinȱtheȱmanagementȱofȱsevereȱmalaria.ȱ
Tabletȱ(dispersible):ȱ20ȱmgȱ+ȱ120ȱmgȱ[c].ȱ
artemetherȱ+ȱlumefantrine*ȱ
*ȱNotȱrecommendedȱinȱtheȱfirstȱtrimesterȱofȱpregnancyȱorȱinȱ
childrenȱbelowȱ5ȱkg.ȱ
ȱ
WHOȱModelȱListȱ
Injection:ȱampoules,ȱcontainingȱ60ȱmgȱanhydrousȱartesunicȱacidȱ
withȱaȱseparateȱampouleȱofȱ5%ȱsodiumȱbicarbonateȱsolution.ȱ
Forȱuseȱinȱtheȱmanagementȱofȱsevereȱmalaria.ȱ
Rectalȱdosageȱform:ȱ50ȱmgȱ[c];ȱ200ȱmgȱcapsulesȱ(forȱpreȬreferralȱ
artesunate*ȱ treatmentȱofȱsevereȱmalariaȱonly;ȱpatientsȱshouldȱbeȱtakenȱtoȱanȱ
appropriateȱhealthȱfacilityȱforȱfollowȬupȱcare)ȱ[c].ȱ
Tablet:ȱ50ȱmg.ȱ
*ȱToȱbeȱusedȱinȱcombinationȱwithȱeitherȱamodiaquine,ȱmefloquineȱ
orȱsulfadoxineȱ+ȱpyrimethamine.ȱ
Oralȱliquid:ȱ50ȱmgȱ(asȱphosphateȱorȱsulfate)/5ȱml.ȱ
chloroquine*ȱ Tablet:ȱ100ȱmg;ȱ150ȱmgȱ(asȱphosphateȱorȱsulfate).ȱ
*ȱForȱuseȱonlyȱforȱtheȱtreatmentȱofȱP.vivaxȱinfection.ȱ
Capsule:ȱ100ȱmgȱ(asȱhydrochloride).ȱ
doxycycline*ȱ Tabletȱ(dispersible):ȱ100ȱmgȱ(asȱmonohydrate).ȱ
*ȱForȱuseȱonlyȱinȱcombinationȱwithȱquinine.ȱ
Tablet:ȱ250ȱmgȱ(asȱhydrochloride).ȱȱ
mefloquine*ȱ
*ȱToȱbeȱusedȱinȱcombinationȱwithȱartesunateȱ50ȱmg.ȱ
Tablet:ȱ7.5ȱmg;ȱ15ȱmgȱ(asȱdiphosphate).ȱ
primaquine*ȱ *ȱOnlyȱforȱuseȱtoȱachieveȱradicalȱcureȱofȱP.vivaxȱandȱP.ovaleȱ
infections,ȱgivenȱforȱ14ȱdays.ȱ
Injection:ȱ300ȱmgȱquinineȱhydrochloride/mlȱinȱ2Ȭmlȱampoule.ȱ
Tablet:ȱ300ȱmgȱ(quinineȱsulfate)ȱorȱ300ȱmgȱ(quinineȱbisulfate).ȱ
quinine*ȱ
*ȱForȱuseȱonlyȱinȱtheȱmanagementȱofȱsevereȱmalaria,ȱandȱshouldȱbeȱ
usedȱinȱcombinationȱwithȱdoxycycline.ȱ
sulfadoxineȱ+ȱpyrimethamine*ȱ
*ȱOnlyȱinȱcombinationȱwithȱartesunateȱ50ȱmg.ȱ
6.5.3.2 For prophylaxisȱ
Oralȱliquid:ȱ50ȱmgȱ(asȱphosphateȱorȱsulfate)/5ȱml.ȱ
chloroquine*ȱ Tablet:ȱ150ȱmgȱ(asȱphosphateȱorȱsulfate).ȱ
*ȱForȱuseȱonlyȱinȱcentralȱAmericanȱregions,ȱforȱuseȱforȱP.vivax.ȱ
Solidȱoralȱdosageȱform:ȱ100ȱmgȱ(asȱhydrochloride).ȱ
doxycyclineȱa ȱ
a >8 years.ȱ
mefloquineȱa ȱ
a >5 kg or >3 months.ȱ
proguanil*ȱ
*ȱForȱuseȱonlyȱinȱcombinationȱwithȱchloroquine.ȱ
ȱ
WHOȱModelȱListȱ
6.5.4 Antipneumocystosis and antitoxoplasmosis medicinesȱ
pyrimethamineȱ Tablet:ȱ25ȱmg.ȱ
sulfadiazineȱ Tablet:ȱ500ȱmg.ȱ
Injection:ȱȱ
80ȱmgȱ+ȱ16ȱmg/mlȱinȱ5Ȭmlȱampoule;ȱȱ
sulfamethoxazoleȱ+ȱtrimethoprimȱ 80ȱmgȱ+ȱ16ȱmg/mlȱinȱ10Ȭmlȱampoule.ȱ
Oralȱliquid:ȱ200ȱmgȱ+ȱ40ȱmg/5ȱmlȱ[c].ȱ
Tablet:ȱ100ȱmgȱ+ȱ20ȱmg;ȱ400ȱmgȱ+ȱ80ȱmgȱ[c].ȱ
pentamidineȱ Tablet:ȱ200ȱmg;ȱ300ȱmg.ȱ
6.5.5 Antitrypanosomal medicinesȱ
6.5.5.1 African trypanosomiasisȱ
Medicinesȱforȱtheȱtreatmentȱofȱ1stȱstageȱAfricanȱtrypanosomiasisȱ
Powderȱforȱinjection:ȱ200ȱmgȱ(pentamidineȱisetionate)ȱinȱvial.ȱ
pentamidine*ȱ *ȱToȱbeȱusedȱforȱtheȱtreatmentȱofȱTrypanosomaȱbruceiȱgambienseȱ
infection.ȱ
Powderȱforȱinjection:ȱ1ȱgȱinȱvial.ȱ
suraminȱsodium*ȱ *ȱToȱbeȱusedȱforȱtheȱtreatmentȱofȱtheȱinitialȱphaseȱofȱ
Trypanosomaȱbruceiȱrhodesienseȱinfection.ȱ
Medicinesȱforȱtheȱtreatmentȱofȱ2ndȱstageȱAfricanȱtrypanosomiasisȱ
Injection:ȱ200ȱmgȱ(hydrochloride)/mlȱinȱ100Ȭmlȱbottle.ȱ
eflornithine*ȱ *ȱToȱbeȱusedȱforȱtheȱtreatmentȱofȱTrypanosomaȱbruceiȱgambienseȱ
infection.ȱ
Injection:ȱ3.6%ȱsolution,ȱ5Ȭmlȱampouleȱ(180ȱmgȱofȱactiveȱȱ
melarsoprolȱ
compound).ȱ
Tablet:ȱ120ȱmg.ȱ
nifurtimox*ȱ *ȱOnlyȱtoȱbeȱusedȱinȱcombinationȱwithȱeflornithine,ȱforȱȱtheȱ
treatmentȱofȱTrypanosomaȱbruceiȱgambienseȱinfection.ȱ
6.5.5.2 American trypanosomiasisȱ
benznidazoleȱ Tablet:ȱ100ȱmg.ȱ
nifurtimoxȱ Tablet:ȱ30ȱmg;ȱ120ȱmg;ȱ250ȱmg.ȱ
7. ANTIMIGRAINE MEDICINESȱ
7.1 For treatment of acute attackȱ
acetylsalicylicȱacidȱ Tablet:ȱ300ȱmgȱtoȱ500ȱmg.ȱ
ibuprofenȱ[c]ȱ Tablet:ȱ200ȱmg;ȱ400ȱmg.ȱ
paracetamolȱ
ȱ
WHOȱModelȱListȱ
7.2 For prophylaxisȱ
ȱpropranololȱ Tablet:ȱ20ȱmg;ȱ40ȱmgȱ(hydrochloride).ȱ
8. ANTINEOPLASTIC, IMMUNOSUPPRESSIVES AND MEDICINES USED IN

PALLIATIVE CARE
8.1 Immunosuppressive medicines
Powderȱforȱinjection:ȱ100ȱmgȱ(asȱsodiumȱsalt)ȱinȱvial.ȱ
azathioprine
Tablet:ȱ50ȱmg.ȱ
Capsule:ȱ25ȱmg.ȱ
ciclosporin Concentrateȱforȱinjection:ȱ50ȱmg/mlȱinȱ1Ȭmlȱampouleȱforȱorganȱ
transplantation.ȱ
8.2 Cytotoxic medicinesȱ
allopurinolȱ[c]ȱ Tablet:ȱ100ȱmgȱtoȱ300ȱmg.ȱ
asparaginaseȱ Powderȱforȱinjection:ȱ10ȱ000ȱIUȱinȱvial.ȱ
bleomycinȱ Powderȱforȱinjection:ȱ15ȱmgȱ(asȱsulfate)ȱinȱvial.ȱ
calciumȱfolinateȱ
Tablet:ȱ15ȱmg.ȱ
carboplatinȱ Injection:ȱ50ȱmg/5ȱml;ȱ150ȱmg/15ȱml;ȱ450ȱmg/45ȱml;ȱ600ȱmg/60ȱml.ȱ
chlorambucilȱ Tablet:ȱ2ȱmg.ȱ
cyclophosphamideȱ
Tablet:ȱ25ȱmg.ȱ
cytarabineȱ Powderȱforȱinjection:ȱ100ȱmgȱinȱvial.ȱ
dacarbazineȱ Powderȱforȱinjection:ȱ100ȱmgȱinȱvial.ȱ
dactinomycinȱ Powderȱforȱinjection:ȱ500ȱmicrogramsȱinȱvial.ȱ
daunorubicinȱ Powderȱforȱinjection:ȱ50ȱmgȱ(asȱhydrochloride)ȱinȱvial.ȱ
doxorubicinȱ Powderȱforȱinjection:ȱ10ȱmg;ȱ50ȱmgȱ(hydrochloride)ȱinȱvial.ȱ
etoposideȱ
fluorouracilȱ Injection:ȱ50ȱmg/mlȱinȱ5Ȭmlȱampoule.ȱ
Solidȱoralȱdosageȱform:ȱ200ȱmg;ȱ250ȱmg;ȱ300ȱmg;ȱ400ȱmg;ȱ500ȱmg;ȱ
hydroxycarbamideȱ
1ȱg.ȱ
ifosfamideȱ Powderȱforȱinjection:ȱ1ȱgȱvial;ȱ2ȱgȱvial.ȱ
mercaptopurineȱ Tablet:ȱ50ȱmg.ȱ
ȱ
WHOȱModelȱListȱ
Injection:ȱ100ȱmg/mlȱinȱ4Ȭmlȱandȱ10Ȭmlȱampoules.ȱ
mesnaȱ
Powderȱforȱinjection:ȱ50ȱmgȱ(asȱsodiumȱsalt)ȱinȱvial.ȱ
methotrexateȱ
Tablet:ȱ2.5ȱmgȱ(asȱsodiumȱsalt).ȱ
procarbazineȱ Capsule:ȱ50ȱmgȱ(asȱhydrochloride).ȱ
vinblastineȱ Powderȱforȱinjection:ȱ10ȱmgȱ(sulfate)ȱinȱvial.ȱ
vincristineȱ Powderȱforȱinjection:ȱ1ȱmg;ȱ5ȱmgȱ(sulfate)ȱinȱvial.ȱ
8.3 Hormones and antihormonesȱ
Injection:ȱ4ȱmgȱdexamethasoneȱphosphateȱ(asȱdisodiumȱsalt)ȱinȱȱ
dexamethasoneȱ 1Ȭmlȱampoule.ȱ
hydrocortisoneȱ Powderȱforȱinjection:ȱ100ȱmgȱ(asȱsodiumȱsuccinate)ȱinȱvial.ȱ
ȱprednisoloneȱ
tamoxifenȱ Tablet:ȱ10ȱmg;ȱ20ȱmgȱ(asȱcitrate).ȱ
8.4 Medicines used in palliative care
TheȱWHOȱExpertȱCommitteeȱrecognizesȱtheȱimportanceȱofȱlistingȱspecificȱmedicinesȱinȱtheȱPalliativeȱCareȱ
Section.ȱȱSomeȱmedicinesȱcurrentlyȱusedȱinȱpalliativeȱcareȱareȱincludedȱinȱtheȱrelevantȱsectionsȱofȱtheȱModelȱ
List,ȱ accordingȱ toȱ theirȱ therapeuticȱ use,ȱ e.g.ȱ analgesics.ȱ ȱ Theȱ Guidelinesȱ forȱ Palliativeȱ Careȱ thatȱ wereȱ
referencedȱ inȱ theȱ previousȱ listȱ areȱ inȱ needȱ ofȱ update.ȱ ȱ Theȱ Committeeȱ expectsȱ applicationsȱ forȱ medicinesȱ
neededȱforȱpalliativeȱcareȱtoȱbeȱsubmittedȱforȱtheȱnextȱmeeting.ȱForȱpalliativeȱcareȱmedicinesȱinȱchildren,ȱ
seeȱtheȱsecondȱEMLc.ȱ
9. ANTIPARKINSONISM MEDICINESȱ
Injection:ȱ5ȱmgȱ(lactate)ȱinȱ1Ȭmlȱampoule.ȱ
biperidenȱ
Tablet:ȱ2ȱmgȱ(hydrochloride).ȱ
levodopaȱ+ȱȱcarbidopaȱȱ Tablet:ȱ100ȱmgȱ+ȱ10ȱmg;ȱ250ȱmgȱ+ȱ25ȱmg.ȱ
10. MEDICINES AFFECTING THE BLOODȱ
10.1 Antianaemia medicinesȱ
Oralȱliquid:ȱequivalentȱtoȱ25ȱmgȱironȱ(asȱsulfate)/ml.ȱ
ferrousȱsaltȱ
Tablet:ȱequivalentȱtoȱ60ȱmgȱiron.ȱ
Tabletȱequivalentȱtoȱ60ȱmgȱironȱ+ȱ400ȱmicrogramsȱfolicȱacidȱ
ferrousȱsaltȱ+ȱfolicȱacidȱȱ
(Nutritionalȱsupplementȱforȱuseȱduringȱpregnancy).ȱ
folicȱacidȱ Tablet:ȱ1ȱmg;ȱ5ȱmg.ȱ
hydroxocobalaminȱ Injection:ȱ1ȱmgȱinȱ1Ȭmlȱampoule.ȱ
ȱ
WHOȱModelȱListȱ
10.2 Medicines affecting coagulationȱ
heparinȱsodiumȱ Injection:ȱ1000ȱIU/ml;ȱ5000ȱIU/ml;ȱ20ȱ000ȱIU/mlȱinȱ1Ȭmlȱampoule.ȱ
Injection:ȱ1ȱmg/mlȱ[c];ȱ10ȱmg/mlȱinȱ5Ȭmlȱampoule.ȱ
phytomenadioneȱ
Tablet:ȱ10ȱmg.ȱ
protamineȱsulfateȱ Injection:ȱ10ȱmg/mlȱinȱ5Ȭmlȱampoule.ȱ
ȱwarfarinȱ Tablet:ȱ1ȱmg;ȱ2ȱmg;ȱ5ȱmgȱ(sodiumȱsalt).ȱ
heparinȱsodiumȱȱ Injection:ȱ1000ȱIU/ml;ȱ5000ȱIU/mlȱinȱ1Ȭmlȱampoule.ȱ
protamineȱsulfateȱȱ Injection:ȱ10ȱmg/mlȱinȱ5Ȭmlȱampoule.ȱ
ȱwarfarinȱȱ Tablet:ȱ0.5ȱmg;ȱ1ȱmg;ȱ2ȱmg;ȱ5ȱmgȱ(sodiumȱsalt).ȱ
11. BLOOD PRODUCTS AND PLASMA SUBSTITUTES
11.1 Plasma substitutes
Injectableȱsolution:ȱ6%.ȱ
ȱdextranȱ70*ȱ
*ȱPolygeline,ȱinjectableȱsolution,ȱ3.5%ȱisȱconsideredȱasȱequivalent.ȱ
11.2 Plasma fractions for specific use
Allȱ plasmaȱ fractionsȱ shouldȱ complyȱ withȱ theȱ WHOȱ Requirementsȱ forȱ theȱ Collection,ȱ Processingȱ andȱ
Qualityȱ Controlȱ ofȱ Blood,ȱ Bloodȱ Componentsȱ andȱ Plasmaȱ Derivativesȱ (Revisedȱ 1992).ȱ (WHOȱ Technicalȱ
ReportȱSeries,ȱNo.ȱ840,ȱ1994,ȱAnnexȱ2).ȱ
ȱfactorȱVIIIȱconcentrateȱ Dried.ȱ
ȱfactorȱIXȱcomplexȱ(coagulationȱ
Dried.ȱ
factors,ȱII,ȱVII,ȱIX,ȱX)ȱconcentrateȱ
Intramuscularȱadministration:ȱ16%ȱproteinȱsolution.*ȱ
Intravenousȱadministration:ȱ5%;ȱ10%ȱproteinȱsolution.**ȱ
humanȱnormalȱimmunoglobulinȱ Subcutaneousȱadministration:ȱ15%;ȱ16%ȱproteinȱsolution.*ȱȱ
*ȱȱȱIndicatedȱforȱprimaryȱimmuneȱdeficiency.ȱ
**ȱIndicatedȱforȱprimaryȱimmuneȱdeficiencyȱandȱKawasakiȱdisease.ȱ
12. CARDIOVASCULAR MEDICINES
12.1 Antianginal medicines
ȱatenololȱ Tablet:ȱ50ȱmg;ȱ100ȱmg.ȱ
glycerylȱtrinitrate Tabletȱ(sublingual):ȱ500ȱmicrograms.ȱ
ȱisosorbideȱdinitrateȱ Tabletȱ(sublingual):ȱ5ȱmg.ȱ
verapamilȱ Tablet:ȱ40ȱmg;ȱ80ȱmgȱ(hydrochloride).ȱ
12.2 Antiarrhythmic medicines
ȱ
WHOȱModelȱListȱ
Injection:ȱ250ȱmicrograms/mlȱinȱ2Ȭmlȱampoule.ȱ
digoxinȱ Oralȱliquid:ȱ50ȱmicrograms/ml.ȱ
Tablet:ȱ62.5ȱmicrograms;ȱ250ȱmicrograms.ȱ
Injection:ȱ100ȱmicrograms/mlȱ(asȱacidȱtartrateȱorȱhydrochloride)ȱinȱ
epinephrineȱ(adrenaline)ȱ
10Ȭmlȱampoule.ȱ
lidocaineȱ Injection:ȱ20ȱmgȱ(hydrochloride)/mlȱinȱ5Ȭmlȱampoule.ȱ
Injection:ȱ2.5ȱmgȱ(hydrochloride)/mlȱinȱ2Ȭmlȱampoule.ȱ
verapamilȱ
Tablet:ȱ40ȱmg;ȱ80ȱmgȱ(hydrochloride).ȱ
Injection:ȱ50ȱmg/mlȱinȱ3Ȭmlȱampouleȱ(hydrochloride).ȱ
amiodaroneȱ
Tabletȱ(HCI):ȱ100ȱmg;ȱ200ȱmg;ȱ400ȱmgȱ(hydrochloride).ȱ
12.3 Antihypertensive medicines
ȱamlodipineȱ Tablet:ȱ5ȱmg.ȱ
ȱenalaprilȱ Tablet:ȱ2.5ȱmg;ȱ5ȱmg.ȱ
Powderȱforȱinjection:ȱ20ȱmgȱ(hydrochloride)ȱinȱampoule.ȱ
Tablet:ȱ25ȱmg;ȱ50ȱmgȱ(hydrochloride).ȱ
*ȱHydralazineȱisȱlistedȱforȱuseȱinȱtheȱacuteȱmanagementȱofȱsevereȱ
hydralazine*ȱ
pregnancyȬinducedȱhypertensionȱonly.ȱItsȱuseȱinȱtheȱtreatmentȱofȱ
essentialȱhypertensionȱisȱnotȱrecommendedȱinȱviewȱofȱtheȱ
availabilityȱofȱmoreȱevidenceȱofȱefficacyȱandȱsafetyȱofȱotherȱ
medicines.ȱ
ȱhydrochlorothiazideȱ
Solidȱoralȱdosageȱform:ȱ12.5ȱmg;ȱ25ȱmg.ȱ
Tablet:ȱ250ȱmg.ȱ
*ȱMethyldopaȱisȱlistedȱforȱuseȱinȱtheȱmanagementȱofȱpregnancyȬ
methyldopa* inducedȱhypertensionȱonly.ȱItsȱuseȱinȱtheȱtreatmentȱofȱessentialȱ
hypertensionȱisȱnotȱrecommendedȱinȱviewȱofȱtheȱavailabilityȱofȱ
moreȱevidenceȱofȱefficacyȱandȱsafetyȱofȱotherȱmedicines.ȱ
sodiumȱnitroprusside Powderȱforȱinfusion:ȱ50ȱmgȱinȱampoule.ȱ
12.4 Medicines used in heart failure
Injection:ȱ250ȱmicrograms/mlȱinȱ2Ȭmlȱampoule.ȱ
digoxin Oralȱliquid:ȱ50ȱmicrograms/ml.ȱ
Tablet:ȱ62.5ȱmicrograms;ȱ250ȱmicrograms.ȱ
ȱenalapril Tablet:ȱ2.5ȱmg;ȱ5ȱmg.ȱ
ȱ
WHOȱModelȱListȱ
ȱfurosemide Oralȱliquid:ȱ20ȱmg/5ȱmlȱ[c].ȱ
Tablet:ȱ40ȱmg.ȱ
ȱhydrochlorothiazide
Solidȱoralȱdosageȱform:ȱ25ȱmg.ȱ
dopamine Injection:ȱ40ȱmg/mlȱ(hydrochloride)ȱinȱ5Ȭmlȱvial.ȱ
12.5 Antithrombotic medicines
acetylsalicylicȱacid Tablet:ȱ100ȱmg.ȱ
streptokinaseȱ Powderȱforȱinjection:ȱ1.5ȱmillionȱIUȱinȱvial.ȱ
12.6 Lipid-lowering agents
Tablet:ȱ5ȱmg;ȱ10ȱmg;ȱ20ȱmg;ȱ40ȱmg.ȱ
ȱsimvastatin*ȱ
*ȱForȱuseȱinȱhighȬriskȱpatients.ȱ
13. DERMATOLOGICAL MEDICINES (topical)
13.1 Antifungal medicines
benzoicȱacidȱ+ȱsalicylicȱacidȱȱ Creamȱorȱointment:ȱ6%ȱ+ȱ3%.ȱ
ȱmiconazoleȱ Creamȱorȱointment:ȱ2%ȱ(nitrate).ȱ
sodiumȱthiosulfateȱ Solution:ȱ15%.ȱ
seleniumȱsulfideȱ DetergentȬbasedȱsuspension:ȱ2%.ȱ
13.2 Anti-infective medicines
ȱmethylrosaniliniumȱchlorideȱ Aqueousȱsolution:ȱ0.5%.ȱ
(gentianȱviolet)ȱ Tincture:ȱ0.5%.ȱ
neomycinȱsulfateȱ+ȱȱbacitracinȱȱ Ointment:ȱ5ȱmgȱneomycinȱsulfateȱ+ȱ250ȱIUȱbacitracinȱzinc/g.ȱ
potassiumȱpermanganateȱ Aqueousȱsolution:ȱ1:10ȱ000.ȱ
Cream:ȱ1%.ȱ
silverȱsulfadiazineȱa ȱ
a >2 months.ȱ
13.3 Anti-inflammatory and antipruritic medicines
Creamȱorȱointment:ȱ0.1%ȱ(asȱvalerate).ȱ
ȱbetamethasoneȱa ȱ
a Hydrocortisone preferred in neonates.ȱ
ȱcalamineȱlotionȱ Lotion.ȱ
ȱhydrocortisoneȱ Creamȱorȱointment:ȱ1%ȱ(acetate).ȱ
ȱ
WHOȱModelȱListȱ
13.4 Astringent medicines
aluminiumȱdiacetateȱ Solution:ȱ5%.ȱ
13.5 Medicines affecting skin differentiation and proliferation
benzoylȱperoxide Creamȱorȱlotion:ȱ5%.ȱ
coalȱtarȱ Solution:ȱ5%.ȱ
dithranolȱ Ointment:ȱ0.1%ȱtoȱ2%.ȱ
fluorouracilȱ Ointment:ȱ5%.ȱ
ȱpodophyllumȱresinȱ Solution:ȱ10%ȱtoȱ25%.ȱ
salicylicȱacid Solution:ȱ5%.ȱ
urea Creamȱorȱointment:ȱ10%.ȱ
13.6 Scabicides and pediculicides
Lotion:ȱ25%.ȱ
ȱbenzylȱbenzoateȱa ȱ
a >2 years.
Cream:ȱ5%.ȱ
permethrinȱ
Lotion:ȱ1%.ȱ
14. DIAGNOSTIC AGENTS
14.1 Ophthalmic medicines
fluoresceinȱ Eyeȱdrops:ȱ1%ȱ(sodiumȱsalt).ȱ
ȱtropicamideȱ Eyeȱdrops:ȱ0.5%.ȱ
14.2 Radiocontrast media
Injection:ȱ140ȱmgȱtoȱ420ȱmgȱiodineȱ(asȱsodiumȱorȱmeglumineȱ
ȱamidotrizoate
salt)/mlȱinȱ20Ȭmlȱampoule.ȱ
bariumȱsulfate Aqueousȱsuspension.ȱ
Injection:ȱ140ȱmgȱtoȱ350ȱmgȱiodine/mlȱinȱ5Ȭml;ȱ10Ȭml;ȱ20Ȭmlȱ
ȱiohexol
ampoules.ȱ
bariumȱsulfateȱ[c]ȱ Aqueousȱsuspension.ȱ
ȱmeglumineȱiotroxate Solution:ȱ5gȱtoȱ8ȱgȱiodineȱinȱ100ȱmlȱtoȱ250ȱml.ȱ
15. DISINFECTANTS AND ANTISEPTICS
15.1 Antiseptics
Solution:ȱ5%ȱ(digluconate);ȱ20%ȱ(digluconate)ȱ(needsȱtoȱbeȱdilutedȱ
ȱchlorhexidineȱ
priorȱtoȱuseȱforȱcordȱcare)ȱ[c].ȱ
ȱethanolȱ Solution:ȱ70%ȱ(denatured).ȱ
ȱpolyvidoneȱiodineȱ Solution:ȱ10%.ȱ
ȱ
WHOȱModelȱListȱ
15.2 Disinfectants
ȱchlorineȱbaseȱcompound Powder:ȱ(0.1%ȱavailableȱchlorine)ȱforȱsolution.ȱ
ȱchloroxylenol Solution:ȱ4.8%.ȱ
glutaral Solution:ȱ2%.ȱ
16. DIURETICS
amiloride Tablet:ȱ5ȱmgȱ(hydrochloride).ȱ
ȱfurosemide Oralȱliquid:ȱ20ȱmg/5ȱmlȱ[c].ȱ
Tablet:ȱ10ȱmgȱ[c];ȱ20ȱmgȱ[c];ȱ40ȱmg.ȱ
ȱhydrochlorothiazide Solidȱoralȱdosageȱform:ȱ25ȱmg.ȱ
mannitol Injectableȱsolution:ȱ10%;ȱ20%.ȱ
spironolactone Tablet:ȱ25ȱmg.ȱ
ȱhydrochlorothiazide Tabletȱ(scored):ȱ25ȱmg.ȱ
mannitolȱ Injectableȱsolution:ȱ10%;ȱ20%.
Oralȱliquid:ȱ5ȱmg/5ȱml;ȱ10ȱmg/5ȱml;ȱ25ȱmg/5ȱml.ȱ
spironolactoneȱ
Tablet:ȱ25ȱmg.
17. GASTROINTESTINAL MEDICINES
AgeȬappropriateȱformulationsȱandȱdosesȱincludingȱlipase,ȱproteaseȱandȱ
ȱpancreaticȱenzymes
amylase.ȱ
17.1 Antacids and other antiulcer medicinesȱ
aluminiumȱhydroxideȱ
Tablet:ȱ500ȱmg.ȱ
magnesiumȱhydroxideȱ Oralȱliquid:ȱequivalentȱtoȱ550ȱmgȱmagnesiumȱoxide/10ȱml.ȱ
Powderȱforȱoralȱliquid:ȱ20ȱmg;ȱ40ȱmgȱsachets.ȱ
ȱomeprazole
ȱranitidineȱ Oralȱliquid:ȱ75ȱmg/5ȱml.ȱ
17.2 Antiemetic medicines
dexamethasoneȱ Oralȱliquid:ȱ0.5ȱmg/5ȱml;ȱ2ȱmg/5ȱml.ȱ
Solidȱoralȱdosageȱform:ȱ0.5ȱmg;ȱ0.75ȱmg;ȱ1.5ȱmg;ȱ4ȱmg.ȱ
ȱ
WHOȱModelȱListȱ
metoclopramideȱaȱȱ Tablet:ȱ10ȱmgȱ(hydrochloride).ȱ
a Not in neonates.ȱ
Injection:ȱ2ȱmgȱbase/mlȱinȱ2Ȭmlȱampouleȱ(asȱhydrochloride).ȱ
Oralȱliquid:ȱ4ȱmgȱbase/5ȱml.ȱ
ondansetronȱaȱ Solidȱoralȱdosageȱform:ȱEqȱ4ȱmgȱbase;ȱEqȱ8ȱmgȱbase;ȱEqȱ24ȱmgȱ
base.ȱ
a >1 month.ȱ
17.3 Anti-inflammatory medicines
Retentionȱenema.ȱ
ȱsulfasalazineȱ Suppository:ȱ500ȱmg.ȱ
Tablet:ȱ500ȱmg.ȱ
Retentionȱenema.ȱ
ȱhydrocortisoneȱ Suppository:ȱ25ȱmgȱ(acetate).ȱ
(theȱȱonlyȱappliesȱtoȱhydrocortisoneȱretentionȱenema).ȱ
17.4 Laxatives
ȱsenna Tablet:ȱ7.5ȱmgȱ(sennosides)ȱ(orȱtraditionalȱdosageȱforms).ȱ
17.5 Medicines used in diarrhoea
17.5.1 Oral rehydration
glucose:ȱȱ ȱ ȱ 75ȱmEqȱȱ
sodium:ȱȱ ȱ ȱ 75ȱmEqȱorȱmmol/Lȱȱ
chloride:ȱȱ ȱ ȱ 65ȱmEqȱorȱmmol/Lȱ
potassium:ȱȱ ȱ ȱ 20ȱmEqȱorȱmmol/Lȱȱ
citrate:ȱȱȱ ȱ ȱ 10ȱmmol/Lȱȱ
osmolarity:ȱȱ ȱ ȱ 245ȱmOsm/Lȱȱ
glucose:ȱȱ ȱ ȱ 13.5ȱg/Lȱȱ
sodiumȱchloride:ȱ ȱ ȱȱ2.6ȱg/Lȱ
oralȱrehydrationȱsaltsȱ potassiumȱchloride:ȱ ȱ ȱȱ1.5ȱg/Lȱȱ
trisodiumȱcitrateȱdihydrate+:ȱ ȱȱ2.9ȱg/Lȱȱ
+ȱtrisodiumȱcitrateȱdihydrateȱmayȱbeȱreplacedȱbyȱsodiumȱ
hydrogenȱcarbonateȱ(sodiumȱbicarbonate)ȱ2.5ȱg/L.ȱHowever,ȱasȱtheȱ
stabilityȱofȱthisȱlatterȱformulationȱisȱveryȱpoorȱunderȱtropicalȱ
conditions,ȱitȱisȱonlyȱrecommendedȱwhenȱmanufacturedȱforȱ
immediateȱuse.ȱȱ
Powderȱforȱdilutionȱinȱ200ȱml;ȱ500ȱml;ȱ1ȱL.ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
WHOȱModelȱListȱ
17.5.2 Medicines for diarrhoea in children
Oralȱliquid:ȱinȱ10ȱmgȱperȱunitȱdosageȱforms.ȱ
Tablet:ȱinȱ10ȱmgȱperȱunitȱdosageȱforms.ȱ
zincȱsulfate*ȱ
*ȱInȱacuteȱdiarrhoeaȱzincȱsulfateȱshouldȱbeȱusedȱasȱanȱadjunctȱtoȱ
oralȱrehydrationȱsalts.ȱ
17.5.3 Antidiarrhoeal (symptomatic) medicines in adults
Tablet:ȱ30ȱmgȱ(phosphate).ȱ
codeine*ȱ *ȱTheȱroleȱofȱthisȱitemȱhasȱbeenȱquestionedȱandȱitsȱcontinuedȱ
inclusionȱonȱtheȱlistȱwillȱbeȱreviewedȱatȱtheȱnextȱmeetingȱofȱtheȱ
ExpertȱCommittee.ȱ
18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES
18.1 Adrenal hormones and synthetic substitutes
fludrocortisoneȱȱ Tablet:ȱ100ȱmicrograms.ȱ
hydrocortisoneȱȱ Tablet:ȱ5ȱmg;ȱ10ȱmg;ȱ20ȱmg.ȱ
18.2 Androgens
testosteroneȱ Injection:ȱ200ȱmgȱ(enantate)ȱinȱ1Ȭmlȱampoule.ȱ
18.3 Contraceptives
18.3.1 Oral hormonal contraceptives
ȱethinylestradiolȱ+ȱȱlevonorgestrelȱȱ Tablet:ȱ30ȱmicrogramsȱ+ȱ150ȱmicrograms.ȱ
ȱethinylestradiolȱ+ȱȱnorethisteroneȱȱ Tablet:ȱ35ȱmicrogramsȱ+ȱ1ȱmg.ȱ
levonorgestrel Tablet:ȱ30ȱmicrograms;ȱ750ȱmicrogramsȱ(packȱofȱtwo);ȱ1.5ȱmg.ȱ
18.3.2 Injectable hormonal contraceptives
estradiolȱcypionateȱ+ȱ
Injection:ȱ5ȱmgȱ+ȱ25ȱmg.ȱ
medroxyprogesteroneȱacetateȱȱ
medroxyprogesteroneȱacetateȱ Depotȱinjection:ȱ150ȱmg/mlȱinȱ1Ȭmlȱvial.ȱ
norethisteroneȱenantateȱ Oilyȱsolution:ȱ200ȱmg/mlȱinȱ1Ȭmlȱampoule.ȱ
18.3.3 Intrauterine devices
copperȬcontainingȱdeviceȱ
18.3.4 Barrier methods
condomsȱ
diaphragmsȱ
18.3.5 Implantable contraceptives
TwoȬrodȱlevonorgestrelȬreleasingȱimplant,ȱeachȱrodȱcontainingȱ
levonorgestrelȬreleasingȱimplant
75ȱmgȱofȱlevonorgestrelȱ(150ȱmgȱtotal).
ȱ
WHOȱModelȱListȱ
18.4 Estrogens
Tablet:ȱ10ȱmicrograms;ȱ50ȱmicrograms.ȱ
*ȱTheȱpublicȱhealthȱrelevanceȱand/orȱcomparativeȱefficacyȱand/orȱ
ȱethinylestradiol*ȱ safetyȱofȱthisȱitemȱhasȱbeenȱquestionedȱandȱitsȱcontinuedȱinclusionȱ
onȱtheȱlistȱwillȱbeȱreviewedȱatȱtheȱnextȱmeetingȱofȱtheȱExpertȱ
Committee.ȱ
18.5 Insulins and other antidiabetic agents
glibenclamideȱ Tablet:ȱ2.5ȱmg;ȱ5ȱmg.ȱ
insulinȱinjectionȱ(soluble)ȱ Injection:ȱ40ȱIU/mlȱinȱ10Ȭmlȱvial;ȱ100ȱIU/mlȱinȱ10Ȭmlȱvial.ȱȱ
Injection:ȱ40ȱIU/mlȱinȱ10Ȭmlȱvial;ȱ100ȱIU/mlȱinȱ10Ȭmlȱvialȱȱ
intermediateȬactingȱinsulinȱȱ
(asȱcompoundȱinsulinȱzincȱsuspensionȱorȱisophaneȱinsulin).ȱ
metforminȱ Tablet:ȱ500ȱmgȱ(hydrochloride).ȱ
metforminȱȱ Tablet:ȱ500ȱmgȱ(hydrochloride).ȱ
18.6 Ovulation inducersȱ
clomifeneȱ Tablet:ȱ50ȱmgȱ(citrate).ȱ
18.7 Progestogensȱ
Tablet:ȱ5ȱmg.ȱ
norethisterone*ȱ safetyȱofȱthisȱitemȱhasȱbeenȱquestionedȱandȱitsȱcontinuedȱinclusionȱ
Committee.ȱ
Tablet:ȱ5ȱmg.ȱ
medroxyprogesteroneȱacetate*ȱ safetyȱofȱthisȱitemȱhasȱbeenȱquestionedȱandȱitsȱcontinuedȱinclusionȱ
Committee.ȱ
18.8 Thyroid hormones and antithyroid medicinesȱ
Tablet:ȱ25ȱmicrogramsȱ[c];ȱ50ȱmicrograms;ȱ100ȱmicrogramsȱ
levothyroxineȱ
(sodiumȱsalt).ȱ
potassiumȱiodideȱ Tablet:ȱ60ȱmg.ȱ
ȱpropylthiouracilȱ Tablet:ȱ50ȱmg.ȱ
Lugolȇsȱsolutionȱ Oralȱliquid:ȱaboutȱ130ȱmgȱtotalȱiodine/ml.ȱ
potassiumȱiodideȱ Tablet:ȱ60ȱmg.ȱ
propylthiouracilȱȱ Tablet:ȱ50ȱmg.ȱ
ȱ
WHOȱModelȱListȱ
19. IMMUNOLOGICALS
19.1 Diagnostic agents
AllȱtuberculinsȱshouldȱcomplyȱwithȱtheȱWHOȱRequirementsȱforȱTuberculinsȱ(Revisedȱ1985).ȱWHOȱExpertȱ
CommitteeȱonȱBiologicalȱStandardization.ȱThirtyȬsixthȱreport.ȱ(WHOȱTechnicalȱReportȱSeries,ȱNo.ȱ745,ȱ
1987,ȱAnnexȱ1).ȱȱ
tuberculin,ȱpurifiedȱproteinȱderivativeȱ
Injection.ȱ
(PPD)ȱ
19.2 Sera and immunoglobulins
AllȱplasmaȱfractionsȱshouldȱcomplyȱwithȱtheȱWHOȱRequirementsȱforȱtheȱCollection,ȱProcessingȱandȱ
QualityȱControlȱofȱBlood,ȱBloodȱComponentsȱandȱPlasmaȱDerivativesȱ(Revisedȱ1992).ȱWHOȱExpertȱ
CommitteeȱonȱBiologicalȱStandardization.ȱFortyȬthirdȱreport.ȱ(WHOȱTechnicalȱReportȱSeries,ȱNo.ȱ840,ȱ1994,ȱ
Annexȱ2).ȱ
antiȬDȱimmunoglobulinȱ(human)ȱ Injection:ȱ250ȱmicrogramsȱinȱsingleȬdoseȱvial.ȱ
antitetanusȱimmunoglobulinȱ(human)ȱ Injection:ȱ500ȱIUȱinȱvial.ȱ
Injection.ȱ
antivenomȱimmunoglobulin*ȱ
*ȱExactȱtypeȱtoȱbeȱdefinedȱlocally.ȱ
diphtheriaȱantitoxinȱ Injection:ȱ10ȱ000ȱIU;ȱ20ȱ000ȱIUȱinȱvial.ȱ
ȱrabiesȱimmunoglobulinȱ Injection:ȱ150ȱIU/mlȱinȱvial.ȱ
19.3 Vaccines
SelectionȱofȱvaccinesȱfromȱtheȱModelȱListȱwillȱneedȱtoȱbeȱdeterminedȱbyȱeachȱcountryȱafterȱconsiderationȱofȱ
internationalȱ recommendations,ȱ epidemiologyȱ andȱ nationalȱ priorities.ȱ Theȱ listȱ belowȱ detailsȱ theȱ vaccinesȱ
forȱwhichȱthereȱisȱeitherȱaȱrecommendationȱfromȱtheȱStrategicȱAdvisoryȱGroupȱofȱExpertsȱonȱImmunizationȱ
(SAGE)ȱ (http://www.who.int/immunization/sage_conclusions/en/index.html)ȱ and/orȱ aȱ WHOȱ positionȱ
paperȱ (http://www.who.int/immunization/documents/positionpapers/en/index.html).ȱ Thisȱ siteȱ willȱ beȱ
updatedȱ asȱ newȱ positionȱ papersȱ areȱ publishedȱ andȱ containsȱ theȱ mostȱ recentȱ informationȱ andȱ
recommendations.ȱ
AllȱvaccinesȱshouldȱcomplyȱwithȱtheȱWHOȱRequirementsȱforȱBiologicalȱSubstances.ȱ
BCGȱvaccineȱ ȱ
choleraȱvaccineȱ ȱ
diphtheriaȱvaccineȱ ȱ
hepatitisȱAȱvaccineȱ ȱ
hepatitisȱBȱvaccineȱ ȱ
Haemophilusȱinfluenzaeȱtypeȱbȱvaccineȱ ȱ
influenzaȱvaccineȱ ȱ
Japaneseȱencephalitisȱvaccineȱ ȱ
measlesȱvaccineȱ ȱ
meningococcalȱmeningitisȱvaccineȱ ȱ
mumpsȱvaccineȱȱ ȱ
ȱ
WHOȱModelȱListȱ
pertussisȱvaccineȱ ȱ
pneumococcalȱvaccineȱ ȱ
poliomyelitisȱvaccineȱȱ ȱ
rabiesȱvaccineȱȱ ȱ
rotavirusȱvaccineȱ ȱ
rubellaȱvaccineȱȱ ȱ
tetanusȱvaccineȱȱ ȱ
typhoidȱvaccineȱȱ ȱ
varicellaȱvaccineȱ ȱ
yellowȱfeverȱvaccineȱ ȱ
20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE

INHIBITORSȱ
ȱalcuroniumȱ Injection:ȱ5ȱmgȱ(chloride)/mlȱinȱ2Ȭmlȱampoule.ȱ
Injection:ȱ500ȱmicrogramsȱinȱ1Ȭmlȱampoule;ȱ2.5ȱmgȱ(metilsulfate)ȱ
neostigmineȱ inȱ1Ȭmlȱampoule.ȱ
Tablet:ȱ15ȱmgȱ(bromide).ȱ
Injection:ȱ50ȱmgȱ(chloride)/mlȱinȱ2Ȭmlȱampoule.ȱ
suxamethoniumȱ
Powderȱforȱinjectionȱ(chloride),ȱinȱvial.ȱ
ȱvecuroniumȱ[c]ȱ Powderȱforȱinjection:ȱ10ȱmgȱ(bromide)ȱinȱvial.ȱ
Injection:ȱ1ȱmgȱinȱ1Ȭmlȱampoule.ȱ
pyridostigmineȱ
Tablet:ȱ60ȱmgȱ(bromide).ȱ
ȱvecuroniumȱ Powderȱforȱinjection:ȱ10ȱmgȱ(bromide)ȱinȱvial.ȱ
21. OPHTHALMOLOGICAL PREPARATIONS
ThisȱsectionȱwillȱbeȱreviewedȱatȱtheȱnextȱmeetingȱofȱtheȱExpertȱCommittee.ȱ
21.1 Anti-infective agents
aciclovirȱ Ointment:ȱ3%ȱW/W.ȱ
ȱgentamicin Solutionȱ(eyeȱdrops):ȱ0.3%ȱ(sulfate).ȱ
ȱtetracycline Eyeȱointment:ȱ1%ȱ(hydrochloride).ȱ
21.2 Anti-inflammatory agentsȱ
ȱprednisolone Solutionȱ(eyeȱdrops):ȱ0.5%ȱ(sodiumȱphosphate).ȱ
21.3 Local anaestheticsȱ
Solutionȱ(eyeȱdrops):ȱ0.5%ȱ(hydrochloride).ȱ
ȱtetracaineȱa
a Not in preterm neonates.ȱ
ȱ
ȱ
WHOȱModelȱListȱ
21.4 Miotics and antiglaucoma medicinesȱ
acetazolamideȱ Tablet:ȱ250ȱmg.ȱ
ȱpilocarpineȱ Solutionȱ(eyeȱdrops):ȱ2%;ȱ4%ȱ(hydrochlorideȱorȱnitrate).ȱ
ȱtimololȱ Solutionȱ(eyeȱdrops):ȱ0.25%;ȱ0.5%ȱ(asȱmaleate).ȱ
21.5 Mydriatics
Solutionȱ(eyeȱdrops):ȱ0.1%;ȱ0.5%;ȱ1%ȱ(sulfate).ȱ
atropine*ȱ aȱȱ *ȱ[c]ȱORȱhomatropineȱORȱcyclopentolate.ȱ
a >3 months.ȱ
epinephrineȱ(adrenaline)ȱ Solutionȱ(eyeȱdrops):ȱ2%ȱ(asȱhydrochloride).ȱ
22. OXYTOCICS AND ANTIOXYTOCICS
22.1 Oxytocics
ȱergometrineȱ Injection:ȱ200ȱmicrogramsȱ(hydrogenȱmaleate)ȱinȱ1Ȭmlȱampoule.ȱȱ
oxytocin Injection:ȱ10ȱIUȱinȱ1Ȭmlȱampoule.ȱ
Tablet:ȱ200ȱmicrograms.*ȱ
misoprostolȱ *ȱForȱmanagementȱofȱincompleteȱabortionȱandȱmiscarriage.ȱ
Vaginalȱtablet:ȱ25ȱmicrograms.ȱ
mifepristone*ȱ–ȱmisoprostol*ȱ Tabletȱ200ȱmgȱ–ȱtabletȱ200ȱmicrograms.ȱ
*ȱRequiresȱcloseȱmedicalȱsupervision.ȱ
Whereȱpermittedȱunderȱ
nationalȱlawȱandȱwhereȱ ȱ
culturallyȱacceptable.ȱ
ȱ
ȱ
22.2 Antioxytocics (tocolytics)
nifedipineȱ ImmediateȬreleaseȱcapsule:ȱ10ȱmg.ȱ
23. PERITONEAL DIALYSIS SOLUTION
intraperitonealȱdialysisȱsolutionȱ
Parenteralȱsolution.ȱ
ȱ(ofȱappropriateȱcomposition)ȱ
24. PSYCHOTHERAPEUTIC MEDICINES
24.1 Medicines used in psychotic disorders
ȱchlorpromazineȱ Oralȱliquid:ȱ25ȱmgȱ(hydrochloride)/5ȱml.ȱ
Tablet:ȱ100ȱmgȱ(hydrochloride).ȱ
ȱfluphenazineȱ Injection:ȱ25ȱmgȱ(decanoateȱorȱenantate)ȱinȱ1Ȭmlȱampoule.ȱ
ȱ
WHOȱModelȱListȱ
ȱhaloperidolȱ
chlorpromazine Oralȱliquid:ȱ25ȱmgȱ(hydrochloride)/5ȱml.ȱ
Tablet:ȱ10ȱmg;ȱ25ȱmg;ȱ50ȱmg;ȱ100ȱmgȱ(hydrochloride).ȱ
haloperidol Oralȱliquid:ȱ2ȱmg/ml.ȱ
Solidȱoralȱdosageȱform:ȱ0.5ȱmg;ȱ2ȱmg;ȱ5ȱmg.ȱ
24.2 Medicines used in mood disordersȱ
24.2.1 Medicines used in depressive disordersȱ

ȱamitriptyline Tablet:ȱ25ȱmgȱ(hydrochloride).ȱ
fluoxetineȱ Solidȱoralȱdosageȱform:ȱ20ȱmgȱ(presentȱasȱhydrochloride).ȱ
Solidȱoralȱdosageȱform:ȱ20ȱmgȱ(presentȱasȱhydrochloride).ȱ
fluoxetineȱa
a >8 years.ȱ
24.2.2 Medicines used in bipolar disordersȱ

carbamazepine Tabletȱ(scored):ȱ100ȱmg;ȱ200ȱmg.ȱ
lithiumȱcarbonate Solidȱoralȱdosageȱform:ȱ300ȱmg.ȱ
valproicȱacid Tabletȱ(entericȬcoated):ȱ200ȱmg;ȱ500ȱmgȱ(sodiumȱvalproate).ȱ
24.3 Medicines used in generalized anxiety ȱ

ȱdiazepam Tabletȱ(scored):ȱ2ȱmg;ȱ5ȱmg.ȱ
24.4 Medicines used for obsessive compulsive disorders and panic attacksȱ
clomipramine Capsule:ȱ10ȱmg;ȱ25ȱmgȱ(hydrochloride).ȱ
24.5 Medicines used in substance dependence programmesȱ

Chewingȱgum:ȱ2ȱmg;ȱ4ȱmg.ȱ
nicotineȱreplacementȱtherapyȱ(NRT)ȱȱ
Transdermalȱpatch:ȱ5ȱmgȱtoȱ30ȱmg/16ȱhrs;ȱ7ȱmgȱtoȱ21ȱmg/24ȱhrs.ȱ
Concentrateȱforȱoralȱliquid:ȱ5ȱmg/ml;ȱ10ȱmg/mlȱ(hydrochloride).ȱ
Oralȱliquid:ȱ5ȱmg/5ȱml;ȱ10ȱmg/5ȱml.ȱ
ȱmethadone*ȱ
*ȱTheȱsquareȱboxȱisȱaddedȱtoȱincludeȱbuprenorphine.ȱTheȱmedicinesȱ
shouldȱonlyȱbeȱusedȱwithinȱanȱestablishedȱsupportȱprogramme.ȱ
ȱ
ȱ
ȱ
ȱ
ȱ
WHOȱModelȱListȱ
25. MEDICINES ACTING ON THE RESPIRATORY TRACTȱ
25.1 Antiasthmatic and medicines for chronic obstructive pulmonary diseaseȱ

Inhalationȱ(aerosol):ȱ50ȱmicrogramsȱ(dipropionate)ȱperȱdose;ȱ
ȱbeclometasoneȱ
100ȱmicrogramsȱ(dipropionate)ȱperȱdoseȱ(asȱCFCȱfreeȱforms).ȱ
Inhalationȱ(aerosol):ȱ100ȱmicrogramsȱperȱdose;ȱ200ȱmicrogramsȱ
ȱbudesonideȱ[c]
perȱdose.ȱ
Injection:ȱ1ȱmgȱ(asȱhydrochlorideȱorȱhydrogenȱtartrate)ȱinȱȱ
epinephrineȱ(adrenaline)ȱ
1Ȭmlȱampoule.ȱ
ipratropiumȱbromideȱ Inhalationȱ(aerosol):ȱ20ȱmicrograms/meteredȱdose.ȱ
Inhalationȱ(aerosol):ȱ100ȱmicrogramsȱ(asȱsulfate)ȱperȱdose.ȱ
Injection:ȱ50ȱmicrogramsȱ(asȱsulfate)/mlȱinȱ5Ȭmlȱampoule.ȱ
Meteredȱdoseȱinhalerȱ(aerosol):ȱ100ȱmicrogramsȱ(asȱsulfate)ȱperȱ
dose.ȱ
ȱsalbutamol*ȱ Oralȱliquid:ȱ2ȱmg/5ȱml.ȱ
Respiratorȱsolutionȱforȱuseȱinȱnebulizers:ȱ5ȱmgȱ(asȱsulfate)/ml.ȱ
Tablet:ȱ2ȱmg;ȱ4ȱmgȱ(asȱsulfate).ȱ
*ȱOralȱsalbutamolȱtreatmentȱshouldȱonlyȱbeȱconsideredȱwhenȱ
inhaledȱasthmaȱtherapyȱisȱnotȱfeasible.ȱ
26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE
DISTURBANCESȱ
26.1 Oralȱ
oralȱrehydrationȱsaltsȱȱ Seeȱsectionȱ17.5.1.ȱȱ
potassiumȱchlorideȱ Powderȱforȱsolution.ȱ
26.2 Parenteral
Injectableȱsolution:ȱ5%ȱ(isotonic);ȱ10%ȱ(hypertonic);ȱȱ
glucoseȱ
50%ȱ(hypertonic).ȱ
Injectableȱsolution:ȱ4%ȱglucose,ȱ0.18%ȱsodiumȱchlorideȱȱ
(equivalentȱtoȱNa+ȱ30ȱmmol/L,ȱClȬȱ30ȱmmol/L).ȱ
glucoseȱwithȱsodiumȱchlorideȱ Injectableȱsolution:ȱ5%ȱglucose,ȱ0.9%ȱsodiumȱchlorideȱ(equivalentȱ
toȱ150ȱmmol/LȱNa+ȱandȱ150ȱmmol/LȱClȬ);ȱ5%ȱglucose,ȱ0.45%ȱ
sodiumȱchlorideȱ(equivalentȱtoȱ75ȱmmol/LȱNa+ȱandȱ75ȱmmol/Lȱȱ
ClȬ)ȱ[c].ȱ
Solution:ȱ11.2%ȱinȱ20Ȭmlȱampouleȱ
(equivalentȱtoȱK+ȱ1.5ȱmmol/ml,ȱClȬȱ1.5ȱmmol/ml).ȱ
potassiumȱchlorideȱ Solutionȱforȱdilution:ȱ7.5%ȱ(equivalentȱtoȱKȱ1ȱmmol/mlȱandȱȱ
Clȱ1ȱmmol/ml)ȱ[c];ȱ15%ȱ(equivalentȱtoȱKȱ2ȱmmol/mlȱandȱȱ
Clȱ2ȱmmol/ml)ȱ[c].ȱ
Injectableȱsolution:ȱ0.9%ȱisotonicȱ(equivalentȱtoȱNa+ȱ154ȱmmol/L,ȱ
sodiumȱchlorideȱ
ClȬȱ154ȱmmol/L).ȱ
ȱ
WHOȱModelȱListȱ
Injectableȱsolution:ȱ1.4%ȱisotonicȱ(equivalentȱtoȱNa+ȱ167ȱmmol/L,ȱ
HCO3Ȭȱ167ȱmmol/L).ȱ
sodiumȱhydrogenȱcarbonateȱ
Solution:ȱ8.4%ȱinȱ10Ȭmlȱampouleȱ(equivalentȱtoȱNa+ȱ1000ȱmmol/L,ȱ
HCO3Ȭ1000ȱmmol/L).ȱ
ȱsodiumȱlactate,ȱcompoundȱsolutionȱ Injectableȱsolution.ȱ
26.3 Miscellaneousȱ
waterȱforȱinjectionȱ 2Ȭml;ȱ5Ȭml;ȱ10Ȭmlȱampoules.ȱ
27. VITAMINS AND MINERALSȱ
ascorbicȱacidȱ Tablet:ȱ50ȱmg.ȱ
Oralȱliquid:ȱ400ȱIU/ml.ȱ
cholecalciferol*ȱ[c] Solidȱoralȱdosageȱform:ȱ400ȱIU;ȱ1000ȱIU.ȱ
*ȱErgocalciferolȱcanȱbeȱusedȱasȱanȱalternative.ȱ
Oralȱliquid:ȱ250ȱmicrograms/mlȱ(10ȱ000ȱIU/ml).ȱ
ȱergocalciferolȱ
Solidȱoralȱdosageȱform:ȱ1.25ȱmgȱ(50ȱ000ȱIU).ȱ
iodineȱȱ Iodizedȱoil:ȱ1ȱmlȱ(480ȱmgȱiodine);ȱ0.5ȱmlȱ(240ȱmgȱiodine)ȱinȱ
ampouleȱ(oralȱorȱinjectable);ȱ0.57ȱmlȱ(308ȱmgȱiodine)ȱinȱdispenserȱ
bottle.ȱ
ȱnicotinamideȱ Tablet:ȱ50ȱmg.ȱ
pyridoxineȱ Tablet:ȱ25ȱmgȱ(hydrochloride).ȱ
Capsule:ȱ50ȱ000ȱIU;ȱ100ȱ000ȱIU;ȱ200ȱ000ȱIUȱ(asȱpalmitate).ȱ
Oralȱoilyȱsolution:ȱ100ȱ000ȱIUȱ(asȱpalmitate)/mlȱinȱmultidoseȱ
dispenser.ȱ
retinolȱ
Tabletȱ(sugarȬcoated):ȱ10ȱ000ȱIUȱ(asȱpalmitate).ȱ
WaterȬmiscibleȱinjection:ȱ100ȱ000ȱIUȱ(asȱpalmitate)ȱinȱȱ
2Ȭmlȱampoule.ȱ
riboflavinȱ Tablet:ȱ5ȱmg.ȱ
sodiumȱfluorideȱ Inȱanyȱappropriateȱtopicalȱformulation.ȱ
thiamineȱ Tablet:ȱ50ȱmgȱ(hydrochloride).ȱ
calciumȱgluconateȱ Injection:ȱ100ȱmg/mlȱinȱ10Ȭmlȱampoule.ȱ
28. EAR, NOSE AND THROAT CONDITIONS IN CHILDREN [c]ȱ

aceticȱacidȱ Topical:ȱ2%,ȱinȱalcohol.ȱ
budesonideȱȱ Nasalȱspray:ȱ100ȱmicrogramsȱperȱdose.ȱ
ciprofloxacinȱ Topical:ȱ0.3%ȱdrops.ȱ
Nasalȱspray:ȱ0.05%.ȱȱ
xylometazolineȱa ȱ
aȱNot in children less than 3 months.ȱ
ȱ
WHOȱModelȱListȱ
29. SPECIFIC MEDICINES FOR NEONATAL CARE [c]ȱ
Injection:ȱ20ȱmg/mlȱ(equivalentȱtoȱ10ȱmgȱcaffeineȱbase/ml).ȱ
caffeineȱcitrate
Oralȱliquid:ȱ20ȱmg/mlȱ(equivalentȱtoȱ10ȱmgȱcaffeineȱbase/ml).ȱ
ȱibuprofenȱ Solutionȱforȱinjection:ȱ5ȱmg/ml.ȱ
Solutionȱforȱinjection:ȱȱ
ȱprostaglandinȱEȱ ProstaglandinȱE1:ȱ0.5ȱmg/mlȱinȱalcohol.ȱ
ProstaglandinȱE2:ȱ1ȱmg/ml.ȱ
surfactantȱ Suspensionȱforȱintratrachealȱinstillation:ȱ25ȱmg/mlȱorȱ80ȱmg/ml.ȱ
ȱ
Main references
Main references
Australian Medicines Handbook. Adelaide, 2007.

http://www.amh.net.au
British national formulary. British Medical Association and Royal Pharmaceutical Society of
Great Britain, London, 2009.
http://bnf.org
Vidal dictionary, Paris, 2009.

http://www.vidal.fr
Drugs used in bacterial infections. World Health Organisation, Geneva, 2003.

http://www.who.int/medicines/library/bacterial_model_pres/bacterial_content.shtml
Drugs in pregnancy and lactation. G.G. Briggs and al., Philadelphia, 2002.
Guidelines for Drug Donations. World Health Organisation, Geneva, 2000.
Répertoire commenté des médicaments. Belgian Centre for Pharmacotherapeutic information,

Brussels, 2008.
http://www.cbip.be
Prescrire. Numerous articles published between 2000 and 2009.

http://www.prescrire.org
Stability of essential drugs in tropical climate. World Health Organisation, Geneva, 1994.
The extra pharmacopoeia. Martindale, London, 2009.
WHO Model Formulary. World Health Organisation, Geneva, 2008.

http://www.who.int/selection_medicines/list/WMF2008.pdf
WHO model list (16th edition). World Health Organisation, 2009.

http://www.who.int/medicines/publications/essentialmedicines
351
Alphabetical index
Alphabetical index
A
Artesunate rectal...................................................253
Artesunate/amodiaquine, oral.............................25
Abac® ........................................................................15 Artesunate + sulfadoxine/pyrimethamine,
Abacavir (ABC), oral ..............................................15 oral .....................................................................26
Abamune® ................................................................15 Ascorbic acid, oral ..................................................27
AC Vax® .................................................................238 Aspirin, oral.............................................................16
Acetaminophen, injection....................................205 Atenolol, oral...........................................................28
Acetylsalicylic acid (ASA), oral ............................16 Atropine, injection ................................................154
Aciclovir, eye ointment ........................................251 Aviranz 600® ............................................................55
Aciclovir, oral ..........................................................17 Avlosulfon® ..............................................................48
Actrapid®................................................................187 Avocomb® ...............................................................145
Adalat® ...................................................................107 Avocomb N® ...........................................................146
Adalat®LA ..............................................................107 Azithromycin, oral..................................................29
Adiazine®................................................................137 AZT/3TC, oral ......................................................145
Adrenaline, injection ............................................172 AZT/3TC/NVP, oral............................................146
Advil® .......................................................................77
Albendazole, oral....................................................18
Albuterol, injection ...............................................213 B
Bactrim® ...................................................................47
Albuterol, oral .......................................................130
Albuterol, aerosol .................................................131 BCG vaccine...........................................................233
Albuterol, nebuliser solution ..............................132 Beclametasone, aerosol ..........................................30
Alcohol-based (sol. or gel), external use............252 Beclazone® ................................................................30
Aldactone®..............................................................134 Becotide®...................................................................30
Aldomet® ..................................................................94 Benadon® ................................................................123
Aluminium hydroxide, oral ..................................19 Benerva® ..........................................................139,218
Aluvia® .....................................................................90 Benzathine benzylpenicillin, injection...............155
Amitriptyline, oral..................................................20 Benzoic acid + salicylic acid, external use.........254
Amodiaquine (AQ), oral........................................21 Benzyl benzoate, external use.............................255
Amoxicillin, injection ...........................................152 Benzylpenicillin, injection ...................................156
Amoxicillin, oral .....................................................22 Benzylpenicillin procain, injection .....................157
Amoxil®...................................................................22 Benzylpenicillin procaine/benzylpenicillin,
Amphotericin B, injection....................................151 injection ...........................................................158
Ampicillin, injection .............................................152 Betadine dermal solution®......................................275
Anafranil® ................................................................44 Betadine scrub® ......................................................276
Antituberculous vaccine ......................................233 Betaxin®...........................................................139,218
Apresoline®........................................................74,181 Bicillin® ..................................................................158
Arsobal®..................................................................191 Biltricide® ...............................................................117
Arsumax® .................................................................24 Bisacodyl, oral .........................................................31
Artecospe adult®.......................................................26 Brufen® .....................................................................77
Artemether, injection............................................153 Buscopan® .........................................................76,183
Artemether/lumefantrine, oral ............................23 Butylscopolamine, injection ................................183
Artesunate (AS), oral..............................................24 Butylscopolamine, oral ..........................................76
352
Alphabetical index
C
Coragoxine®.......................................................53,169
Cotrimoxazole, oral ................................................47
Cabergoline, oral.....................................................32 Crixivan®..................................................................78
Calamine, external use.........................................256 Crystapen® .............................................................156
Calcium folinate, oral .............................................33 Cyclofem® ...............................................................195
Calcium gluconate, injection...............................159 Cysticide® ...............................................................117
Calypsol® ................................................................188
Camoquin® ...............................................................21
Canestene®..............................................................260 D
d4T/3TC/NVP, oral .............................................136
Carbamazépine, oral ..............................................34
Cataflam® ...............................................................168 Daktarin® ...............................................................268
Cefixime, oral ..........................................................35 Dalacin® ............................................................43,164
Ceftriaxone, injection ...........................................160 Daonil® .....................................................................69
Cerazette® .................................................................49 Dapsone, oral...........................................................48
Chloramphenicol, injection .................................161 Daraprim® ..............................................................124
Chloramphenicol, oral ...........................................38 Depakine® ...............................................................143
Chloramphenicol - long-acting oily, injection ....162 Depocillin® .............................................................157
Chlorhexidine, external use ................................257 Depo-Provera®........................................................194
Chlorine-releasing compounds ..........................258 Dermazin®..............................................................278
Chloromycetin® .................................................38,161 Desogestrel, oral......................................................49
Chloroquine, oral ....................................................36 Dexambutol® ............................................................60
Chlorphenamine, oral ............................................39 Dexamethasone, injection....................................166
Chlorpheniramine, oral .........................................39 Dextrose 5%, infusion ..........................................225
Chlorpromazine, injection...................................163 Dextrose 10%, infusion ........................................226
Chlorpromazine, oral .............................................40 Dextrose 50%, injection ........................................177
Ciflox® ......................................................................42 Diazepam, injection..............................................167
Cimetidine, oral ......................................................41 Diazepam, oral ........................................................50
Ciprofloxacin, oral ..................................................42 Diclofenac, injection .............................................168
Clamoxyl®..........................................................22,152 Didanosine (ddI), oral ............................................51
Clindamycin, injection .........................................164 Diethizine® ...............................................................52
Clindamycin, oral ...................................................43 Diethylcarbamazine, oral ......................................52
Clomipramine, oral ................................................44 Digoxin, injection..................................................169
Clotrimazole, external use...................................260 Digoxin, oral ............................................................53
Cloxacillin, injection .............................................165 Di-hydan®...............................................................115
Cloxacillin, oral .......................................................45 Dihydralazine, oral.................................................74
Cloxapen® ..........................................................45,165 Dilantin® ................................................................115
Coarsucam® ..............................................................25 Dinoprostone, external use..................................261
Coartem® ..................................................................23 Diphthria-tetanus-pertussis vaccine (DTP) ......234
Coartemether, oral ..................................................23 Dipyrone, injection ...............................................196
Codeine, oral ...........................................................46 Dipyrone, oral .........................................................93
Colecalciferol, oral ..................................................57 Disulone® .................................................................48
Combantrin® ..........................................................121 Divir® .......................................................................51
Combivir® ...............................................................145 Doliprane® ..............................................................112
Compound sodium lactate, infusion .................228 Dostinex® .................................................................32
Condyline® .............................................................273 Doxycycline, oral ....................................................54
Condylox®...............................................................273 Dulcolax® .................................................................31
Convulex®...............................................................143 Duovir® ..................................................................145
353
Alphabetical index
Duovir N® ..............................................................146 Folinic acid, oral......................................................33

Duphalac® ................................................................84 Fortified penicillin procaine, injection...............158
Duracillin® .............................................................157 Fortovase®...............................................................133
Fosfomycin tromethamine, oral............................67
E
Efavir 600® ...............................................................55
Frusemide, injection .............................................175
Frusemide, oral .......................................................68
Fulcine® ....................................................................71
Efavirenz (EFV – EFZ), oral...................................55 Fungizone® .............................................................151
Efcortesol® ..............................................................182 Furadantin®............................................................108
Eflornithine, injection...........................................170 Furosemide, injection ...........................................175
Egaten®...................................................................142 Furosemide, oral .....................................................68
Elavil®.......................................................................20
Enalapril, oral ..........................................................56
Epanutin® ...............................................................115
Ephedrine, injection .............................................171
G
Gardenal® ........................................................113,207
Epilim® ...................................................................143 Gelofusine® .............................................................227
Epinephrine (EPN), injection ..............................172 Gentamicin, injection ...........................................176
Epivir®......................................................................85 Gentian violet, external use.................................267
Ergocalciferol, oral..................................................57 Genticin® ................................................................176
Ergometrine, injection ..........................................173 Germanin®..............................................................217
Ergometrine, oral ....................................................58 Glibenclamide, oral ................................................69
Ergotrate®..........................................................58,173 Glucose 5%, infusion ............................................225
Erythrocin®...............................................................59 Glucose 10%, infusion ..........................................226
Erythromycin, oral..................................................59 Glucose 50%, injection .........................................177
Esidrex® ....................................................................75 Glyceryl trinitrate, oral ..........................................70
Eskazole® ..................................................................18 Grisefuline® ..............................................................71
Ethambutol, oral .....................................................60 Griseofulvin, oral ....................................................71
Ethanol ...................................................................262 Grisovin®..................................................................71
Ethinylestradiol/levonorgestrel, oral ..................61
Ethyl alcohol..........................................................262
Etonogestrel, implant ...........................................174 H
Haemaccel®.............................................................227
Euglucon® ................................................................69
Extencilline®...........................................................155 Haldol® ..............................................................73,180
Halfan® .....................................................................72
F
Fansidar®................................................................138
Halofrantrine, oral ..................................................72
Haloperidol, injection ..........................................180
Haloperidol, oral.....................................................73
Fasigyn® .................................................................140 Heparin, injection .................................................178
Fasinex®..................................................................142 Hepatitis B vaccine ...............................................235
Ferrous salts, oral....................................................62 Hetrazan® .................................................................52
Ferrous salts/folic acid, oral .................................63 Hibitane® ................................................................257
Flagyl®...............................................................96,198 Hydralazine, injection..........................................181
Flamazine® .............................................................278 Hydralazine, oral ....................................................74
Fluconazole, oral.....................................................64 Hydrochlorothiazide, oral .....................................75
Fluctine®...................................................................66 Hydrocortisone, injection ....................................182
Fluorescein, external use......................................263 HydroSaluric® ..........................................................75
Fluoxetine, oral........................................................66 Hyoscine butylbromide, injection ......................183
Folic acid, oral .........................................................63 Hyoscine butylbromide, oral ................................76
354
Alphabetical index
I
Laniazid® ..................................................................80
Lanoxin®............................................................53,169
Ibuprofen, oral.........................................................77 Largactil®...........................................................40,163
Imodium® .................................................................89 Lariam®.....................................................................92
Imogam Rabies® .....................................................241 Laroscorbine®............................................................27
Imovax Rabies®.......................................................242 Laroxyl®....................................................................20
Implanon®...............................................................174 Lasilix® ..............................................................68,175
Indinavir (IDV), oral...............................................78 Lasix® ................................................................68,175
Insulatard® .............................................................186 Levodopa/carbidopa, oral ....................................86
Insuline - general information, injection ...........184 Levonorgestrel, implant.......................................189
Insuline - intermediate-acting, injection............186 Levonorgestrel, oral................................................87
Insuline - long-acting, injection ..........................186 Levonorgestrel (emergency), oral.........................88
Insuline - short-acting, injection .........................187 Lidocaine, injection...............................................190
Invirase® .................................................................133 Lignocaine, injection ............................................190
Iodine (alcoholic solutions), external use ..........264 Lipiodol® ...................................................................79
Iodine tincture .......................................................264 Loperamide, oral.....................................................89
Iodised alcohol ......................................................264 Lopinavir/ritonavir (LPV/r), oral .......................90
Iodized oil, oral .......................................................79 Luminal®..........................................................113,207
Isoniazid (INH), oral ..............................................80 Lunelle® ..................................................................195
Isordil®......................................................................81
Isosorbide dinitrate, oral........................................81
Itraconazole, oral ....................................................82 M
Magnesium sulfate, injection ..............................192
Ivermectin, oral .......................................................83
Ixiaro®.....................................................................236 Malathion, external use........................................265
Malocide® ...............................................................124
J
Manugel® ...............................................................252
Manurub® ..............................................................252
Jadelle®....................................................................189 Measles vaccine.....................................................237
Japanese encephalitis vaccine .............................236 Mebendazole, oral ..................................................91
Je-Vax®....................................................................236 Mectizan® .................................................................83
Medroxyprogesterone, injection.........................194
K
Medroxyprogesterone/estradiol, injection .......195
Mefloquine (MQ), oral ...........................................92
Kaleorid®LP ............................................................116 Megaphen® ...............................................................40
Kaletra® ....................................................................90 Melarsoprol, injection ..........................................191
Kapanol®.................................................................100 Mencevax® AC .......................................................238
Kemicetine® .......................................................38,161 Mencevax® ACW ...................................................239
Kempi®....................................................................215 Mengivac® AC .......................................................238
Ketalar® ..................................................................188 Meningococcal vaccine A+C ...............................238
Ketamine, injection ...............................................188 Meningococcal vaccine A+C+W135 ..................239
Ketanest® ................................................................188 Merbromin, external use......................................266
Mercurochrome®.....................................................266
L
Mesygina® ..............................................................202
Metamizole, injection ...........................................196
Lactulose, oral .........................................................84 Metamizole, oral .....................................................93
Lamivir® ...................................................................85 Methergin® ........................................................58,173
Lamivudine (3TC), oral..........................................85 Methyldopa, oral ....................................................94
355
Alphabetical index
Methylergometrine, injection..............................173 Noramidopyrine, oral ............................................93

Methylergometrine, oral........................................58 Norethisterone, injection .....................................201
Methylrosanilinium chloride, external use .......267 Norethisterone/estradiol, injection....................202
Metoclopramide, injection...................................197 Norgeston® ...............................................................87
Metoclopramide, oral.............................................95 Noristerat® .............................................................201
Metronidazole, injection ......................................198 Norlevo® ...................................................................88
Metronidazole, oral ................................................96 Norvir® ...................................................................129
Micatin® .................................................................268 Notezine®..................................................................52
Miconazole, cream................................................268 Novalgin® ..........................................................93,196
Miconazole, muco-adhesive buccal tablet ........269 Nureflex® ..................................................................77
Microgynon 30® .......................................................61 Nystan® ..................................................................109
Microlut®..................................................................87 Nystatin, external use ..........................................270
Microval® .................................................................87 Nystatin, oral.........................................................109
Mifepristone, oral ...................................................97
Minidril® ..................................................................61
Misoprostol, oral .....................................................98
Modified fluid gelatin, infusion .........................227
O
Omeprazole, injection ..........................................203
Monuril® ..................................................................67 Omeprazole, oral...................................................110
Mopral® ...........................................................110,203 Oracilline® ..............................................................114
Morphine, injection ..............................................199 Oral antipoliomyelitis vaccine (OPV)................240
Morphine immediate-release, oral .......................99 Oral rehydration salts (ORS), oral ......................111
Morphine sustained-release, oral .......................100 Orbenin® ...........................................................45,165
Multivitamins, oral ...............................................102 Ornidyl® .................................................................170
Myambutol® .............................................................60 Ospen®....................................................................114
Mycoril® .................................................................260 Oxytocin, injection................................................204
Mycostatin®.....................................................109,270
N P
Paludrine® ..............................................................119
NaDCC ............................................................258,279 Paluther® ................................................................153
Nalidixic acid, oral................................................103 Panadol® .................................................................112
Nalone®...................................................................200 Pantelmin® ...............................................................91
Naloxone, injection...............................................200 Pantomicina®............................................................59
Narcan® ..................................................................200 Paracetamol, injection ..........................................205
Negram® .................................................................103 Paracetamol, oral...................................................112
Nepressol® ................................................................74 Acetaminophen, oral ............................................112
Neravir® .................................................................104 Penadur® ................................................................155
Nevimune® .............................................................104 Penicillin G, injection ...........................................156
Nevirapine (NVP), oral........................................104 Penicillin G procaine, injection ...........................157
Niclosamide, oral..................................................105 Penicillin V, oral ....................................................114
Nicotinamide, oral................................................106 Penidural® ..............................................................155
Nifedipine, oral .....................................................107 Penilevel® ...............................................................156
Nitrofurantoin, oral ..............................................108 Penilevel retard®.....................................................155
Nitroglycerin, oral ..................................................70 Pentacarinat® .........................................................206
Nivaquine® ...............................................................36 Pentam®..................................................................206
Nolotil®..............................................................93,196 Pentamidine, injection..........................................206
Noramidopyrine, injection ..................................196 Pentrexyl® ..............................................................152
356
Alphabetical index
R
Perfalgan®...............................................................205
Perfusalgan®...........................................................205
Permethrin 1%, external use ...............................271 Rabies immunoglobulin (human) ......................241
Permethrin 5%, external use ...............................272 Rabies vaccine .......................................................242
Phenergan®......................................................120,210 Rabipur® .................................................................242
Phenobarbital, injection .......................................207 Redoxon® ..................................................................27
Phenobarbital, oral................................................113 Refolinon®.................................................................33
Phenoxymethylpenicillin, oral ............................114 Renitec® ....................................................................56
Phenytoin, oral ......................................................115 ReSoMal, oral ........................................................126
Phytomenadione, injection..................................208 Retinol, oral ...........................................................127
Plan B® .....................................................................88 Retrovir®.................................................................144
Plasmion® ...............................................................227 Riamet®.....................................................................23
Plasmotrim® ......................................................24,253 Rifadin® ..................................................................128
Podophyllotoxin, external use ............................273 Rifampicin, oral.....................................................128
Podophyllum resin, external use........................274 Rimifon® ...................................................................80
Polygeline, infusion..............................................227 Ringer lactate, infusion ........................................228
Polyvidone iodine - aqueous solution, Risordan® .................................................................81
external use .....................................................275 Ritonavir (RTV), oral ............................................129
Polyvidone iodine - scrub solution, Rocephin® ...............................................................160
external use .....................................................276 RU486, oral ..............................................................97
Potassium chloride, oral ......................................116
Potassium chloride 10%, injection......................209
Potassium permanganate, external use.............277
Povidone iodine - aqueous sol., external use .....275
S
Salbumol® ...............................................................213
Povidone iodine - scrub sol., external use.........276 Salbutamol, injection ............................................213
Praziquantel, oral..................................................117 Salbutamol, oral ....................................................130
Prednisolone, oral .................................................118 Salbutamol, aerosol ..............................................131
Prednisone, oral.....................................................118 Salbutamol, nebuliser solution ...........................132
Primperan®........................................................95,197 Saquinavir (SQV), oral .........................................133
Prioderm® ...............................................................265 Seguril® .............................................................68,175
Proguanil, oral .......................................................119 Semitard® ...............................................................186
Promethazine, injection .......................................210 Serenace® ...........................................................73,180
Promethazine, oral................................................120 Sevredol® ..................................................................99
Propiocine® ...............................................................59 Sicazine®.................................................................278
Prosulf®...................................................................211 Silver sulfadiazine, external use .........................278
Protamine, injection..............................................211 Sinemet® ...................................................................86
Prozac® .....................................................................66 Slow-K® ..................................................................116
Pyrantel, oral .........................................................121 Sodium bicarbonate 8.4%, injection ...................214
Pyrazinamide, oral ...............................................122 Sodium chloride 0.9%, infusion..........................229
Pyridoxine, oral.....................................................123 Sodium dichloroisocyanurate ......................258,279
Pyrimethamine, oral.............................................124 Sodium mercurescein, external use....................266
Pyroxin® .................................................................123 Sodium valproate, oral.........................................143
Solu-cortef® ............................................................182
Q
Quinine, injection..................................................212
Sorbitrate® ................................................................81
Spectinomycin, injection......................................215
Spiroctan®...............................................................134
Quinine, oral..........................................................125 Spironolactone, oral..............................................134
357
Alphabetical index
Sporanox®.................................................................82 Trinitrin, oral ...........................................................70

Stanilo®...................................................................215 Triomune®...............................................................136
Stavir® ....................................................................135 Triptyzol® .................................................................20
Stavudine (d4T), oral............................................135 Triviro® ...................................................................136
Stavudine/lamivudine/nevirapine, oral ..........136 Trobicin® .................................................................215
Sterillium®..............................................................252
Stocrin® ....................................................................55
Streptomycin, injection ........................................216
Stromectol®...............................................................83
U
Ultralente® .............................................................186
Sulfadiazine, oral ..................................................137 Ultratard®...............................................................186
Sulfadoxine/pyrimethamine (SP), oral .............138
Sulfamethoxazole/trimethoprim, oral ................47
Sulfamon®.................................................................26
Suprax® ....................................................................35
V
Valium® .............................................................50,167
Suramin, injection.................................................217 Valproic acid, oral .................................................143
Sustiva®....................................................................55 Velosulin® ...............................................................187
Syntocinon®............................................................204 Ventolin® ..................................................130,131,132
Vermox®....................................................................91
T
Tagamet®...................................................................41
Verorab®..................................................................242
Vibramycin® .............................................................54
Videne scrub® .........................................................276
Tegretal® ...................................................................34 Videx®.......................................................................51
Tegretol® ...................................................................34 Vikela® ......................................................................88
Teldrin®.....................................................................39 Viramune® ..............................................................104
Tenormin®.................................................................28 Viratop® ....................................................................17
Tetanus antitoxin (equine)...................................247 Vitamin A, oral ......................................................127
Tetanus immunoglobulin (human) ....................246 Vitamin B complex, oral.......................................102
Tetanus vaccine (TT).............................................244 Vitamin B1, injection ............................................218
Tetracycline, dermal ointment ............................280 Vitamin B1, oral.....................................................139
Tetracycline, eye ointment...................................281 Vitamin B3, oral.....................................................106
Thiamine, injection ...............................................218 Vitamin B6, oral.....................................................123
Thiamine, oral .......................................................139 Vitamin B9, oral.......................................................63
Thorazine®................................................................40 Vitamin C, oral ........................................................27
Tibozole® .................................................................269 Vitamin D2, oral ......................................................57
Tindamax®..............................................................140 Vitamin D3, oral ......................................................57
Tindol®....................................................................140 Vitamin K1, injection ............................................208
Tinidazole, oral......................................................140 Vitamin PP, oral.....................................................106
Tramadol, injection ...............................................219 Vitascorbol® ..............................................................27
Tramadol, oral .......................................................141 Voltaren® ................................................................168
Tramal®............................................................141,219 Voltarol® .................................................................168
Trebazid®.................................................................122
Tredemine®..............................................................105
Triclabendazole, oral ............................................142
Triflucan® .................................................................64
W
Wartec®...................................................................273
Trimeton® .................................................................39 Wormin®...................................................................91
358
Alphabetical index
Y
Xylocaine® ..............................................................190
Yellow fever vaccine.............................................248
Yomesan®................................................................105
Z
Zamadol®.........................................................141,219
Zentel®......................................................................18
Zerit®......................................................................135
Zeritavir® ...............................................................135
Ziagen®.....................................................................15
Zidovudine (AZT – ZDV), oral...........................144
Zidovudine/lamivudine, oral ............................145
Zidovudine/lamivudine/nevirapine, oral .......146
Zinamide®...............................................................122
Zinc oxide, external use .......................................282
Zinc sulfate, oral ...................................................147
Zithromax®...............................................................29
Zovirax® ............................................................17,251
Zydol®..............................................................141,219
Zynox® ...................................................................200
359
Notes
In the same collection
Clinical guidelines - diagnostic and treatment manual

English, French, Spanish
Obstetrics in remote settings

English, French
Management of epidemic meningococcal meningitis

English, French
Tuberculosis
English, French
Public health engineering in emergency situations

English, French
Rapid health assessment of refugee or displaced populations

English only
Refugee health - an approach to emergency situations

Ed. MacMillan/MSF
English only
Belgium Médecins Sans Frontières/Artsen Zonder Grenzen
Rue Dupréstraat 94, 1090 Bruxelles/Brussel
Tel.: +32 (0)2 474 74 74
Fax: +32 (0)2 474 75 75
E-mail: info@msf.be
France Médecins Sans Frontières

8 rue Saint-Sabin, 75544 Paris cedex 11
Tel.: +33 (0)1 40 21 29 29
Fax: +33 (0)1 48 06 68 68
Telex: (042) 214360 MSF F
E-mail: office@paris.msf.org
Netherlands Artsen Zonder Grenzen

Plantage Middenlaan 14, 1018 DD Amsterdam
Tel.: +31 (0)20 52 08 700
Fax: +31 (0)20 62 05 170
Telex: (044) 10773 MSF NL
E-mail: office@amsterdam.msf.org
Spain Medicos Sin Fronteras

Nou de la Rambla 26, 08001 Barcelona
Tel.: +34 933 046 100
Fax: +34 933 046 102
E-mail: oficina@barcelona.msf.org
Switzerland Médecins Sans Frontières

78 rue de Lausanne - Case postale 116 - 1211 Genève 27
Tel.: +41 (0)22 849 84 84
Fax: +41 (0)22 849 84 88
Telex: (045) 421 927 MSF CH
E-mail: office-gva@geneva.msf.org
Achevé d’imprimer en France par ISI, 75020 Paris

Janvier 2010

Essential Drugs

Uploaded by

Copyright:

Available Formats

Essential Drugs

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Essential Drugs

Uploaded by

Copyright:

Available Formats

Essential

intended for physicians, pharmacists,

(MD) Medical doctor, (Ph) Pharmacist, (N) Nurse, (AA) Anaesthetist-assistant

Translated from French by V. Grouzard, N. Harris and C. Lopez-Serraf.

Design and layout: Evelyne Laissu

This guide is not a dictionary of pharmacological agents. It is a practical

We have tried to provide simple, practical solutions to the questions and

The entries are classified according to the route of administration and in

Only the main contra-indications, adverse effects, precautions and drug

This manual is a collective effort by medical professionals from many

Comments should be addressed to:

This manual is also available on the internet at www.msf.org. As treatment protocols

This box indicates potentially toxic drugs,

Drugs marked with a grey diagonal line are

Practical recommendations for drug storage:

If no temperature for storage is recommended, this indicates that no information was

Units Administration route Others

kg = kilogram IM = intramuscular v/v = volume in volume

1 Oral drugs page 13

2 Injectable drugs page 149

3 Infusion solutions page 221

4 Vaccines, immunoglobulins and antisera page 231

5 Drugs for external use, antiseptics and disinfectants page 249

Organisation and management of a pharmacy page 285

Drug quality and storage page 297

Prescription, cost, compliance page 301

Use of antibacterials page 305

Antiseptics and disinfectants page 311

WHO model list of essential medicines page 317

Main references page 351

Alphabetical index page 352

Duration: depending on the efficacy and tolerance of abacavir.

Contra-indications, adverse effects, precautions

AGE 0 2 months 1 year 5 years 15 years

100 mg tablet – – 1 1/2 tab x 3 3 tab x 3 –

Dosage and duration

Contra-indications, adverse effects, precautions

Prescription under medical supervision

Dosage and duration

Contra-indications, adverse effects, precautions

Duration: according to clinical response

Contra-indications, adverse effects, precautions

Prescription under medical supervision

Dosage and duration

153 mg base tablet

Contra-indications, adverse effects, precautions

Prescription under medical supervision

– In severe infections, double the dose.

Contra-indications, adverse effects, precautions

Dosage and duration

Contra-indications, adverse effects, precautions

Prescription under medical supervision

Artesunate must be used in combination with another

Dosage and duration

Contra-indications, adverse effects, precautions

Dosage and duration

Age Weight Tablets D1 D2 D3

2 to 11 months 4.5 to 8 kg 25 mg AS/67.5 mg AQ 1 tab 1 tab 1 tab

1 to 5 years 9 to 17 kg 50 mg AS/135 mg AQ 1 tab 1 tab 1 tab

Contra-indications, adverse effects, precautions